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This thesis is organized in eight chapters, that intend to guide the reader from 
Introduction, were the Background and Rationale are described, to Aims and Research 
Questions, to each of the Methodologies that were developed and explored. The 
application in Ophthalmology and the specificities of ophthalmic adverse drug 
reactions are described in another chapter. Finally, the Discussion is presented, with 
the main findings, limitations and conclusions. Respective References are presented. In 
the Appendices chapter, the scientific articles that were built as a result of this work 
and that were published in peer-reviewed journals are available for consultation. 
 
I. Introduction 
In the first chapter, the importance of adverse drug reactions (ADRs) is described, as is 
the need for the development of new methodologies for ADRs detection. General 
concepts and definitions of drug-related problems are presented. Adverse drug 
reactions are approached according to WHO's definition of ADR: “any noxious, 
unintended and undesired effect of a drug, which occurs at doses used in humans for 
prophylaxis, diagnosis, or therapy”. General methodologies of Pharmacovigilance are 
described, as well as their methodological issues. 
 
II. Aims and research questions 
In the second chapter, the aims and the respective research questions are stated, 
namely regarding the frequency of adverse drug reactions (ADRs), the application of a 
database methodology for detection of ADRs, and the application of these and other 
adapted methodologies for the detection of ophthalmic ADRs. The work performed to  
answer the research questions is described in the following chapters. 
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III. Frequency of adverse drug reactions in hospitalized patients 
In the third chapter, the methodologies and results of one of our systematic reviews 
are presented, as well as its main conclusions, leading to the characterization and 
estimate of frequency of ADRs that occur in hospitalized patients. This original 
research led to publication of a scientific paper, available in appendix 1. 
 
IV. Development of new methodologies for the detection of adverse drug reactions 
In the fourth chapter, the methodologies that were approached in this thesis are 
described. The pilot studies, validation studies, development of new methodologies 
and respective results for ADR detection are presented, either for the utilization of 
administrative databases in the detection of ADRs, and for computer-assisted chart 
review for the detection of ADRs. The methodological issues and study limitations are 
explored for each of these methodologies. From the study of these methodologies, 
three scientific papers arose, available for consultation in appendices 2-4. 
 
V. Application in Ophthalmology 
In the fifth chapter, the main general ophthalmic adverse drug reactions are 
characterized and assessed through a general systematic review. A specific systematic 
review is also presented about ophthalmic adverse drug reactions caused by statins. 
An original study was additionally performed with the adaptation of the database 
methodology to the detection of ophthalmic ADRs. The corresponding articles are 
available in appendices 5-9.  
 
VI. Discussion 
In the sixth chapter, the main findings and the answers to the research questions are 
discussed, as the strengths and limitations of our work. Conclusions and 
recommendations are then described. 
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VII. References 
The seventh chapter contains the references that were consulted in this thesis. 
 
VIII. Appendices 
This chapter includes 10 appendices regarding 8 scientific articles and 2 chapter books; 
all of them resulted from the original work developed during this thesis.  
Appendix 1 is a systematic review about ADRs, published in Pharmacoepidemiology 
and Drug Safety Journal (PDS). Appendices 2 and 3 are scientific articles published in 
PDS regarding a methodology using hospital databases to detect ADRs, appendix 4 is a 
published paper regarding a computerized methodology to detect ADRs. Appendices 5, 
6 and 8 are articles about ocular ADRs provoked by systemic drugs and appendix 7 is 
an article in which a nation-wide estimate of ocular ADRs in Portugal was performed. 
Appendix 9 is a chapter about ocular ADRs, written for a portuguese Ophthalmology 
book for residents (which is currently in construction). Appendix 10 is a chapter about 
ADRs, written after invitation for an international publication about Biotechnology and 
its recent developments. 
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Adverse drug reactions (ADRs) are important, costly and fatal events in any healthcare system. However, 
there are many methodological problems associated with its detection, which hinders the prevention 
and early treatment of ADRs. This thesis intends to contribute to the improvement of the current 
methodologies of detection of ADRs and its application in Ophthalmology. 
According to the World Health Organization (WHO), an ADR is “any noxious, unintended and undesired 
effect of a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy”. The 
prevention through the knowledge gathered by the identification and detection of ADRs represent one 
of the ways in which it is possible to increase the quality of healthcare while decreasing its related costs.  
Several methodologies can be used for ADR detection, namely: 
• Spontaneous reporting is the main methodology used by WHO's International Drug Monitoring 
Program and the only one used regularly in the majority of countries. Although it is usually 
considered one of the cheapest ways to detect ADR, it has also one of the smallest detection rate 
among all available methods, mainly because of underreporting. 
• Analysis of health databases (for example, hospital episodes statistics and large insurance claims 
data) is not commonly used but it might represent a relevant source of ADRs since these datasets 
contain large amounts of patient clinical data. 
• Computerized systems is a potentially useful method but attention is needed to build rules and 
algorithms with high specificity, otherwise it will be too resource consuming. Another problem is its 
high dependency of structured data i.e. the difficulty with using data from patient narrative notes.  
•  Chart review is also useful for ADR detection but it requires a lot of skilled human resources. 
• Prospective and intensive monitoring of patients are too costly methods (intensive monitoring has 
the largest detection rate, being considered by most as the gold standard) to allow for their regular 
use in pharmacovigilance and they are mostly used in short and/or specific drug studies. 
• Postmarketing trials are seldom used and each of them is also too specific for being developed as a 
common pharmacovigilance methodology. 
In Portugal as in many other countries, there are still many limitations in the current spontaneous 
reporting system and there are no real and complete data about ADRs that occur during hospitalization 
(ADRIn). In addition, there are too high costs involved in implementing an intensive monitoring 
programme or in implementing a good computerized system. My main motivation to start this thesis 
was therefore to try to contribute to overcome some of these issues. 
Ophthalmology represents a particular challenge in pharmacovigilance. Many ocular ADRs are detected 
solely after spontaneous reporting, often lacking causality assessments to determine the probability of 
an ADR alert being a true ADR, and lacking systematic reviews about ocular ADRs caused by a specific 
drug. Furthermore, the actual frequency of ophthalmic ADRs remains mostly unknown. Consequently, 
ophthalmic ADRs are a heterogeneous group of ADRs that still lack systematization and assessment. 
Purposes of this thesis 
We had several purposes: (a) to identify the frequency of ADRs that occur during hospitalization; (b) to 
explore methodological issues of several different Pharmacovigilance methods; and (c) to explore, 
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characterize and validate new methodological Pharmacovigilance approaches. Additionally, with these 
validated methodological approaches, we intended (d) to contribute to the improvement of the 
Portuguese pharmacovigilance system namely by building a nation-wide estimate of ADRs. We also 
aimed (e) to detect and characterize ophthalmic ADRs. Additionally, we intended (f) to build a general 
systematic review of ophthalmic ADRs and then (g) to perform specific systematic reviews of ophthalmic 
ADRs to systemic drugs that needed further assessment. 
Adverse drug reactions in hospitalized patients 
We performed a systematic review to estimate the frequency of ADRs in hospitalized patients. Our 
meta-analysis indicated that ADRs may occur in 17% (CI95%: 14, 20%) of patients during hospitalization; 
however, there was significant heterogeneity (I2 = 99%). The most significant moderators of 
heterogeneity were: risk of bias, population, ward, and methodology for ADR identification. Low risk of 
bias studies adjusted for population (pediatric versus adult) had I2 = 0%. 
Development of new methodologies for the detection of ADRs 
We developed new methodologies for ADR detection using hospital databases and using a computerized 
approach. In this thesis we explored spontaneous reporting, administrative databases, chart review and 
computerized systems that assisted chart review.  
Spontaneous reporting is the most commonly used method for Pharmacovigilance due to its reduced 
costs but has several limitations: underreporting, heterogeneous report quality and risk of bias.  
Regarding the database methodology (a methodology developed to allow the detection of ADRs through 
hospital administrative databases), we performed first a validation study and then a nation-wide study. 
The validation study was performed in a university hospital of Coimbra: a retrospective analysis was 
conducted to identify ADRs using 114 diagnostic codes from administrative databases, later validated by 
chart review. An independent chart review was performed for comparison, as well as assessment of 
spontaneous reports. 325 ADRs were identified (prevalence of 2.4%, positive predictive value of 88%). 
Independent chart review identified 9% of ADRs at a cost of 35 person-hours (PH), versus 2 PH in the 
database methodology. There were 7 spontaneous reports in this period in the same population. 
From the application of the database methodology to nation-wide data, we were able to detect 116720 
hospital ADRs of 9271122 hospitalizations (prevalence of 1.3%; 97% of the ADRs were ADRIn), in public 
hospitals from Portugal from 2000 to the first semester of 2009. 
Two chart reviews were performed in this thesis: the first was performed for comparison with database 
methodology in simple detection of ADRs (detecting a prevalence of 9% of ADRs with the cost of 35PH), 
and the second chart review, more detailed (prevalence of 10.2% and cost of 69 PH), was performed for 
comparison with a computerized methodology and for deep characterization of ADRs. 
Finally, a computerized-assisted chart review was developed and validated, with a high detection rate 
(prevalence of ADRs identified of 25%) with moderate resources needed (29 PH), much lower than 
manual chart review. This program also provides a list of ADR for each drug, as a memory support tool 
for inexperienced reviewers. It integrates validation and causality assessment during each assessment. 
The following table resumes the comparison on several methodologies. 
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Methodology 
Number of ADRs / 
number of 
patients exposed 
Prevalence 
(%) of ADRs  
detected 
Resources spent 
(PH: person-hours) 
Adjusted 
resources 
(PH per 100 
ADRs detected) 
Database analysis 325 / 13,471 2.4% 2 PH (per 325 ADRs) 0.6 
Spontaneous 
reporting 7/13,471 0.05% 1 PH (7 ADR reports) 14 
Computerized 65 / 117 25% 29.5 PH (65 ADRs) 45 
Succint chart review 9/100 9% 35 PH (9 ADRs) 389 
Comprehensive 
chart review 12/117 10% 69 PH (12 ADRs) 575 
 
Application in Ophthalmology 
First, we performed a general systematic overview of ophthalmic ADRs to add systematization and to 
identify specific ADRs lacking assessment. From 562 studies, we included 32 studies that summarized 
the most known systemic drugs causing ADRs and identified areas lacking specific systematic reviews. 
Second, we performed specific systematic reviews to drugs in those areas (namely ophthalmic ADRs 
caused by statins). Third, we utilized that knowledge in the adaptation of our database methodology to 
the specificities of Ophthalmology to detect ophthalmic ADRs. From all public hospitals in Portugal from 
2000 to 2009, 1524 specific probable ocular ADRs were detected through the search of codes that could 
represent particular ocular ADRs.  
Discussion 
From the comparison of all methodologies, we can conclude that the methodologies developed in this 
thesis (database methodology and computerized chart review) are promising and might be integrated as 
effective and even low resource Pharmacovigilance methodologies. The database methodology 
validated by us, is resource-sparing for continuous application but with a detection rate higher than 
spontaneous reporting. Computerized chart review might be an useful Pharmacovigilance methodology, 
since it may allow regular surveillance with a higher ADR detection with half the resources needed by 
manual chart review.  
Different methods tend to identify different ADRs, therefore, multiple methods for ADR detection 
should be used complementarily for patient safety enhancement. We suggest that the database 
methodology is utilized as a screening method for detecting ADRs, and computerized chart review is 
utilized at high-risk populations. 
As for application in Ophthalmology, we conclude that our adapted methodologies were successful in 
detecting either general and specific ophthalmic ADRs. Ophthalmologists' knowledge about ophthalmic 
ADRs is essential for its detection and should be stimulated. 
 RESUMO 
 
| xxix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESUMO 
 RESUMO 
 
| xxx 
 
As reacções adversas medicamentosas (RAM) são frequentes, caras e podem ser fatais. Todavia, há 
inúmeros problemas metodológicos associados com a sua detecção, o que reduz a prevenção e o 
tratamento de RAM. Esta tese pretende dar um contributo na exploração e validação de metodologias 
para a detecção de RAMs e para a sua aplicação na Oftalmologia. 
De acordo com a Organização Mundial de Saúde (OMS), uma reacção adversa medicamentosa (RAM) é: 
"qualquer efeito nocivo, não programado ou indesejado de um medicamento, que ocorra em doses 
utilizadas nos humanos para profilaxia, diagnóstico ou terapêutica. A detecção de RAMs representa uma 
das formas de simultaneamente aumentar a qualidade e reduzir os custos nos Serviços de Saúde.  
Várias metodologias podem ser utilizadas para a detecção de RAMs, nomeadamente: 
• Notificação espontânea, a metodologia mais barata e a única continuamente utilizada em vários 
países como a base do Programa Internacional de Monitorização de Medicamentos. Contudo, tem a 
menor taxa de detecção de RAMs de todas as metodologias (devido à subnotificação). 
• Bases de dados (administrativas, ou bases de dados de seguros, ou bases de dados hospitalares com 
informação clínica) não são habitualmente utilizadas, mas podem representar uma oportunidade 
considerando que contêm vasta informação clínica que pode ser utilizada na detecção de RAMs. 
• Os Sistemas computorizados/informáticos podem representar uma metodologia interessante, mas 
é necessário construir regras e algoritmos de alta especificidade, caso contrário tornam-se caros. 
Outros problemas dos sistemas computorizados incluem a necessidade de dados clínicos 
previamente estruturados e a dificuldade de aproveitar a informação de processos clínicos. 
• A revisão de processos clínicos é útil para a detecção de RAMs, mas é cara e dependente de peritos. 
• As monitorizações prospectivas e intensivas (feita por peritos que avaliam regularmente doentes 
durante o internamento para identificar RAMs) apresentam as taxas de detecção mais altas, mas os 
custos são tão altos que impossibilitam a sua utilização contínua na farmacovigilância.  
• Os ensaios clínicos randomizados são habitualmente demasiado restritos a um medicamento ou 
patologia para serem implementados como método de farmacovigilância geral. 
As motivações da presente tese incluem as limitações das notificações espontâneas, o elevado custo da 
monitorização intensiva e a dificuldade de construir um sistema computorizado nacional para detecção 
de RAMs, assim como a motivação de complementar o sistema de farmacovigilância português com 
outras metodologias para além das notificações espontâneas, e a necessidade de estimar a frequência 
das RAMs que ocorrem em doentes durante o internamento. 
A Oftalmologia apresenta um desafio e simultaneamente uma oportunidade na farmacovigilância. 
Várias RAMs oculares são detectadas apenas por notificação espontânea, frequentemente sem 
avaliação da causalidade de RAM (cujo objetivo é determinar qual a probabilidade de uma suspeita de 
RAM corresponder a uma RAM verdadeira). Adicionalmente, há várias revisões narrativas sobre RAMs 
oculares mas faltam revisões sistemáticas de RAMs oculares provocadas por medicação sistémica com 
meta-análise e faltam estimativas de frequência de RAMs oculares específicas. Consequentemente, as 
RAMs oculares integram um grupo de RAMs heterogéneo que necessita de avaliação e sistematização. 
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Objectivos da tese 
Esta tese teve vários objectivos: (a) estimar a frequência de RAMs que ocorrem em doentes durante o 
internamento, (b) explorar as questões metodológicas de várias metodologias para a detecção de RAMs, 
e validar novas abordagens para aumentar a detecção de RAMs. Adicionalmente, pretendeu-se (c) 
realizar uma estimativa das RAMs que ocorreram em Portugal na última década, (d) assim como das 
RAMs oculares, auxiliando assim a farmacovigilância portuguesa. Pretendeu-se também (e) adaptar as 
metodologias de detecção de RAMs gerais para a aplicação na detecção de RAMs oculares. Finalmente, 
pretendeu-se (f) construir uma revisão sistemática geral para clarificação das RAMs oculares a 
medicação sistémica, e uma (g) revisão sistemática de RAMs oculares provocadas por estatinas.  
RAMs em doentes internados 
Realizámos uma revisão sistemática para estimar a frequência de RAMs em doentes internados. A meta-
análise indicou que as RAMs ocorreram em média em 17% dos doentes (IC95% 13 - 20%); todavia, 
houve heterogeneidade (I2 = 99%). Os moderadores de heterogeneidade foram: risco de viés, 
população, serviço e metodologia usada para identificação da RAM. Os estudos sobre RAMs com baixo 
risco de viés ajustados para população (pediátrica versus adulta) não apresentaram heterogeneidade 
estatística: I2 = 0%. 
Desenvolvimento de novas metodologias para a detecção de RAMs 
Na presente dissertação foram exploradas as seguintes metodologias de detecção de RAMs: notificação 
espontânea, bases de dados hospitalares, sistemas computorizados e revisão de processos clínicos. 
Validámos duas metodologias de detecção de RAMs: uma metodologia que utilizou bases de dados 
hospitalares e outra que utilizou uma abordagem computorizada.  
A notificação espontânea tem custos reduzidos, todavia tem limitações como a subnotificação, a 
qualidade de notificação heterogénea e o risco de viés.  
Relativamente à metodologia de bases de dados (metodologia essa em que se utilizou a informação 
clínica codificada para detectar RAMs), realizámos primeiro um estudo de validação e depois um estudo 
de prevalência nacional. O estudo de validação foi realizado no Centro Hospitalar e Universitário de 
Coimbra com exploração retrospectiva de 114 códigos de diagnóstico (procurando identificar os códigos 
que detectariam maior número de alertas de RAM) e revisão de processos clínicos para validação das 
suspeitas de RAM (avaliando primeiramente o valor preditivo positivo, VPP, de cada código e 
seleccionando depois os códigos com maior VPP global). Realizou-se também uma revisão de processos 
clínicos independente e obtenção do número de notificações espontâneas para a mesma população e 
período de tempo.  
Identificaram-se 325 RAMs através das bases de dados (prevalência de 2%, valor preditivo positivo de 
88%). A revisão de processos clínicos independente detectou 9% de RAMs com um custo de 35 pessoas-
horas (PH), por oposição a 2 PH na metodologia de bases de dados. Na mesma população e período, 
obtiveram-se 7 notificações espontâneas. 
 Aplicou-se a metodologia das bases de dados (com os códigos previamente seleccionados de maior 
VPP) a bases de dados dos hospitais públicos portugueses de 2000 ao 1º semestre de 2009 e 
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detectaram-se 116720 RAMs de entre 9271122 hospitalizações (prevalência de 1.3%; 97% das RAMs 
ocorreram durante o internamento). 
Realizaram-se duas revisões de processos nesta tese: uma revisão de processos sumária para 
comparação com a metodologia de bases de dados (permitiu detectar uma prevalência de 9% de RAMs 
com um custo de 35 PH); e outra revisão de processos detalhada, para caracterização das RAMs e para 
comparação com a metodologia computorizada (detectou 10% de RAMs com um custo de 69 PH). 
Adicionalmente, desenvolveu-se e validou-se uma metodologia computorizada para auxílio da revisão 
de processos clínicos, com uma alta taxa de detecção (prevalência de RAMs de 25%) e custo moderado 
(29 PH), muito menor do que a revisão manual de processos clínicos. Esta metodologia incluiu a 
construção de um programa (ChartHelper) que mostra uma lista de RAMs possíveis para cada 
medicamento, funcionando como auxiliar de memória em utilizadores inexperientes; e obriga o 
utilizador a realizar a avaliação da causalidade da OMS para cada suspeita de RAMs. A tabela seguinte 
resume a comparação das diferentes metodologias para detecção de RAMs exploradas nesta tese.  
Metodologia 
Número de 
RAMs / nº de 
doentes com 
medicação 
Prevalência(%) 
de RAMs 
detectadas 
Recursos 
dispendidos (PH: 
pessoas-horas) 
Recursos 
ajustados 
(PH por 100 
RAMs 
detectadas) 
Bases de dados 325 / 13471 2.41% 2 PH (por 325 RAMs) 0.6 
Notificação 
espontânea 7/13471 0.05% 
1 PH (por 7 
notificações) 14 
Computorizada 65 / 117 25% 29.5 PH (65 RAMs) 45 
Revisão de 
processos sumária 9/100 9% 35 PH (9 RAMs) 389 
Revisão de 
processos expandida 12/117 10% 69 PH (12 RAMs) 575 
 
Aplicação na Oftalmologia 
Primeiro, realizámos uma revisão sistemática geral de RAMs oculares para sistematização e para 
identificação de RAMs oculares específicas (a medicação sistémica específica com estudos originais mas 
sem meta-análise), para identificar RAMs oculares que necessitassem ou beneficiassem de avaliação 
posterior. De 562 estudos, incluímos 32 e sumariámos as RAMs oculares mais frequentes e a respectiva 
medicação, caracterizando-as. Depois, realizámos revisões sistemáticas de RAMs oculares a medicação 
sistémica específica (nomeadamente RAMs oculares provocadas por estatinas). Em terceiro lugar, 
utilizámos o conhecimento obtido para adaptação da metodologia das bases de dados para detecção de 
RAMs especificamente oculares. De todos os hospitais públicos portugueses de 2000 a 2009, 
detectaram-se 1524 RAMs oculares prováveis (através da pesquisa de códigos de diagnóstico específicos 
que pudessem representar RAMs oculares).  
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Discussão 
A partir da comparação de todas as metodologias, podemos concluir que as metodologias exploradas e 
validadas nesta dissertação (bases de dados e computorizada), são promissoras e poderão ser 
integradas como efectivas e baratas na farmacovigilância portuguesa.  
A metodologia das bases de dados utiliza poucos recursos, permitindo aplicação contínua e com maior 
detecção da prevalência de RAMs do que a notificação espontânea.  
Também a metodologia computorizada (de auxílio à revisão de processos clínicos) pode ser útil na 
farmacogivilância, uma vez que poderá permitir vigilância e detecção regular de RAMs gastando uma 
fracção dos recursos que seriam necessários para uma revisão manual de processos.  
Tem sido sugerido que diferentes métodos tendem a identificar diferentes RAMs, consequentemente, 
vários métodos deverão ser utilizados complementarmente para aumentar a segurança do doente. Por 
exemplo, sugerimos que a metodologia de bases de dados seja utilizada como rastreio para detectar 
RAMs, e a metodologia computorizada seja utilizada em populações de alto risco. 
Quanto à aplicação na Oftalmologia, concluímos que a adaptação de metodologias pode ter sucesso na 
identificação de RAMs oculares a medicação sistémica. Apesar destas RAMs oculares não serem 
frequentes relativamente às RAM gerais, os oftalmologistas devem saber reconhecê-las para melhor as 
poderem tratar. Protocolos de colaboração entre diferentes especialidades é recomendado (para 
permitir a vigilância por oftalmologistas sempre que há prescrição de drogas de alto risco).  
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"Primum non nocere" 
"First, do not harm" 
Hippocrates 
 
 BACKGROUND: ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE 
 
History of adverse drug reactions 
Adverse drug reactions (ADRs) are frequent, important, expensive and can be fatal 
(Davies et al, 2007). 
Since the "disaster of Thalidomide" in 1960's (D'Arcy and Griffin, 1994), public and 
scientific attention has been drawn to the problem of ADR detection, changing the way 
drugs are developed, tested and regulated in the World. Physicians first prescribed 
thalidomide in the late 1950s to treat anxiety, insomnia and, in pregnant women, 
morning sickness. It was marketed in Europe as well as in Japan, Australia and Canada. 
It was withdrawn from the market in the early 1960s when scientific community 
noticed that it caused phocomelia in children exposed to thalidomide during gestation. 
Besides of the phocomelia (a severe shortening of the limbs), thalidomide also causes 
malformations in the eyes, ears, gastrointestinal tract, kidneys and genitals (Martínez-
Frías, 2012). 40% of the fetuses exposed to thalidomide die before or soon after 
delivery (Franks et al, 2004). Despite this strong teratogenic effect, since there was no 
ADR monitoring system it took several years, from 1957 to 1961 (Routledge, 1998) to 
attribute phocomelia to the use of thalidomide during pregnancy, when about 10000 
children around the world were already born with major malformations (Franks et al, 
2004). 
Afterwards, in 1963 the World Health Organization (WHO) reunited in Geneva and 
decided to build an International Drug Monitoring Program (WHO, 2005). Also, in the 
United States the Food and Drug Administration (FDA) reinforced the security 
monitoring of drugs.  
Therefore, an active interest in drug safety and monitoring began worldwide.  
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Several concepts of drug-related problems arose; to clarify this issue, we present some 
definitions. 
 
Definitions of drug-related problems and ADRs 
An adverse event is: "an injury related to medical management, in contrast to 
complications of disease" (WHO, 2005). Medical management includes all aspects of 
care, including diagnosis and treatment, failure to diagnose or treat, and the systems 
and equipment used to deliver care (WHO, 2005).  
Drug-related problems are a heterogeneous group that includes ADRs. They are: “a 
circumstance that involves a patient’s drug treatment that actually, or potentially, 
interferes with the achievement of an optimal outcome (Johnson and Bootman, 1995). 
Adverse drug event (ADE): “An injury related to the use of a drug, although the 
causality of this relationship may not be proven” (Nebeker et al, 2004). These events 
include medication errors (namely the prescription of a wrong dose) and adverse drug 
reactions. 
Medication error: “Any error in the process of prescribing, dispensing or administering 
a drug, whether there are adverse consequences or not” (Leape et al, 1995). 
 
An adverse drug reaction (ADR) is: “any noxious, unintended and undesired effect of a 
drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy”, 
according to WHO’s definition of 1972 (WHO, 1972). This definition is the most widely 
used, but there are others, like Karch and Lasagna’s (1975) (whose definition is similar 
to this but excludes therapeutic failures). The definition of Edwards and Aronson 
(2000) is conceptually different (it excludes minor ADRs): “an appreciably harmful or 
unpleasant reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, or withdrawal of the product”. 
Some ADRs may be the result of errors, such as the prescription of a drug in the correct 
dose as recommended in textbooks, but without adjustment in a patient with renal 
failure.  
This thesis follows WHO's definition of ADR. 
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Figure I1. Schematic conceptualization of adverse events. Adverse events are injuries related to 
medical care. Drug related problems are caused by drugs and include medication errors, adverse drug 
events (ADE) and adverse drug reactions (ADR). Adapted from WHO, 2005. 
 
 
Importance of ADRs 
ADRs are a major Public Health problem. In a study performed in the United States 
(US) it was estimated that more than 100000 people die every year as a consequence 
of fatal ADRs, placing fatal ADRs between the fourth and sixth leading causes of death 
in the US (Lazarou et al, 1998). More recent estimates report that ADRs are  the cause 
of 5.3% hospital admissions (Kongkaew et al, 2008), but there are different estimates 
of the frequency of ADRs (see chapter below). They may lead to US$1.56 billion in 
direct hospital costs per year in the USA (Classen et al, 1997) and drug related 
morbidity may lead to US$136.8 billion in indirect costs (Johnson and Bootman, 1995).  
Each ADR may represent a cost of US$2500 per patient (Bates et al, 1995).  
Therefore, the detection and prevention of ADRs through Pharmacovigilance represent 
one of the few ways in which it is possible to increase Healthcare quality while 
decreasing related costs (Stefanovic et al, 2011). 
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Pharmacovigilance 
Pharmacovigilance is the science and activities relating to the detection, assessment, 
understanding and prevention of adverse drug reactions and of any other drug-related 
problem (WHO, 2002). 
At the time a drug is licensed, information about its ADRs is limited (Lasser et al, 2002). 
Some ADRs are difficult to detect during the clinical research phases prior to 
commercialization, namely ADRs of low incidence or ADRs that occur several years 
after administration. This may also be due to the fact that pre-marketing trials are 
often underpowered, have limited follow-up or that drug information sent from 
companies to health authorities might sometimes be incomplete (Psaty et al, 2004; 
Ioannidis and Lau, 2001; Ahmed, 2003). 
In figure I2 we depict the four stages of clinical trials, in which ADRs of a drug can be 
detected, before and after a drug commercialization. In Phase 1 trials, researchers test 
an experimental drug or treatment in a small group of volunteers (20-80) for the first 
time, to evaluate its general safety. In Phase 2 trials, the experimental study drug is 
administered to a larger group of people (100-300) to see if it is effective and to 
further evaluate its safety. In Phase 3 trials, the experimental study drug is 
administered to large groups of people (1000-3000) under strict inclusion criteria to 
confirm its effectiveness, to identify further ADRs, to compare it to commonly used 
treatments and to collect information that will allow the experimental drug or 
treatment to be used safely. In Phase 4 trials, postmarketing trials identify additional 
information such as rare or late-effect ADRs. The pyramid (figure I2) represents the 
increasing number of patients throughout the different trial phases.  
After the drug approval, not only postmarketing trials but also postmarketing 
observational studies can be performed to identify ADRs. 
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Figure I2. Trial phases and possibilities for ADR detection. 
 
Several drugs have been withdrawn from the market in the last decade after being 
approved by competent health authorities, such as rofecoxib, that has caused 100000 
cardiovascular events in the US before the market withdrawal (Gudbjornsson 2010), 
among other examples (Graham et al, 2010; Giles et al, 2004) that we depict in Table 
I1. These examples demonstrate the importance of postmarketing surveillance. 
 
 
Table I1. Drugs recently withdrawn from the market. This table mentions some examples of drugs recently 
withdrawn from the market after previous approval by competent authorities. Adapted from: 
http://en.wikipedia.org/wiki/List_of_withdrawn_drugs (Accessed December 2013). 
 
 
 
Drug Year Reason 
Rosiglitazone 
(antidiabetic) 
2010 Withdrawn in Europe  because of increased risk of heart attacks and death. Utilized in the US 
with some restrictions (Graham et al, 2010) 
Gemtuzumab 
ozogamicin 
2010 This monoclonal antibody was used to treat acute myelogenous leukemia from 2000-2010. It was 
withdrawn from market in June 2010, years after a clinical trial showed the drug increased 
patient death and added no benefit over conventional cancer therapies (Giles et al, 2004). 
Sibutramine 2010 This weight-loss drug was withdrawn in the US because of an increase of cardiovascular events. It 
has not been withdrawn in all countries, but a recent systematic review has shown increase in 
cardiovascular risk (Zhou et al, 2012) 
Rofecoxib 2004 Risk of increased cardiovascular events such as myocardial infarction (Gudbjornsson 2010) 
Co-proxamol 2004 This analgesic was removed due to risk of death in overdoses (Hawton et al, 2009) 
I. INTRODUCTION 
 
| 7 
 
Pharmacovigilance - state of the art 
The World Health Organization (WHO) has built an International Drug Monitoring 
Program, that incorporated adverse events' information derived from State Members 
later in 1971. The number of State Members continuously continues to rise, as shown 
in figure I3.  
 
 
 
Figure I3. State members involved in the International Drug Monitoring by WHO in 2010. 
http://www.who.int/medicines/areas/quality_safety/safety_efficacy/en/index.html. 
(used with written permission from WHO) 
 
 
The Program for International Drug Monitoring relies on spontaneous reports from 
more than 100 countries including Portugal, and builds a global database to identify 
possible relationships between the use of a drug and adverse effects and ADRs. 
Whenever a report of a suspect ADR arises, its data is shared through every State 
Member. Also, the majority of countries have a National Health Drug Regulatory 
Agency. Portuguese Drug Regulatory Authority is INFARMED (INFARMED, 2012). 
However, these agencies rely mainly on spontaneous reporting (WHO, 2005; 
INFARMED, 2012), largely underestimating the real number of ADRs (as will be 
described below). In summary, National and International Drug Regulatory Agencies 
currently use spontaneous reporting as a continuous Pharmacovigilance method. 
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Adverse drug reactions in Ophthalmology 
Ophthalmology is perhaps one of the medical specialties in which there are the fewest 
assessed ADRs, representing a particular challenge in Pharmacovigilance (Fraunfelder 
2007).  
 
The eye is a complex organ in which minimal impairment can produce a substantial 
functional effect (American Academy of Ophthalmology, 2012). Ophthalmic ADRs are 
usually not continuously detected, although they might be either frequent or specific 
of a drug or drug group, such as acute angle-closure glaucoma and myopic shift caused 
by topiramate (Luykx et al, 2009), cataracts caused by corticosteroids (Fel et al, 2012), 
floppy iris syndrome caused by tamsulosine (Abdel-Aziz and Mamalis, 2009) and uveitis 
caused by rifabutin (Cano-Parra and Díaz-Llopis, 2005). Some ADRs are rare but can 
cause irreversible blindness, such as in optic atrophy caused by ethambutol (Carelli et 
al, 2002), while others are extremely frequent but usually harmful, namely cornea 
verticillata caused by amiodarone (Hollander et al, 2004).  
There are reports that suggest specific ophthalmic ADRs caused by a systemic drug, but 
unsupported because no systematic review has been performed. Also, the frequency 
of ophthalmic ADRs is not known. 
In conclusion, ophthalmic ADRs are a heterogeneous group of ADRs that lack 
assessment and systematization. 
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 RATIONALE: METHODOLOGICAL ISSUES IN THE DETECTION OF ADRS 
 
General methodological issues in the detection of ADRs 
The methodologies of ADR detection and monitoring vary widely and are one of the 
heterogeneity sources found in systematic reviews about ADRs. 
The main methods include (Davies et al, 2007): 
1. Spontaneous reporting (in which a health team member reports a presumable 
ADR) is the main Pharmacovigilance method used in Europe, since it is cheap; 
however underreporting (Figueiras et al, 2006; Herdeiro et al, 2008) is a problem. 
2. Administrative databases. Recurring to national databases is not a widely used 
method for ADR detection, but it may have some advantages, like low cost and the 
possibility of a national perspective (Salmerón-García et al, 2010). 
3. Chart review (prospective or retrospective) is a reasonable methodology for ADR 
(Mullins et al, 2011), however it is also resource and time consuming (Thomas and 
Brennan, 2000). 
4. Computerized systems include all methods in which a computerized hospital 
system generates ADR alerts in several groups of patients, later validated by an 
expert team (Tinoco et al, 2011; Kane-Gill et al, 2011). This is an evolving and 
interesting method of Pharmacovigilance, but attention is needed to build rules 
and algorithms with high specificity (too many ADR alerts with little specificity 
consume time in ADR validation and make it unpractical). 
5. Intensive monitoring is the gold standard, in which an expert team prospectively 
examines a cohort of patients (recurring to chart review, patient examination and 
medical team interview) and applies strict criteria to identify and classify ADRs. 
However, this method is extremely resource and time consuming (Pourseyed et al, 
2009), making it unpractical to perform regularly. 
6. Prospective monitoring is a monitoring similar to intensive monitoring but less 
rigorously (Fattinger et al, 2000). 
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7. Trials are usually used for the identification of ADRs caused by a particular drug. 
Trials are increasingly being used for assessing ADRs as an essential component of 
a drug evaluation (de Vries and van Roon, 2010). 
 
These methodologies are different although not necessarily mutually exclusive (for 
example, intensive monitoring can and should include chart review and prospective 
monitoring), and each of which presents its own advantages and disadvantages. 
In this thesis, we have explored 4 methodologies for ADR detection: spontaneous 
reporting, administrative databases, manual chart review and computer-assisted chart 
review. However, since the original work of new methodologies' development was 
performed solely regarding administrative databases and computerized systems, we 
will assess in the Introduction both the spontaneous reporting and the manual chart 
review. 
 
 
1. Spontaneous reporting 
In Portugal, the National System of Pharmacovigilance was created in 1992 after the 
adhesion of Portugal to the European Union. This system has a network of connections 
and functions, as illustrated in figure I4. 
 
 
 
Figure I4. Portuguese National System of Pharmacovigilance and respective connections with 
International Pharmacovigilance Systems.  Adapted with permission from: 
http://www.infarmed.pt/portal/page/portal/SOBRE_O_INFARMED/ESTRUTURA_E_ORGANIZACAO. 
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The Portuguese National System of Pharmacovigilance is articulated with the European 
System of Pharmacovigilance, which includes: the Committee for Proprietary Medicinal 
Products (CPMP) of European Agency for Evaluation of Medicinal Products (EMEA) and 
the respective Pharmacovigilance group (Pharmacovigilance working party - PhVWP). 
INFARMED is also articulated with the WHO International Drug Monitoring, as it is one 
of its state members who share ADR information, relying particularly in the utilization 
of spontaneous reports. 
The Portuguese National System of Pharmacovigilance relies mainly on spontaneous 
reports of ADRs, by health professionals. The "Yellow Card", a spontaneous reporting 
form used in England was adapted to the Portuguese National Pharmacovigilance 
System in 1992 for reporting of ADRs, as shown in figure I5.  
 
 
 
 
Figure I5. Portuguese Report Forms for Notifying a possible ADR. The Yellow Form is destined to 
physicians, the purple form to pharmacists and the white form to nurses. (Adapted from: 
http://www.infarmed.pt/portal/page/portal/INFARMED/PUBLICACOES/TEMATICOS/SAIBA_MAIS_SOBR
E/SAIBA_MAIS_ARQUIVO/Farmacovigil%E2ncia.pdf, in INFARMED's site, reproduced with permission). 
 
 
Spontaneous reporting in Portugal 
We have searched through the trends in spontaneous reporting in Portugal in the last 
years: from 1992, we can identify an increase in the number of reports, with 2696 
reports in Portugal in 2011 (figure I6). In figure I7, those reports are classified 
according to origin (there is a trend of increase in the number of reports performed by 
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Pharmaceutical Industries). However, the spontaneous reporting rate could still be 
markedly improved. 
 
 
 
Figure I6. Number of spontaneous reports received by the Portuguese Pharmacovigilance System. 
Data kindly provided by INFARMED. 
 
 
 
 
Figure I7. Number of spontaneous reports according to origin. Data kindly provided by INFARMED. 
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Methodological issues of spontaneous reporting 
In spite of being the most commonly used method for Pharmacovigilance due to its 
reduced costs, there are several limitations to spontaneous reporting: underreporting, 
heterogeneous report quality and risk of bias.  
Underreporting is the main limitation: several studies have estimated that 
spontaneous reporting only detects 5-10% of ADRs (McGettigan et al, 1997; Smith et 
al, 1996). Some studies assessed factors associated with underreporting (Herdeiro et 
al, 2004): intrinsic (knowledge, attitudes) and extrinsic (relationship between health 
professionals and their patients, the national health system and pharmaceutical 
companies). An European Survey (Belton, 1997) also identified factors for 
underreporting, such as lack of availability of report forms, lack of information on how 
to report, and not having enough time to report. 
Some studies have demonstrated that spontaneous reporting rate can be increased 
(Biagi et al, 2012; Figueiras et al, 2006), however this effect was temporary. Therefore, 
health professionals that can report ADRs should be subject to continuous education 
on Pharmacovigilance, to maintain an acceptable reporting rate, which has costs.  
Other limitation is the report quality. Since detailed information is required to justify 
the report of a possible ADR, different quality in reporting will result as different skilled 
health professionals assess and write that information. Also, in different countries 
there are different forms, which might result in discrepancy in data captured and 
inappropriate causality assessment (Bandekar et al, 2010). 
The third limitation is methodological bias. This occurs because a simple report may 
have uncontrolled information, which in comparison with namely a trial, is more prone 
to suffer from bias, as suggested by some authors (Pariente et al, 2007). 
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2. Manual chart review 
Manual chart review for ADR detection consists of retrospectively or prospectively 
reviewing patient charts to identify ADRs, generally performed by one or two experts 
in ADRs, that latter assess concordance for verification of ADRs (Mullins et al, 2011; 
Thomas and Brennan, 2000; Tinoco et al, 2011). Specific, strict and objective guidelines 
are recommended for this assessment (Loke et al, 2007; Cornelius et al, 2009; 
McIntosh et al, 2004), namely the use of a definition of ADR (usually WHO definition) 
and causality assessment of ADRs. Causality assessment criteria are objective criteria 
used to determine the probability that a possible ADR might correspond to a real ADR. 
The most used causality criteria for an ADR are from Naranjo et al (1981) and WHO 
(2005). 
Two chart reviews were performed in this thesis: the first chart review was performed 
for comparison with database methodology in simple detection of ADRs, and the 
second chart review was performed for comparison with a computerized methodology 
and for deep characterization of ADRs. Respective methodologies and results will be 
discussed with detail in chapter IV and in appendices 2 and 4.  
 
Methodological issues of chart review 
Manual chart review has good detection rates and is considered by some (Tinoco et al,  
2011) as the "gold standard" to identify adverse drug reactions in healthcare 
organizations (although many other authors consider that the "gold standard" for ADR 
detection is intensive monitoring (Forster et al, 2012)), but it is time and personnel 
costly: some studies estimated a cost of 55 person-hours per week (Jha et al, 1998). 
For example, our first general chart review detected a prevalence of 9% ADRs with a 
cost of 35 person-hours (Miguel et al, 2013a; appendix 2). Our second chart review, 
more detailed to further characterize ADRs, unfortunately obtained a similar 
prevalence of ADRs, 10.2%, at a much higher cost: 69 person-hours (Miguel et al, 
2013c; appendix 4). 
Other limitations of chart review include the methodological heterogeneity between 
the different studies (Davies et al, 2007), namely because of the use of different 
definitions of ADR, the use of different causality assessment for ADRs, prospective or 
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retrospective design of study (and different time of data collection), and the use of 
different number of sources for detection of ADRs: some just search through patient 
charts (Bates et al, 1993), while others also interview health team whenever doubts 
arise (Somers et al, 2003). 
Additionally, the quality of records in different hospitals can vary, generating 
differences in the detection of ADRs through chart review (Davies et al, 2007; Cassidy 
et al, 2002; Localio and Landis, 1995), further adding heterogeneity. 
Consequently, there is a need to develop a methodology to reduce the costs of chart 
review. A computerized approach with high level of automation and integration is not 
yet possible to develop in Portugal, considering that in several portuguese hospitals 
the patient data is not entirely computerized. Therefore, the development of a 
computerized-assisted chart review methodology can be an interesting alternative for 
the detection of ADRs. 
  
 
 
Aim 
Due to the limitations of spontaneous reporting, the high cost of intensive monitoring, 
the fact that in Portugal there are no real, complete and continuous data about ADRs 
that occur during hospitalization, and the particular scientific challenges of ophthalmic 
ADRs were the motivations of this thesis. This general scope can be described in the 
research questions, in the next chapter. 
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1.  
What is known about the frequency of ADRs in hospitalized patients?  
 
 
 
 
 
2.  
What methodologies can be explored for the detection of ADRs besides spontaneous 
reporting?  
        2.1  Can a methodology based on hospital databases be developed, validated for 
detection of ADRs and explored regarding methodological issues? 
 2.2  Can the database methodology be used to obtain a nation-wide estimate of 
ADRs in Portugal? 
 2.3  Can a computerized methodology be developed for ADR detection with low 
resources and with a good detection rate? 
 
 
 
 
3.  
How can ocular ADRs be systematized and characterized? 
3.1  What is known about ocular ADRs that occur after systemic medication?  
3.2  Can a nation-wide estimate of the frequency of ocular ADRs be built? 
3.3  Can specific ocular ADRs be characterized?  
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Many different measures of health and disease are used to describe the health of 
populations. In order to characterize ADRs as a Public Health Problem, one must assess 
their frequency. Fundamental measures of disease frequency include prevalence and 
incidence. For the estimate of ADRs in hospitalized patients (ADRIn), we preferred the 
period prevalence or the cumulative incidence (in incidence rate one would need to 
know length of stay for each patient, which is rarely possible to assess). This work led 
to a published article, that is available for further detail in appendix 1. 
 
 
Frequency of ADRs - aspects to clarify 
Types of ADRs according to setting 
ADRs can occur in each and every patient that is taking a drug; therefore, they can 
occur in different clinical scenarios (as illustrated in figure III1): 
 ADRs that occur in the ambulatory setting - a person that takes a drug (either usual 
medication or medication prescribed because of an acute pathology) may have an ADR 
(WHO's definition of ADR assumes that the drug is correctly prescribed and 
administered). At this time, the patient might: 
  ◦ Do nothing, if the ADR is minor and unrecognized (these ADRs are undetected) 
  ◦ Go to the emergency department because of the ADR, consequently being treated 
for the ADR but without the need of being hospitalized (ADRs that are studied in 
emergency departments) 
  ◦  Be hospitalized due to the ADR (ADRs that cause hospital admission - ADRAd) 
 ADRs that occur during hospitalization (ADRIn) - these ADRs generally occur to 
medication administered to a hospitalized patient, in spite of the increased clinical 
surveillance. Hospitalized patients might be at an increased risk of experiencing an 
ADR, because they have significant comorbidities and are exposed to a higher number 
of drugs, among other factors (discussed below). 
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Figure III1. Types of ADRs according to occurrence pattern. ADRs can occur in the ambulatory setting or 
in the hospital. There are two types of hospital ADRs: ADRs that led to admission (but that occurred in 
the ambulatory -ADRAd) and ADRs that occurred during hospitalization (ADRIn). The last group (ADRIn) is 
the one that we aim to study in this chapter. 
 
Lazarou (1998) estimated that serious ADRs that occurred in the hospital setting (both 
ADRIn and ADRAd) had an overall incidence of 6.7% (with a 95% confidence interval of 
5.2%-8.2%), placing fatal ADRs between the fourth and the sixth leading causes of 
death in the US. However, these estimates were criticized because there was 
heterogeneity (Kvasz et al, 2000). There is almost always heterogeneity in systematic 
reviews of studies about ADRs for several reasons, namely different definition of ADR 
in different studies, different settings and different methodologies applied for the 
detection of ADRs. Nevertheless, it is important to try to identify the frequency of 
ADRs and to try to surpass heterogeneity.  
There are several estimates of the frequency of ADRAd, namely the systematic review 
performed by Kongkaew et al (2008): median incidence of 5.3% (interquartile range 
2.7-9.0%), and the prospective study of Pirmohamed et al (2004), that analyzed over 
18000 patients and estimated a mean prevalence of ADRAd of 6.5%.  
Estimates of ambulatory ADRs are scarce. There are, however, some estimates on 
adverse drug events that occur in the ambulatory setting: a recent systematic review 
has estimated that the mean prevalence of ambulatory ADEs in retrospective studies 
was 3.3% (interquartile range 2.3-7.1%) versus 9.6% (interquartile range 3.3-17.3%) in 
prospective studies (Taché et al, 2011). However, ADRs offer some methodological 
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difficulties such as assessing all over-the-counter drugs, estimating the number of 
patients that were administered a drug, and particularly estimating the number of 
patients that were correctly prescribed and administered a drug (such as the definition 
of ADR implies).  
 
Although there are several studies of ADRs that occur during hospitalization (ADRIn), no 
recent and strict systematic review has been performed, therefore there is a need of a 
recent global estimate on the number of ADRIn. 
 
 
Difficulties in building a systematic review about ADRIn 
There are several difficulties in building a good systematic review about ADRs and 
adverse drug events, such as appointed by many authors (Palaian et al, 2006; Lee and 
Thomas, 2002; Cuervo and Clarke, 2003). Some studies have established useful 
recommendations specific for ADRs (Loke et al, 2007; Cornelius et al, 2009; McIntosh 
et al, 2004). There are interesting systematic reviews about ADRs that cause hospital 
admission (ADRAd) (Kongkaew et al, 2008; Howard et al, 2006), however it is still 
lacking in the literature a current and adequately performed systematic review 
regarding the frequency of ADRs occurring during hospitalization (ADRIn). Moreover, in 
systematic reviews of general ADRs there is the need for more complete, thorough and 
meticulous systematic literature search; using a single and standardized definition of 
ADR; and a more thorough  and appropriate heterogeneity analysis. 
 
 
Objectives of the systematic review 
Our primary purpose was to systematically review the literature regarding the 
frequency of ADRIn according to the definition of WHO. Secondary objectives were the 
characterization of ADRs and their identification by each pharmacovigilance method. 
We also aimed to undertake a thorough analysis of the methodological quality of the 
included studies and the evaluation of  factors associated with heterogeneity. 
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Methods 
We performed a systematic review of studies that assessed ADR frequency among 
hospitalized patients after admission, searching through several databases and using 
strict inclusion criteria (Miguel et al, 2012, appendix 1).  
Studies were included if they followed all inclusion criteria listed below:  
1. Prospective studies, that followed hospitalized patients from admission to discharge, 
assessing in all patients the existence of ADRs prior to discharge, and in which 
investigators were able to interview physicians, patients or nurses at least once per 
week. Studies assessing ADRs only at hospital entry or in emergency wards were not 
included.  
2. Studies that previously planned and described a consistent and reproducible 
methodology for ADR detection, later applied to all patients in a standardized manner. 
These methodologies included: 
    2.1. Intensive monitoring applied to all patients. To reduce the high methodological 
variability of studies that claim to perform intensive monitoring, we created strict 
criteria for considering a methodology as intensive monitoring: 
     Monitoring was performed by specialized team member(s) with experience in 
ADR identification. 
     Monitoring included a daily review of the chart, daily visit of the ward and daily 
interview of the patient. If necessary, the patient was examined. 
     Monitoring included an interview of the health care team at least once a week.  
    A daily chart review without patient interview nor examination was not considered 
intensive monitoring (it was considered chart review). 
    2.2. Prospective monitoring applied to all patients. This would include studies in 
which monitoring of patients was performed with assessment of ADRs before 
discharge,  with patient interview or examination or health team interview at least 
weekly, but without fulfilling all the criteria above for intensive monitoring (even if the 
authors called it intensive monitoring). 
    2.3 Prospective chart review applied to all patients, with patient interview or 
examination or health team interview. 
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    2.4 Computerized monitoring if another methodology (chart review, prospective or 
intensive monitoring) was also applied to all patients. Computerized monitoring in 
which only computer alerts were validated were excluded, because it was not a 
methodology equally applied to all patients. 
    2.5 Database search if another methodology (chart review, prospective or intensive 
monitoring) was equally applied to all patients. 
    2.6 Spontaneous or solicited reporting if another methodology (chart review, 
prospective or intensive monitoring) was applied to all patients. 
3. Studies with sufficient data about frequency of ADRs (if a study focused on ADE, it 
needed to have separate data on frequency of ADRs) 
4. Studies of ADRs that occurred during hospitalization (ADRIn). We were not 
interested on ADRs as a cause of hospital admissions (ADRAd). 
5. Studies that used WHO’s definition of ADR (1972). Studies with other similar 
definitions (like Karch and Lasagna, 1975) were included but analyzed separately (in 
order to identify if this added heterogeneity). When studies provided their own 
definition described in detail, we sought inconsistencies with WHO’s definition (if 
inconsistent, they were excluded). When no definition or an imprecise definition was 
reported, we emailed authors. Studies that claimed to assess frequency of ADEs but 
provided WHO’s definition and criteria of ADRs were included (they studied ADRs 
although they inappropriately called them ADEs). Studies with Edwards and Aronson's 
(2000) ADR definition were not included because although it is a good definition, it is 
rather different from WHO's definition. 
We also included studies with different languages (English, Portuguese, Spanish, 
French, German- we hired a translator), any country, any ward (we included pediatric 
wards for a comprehensive view), experimental studies (if any) and year of study 
(although we only included studies after WHO’s definition of 1972). We did so to have 
a more thorough and complete literature search,  and to have the opportunity to 
analyze them as subgroups and identify sources of heterogeneity. 
 
Exclusion criteria were: 
1. Studies including only patients with particular pathologies (we did not exclude 
studies that systematically identified ADRs in particular wards; although we planned 
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to analyze them separately). 2. Studies for specific drug exposures (specific ADRs such 
as bleeding were not excluded per se). 3. Studies in which the primary objective was 
not ADR identification (like trials of drug effectiveness), in order to warrant a 
methodology systematically applied to assess ADRs frequency. 
 
 
Data collection and analysis 
Two independent reviewers, AM and MA, first examined each title and abstract to 
exclude obviously irrelevant reports, and then independently examined each full text 
report, to determine eligibility according to inclusion criteria. 
We performed a pilot test to evaluate the selection procedure and criteria on a 
sample of reports, as recommended by the Cochrane approach (Cochrane, 2008). We 
then performed another pilot test with 100 random studies. We used those tests to 
refine criteria and train reviewers. Disagreements were solved by consensus, recorded 
and analyzed using kappa statistics. 
 
 
Risk of bias assessment 
We also performed 2 pilot studies using a standardized form to evaluate the 
methodological quality of included studies. We did not use scales (discouraged by the 
Cochrane approach) but criteria from Cochrane (2008), STROBE (Vandenbroucke et al, 
2007), QUOROM (Moher et al, 1999) and PRISMA (Moher et al, 2009) adapted to the 
scope of ADRs frequency evaluation, which included:  
• complete description of study design 
• verification if all parts of study were prospective 
• number of hospitals in which study occurred 
• adequate selection criteria 
• definition of ADR 
• rationale for study size 
• causality assessment of ADR 
• avoidability assessment of ADR 
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• description of all statistical methods 
• characterization of study participants and of number of participants at each stage 
• description of methods to prevent information and selection bias 
• intensive monitoring 
• description of methods to avoid other bias 
• presentation of complete summary measures 
The two reviewers independently assessed study quality and risk of bias; 
disagreements were solved by consensus. Studies were divided in low risk of bias (5 or 
less parameters with medium, unclear or high risk of bias), medium risk (6 to 9) and 
high risk (10 or more parameters evaluated as medium, unclear or high risk of bias). 
 
 
Subgroup analyses 
High heterogeneity was expected according to previous studies. Our purpose was to 
identify heterogeneity sources, therefore, several subgroup analyses were planned: 
 
Study location - subgroups based on continent or country 
Methodology for ADR detection - Intensive monitoring; Prospective monitoring; Chart 
review; Computerized monitoring that generated ADR alerts - included only if alerts 
were validated by team and if other methodology was also applied to all patients, such 
as chart review or prospective or intensive monitoring; Database monitoring -included 
only if other concurrent methodology applied to all patients; Spontaneous or solicited 
reporting - included only if other methodology was concurrently used in all patients.  
If several methodologies were concurrently applied in a study, we planned to compare 
them (only if the population was strictly the same). 
Ward type - Internal Medicine, General Surgery, Intensive care unit, Pediatric, 
Geriatric, Obstetric, or other as reported by authors. We registered if the study was 
performed on several wards without specifying number of patients for each, and also if 
ward was not reported. 
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Hospital type - teaching/university versus non teaching hospital - as reported by 
authors (if conflicting or unreported, we searched the internet). 
Risk of bias 
Population - adult Vs pediatric (<18 years) Vs geriatric (>64years) population.  
ADR definition - WHO's strict definition versus Karch and Lasagna's or WHO's 
definition with slight imprecisions in application. 
Study duration  (short follow-up studies<3 months, medium 4 to 11 months, long 
≥12months). 
 
 
Results 
I. Literature search and selection process 
From 4139 studies initially found (corresponding to 2853 distinct studies), 230 were 
selected to obtain full-text and then 22 studies were included (Figure III2 represents 
the flowchart of the literature search).  
 
 
Figure III2. Flowchart of the search strategy. 
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From the 4139 studies found: Pubmed search yielded 1124 results; EMBASE yielded 
653 results; CINAHL 173; Cochrane 7; ISI Conference Proceedings 95; ISI Web of 
Knowledge 573; International Pharmaceutical Abstracts 887; Google Scholar 60; Scirus 
61; NHS economic evaluations database 14; others yielded 492.  
During the first phase, Kappa agreement for study inclusion was 0.77; during the full 
text review, was 0.89 (good agreement). 
 
 
Characteristics of included studies 
From the 22 included studies, there were 18818 hospitalized patients exposed to 
drugs; 2458 of them suffered an ADR while hospitalized;  3553 ADRIn  were identified. 
In table I2, we present the summary characteristics of included studies. 
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Study 
Country 
Hospital 
WardA 
SampleB  
Dura- 
tion 
MethodC 
for ADR 
detection 
ADR incidence D Summary of study Remarks E 
1993 
Bates 
United 
States.1G 
7 wards: 
2Med,2S, 
2Ob,1ICU 
420 p 
1.2m  
P, R, Sl 15 ADR in 15 p  
I=0.0357 
E=0.00901 
Prospective cohort in 7 wards of a tertiary hospital, with 
daily chart review by a nurse and solicited reporting, to 
evaluate incidence and preventability of ADEs 
*ADE study with separate data of frequency of ADRs  
* Doesn't  explicitly report ADRIn but "ADR during hospitalization"  
*2967 patient-days (number of patients with ADR was not explicitly 
stated but possible to calculate) 
1998 
Moore 
France 
1G 
1Med 
329 p  
6 m 
Sl, I 21 ADR in 21 p 
(31ADRT) 
I=0.0638    E=0.01345 
Prospective cohort with intensive surveillance (daily 
monitoring) of all patients consecutively admitted to a 
ward to identify "serious ADRs" (it didn't identify all ADRs)  
* Although they present a definition similar to WHO’s definition of 
ADR, there were imprecisions, like: "involuntary over or underdosing 
were included [as ADR]..." 
*ADR incidence was calculated (modified data for further precision) 
1999 
Gholami 
Iran 
1T 
2 Med 
370p 
10m 
S, I 95ADR in 29p 
(102ADRT) 
I=0.0784   E=0.0140 
Prospective study, randomized sample, with spontaneous 
reporting and intensive monitoring (in which a pharmacist 
daily reviewed patient charts, laboratory data and 
interviewed patient) 
* Randomized sample 
* “ADRs increased an average length of stay in 29.9% of patients” 
* “ADRs were more predictable if the reaction was hematologic” 
1999 
Martíne
z-Mir 
Spain  
1 T 
2 Ped 
409p 
6.7m 
I, S, Sl, C, 
Co, R 
 
56 ADR in 56p 
(112ADRT) 
I=0.137 
E=0.0170 
Prospective study to assess the extent, pattern and profile 
risk for ADRs in hospitalized patients aged 1-24 months. 
Records were screened daily and there was parent 
interview and daily visit wards. 
*Authors specify number of patients exposed to drugs: 409 
* “Consistent relation between nr drugs and cumulative incidence of 
ADR” 
* Children with ADR had longer hospital stay; female had more risk of 
having ADR 
* We excluded 1unlikely ADR reported by authors: modified data 
2000 
Bemt 
Nether-
lands 
2 G 
2 Med 
538p 
2m 
S, Sl, I 
 
248 ADR in149p 
I=0.280 
E=0.0193 
Prospective cohort study in a medical ward in two 
hospitals, to identify ADR and its risk factors, by several 
methods: spontaneous reporting, solicited reporting and 
intensive monitoring by a pharmacist, daily 
*Authors say “adverse drug event” but use WHO’s definition of ADR 
*They present adjusted Odds Ratio(OR)  to: age, sex, nº drugs and 
time of stay 
*Authors propose intensive monitoring if ≥7 drug/ patient  
*Modified data 
2000 
Fattinge
r 
Switzer-
land 
2 T 
2 Med 
3624p  
36 m 
P, R, Co, C 
 
317 ADR in 317p (461 
ADRT) 
I=0.0875 
E=0.00469 
Prospective cohort of two teaching hospitals in which all 
consecutive patients were admitted and data recorded 
(like symptoms, laboratorial data, ICD10 codes) to a 
computerized system generating alerts of ADRs, confirmed 
by a physician. Chart review was performed in all patients; 
intensive monitoring only of ADR alerts. 
*From several data: possibly drug related events, drug related 
disease, unrelated and clinically relevant ADRs, we chose the last. We 
calculated ADRIn from table 2 (text and table had some 
inconsistencies): 461 ADRT  - 144 ADRAd= 317 ADRIn (modified data) 
 * ADR’s definition of Karch and Lasagna; they didn’t exclude all cases 
of involuntary overdosing (and don’t report its number) 
* "Clinically relevant ADRs": not all ADRs were identified. 
2002 
Buajord
et 
Norway 
1T 
1 Ped 
579 p 
5m 
S, Sl, R  
 
407ADR in 161p 
I=0.278 
E=0.0186 
Prospective pediatric ADE study (with daily chart review) 
that includes frequency of ADRs 
 
*Authors specify that all participants are taking drugs 
*Study about ADE that has separate ADR data (however, does not 
specify if they are only referring to ADRIn) 
*Authors call it "intensive" but doesn't match our criteria 
2002 
Weiss 
Germany 
1G 
1Ped 
214p  
8m 
Sl, R, C 
 
64 ADR in 46p [68ADRT] 
 I=0.215   E=0.0281 
An 8-month prospective study in a 10-bed pediatric ward 
using computerized system, chart review weekly and 
solicited reporting to identify ADRs  
*Intensive monitoring was only applied to ADR suspects 
* Modified data to include only ADRIn 
2003 
Egger 
Germany 
1G 
1 Ger 
163 p 
4m 
R, C, P 153 ADR in 99p  
(Computer identified 
64 ADRs) 
I=0.607   E=0.0383 
Prospective monitoring of all patients admitted to a 
geriatric ward to compare the ADR rate predicted by a 
computerized pharmaceutical database to that 
determined by direct observation  
*They didn’t explicitly exclude ADRAd, but studied “ADRs during 
hospitalization” 
* “Computerized drug databases are a useful tool for detecting and 
avoiding ADRs.”   
* Authors report intensive monitoring but it doesn't fulfill our criteria 
of intensive 
2003 
Ramesh 
India 
1T 
3717 p 
7m 
S, Sl, R, P 244 ADR in 138 p (270 
ADRT) 
Spontaneous and solicited notification and chart review of 
all patients from one hospital. Intensive monitoring was 
*Authors say that they used WHO's causality criteria but don’t report 
respective results 
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R I=0.0371    E=0.00310 performed in patients suspects of having an ADR. *Authors don't explicitly state ADRIn, but possible to calculate 
("3.7%"): modified data 
*Ward type not reported 
2003 
Somers 
Belgium 
1T 
1Ger 
56 p (see 
remarks) 
 8m 
P, Sl 
 
21 ADR in 12p I=0.214 
E=0.0548 
Pilot study of all patients admitted to a geriatric ward, 
comparing two methods of ADR identification: prospective 
monitoring (with patient interview at admission by 
pharmacist with standardized forms, and chart review 
3times/week, and discussion with medical team weekly) 
Vs solicited reporting. 
 
* The authors call it spontaneous reporting but describe solicited 
reporting  
* "No formal causality assessment was made..." 
*12 notifications of 168 patients; 32 ADR in 22 patients of 56 
interviewed. We only considered the 56 patients eligible for 
prospective assessment and interview.  
*WHO’s definition of ADR was used but :“this does not exclude that 
some events are categorized as not related to the treatment after 
causality assessment” 
2003 
Vargas 
Spain 
1G 
1ICU  
401 p  
20m 
Sl, I, R 39 ADR in37p 
I=0.0922  E=0.0145 
Patients from a surgical ICU were prospectively followed 
to identify ADR and evaluate their effect on length of stay, 
daily. Authors don't report it but describe intensive 
monitoring. 
*ADR’s definition of Karch& Lasagna (which excludes lack of efficacy, 
unlike WHO’s) 
2005 
Fattahi 
Iran 
1T 
1 Ped 
380p  
5m 
S, Sl, I, R 
 
82 ADR in 40p  
(94 ADRT) 
I=0,105 
E=0,0157 
Prospective study in children < 14 years to identify ADR as 
a cause of admission and ADR that occurred during 
hospitalization (separate data). Intensive monitoring was 
performed with daily evaluation.  
* The incidence calculated by the authors includes nr of participants 
(404) but only 380 patients were exposed to drugs (we used the 
number 380: modified data) 
* "Consistent relationship between number of drugs and number of 
ADR” 
2005 
Haffner 
Germany 
1T 
3 Ped  
703p 
3m 
C, I 
 
124 ADR in 99p 
(101ADRT) 
I=0.141 
E=0.0131 
Prospective study to identify ADR in which 2 methods 
were compared: intensive monitoring(101ADRT) Vs 
automated search (45 ADRT). Children were assessed 
daily(except weekends), there were parent and medical 
team interviews. 
*703 participants for intensive monitoring but only 636 for 
computerized analysis; slightly different follow-up time (45 ADR 
identified by PC): modified data 
*Responded to email with useful data 
*"ADRs occur as frequently in pediatric as in adult patients." 
2006 
Camarg
o 
Brazil 
1T 
5 Med 
333p  
9m 
P, R 119 ADR in 86p 
I=0.258 
E=0.0239 
  
Prospective study (until discharge) with previously trained 
researchers that performed chart review before patient 
discharge (however, patient interview is not reported). 
 
*333 participants, but only “268 were followed until discharge”(losses 
to follow-up) 
*ADR results in table don't match with text; we used data from table 1  
*One of the few studies with a randomized sample and the only 
included study that previously calculated sample size (data collection 
interrupted after an interim analysis) 
*Although authors refer intensive monitoring, it doesn't match our 
criteria 
2006 
Santos 
Brazil 
1G  
1Ped  
265p 
5m 
I, R 47 ADR in 33p 
I=0.124 
E=0.0203 
Prospective study with intensive daily monitoring of a 
pediatric ward (children from 0 to 16 years) with 36 beds 
to identify ADEs. 
 
*Studies ADEs but has separate data for ADRs 
*ADRs were more frequent with more drugs (p<0,081), longer 
hospital stay (p<0,008) and younger age (p<0,020) 
*"265 patients exposed to drugs from 273 participants" 
2006 
Tribiño 
Colombia 
1G 
1Med 
836p 
5m 
S, SI, P, R 268 ADR in 208p 
I=0.249 
E=0.0150 
Prospective monitoring study over 5 month in a medical 
ward to identify ADRs and calculate its costs.  
*Doubtful ADRs were excluded 
*"Solicited reporting, chart review, and patient exam and interview 
when necessary". However, doesn't specify daily patient evaluation 
*Direct costs were calculated from the perspective of the payer; 
calculated range of costs from ADR: USD$ 35011.92 to 45011.94 
2007 
Arulman
i 
India 
1G  
3 wards: 
1med, 1 
S,1ICU 
1682 p 
9m 
P, Sl, R 
 
63 ADR in 63p 
(121ADRT) 
I=0.0375 
E=0.00463 
 
Prospective cohort study of patients admitted to 3 wards, 
using solicited reporting and monitoring to ascertain ADR 
frequency, severity and costs. 
 
* The authors say spontaneous reporting but describe solicited, e.g.: 
“during the ward rounds, these pharmacists encouraged the doctors 
to report suspected ADR” 
*Some sums of results don’t match with the text (e.g. table 1: ADRIn: 
23 male & 43 female; total 64 ADRIn; in text: “63 ADRIn”); we used data 
from the text. 
*"Pharmacists attended ward rounds and [...] encouraged doctors to 
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Table III1. General characteristics on included studies of ADRIn.  
ASecond column: Hospital type: Defines number of hospitals and hospital type: T: teaching or university hospital; G: non teaching hospital (for example, "2T" means 2 teaching hospitals). Wards: Number and type of wards in which 
study occurred. The following abbreviations were used for type of ward: Med: Internal Medicine, S: surgery, ICU: intensive care unit, Ped: pediatric ward, Ger: geriatric ward/unit, Ob: Gynecology/Obstetrics, R: not reported (for 
example, "1Ped" means the study was performed in 1 pediatric ward. 
BThird column. Sample size: number of patients exposed to drugs (p: patients). Duration of study (m: months). 
CFourth column. Method for ADR identification: Every method that authors used for ADR identification is reported, according to our criteria (see text). Abbreviations used: S: spontaneous reporting, Sl: Solicited reporting, I: Intensive 
monitoring, P: prospective monitoring, C: computerized system with investigation of every alert to validate ADR; Co: Codification/codes; R: chart review. 
DFifth column: ADR incidence: Number of ADRs, patients with ADRs, cumulative incidence of ADR and Standard Error are represented. For example: "21 ADR in 21 p (31ADRT). I=0.0639 ; E=0.0135" means that: 21 ADRIn (ADR) were 
identified in 21 patients(p), the number of total ADR (ADRT, which includes ADRIn and ADRAd) was 31, the calculated cumulative incidence of ADRIn(I) was 0.0639 and its Standard Error (E) was 0.0135.  Note: when the number of 
patients is italic underlined, it means that we had to assume number of ADR was equal to number of patients that suffered an ADR, because number of patients with ADRIn was not supplied (just number of ADRIn was reported). 
ERemarks
 
: some authors' remarks for each study are presented. "Modified data" refers to studies in which we didn't use raw data in order to correct inconsistencies or to exclude ADRAd. 
report [...], several forms were designed..."  
2008 
Zopf 
Germany 
2 T 
2 Med 
907 p 
6m 
I, R 566 ADR in 319p 
I=0.352 
E=0.0158 
Cohort of all patients admitted to 2 medical wards in 2 
university hospitals, with intensive monitoring (daily, by a 
trained team of 3 physicians, 1 pharmacologist and 2 
pharmacists) to characterize risk factors associated with 
ADRs after admission 
*Included 26 intoxications diagnosis, which we excluded: modified 
data 
*Slight problems with table sums: “907 patients, from which 480 men 
and 423 women” 
*Doesn’t explicitly exclude ADRAd, although mentions “ADRs following 
admission”.  
*“The predictability of ADR depends on: raised temperature, low 
erythrocytes, low thrombocytes, high number of drugs and female 
sex” 
2009 
Joshua 
India 
1T 
1ICU 
728p 12m P, C 239 ADR in 188p (294 
ADRT ) 
I=0.258 
E=0.0162 
Prospective study of 12 months to identify ADRs in an 
intensive care unit, by a team that accompanied clinicians 
6 days in a week, viewed patients records. They  mention 
intensive monitoring but no patient interview nor 
examination is reported. 
*Nr of comorbidities was higher in patients with ADR: 5,7±1,7 versus 
4,6±1,6(p<0,0001) 
*Authors mention 902 participants but don’t justify why only 
“included 728” 
*Authors wrote “of the 222 patients with ADRs, 188 developed ADRs 
(n=239) during hospital stay”; but in the table:”294 ADRs”; we 
considered the text: modified data 
2009 
Poursey
ed 
Iran 
1T 
1Med  
400  p 
3.75m 
I, R 63 ADR in 40p (47ADRT) 
I=0.100   E=0.0150 
Prospective cohort with intensive monitoring (by a 
pharmacist and a pharmacologist) with two questionnaires 
to characterize ADRs and "all patients [...]were followed 
daily until discharge".  
*Authors exclude: hospital stay <1 day, administrative errors and non 
compliance 
*3276 patient-days were studied 
*Explicitly mention: "patients who did not consume any drugs were 
omitted" 
2009 
Santos 
Brazil   1T 
1Ped  
1764  p 
24m 
R, S 302 ADR in 302p 
I=0.0081  E=0,0045 
Chart review of all patients (children < 16 years) were 
performed 3 times a week. 
*"Pharmacy interns were trained to detect and report suspected 
ADRs, under the supervision of pharmacists" 
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ADR incidence 
The pooled ADR cumulative incidence estimated in the meta-analysis was 16.88% 
(CI95% 13.56,20.21%), however there was heterogeneity: I2=99% (as shown in figure 
III3). 
 
Figure III3. Forest plot. The global forest plot of the meta-analysis is presented. 
 
 
Studies with the highest incidence estimates were: 
 Egger (2003): 60.7% (CI95%: 53.2,68.2). A study from Germany that performed 
prospective monitoring of all patients admitted to a geriatric ward to compare the ADR 
rate predicted by a computerized pharmaceutical database to that determined by 
direct observation. 
 Zopf (2008): 35.2% (CI95%: 32.0,38.3). A Germany cohort of all patients admitted to 2 
medical wards in 2 university hospitals, with intensive monitoring (daily, by a trained 
team of 3 physicians, 1 pharmacologist and 2 pharmacists) to characterize risk factors 
associated with ADRs after admission. 
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Studies with the lowest incidences were:  
 Bates (1993): 3.6% (CI95%: 1.8,5.4). An American prospective cohort in 7 wards of a 
tertiary hospital, with daily chart review by a nurse and solicited reporting, to evaluate 
incidence and preventability of ADEs. 
 Ramesh (2003): 3.7%(CI95%:3.1,4.3). An Indian study in which spontaneous, solicited 
notification and chart review were performed in all hospitalized patients. Intensive 
monitoring was performed only in patients suspects of having an ADR.  
 Arulmani (2006): 3.8% (CI95%: 2.9,4.7). An Indian prospective cohort study of 
patients admitted to 3 wards, using solicited reporting and prospective monitoring to 
ascertain ADR frequency, severity and cost. 
 
 
Subgroup analysis  
The most relevant heterogeneity moderators were 1st: risk of bias, 2nd: population, 3rd: 
ward, 4st: method. We present all of the subgroup analyses' results below (figures III4-
III12).  
III. FREQUENCY OF ADRs IN HOSPITALIZED PATIENTS 
 
| 33 
 
Figure III4. Subgroup analysis based on risk of bias, according to population type (adult Vs 
pediatric). Moderate and high risk of bias studies presented high heterogeneity (I2 = 99%), that did 
not disappear after we adjusted for population age (pediatric versus adult). Low risk of bias studies 
presented low heterogeneity (I2 = 54%) that disappeared when we adjusted for population type 
(I2=0% either in adult or in pediatric group). 
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Figure III5. Subgroup analysis based on study location. There was also heterogeneity (I2≥98%) 
and statistically significant difference between continents (p=0.01). 
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Figure III6. Subgroup analysis of ADR frequency based on wards. There is heterogeneity in all of 
them (I2=99%), slightly smaller in the Pediatric ward (I2=98%). 
 
 
 
Except for the subgroup of risk of bias (adjusted to population), all subgroups 
presented heterogeneity. Studies with low risk of bias, adjusted to population, had no 
statistical heterogeneity (I2=0%): mean incidence of ADRs in low risk of bias studies 
performed in adults was 8.97% (CI95%: 7.33-10.61%) and in children was 
13.18%(CI95%: 10.62-15.73). 
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Figure III7. Subgroup analysis according to method used to detect ADRs. Many studies had more 
than one methodologies but none applied exactly to the same population (not comparable); in that 
case, we attributed to that study the methodology that was more comprehensive. All subgroups 
presented heterogeneity, slightly smaller in intensive monitoring (I2 = 98%), not statistically 
significant (p=0.90). 
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Figure III8. Subgroup analysis according to hospital type. There was heterogeneity in all subgroups. 
 
Figure III9. Subgroup analysis according to population. Every subgroup had heterogeneity (I2=96%-
99%); there was no statistically significant difference between subgroups of population. 
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Figure III10. Subgroup analysis according to study duration. There was heterogeneity in all 
subgroups. 
 
Figure III11. Subgroup analysis according to definition of ADR. Subgroup "Yes" for a strict 
application of WHO's definition of ADR; subgroup "imprecisions" for studies that had slight 
imprecisions for application of ADR definition. There was heterogeneity in both subgroups. 
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Figure III12. Subgroup analysis according to expert that detected ADR: physician, pharmacist, 
nurse or team composed of several different experts. There was heterogeneity in all subgroups, 
slightly smaller in physicians (I2=81%), with statistically significant difference between subgroups 
(p<0.00001). 
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We plotted ADR incidence against study size: smaller studies tended to identify higher 
incidences. Our funnel plot was not completely symmetric (probably because although 
we emailed authors asking for unpublished data, none was supplied). 
 
 
 
Risk of bias assessment 
All studies had low risk of bias in the description of study design, while only one study 
calculated the intended study sample size. Most studies reported strategies to prevent 
selection bias (like strict intensive or prospective monitoring, applied to all patients 
and not just to ADR suspects), but the majority did not report strategies to prevent 
information bias. In figures 21 and 22 we present the summary of our quality 
evaluation of included studies, according to each parameter assessed - risk of bias 
graph and risk of bias summary. 
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Figure III13. Risk of bias summary. Performance of major risk of bias criteria for each study. Green 
circles: low risk of bias. Yellow circles: moderate or unknown risk of bias. Red circles: high risk of bias. 
 
III. FREQUENCY OF ADRs IN HOSPITALIZED PATIENTS 
 
| 42 
 
Figure III14. Risk of bias graph. Summary of global study performance for risk of bias criteria. 
 
 
In summary, from 4139 studies initially found, 22 were included. Our meta-analysis 
indicates that ADRs may occur in 16.9% (CI95%: 13.6, 20.2%) of patients during 
hospitalization; however, this estimate has to be viewed with caution because there 
was significant heterogeneity (I2 = 99%), as expected. The most significant 
moderators of heterogeneity were risk of bias, population, ward, and methodology 
for ADR identification. Low risk of bias studies adjusted for population (pediatric 
versus adult) had I2 = 0%. 
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Table III2. Risk of bias assessment for every quality criteria and for each study 
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1993 
Bates N Y Y Y Y (WHO) 
Y 
(Naran-
jo) 
Y (“4 
point 
scale”) 
U Y N Y Y U U Y U (nurse) U 
1998 
Moore N Y Y U  
U (just 
serious 
ADRs) 
y U N N N Y Y Y Y Y Y U 
1999 
Ghola
mi 
N Y Y Y Y (WHO) 
Y 
(Naran-
jo) 
Y 
(Schu
mock) 
Y Y N Y Y U N U Y Y 
1999 
Martín
ez-Mir 
N Y Y Y Y (WHO) 
Y( 
Spanish 
Drug) 
N Y Y N Y U Y Y Y Y U 
2000 
Bemt Y Y Y Y 
Y (WHO 
definition
) 
U N Y  
Y 
(adjust
ed 
Odds 
Ratio) 
N Y Y N Y Y 
Y 
(pharmaci
st) 
U 
2000 
Fatting
er 
Y Y Y U U:"clinically relevant" 
Y 
(Naranj
o) 
U N N N N Y Y Y Y N N 
2002 
Buajor
det 
N Y Y Y Y N N U U N N N U Y U N (chart review) U 
2002 
Weiss N Y Y Y Y (WHO) 
Y 
(Naranjo 
modified
) 
Y Y N N Y N Y N N N U 
2003 
Egger N Y Y Y Y (WHO) 
Y 
(Schum
ock) 
Y(Nara
njo) U U N U Y U U U N U 
2003 
Rames
h 
N U Y Y Y (WHO) Y (WHO) N N  N  N Y U U U Y N  U 
2003 
Somers N Y Y Y Y Y(WHO) U N U N U Y Y U U N U 
2003 
Vargas N Y Y Y 
U(Karch&
Lasagna) 
Y 
(WHO) Y Y  U N Y Y Y Y Y Y U 
2005 
Fattahi N Y Y Y Y (WHO) 
Y 
(WHO) N Y U N Y U U Y U Y U 
2005 
Haffner N Y Y Y Y (WHO) 
Y 
(WHO) N U U N Y Y Y Y Y Y U 
2006 
Camarg
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N Y Y U Y (WHO) Y(Naranjo) N Y U Y Y Y Y Y U N N 
2006 
Santos N Y Y Y Y (WHO) 
Y 
(WHO) N Y U N Y Y Y Y Y Y U 
2006 
Tribiño N Y Y Y Y (WHO) 
Y 
(Naranj
o) 
N U U N Y Y U Y Y N U 
2007 
Arulma
ni 
N Y Y Y Y WHO) 
Y 
(Naranj
o) 
N Y  U N N U U N Y N U 
2008 
Zopf Y Y Y U 
U (WHO, 
imprecisi
ons) 
Y 
(Naranj
o) 
U Y U N Y U N N Y Y Y 
2009 
Joshua N Y Y Y Y(WHO) Y(WHO) N U U N Y Y U Y Y N U 
2009 
Pourse
yed 
N Y Y Y Y (WHO) Y (WHO) 
Y 
(Schu
mock) 
Y  U  N Y Y Y Y Y Y Y 
2009 
Santos N Y Y Y Y (WHO) 
Y 
(Naranj
o) 
N N N N U Y Y Y N N N 
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Methods for ADR detection 
There are several methods for ADR detection (Davies et al, 2007; Smith et al, 1996), 
namely: spontaneous reporting, administrative databases, chart review, computerized 
systems, cohort monitoring (either prospective or intensive) and trials. Figure IV1 
summarizes them, including the ones that were further characterized in this thesis. 
 
 
 
Figure IV1. Some of the main methods of Pharmacovigilance. Cost increases as detection rate grows, 
making several of these approaches impossible to perform as a continuous Pharmacovigilance method. 
Remark: these costs are merely indicative (for example, a computerized methodology may be less 
expensive than a chart review). Asterisks show the methods that were further explored in this thesis. 
 
We aimed to explore four methodologies for the detection of ADRs: spontaneous 
reporting, database methodologies, chart review and a simple computerized method 
(with low computation resources to maintain respective costs low). Our original work 
of developing new methodologies for the detection of ADRs was based on databases 
and on computer-assisted chart review; we will discuss them in depth in this chapter. 
Also, short considerations about spontaneous reporting (assessed in one of our 
studies, Miguel et al, 2013a: appendix 2) and manual chart review (assessed in two of 
our studies, Miguel et al, 2013a: appendix 2 and Miguel et al, 2013b: appendix 3) will 
be performed in this chapter. 
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Spontaneous reporting 
We searched the spontaneous reporting rate in Portugal in the last decade: we found 
an increase in the number of reports. There is also a trend of increase in the number of 
reports performed by Pharmaceutical Industries. However, the spontaneous reporting 
rate could still be markedly improved. 
The number of National spontaneous notifications of ADRs from 2000 to 2009 was 
13,562, corresponding to a mean prevalence of 0.001% ADRs from hospitalizations 
within that period of time in Portugal (more detailed in appendix 3). Furthermore, 
spontaneous reports that arise from hospitals should be stimulated. 
Therefore, there is a need to develop a methodology that has higher detection rates 
than spontaneous reporting. 
 
Chart review 
Two manual chart reviews were performed: the first chart review was performed for 
comparison with database methodology in simple detection of ADRs, and the second 
chart review was performed for comparison with a computerized methodology and for 
deep characterization of ADRs.   
 
2.1 First chart review - simple detection of ADRs 
Methods 
This work is available in appendix 2 for further detail. A retrospective chart review of 
hospitalized patients in CHUC (Central University Hospital of Coimbra) in 2008 was 
performed for ADR detection (that year was selected for enhanced comparability of 
the database methodology, in which most recent year with complete database 
information available was 2008). The number of person-hours spent in this 
methodology was registered. Several strict criteria were utilized (among other data to 
be filled in a previously built and tested formulary): 
• WHO's definition of ADR (WHO 1972) 
• WHO's causality assessment of ADR (WHO 2005) 
• Schumock and Thornton (1992) preventability assessment 
• Hartwig et al (1992) severity assessment 
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• Rawlins and Thompson (1977) classification of each ADR in: type A (predictable 
ADRs of Augmented effect) or type B (Bizarre unpredictable reactions). 
We previously calculated sample size to independent chart review (95 patients 
necessary) using an online calculator (The Survey System, 2011).  
 
Results 
Of 100 random patients selected, all had prescribed drugs, and 9 suffered an ADR (9% 
of prevalence). Seven ADRs occurred during hospital stay and 2 were present on 
admission. According to WHO's causality assessment (2005), 3 ADRs were classified as 
certain, 3 as probable and 1 as unlikely. Four ADRs were preventable (Schumock and 
Thornton, 1992). Three ADRs were severe (Hartwig et al, 1992), 1 was moderate and 4 
were mild. Eight ADRs were type A and one was type B (Rawlins and Thompson, 1977). 
 
 
2.2 Second chart review - complete characterization of ADRs 
Methods 
This work is available in appendix 4 for further detail. A retrospective descriptive study 
was performed at CHUC, Portugal. From all hospitalized patients in 2010, we selected a 
random sample of 118 patients to perform manual chart review. We followed WHO's 
definition of ADR. From each patient, chart was reviewed, including: discharge note, 
diaries, all drugs administrated, laboratory and coding data, as well as every aspect 
that could constitute a symptom or sign of an ADR, even if not detected previously by 
responsible medical team. For complete validation, all cases were reviewed (not just 
the cases with a computer alert).  
All ADRs were registered, described and classified according to WHO's causality 
assessment, preventability (Schumock and Thornton criteria, 1992) and severity 
(Hartwig et al, 1992). Associated drugs (and all administered) were registered. The 
reviewer also registered if ADR was previously undetected, as well as age, gender, 
ward, hospitalization time. Every relevant clinical information was registered.  
 
 
 
IV. DEVELOPMENT OF NEW METHODOLOGIES IN THE DETECTION OF ADRs 
 
| 48 
 
Results 
Chart review allowed the identification of 12 ADRs in 12 patients, one of them fatal 
(due to infection after the use of chemotherapy). 117 patients were exposed to drugs, 
thus ADR prevalence was 10.2% (12/117). The most frequent ADRs were hyperkalemia 
(16.7% of all ADRs) and warfarin leading to International Normalized Ratio levels that 
led to surgery delay (16.7%).  
Systems more frequently affected were hematologic (33.3%), renal (25%) and 
cardiovascular (16.7%). Drugs more frequently involved were non steroidal anti-
inflammatory drugs (NSAIDs, 25%), antibiotics (16.7%), anticoagulants (16.7%) and 
diuretics (16.7%). 
Five ADRs were preventable (according to Schumock and Thornton classification of 
1992). There were 3 severe ADRs, 5 moderate and 4 mild (Hartwig et al, 1992). 
Patients with ADRs were exposed to a higher number of drugs than patients without 
ADRs (Mann-Whitney test, p=0.001); there was no statistically significant difference in 
age, hospitalization time, number of days in intensive care units, or gender (Fisher's 
exact test). 
 
Our first chart review (simpler and destined to detect ADRs) obtained a prevalence of 
ADRs of 9% and a cost of 35 person-hours. Our second chart review (more complete, 
destined to characterize ADRs and all drugs administered) obtained a prevalence of 
10.2%, at a high cost of 69 person-hours. These data are illustrated in figure IV2. There 
is a need to develop a methodology to reduce manual chart review's resources, 
namely a computerized-assisted chart review.  
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Figure IV2. Chart review results in the detection of ADRs.  
P: prevalence. PH: person-hours spent in each methodology. 
 
In summary, every methodology has its methodological issues: 
Spontaneous reporting is the most used methodology (WHO, 2012; Figueiras et al, 
2006), it is cheap, and is the only Pharmacovigilance method continuously used in the 
majority of countries, being the main support of WHO's International Drug 
Programme. However, it has the smallest detection rate of all methods.  
Databases (either administrative, hospital episodes statistics, or large insurance claims 
data) are not widely used, but they might represent an opportunity (since they contain 
large amounts of patient data). 
Computerized systems may be an interesting method, but attention is needed to build 
rules and algorithms with high specificity to avoid high costs (Ammenwerth et al, 2008; 
Bates et al, 2003). Other problems of this methodology are the dependency of 
structured data, the difficulty with using data from narrative notes and the occasional 
inaccuracy of ADR detection algorithms (Forster et al, 2012).  
The Chart review method (either prospective or retrospective) is interesting, but too 
resource-consuming to be used continuously.  
As for Prospective and Intensive monitoring (intensive monitoring has the largest 
detection rate, being considered by most as the gold standard), their resource costs 
are even higher, making it impossible for continuous use as a Pharmacovigilance 
method. 
Postmarketing trials are seldom used and each of them is too specific for being 
developed as a Pharmacovigilance methodology. 
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In Portugal and in many European countries, spontaneous reporting is the only 
continuously applied Pharmacovigilance method, due to its low cost. Prospective 
monitoring is also frequently performed in several countries in Europe, but not 
continuously. In the United States, computerized methods and the search through 
large insurance databases are widely used, because in the US hospitals almost all 
hospitalization data is already computerized.  
 
The limitations of spontaneous reporting, the high cost of intensive monitoring, the 
economic impossibility to build a computerized system in Portugal and the fact that in 
Portugal and many other countries there are no real and complete data about ADRs 
that occur during hospitalization (ADRIn), were the motivations of this thesis. 
 
 
 
Our purpose was to develop and validate methodologies of ADR detection that could 
highly increase detection rate of ADRs, with a small increase in the resources needed 
to use it. We intended to assess methodological issues in each method, and to identify 
one or several methods that could be used as a continuous Pharmacovigilance 
methodology in Portugal. We also intended to estimate how many ADRs exist in 
Portugal in hospitalized patients.     
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 A) ADMINISTRATIVE DATABASES: VALIDATION STUDY 
 
Rationale for the development of an administrative databases 
methodology 
Although the utilization of databases for ADR detection is not popular, it may have 
advantages if developed and validated as a methodology, such as: information of 
several hospitals, years and countries already available, clinical coding data from which 
signals of ADRs might be extracted, low resources needed and a detection rate 
probably higher than spontaneous reporting.  
Therefore, we aimed to develop a database methodology for ADR detection. First we 
performed a validation study, in which several diagnostic codes available in the 
database were searched, selected and validated after manual chart review to identify 
the codes with highest positive predictive value (PPV). The results of this research can 
be found in appendix 2. Then, a nation-wide study was performed with the validated 
database methodology, to obtain the first portuguese national estimate of frequency 
of ADR that occurred in hospitalized patients (appendix 3). 
 
 
Database methodology -  validation study 
In Portugal the only used Pharmacovigilance methodology is spontaneous reporting. In 
the central hospital selected for the validation study (Central University Hospital of 
Coimbra - CHUC), there are no specific methodologies currently applied for ADR 
detection. There is currently no specific continuous formation for physicians, 
pharmacists or nurses to develop prospective or intensive monitoring for ADR 
detection and characterization on a regular basis. Also, considering the portuguese 
economic crisis, it is not possible at the moment for this hospital to invest in building a 
computerized system for ADR detection or even for adjusting the existing 
computerized systems to prospectively detect ADRs in hospitalized patients. These 
aspects enhance the need of building a database methodology. 
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Methods 
A retrospective study was performed for ADR detection using International 
Classification of Diseases 9th Revision, Clinical Modification (ICD-9-CM) diagnostic 
codes of an administrative database, with all hospitalizations in 2008 from CHUC- 
General Hospital (CHUC-HG), Portugal. This study was performed according to CHUC's 
Ethics Committee. 
We intended to develop a methodology that allowed us to, through CHUC-HG 
database: to identify and characterize ADRs (namely prevalence, clinical 
manifestations associated, drugs more frequently involved and risk factors), to select 
the codes within the database with higher PPV and to validate them by chart review.  
As illustrated in figure IV3, we also aimed to compare our database methodology with 
spontaneous reporting and with chart review. We did so in order to build a 
complementary methodology that could help the Portuguese Pharmacovigilance 
System, without increased costs. 
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Figure IV3. Schematic representation of study design of database methodology validation study 
(appendix 2). First, clinical codes were selected from the CHUC database as potential signals for ADR 
(114 codes were tested) and validated by chart  review to assess which codes corresponded to true 
ADRs (PPV, positive predictive value, was assessed). Then, this methodology was compared to 
spontaneous reporting (originated from CHUC during that period of time) and by independent chart 
review (of a random sample of patients, performed by the authors, in CHUC from the same period of 
time). 
 
 
Selection and validation of clinical codes 
The clinical information in our database used coding based on ICD-9-CM.  
Codes searched included not only E codes (from E930 to E949.9, codes designed to 
mark ADRs, already excluding  wrong doses, errors and intoxications) but also 
diagnostic codes, such as "733.09 - Drug-induced osteoporosis" (as reported in the 
literature or others considered useful). We also tested every diagnosis with the 
expressions: "Due to drugs", "drug-related", "medicamentosa" and "iatrogenic".  
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For validation of potential codes for ADR signals, we selected the E codes and the 40 
diagnostic codes that allowed us to identify more cases of ADR suspects which added 
information relatively to E codes, more specifically, that identified more cases of ADR 
suspects and didn't have an E code (this would be the result of bad coding, since ICD-9-
CM instructs to use an E code with every diagnosis signaling an ADR; we wanted to 
detect it to increase ADR detection and improve coding).  
A chart review was performed to validate ADR signals, using several strict criteria 
(among other data to be filled in a previously built and tested formulary). Each code 
was evaluated independently to calculate its PPV. Afterwards, we intended to select a 
few queries with the highest PPV, to build a methodology with a good global 
performance and easily applicable in other databases, other hospitals and other years. 
 
Comparison with other pharmacovigilance methods 
We compared database performance with spontaneous reporting and chart review (for 
that, a randomized group of 100  patients from the same period and hospital was 
selected for independent chart review). The number of person-hours spent during the 
application of each methodology was assessed. 
 
 
Results 
During the year 2008, there were 13471 hospitalizations in CHUC (10600 patients were 
admitted more than once during that year). Mean participant age was 64 years 
(standard deviation = 19.45). Forty five percent were female.  
E codes generated 283 signals in the database, corresponding to 270 ADRs (in 270 
patients) after validation (PPV=95%). 114 diagnostic codes were tested in the 
database, from which the best 40 codes generated 10752 ADR signals. For those 40 
codes, 356 random ADR signals were validated through chart review, allowing the 
detection of 114 true ADRs with a general PPV of 32.0%.  In table IV1 we represent PPV 
values for each of the 40 tested codes. 
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Table IV1. Validation of codes and respective PPV (positive predictive values). 
 
For a simpler global methodology with higher PPV global value, we selected the 6 
queries (groups of codes) with the best PPV, from which we obtained 371 signals that 
corresponded to 325 true ADRs (global PPV of 87.6%, prevalence of ADRs of 2.41%). 
Diagnostic codes submitted to validation Number of signals Number of signals 
subject to 
validation 
Signals that are 
true ADRs 
Positive 
predictive 
value (%) 
E codes 284 20 (randomly 
selected from the 
284 signals) 
19 95% 
Diagnostic codes Signals without E 
code 
   
Other disorders of pancreatic internal secretion including hypoglycemia 6 6 5 83% 
Other specified aplastic anemias including due to drugs 37 16 random 8 50% 
Sideroblastic anemia including due to drugs and unspecified anemia 639 20 random 1 5% 
Acquired coagulation factor deficiency including due to drugs 6 6 3 50% 
Second thrombocytopenia (including due to drugs) 17 17 6 35% 
Drug induced neutropenia or unspecified 32 10 random 6 60% 
Drug-induced mental disorder 4 4 1 25% 
Transient mental disorders due to conditions classified elsewhere 7 7 1 14.3% 
Secondary Parkinsonism (including due to drugs) 12 12 5 41.7% 
Essential and other specified forms of tremor including due to drugs 12 12 3 25% 
Other cerebellar ataxia including drugs 8 8 1 12.5% 
Iatrogenic pulmonary embolism and  infarction 17 12 random 3 25% 
Phlebitis including due to drugs 41 10 random 2 20% 
Mucositis (ulcerative) due to antineoplastic therapy and other drugs 1 1 0 0% 
Gastric ulcer including due to drugs 74 10 random 4 40% 
Hepatitis, unspecified 46 10 random 6 60% 
Myocardial infarction 100 10 random 2 20% 
Gastrointestinal bleeding, intracerebral hemorrhage 192 10 random 4 40% 
Other musculary disorders including due to drugs 17 10 random 5 50% 
Other anaphylactic shock including drugs 2 2 2 100% 
Shock due to anesthesia 1 1 1 100% 
Hypothermia due to anesthesia 2 2 0 0% 
Clostridium difficile colitis pseudomembranous 22 10 random 3 30% 
Acquired hypothyroidism 96 10 random 2 20% 
Acid base disorders 408 10 random 2 20% 
Volume depletion 547 10 random 0 0% 
Disorders of fluid, electrolyte, and acid-base balance 494 10 random 3 30% 
Anemia unspecified 636 10 random 3 30% 
Eosinophilia 6 6 2 30% 
Congestive heart failure, unspecified 756 10 random 0 0% 
Iatrogenic hypotension 7 7 1 14.3% 
Chronic airway obstruction 98 10 random 1 10% 
Nausea and vomiting 132 10 random 0 0% 
Diarrhea 39 11 random 4 36.4% 
Abdominal pain 91 10 random 0 0% 
Venous thrombosis and embolism including pulmonary embolism 42 10 random 1 10% 
Transfer to special care 1497 10 random 1 10% 
Death 832 10 random 1 10% 
Transfer to another hospital 758 10 random 2 20% 
Total of all queries 10752 signals 356 tested signals 114 true ADRs Global PPV of 
32.0% 
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After validation, this method required only 2 person-hours to identify and register 
ADRs. In table IV2, the database methodology with selected final codes is presented. 
 
Frequency of ADRs Number of Signals Positive predictive 
value (%) 
1) E codes (E930-E949) 284 95% 
2) Diagnostic codes (in database records without E 
code, i.e., without ADR diagnosis) 
Number of signals without 
concomitant  
E code 
Positive predictive 
value % 
Other disorders of pancreatic internal secretion 
(including hypoglycemia) 
6 83% 
Drug induced neutropenia or unspecified  32 60% 
Hepatitis, unspecified 46 60% 
Other anaphylactic shock incl. drugs 2 100% 
Shock due to anesthesia  1 100% 
Full algorithm (1+2) 371 signals 87.6% 
 
Table IV2. Final database methodology. This methodology, designed to have few codes with good 
performances, contains E codes and 5 groups of diagnostic codes and it has a global PPV value of 87.6%. 
 
 
Patients with true ADRs were older and had greater length of stay than patients 
without ADRs (p<0.0001 and p=0.027, respectively). There was no statistically 
significant difference in gender. No other risk factors for ADRs were identified. 
 
 
Comparison of the database methodology with other methodologies 
Seven ADRs were detected through spontaneous reporting from CHUC in 2008 
(prevalence of ADR of 0.0005%). Independent chart review identified 9 ADRs (7 ADRIn 
and 2 ADRAd) from 100 patients exposed to drugs: prevalence of 9%. Only 2 ADRs had 
an E code. Both methodologies are compared in table IV3 in further detail. 
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Methodology Database Chart review 
ADR prevalence 
(nr of ADRs / nr patients 
with drugs) 
2.41% 
(325/13471) 
9% 
(9/100) 
% ADR during 
hospitalization (versus 
present on admission) 
45.82% 77.78% 
Mean person-hours 
required 
2 35 
Mean age (sd) 64 years (sd: 19.45) 60 years (sd: 20.23) 
% female 45.48 % 42% 
Most frequent drug groups 
involved 
1. 5.9% Insulins and 
antidiabetic agents 
2. 2.7% Antineoplastic and 
chemotherapy 
3. 2.7% Anticoagulants 
1. 33.3% NSAIDs 
2. 22.2% Diuretics 
3. 11.1% each: antibiotic,  
anticoagulant, chemotherapy, not 
specified 
 
Most frequent 
manifestations associated 
with ADRs 
1. 2.70% Acute renal failure 
2. 2.70% Hypoglycemia 
3. 2.43% Hepatitis 
All with 11.1%: 
• Hypokalemia 
• Disrhythmias 
• Edema 
• Medulary aplasia 
• Acute renal failure 
• Gastrointestinal 
haemorrhages 
• Altered INR 
• Rash 
• Bronchoespasm 
Table IV3. Comparison of database methodology and manual chart review. Abbreviations: nr=number, 
sd=standard deviation. 
 
Methodological issues in the validation of the database methodology 
Some of the methodological issues of the database methodology can be derived from 
its comparison with other methodologies, as illustrated in figure IV4:  
 
 
Figure IV4. Results of the comparison between database methodology, chart review and spontaneous 
reporting. PH: number of person-hours spent in each methodology. 
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This database methodology has interesting strengths in comparison with other studies 
that assessed ADRs in databases, such as: the fact that it identifies ADR signals beyond 
E codes (unlike Salmerón-García, 2010), it was validated by chart review of more than 
350 signals, it identified queries that added information to E codes to complement 
them. The resources required (2 person-hours) were very small, allowing for a 
continuous application in Pharmacovigilance. It also had good a detection rate, 
obtaining an ADR prevalence more than 4500 times higher than the prevalence of ADR 
identified by spontaneous reports in that hospital. 
On the other hand, there are limitations in the database methodology, such as: 
probable incomplete and wrong information that might occur in every databases, 
coding bias and the fact that it has a one hospital centered validation study. We chose 
the codes that best describe this hospital's reality, but other hospitals and countries 
might allow the selection of different codes. Indeed, it may be very interesting to 
retest all codes in other hospitals, populations, years and countries, to understand, on 
the one hand, which are the most universal codes, and on the other hand,  which occur 
more in one country, or in one hospital type, or in a particular population. We are at 
the moment performing another database validation study in an university hospital, 
Hospital São João, to identify differences in the selected codes. 
In conclusion, the database methodology has detection rates much higher than 
spontaneous reporting with an acceptable cost for continuous monitoring (much lower 
costs than chart review). 
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 B) ADMINISTRATIVE DATABASES: NATION-WIDE STUDY 
 
Rationale for a nation-wide study 
After the development and validation of a database methodology with acceptable 
detection rates and costs (appendix 2), we intended use it to build the first national 
portuguese estimate of ADRs in hospitalized patients (available in appendix 3), in an 
attempt to complement spontaneous reporting and to help the Portuguese 
Pharmacovigilance System. 
 
 
Methods 
A retrospective study was performed for ADR identification using Hospital Episodes 
Statistics databases with information from all hospitals in Portugal, from 2000 to 2009, 
obtained from our National Health Department. These databases contained 
information on encrypted patient identification, episode number and process, and also 
information on age, sex, date of admission, date of discharge, ward(s), hospital 
attended (public, private), area of healthcare, district, outcome (death, discharge, 
transfer), payment data and International Classification of Diseases 9th Revision - 
Clinical Modification (ICD-9-CM) codes for: diagnoses (main diagnosis, other diagnosis 
up to 20), procedures (up to 20) and external causes (up to 20). Patient population 
included all patients hospitalized in public hospitals in Portugal, from 2000 to 2009 (we 
excluded ambulatory patients). Only data of the first semester of 2009 was available.  
We searched E codes (from E930 to E949.9) and 5 groups of diagnostic codes selected 
in our validation study (table 5): disorders of pancreatic secretion, drug-induced or 
unspecified neutropenia, hepatitis unspecified, other anaphylactic shock including 
drugs and shock due to anesthesia. We excluded repeated cases basing on episode 
number, hospital, birthday date, sex, year, ward and hospitalization date and hour.  
Statistical analyses were done with the Chi-square test for categorical variables, 
Student's t-test for normally distributed continuous variables and Mann-Whitney or 
Kruskal-Wallis for variables without normal distribution, using SPSS v20. The a priori 
level of significance was p<0.05. 
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Our main outcome was ADR detection. Secondary outcomes were: ADR related to 
admission (ADRAd) versus ADR during hospitalization period (ADRIn), age, gender, 
admission diagnosis, other diagnoses, hospital stay and year (2000 to 2009).  
We also aimed to assess trends in ADRs from 2000 to 2009 as detected by database 
methodology and to compare it to trends detected by spontaneous reporting within 
that period of time. 
 
 
Results 
Study population 
From 2000 to the first half of 2009, there were 9271122 hospitalizations. The mean 
age of hospitalized patients was 46 years (standard deviation of 28) and 56% of the 
patients were female. 4.4% of the hospitalizations were associated with death of the 
patient. Mean hospitalization period was 7.1 days (standard deviation of 3.2). 
 
ADRs detected by the database methodology 
From 2000 to 2008, there was a slight increase in number of hospitalizations in 
Portugal (in 2009, data refer only to first semester). 116720 ADRs were detected from 
2000-2009, with a mean prevalence of 1.26%. There was a trend of increase in number 
of ADRs (in 2000 there were 8301 signals while in 2008 there were 14352 signals). 
2.7% of the ADRs were associated with admission (ADRAd); 97.3% occurred during 
hospitalization (ADRIn). ADRs and respective signals are identified in table IV4. 
 
Adverse drug 
reactions 
Value          
Mean age 60 23.4 standard deviation (sd)      
Female Gender  63186 (54.1%)         
Death 10650 (8.8%)         
Mean hospital 
stay (days) 
13.7 22 sd         
Years 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Number of ADRs 8301 8769 10602 12371 12918 13444 13778 14744 14352 7440 
Prevalence(%) 0.82% 0.91% 1.1% 1.25% 1.31% 1.33% 1.41% 1.53% 1.49% 1.50% 
       
Alert type E code 
 
Hypoglycemia Neutropenia Hepatitis Anaphylactic 
shock 
Shock due to 
anesthesia 
 90260 6684 17036 606 2133 1 
Table IV4. Characterization of ADRs in hospitalized patients in Portugal from 2000-2009: database 
methodology. 
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ADRs detected by spontaneous reporting 
The number of National spontaneous notifications of ADRs from 2000 to 2009 was 
13562, corresponding to a mean prevalence of ADRs of 0.1%. Notice that the 
Portuguese National Pharmacovigilance department did not specify the number of 
spontaneous reports originating from the ambulatory setting versus hospitalizations 
(the number of reports originating just from hospitalizations is smaller than these 
estimates). 
 
In figure IV5, we illustrate trends of hospitalization and ADRs throughout time. 
 
Figure IV5. Comparison of number of hospitalizations and detection of adverse drug reactions 
through databases and spontaneous reports. Notifications refer to spontaneous reports.  
Notice that 2009 refers only to the first semester of 2009 (data of second semester not available). 
 
 
 
Risk factors of ADRs 
In comparison with patients that did not suffer from an ADR, patients with ADRs were: 
older (p<0.001, Mann-Whitney test), had longer mean hospitalization period (p<0.001, 
Mann-Whitney test), more frequently of the female gender (p<0.0002, Fisher's exact 
test) and had a higher risk of death (p<0.001, Fisher's exact test).  
We additionally verified that several comorbidities (identified also through the use of 
diagnostic codes) were associated with a higher risk of developing an ADR: heart 
failure (p<0.0001, Fisher's exact test), septicemia (p<0.0001, Fisher's exact test), 
dysrhythmias (p<0.0001, Fisher's exact test), hypotension (p<0.0001, Fisher's exact 
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test), cerebrovascular disease (p<0.0001, Fisher's exact test), stroke (p=0.0000045, 
Fisher's exact test), diabetes (p<0.0001, Fisher's exact test), ischemic heart disease 
(p<0.0001, Fisher's exact test), malignancies (p<0.0001, Fisher's exact test) and 
pneumonia (p=0.0000026, Fisher's exact test). 
 
 
Main results of the nation-wide estimate of ADRs 
In summary, in Portugal from 2000 to 2009 there were 9,271,122 hospitalizations, with 
116720 hospital ADRs detected by the database methodology (prevalence of 1.26%; 
97.3% of the ADRs were ADRIn). There were 13,562 spontaneous reports of ADRs 
(ambulatory and hospital) from 2000 to 2009 in Portugal (prevalence of 0.1%). The 
number of hospitalizations is increasing, such as the number and prevalence of ADRs 
throughout time. 
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 C) COMPUTERIZED-ASSISTED CHART REVIEW 
 
Rationale for the development of a computerized-assisted chart review 
Computerized surveillance is increasingly appealing (Hassan et al, 2010). Many 
different strategies of computerized Pharmacovigilance were assessed in a recent 
systematic review (Forster et al, 2012), with different levels of complexity in 
implementation and integration, and consequently with a variety of costs in 
acquisition and maintenance.  
Computerized methods are frequently used in US hospitals, in which almost all clinical 
data is already computerized and structured. However, in portuguese and several 
other countries, clinical data in hospitals is not entirely computerized, and it would be 
economically impossible (and not cost-effective) to build a computerized system for 
ADR detection with high level of automation and complexity from unstructured data. 
Therefore, our purpose was to design and validate a simple computerized 
methodology of ADR detection that could assist manual chart review, simultaneously 
increasing detection and decreasing associated costs while allowing for a gold standard 
methodology to be routinely used. Since we live in an era of social and economic crisis, 
we intended to build a program that would have nearly zero costs of implementation 
and maintenance, and that did not require health system integration. We also 
intended to validate and compare this system with manual chart review. 
 
Methods 
In appendix 4, the scientific paper resulting from this research can be found. 
Study setting 
We selected a random sample of 118 hospitalizations in 2010 from CHUC to perform 
manual chart review and computerized assessment, independently, to validate our 
methodology and to compare: number and types of ADRs identified, risk factors for 
ADRs, and time spent in each methodology. The study was approved by hospital's 
institutional review board. 
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Definition of ADR 
World Health Organization's definition of an ADR was applied. Previous works utilized 
computerized systems to identify adverse drug events (Kilbridge et al, 2009; Wolfstadt 
et al, 2008; Bates et al, 1995), but we aimed to assess specifically ADRs. The main 
outcomes measured were the ADR computer-detected and the ADR computer-
undetected.  
 
Comparison with chart review 
Independent chart review was performed for each patient (as described above). 
 
Development of a computerized system - Chart Helper 
Considering the need of a costless computerized system, we built a program that did 
not require Health system integration. The main difficulty was to build manually 
databases with drug information in portuguese, since there were none available in our 
country that linked adverse drug reactions, their symptoms and signs to each drug. We 
used the Hospital Formulary (INFARMED 2009) and the official list of portuguese 
ambulatory drugs, available in the site of INFARMED (2012), the Portuguese regulatory 
authority of drugs, to build a database with all drugs available in Portugal. We then 
built an ADR database with the 10 more frequent ADRs, all ADRs that were potentially 
fatal for each drug, and other clinically relevant ADRs for each drug according to 
INFARMED and Meyler's side effects of Drugs book (Aronson, 2006). We also added to 
that database: the symptoms of each ADR, signs, laboratorial alterations, diagnosis and 
compatible coding information (for that, we used also International Classification of 
Diseases 9th Revision, Clinical Modification: ICD-9-CM. 
We built a program, Chart Helper, with Visual Studio 2010, aiming for a simple and 
user-friendly interface with the reviewer. For each patient, the chart reviewer 
registered age, gender, chart number, hospitalization and discharge dates (duration of 
hospital stay was automatically calculated), and diagnosis and procedures codes (from 
ICD-9-CM). 
All drugs administered during hospitalization were also selected from a list by the 
reviewer, as well as relevant symptoms, signs and laboratorial alterations. The 
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program used these input data, our ADR databases and some algorithms to generate 
two types of results: 
1. Suggested ADR(s) for that patient. The program detected if a symptom, sign, 
diagnostic code or laboratorial alteration that the patient had, was compatible with an 
ADR of any of the drugs administered to him. Respective drug, ADR and alert were 
specified by program and then the reviewer would classify each ADR according to 
WHO's causality assessment (inserted in the program): certain, probable/likely, 
possible, conditional/unclassified, inaccessible /unclassifiable. 
2. Frequent ADRs for each drug. For each drug administered to that patient, a list of 
frequent (and of fatal) ADRs was available for consultation by the reviewer. Therefore, 
this memory support tool would allow less experienced reviewers to pay more 
attention to certain signs and symptoms throughout the chart that could indicate an 
undiagnosed ADR of a drug administered to that patient.  
 
 
All data (input and result data) were automatically stored in a database by Chart 
Helper for further analysis. Conditional and unlikely ADRs were excluded from our 
analysis (but also automatically registered in the database). 
 
Statistical analysis 
Statistical analyses were done with the Chi-square test for categorical variables (or 
Fisher's exact test whenever possible), Student's t-test for normally distributed 
continuous variables and Mann-Whitney or Kruskal-Wallis when dealing with variables 
without normal distribution, using SPSS v20. The a priori level of significance for all 
comparisons was P<0.05. 
 
Results 
Characteristics of participants 
From the random sample of 118 patients hospitalized in 2010, mean participant age 
was 60 years. 40.7% were female. Table IV5 describes socio-demographic participants' 
characteristics. 
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Table IV5. Socio-demographic characteristics of participants of the study of computerized 
methodology validation. 
 
 
Util ization of the computerized system for ADR detection 
Program 
Chart helper, the program built, requires that some data is entered as the chart review 
is performed, as detailed previously and illustrated in figure IV6.  
Afterwards, according to each patient, two types of results are generated: list of 
frequent ADRs for drugs administered to each patient (figure IV7) and list of suggested 
ADRs considering that patient's symptoms, laboratorial alterations, diagnoses, drugs 
and other factors (figure IV8). 
 
 
 
Figure IV6. Data to be entered in Chart Helper. 
 
 
 
Characteristics Number Relative 
frequency (%) 
Female gender 48 40.7 % 
Age (sd: standard deviation) Mean: 60 years sd: 20 
Mean number of days hospitalized (sd) 10.1 sd: 20.0 
Mean number of drugs administered per 
patient 
5.2 sd: 3.8 
Wards more frequently occupied   
    Surgery 18 15.2 % 
    Urology 14 11.9 % 
   Medicine 10 8.5 % 
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Figure IV7. Interface of Chart Helper with ADRs according to drug administered. This helps the 
reviewer to assess if there is a symptom or signal of a possible ADR that was not previously detected. 
 
 
 
 
Figure IV8. Interface of Chart Helper with suggested ADRs for that particular patient. Possible ADRs are 
suggested according to symptoms, laboratorial alterations, drugs and coding data (rectangle).  
The reviewer must then perform for each of those suggestions a WHO causality assessment (arrow). 
 
 
ADR detection 
Sixty-five ADRs (unlikely ADRs were excluded, as recommended in ADR studies) were 
identified by computerized system in 29 patients, leading to a prevalence of ADRs of 
24.8% (29/117; there were 117 patients exposed to drugs) and including 17 ADRs 
certain or probable (prevalence of 14.5%).  
Two ADRs were undetected by computer (both with warfarin leading to INR levels that 
caused surgery delay). On the other hand, 53 ADRs were only detected by 
computerized system (manual chart review did not detect them). 
The most frequent ADRs detected by computer were laboratorial alterations (24.3% of 
ADRs), agitation (14.6%) and diarrhea or constipation (13.8%). Systems more 
frequently affected were: hematologic (31.7%), gastrointestinal (26.0%) and renal 
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(16.2%). The drugs more frequently involved were: NSAIDs (15.5%), antihypertensives 
(14.6%) and antidepressants or antianxiety agents (14.6%).  
 
 
Comparison of methodologies: manual versus computerized chart 
review 
Table IV6 presents the comparison between manual chart review and computerized 
methodology. Computer-assisted chart review detected the double of ADRs with half 
the resources needed by manual chart review. 
 
 Manual chart  review Computerized method 
Total number of ADRs (excluding "unlikely") 12 65 
Patients with ADR 12 29 
ADR prevalence 10.2% 24.8% 
Total number of person-hours spent (in 118 cases) 
69 (mean of 35 
minutes per patient) 
29.5 (mean of 15 minutes 
per patient) 
Fatal ADRs 1 1 
ADRs previously diagnosed in clinical history 3 3 
ADRs previously coded (E code) 1 1 
Number of adverse events (including ADR) 24 77 
Number of ADR associated with admission versus ADR 
that occurred during hospitalization 
2 vs 10 2 vs 63 
WHO's causality assessment   
Certain 4 7 
Probable / likely 5 15 
Possible 3 43 
Unlikely or conditional/unclassified or inaccessible 
/unclassifiable 
0 31 
Table IV6. Comparison of manual and computerized chart review. 
 
Methodological issues of computerized chart review 
This methodology has a remarkable detection rate (prevalence of ADRs identified of 
24.8%) with low resources needed (a mean of 15 minutes per patient), much lower 
than manual chart review, allowing the application of this method as a continuous 
method of Pharmacovigilance, unlike manual chart review. This program provides a list 
of ADR for each drug, as a supporting memory tool for inexperienced reviewers. It 
integrates validation and causality assessment during each assessment.  
However, this methodology needs further validation. In spite of being resource-sparing 
because it has a low level of automation, it would be interesting to integrate it in the 
Health System and to add further automation. 
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In summary, Computerized chart review might be an useful Pharmacovigilance 
methodology with a remarkable detection rate and moderate costs. The program 
Chart Helper is also promising. 
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Ophthalmology represents a challenge in Pharmacovigilance (Fraunfelder 2007), 
considering the heterogeneous number of ADRs that can occur, sometimes years after 
administration of a drug (Hollander and Aldave, 2004), and considering the required 
specific ophthalmological examination for its diagnosis. The anatomy of the ocular 
globe is unique, which causes augmented susceptibility to the occurrence of ADRs. 
 
 
Anatomy of the ocular globe 
The total area of the globe is relatively small compared to the rest of the body. 
Nevertheless, when a drug enters the systemic circulation, it can reach a high 
concentration in ocular tissues through uveal or retinal circulations (American 
Academy of Ophthalmology, 2012; Wren, 2000).  For better understanding of such a 
specific topic, some of the structures of the ocular globe are depicted in figure V1. 
 
 
 
Figure V1. Anatomy of ocular globe and ocular surface. Ocular structures are depicted. 
 
 
The choroid and ciliary body (which belong to the uvea) as well as the sclera have thin, 
fenestrated walls which allow drug molecules to pass. Small, lipid soluble molecules 
may pass freely into the aqueous humor, and can further diffuse into avascular 
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structures such as the lens, cornea, and trabecular meshwork (American Academy of 
Ophthalmology, 2012).  
However, there are barriers that limit access of drugs to intraocular structures, 
namely: the intercellular tight junctions of the corneal epithelium and endothelium 
(which limit anterior access to the interior of the eye and belong to the blood-aqueous 
barrier), the vascular endothelium of the retina (non fenestrated and with tight 
junctions - internal blood-retinal barrier), tight junctions between the retinal pigment 
epithelium (which with the Bruch's membrane consist in the external blood-retinal 
barrier).  
Drug molecules that can enter the intraocular space from the uveal circulation, may 
exit the eye from the Schlemm canal, ciliary body or may diffuse into adjacent 
anatomical structures. Drugs entering from the retinal circulation can reenter the 
systemic circulation, diffuse into the vitreous and anatomical structures, or get actively 
transported out (Wren, 2000). There are three major accumulation sites including the 
cornea, lens and vitreous, but a drug can be deposited in any structure of the eye.  
Therefore, the ability of a drug to overcome ocular barriers determines its probability 
to affect ocular tissues and visual function. 
 
  
Some concepts in Pharmacotherapy in Ophthalmology 
Pharmacogenetics in Ophthalmology 
Pharmacogenetics it the discipline that studies how genetic and heritable factors can 
determine how drugs are chemically metabolized in the body (Pirmohamed et al, 
2011; Davies et al, 2007). Pharmacogenetic causes have also been ascribed to 
variations in response to ophthalmic drugs, such as the increased intraocular pressure 
seen in a segment of the population after prolonged use of topical corticosteroids 
(Danias et al, 2011). 
 
Pharmacokinetics in Ophthalmology 
Pharmacokinetics studies the cycle of a drug after administration, through the body, 
which includes absorption, distribution, metabolism, and excretion (American 
Academy of Ophthalmology, 2012). To achieve a therapeutic effect, a drug must reach 
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its site of action in sufficient concentration. Pharmacokinetics and dose together 
determine bioavailability or concentration of the active drug at the therapeutic site. 
 
Pharmacodynamics in Ophthalmology 
Pharmacodynamics studies the biological activity and clinical effect of a drug 
(American Academy of Ophthalmology, 2012).  
 
Pharmacotherapeutics in Ophthalmology 
Pharmacotherapeutics is the administration of a drug in order to reach a desired 
clinical effect. The therapeutic dose may vary for any patient, based on the patient's 
age, gender, race, other currently prescribed medications, and patient's pathologies. 
 
 
Causality assessment for ADRs 
Almost as important as understanding these concepts and presenting the correct 
definition for an ADR, is the assessment of the probability of a suspected ADR being a 
true ADR. The most important and widely used causality assessments are Naranjo et al 
(1981) and WHO (2005), which apply to all ADRs. In tables V1 and V2 we present both 
causality assessment criteria for ADRs. 
 
Table V1. Naranjo's causality assessment for ADRs (Naranjo et al, 1981). *Interpretation of the total 
score: a) ≥9: Highly probable ADR; b) 5-8: Probable ADR; c) 1-4: Possible ADR: d) ≤ 0: Doubtful ADR. 
 
Naranjo's causality assessment Yes No Don't know 
1. Are there previous conclusive reports of this reaction? +1 0 0 
2. Did the adverse event appear after the suspect drug was administered? +2 -1 0 
3. Did the adverse reaction improve when the drug was discontinued? +1 0 0 
4. Did the adverse reaction reappear when the drug was readministered? +2 -1 0 
5. Are there alternate causes that on their own could have caused the reaction? -1 +2 0 
6. Did the reaction appear when a placebo was given? -1 +1 0 
7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? +1 0 0 
8. Was the reaction more severe when the dose was increased or less severe when decreased? +1 0 0 
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 
10. Was the adverse event confirmed by any objective evidence? +1 0 0 
Total score*  
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Table V2. WHO's causality assessment for ADRs (WHO, 2005).  
 
 
Types of ADRs in Ophthalmology 
There are three main types of ADRs in Ophthalmology: 
A. Topical ADRs to a topical ophthalmic drug 
These ADRs are usually easy to recognize, since the prescribing Ophthalmologist is the 
one who detects these ADRs in the follow-up of the patient. They can be caused either 
by the drug administered or by its topical conservatives. One example is ocular 
hyperemia frequently caused by topical prostaglandins (used in the treatment of 
glaucoma) (Feldman et al, 2003). 
 
B. Systemic ADRs to a topical ophthalmic drug 
Topical ophthalmic medications can be absorbed by the ophthalmic mucosa and in a 
larger dose by the nasal mucosa (the drug descends to the nasal mucosa from the 
lacrimal canal, and is then swallowed, with systemic absorption) (Duval et al, 2006) 
and attain significant levels in the blood, causing rare but sometimes even fatal ADRs. 
The most common topically administered ocular drugs causing systemic side effects 
are the epinephrine-like compounds used to dilate the pupil, which can be rapidly 
WHO's causality assessment 
1. Certain ADR 
A clinical event, including laboratory test abnormality, occurring in a plausible time relationship to drug 
administration, and which cannot be explained by concurrent disease or other drugs or chemicals. The 
response to withdrawal of the drug (dechallenge) should be clinically plausible. The event must be definitive 
pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary. 
2. Probable ADR 
A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of 
the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a 
clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill 
this definition. A clinical event, including laboratory test abnormality, with a reasonable time sequence to 
administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and 
which follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not 
required to fulfill this definition. 
3. Possible ADR 
A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of 
the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on 
drug withdrawal may be lacking or unclear 
4. Unlikely ADR 
A clinical event, including laboratory test abnormality, with a temporal relationship to drug administration 
which makes a causal relationship improbable, and in which other drugs, chemicals or underlying disease 
provide plausible explanations. 
5. Conditional / 
unclassified ADR 
A clinical event, including laboratory test abnormality, reported as an adverse reaction, about which more data 
is essential for a proper assessment or the additional data are under examination. 
6. Inaccessible / 
unclassifiable 
A report suggesting an adverse reaction which cannot be judged because information is insufficient or 
contradictory, and which cannot be supplemented or verified. 
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absorbed through the mucosal membranes of the eye, leading to increased blood 
pressure and tachycardia. Periocular injection of anesthetics combined with 
epinephrine can cause the same effects quite rapidly, leading to respiratory collapse 
and even death (Duval et al, 2006).  
 
C. Topical/ophthalmic ADRs to a systemic drug 
These ADRs generally are extremely difficult to diagnose, considering that in this case a 
general physician prescribes a drug, but a different physician usually is required for the 
diagnosis (an ophthalmologist). Other difficulty is the need of obtaining a complete 
medical history and registering the countless systemic medications prescribed for each 
patient. The correlation of the symptoms and ocular signs of the patient with the 
suspect of an ADR caused by a particular drug is another difficulty, and confirming the 
ADR is by far even more difficult.  
There are several isolated reports of possible ophthalmic ADRs without neither 
causality assessment nor systematic verification. The general frequency of ophthalmic 
ADRs is not known. Ophthalmic ADRs to systemic medication represent an area that 
lacks assessment and clarification. 
Consequently, we intended to build a systematic review of ophthalmic ADRs to 
systemic drugs. We also intended to apply and adapt some of the previously built 
methodologies for the specific ADR detection in Ophthalmology, in order to assess the 
frequency of ophthalmic ADRs and to characterize and systematize ophthalmic ADRs. 
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  A) SYSTEMATIC REVIEW OF OPHTHALMIC ADRS TO SYSTEMIC DRUGS 
 
As previously noted, there is a need of a recent systematic review about ophthalmic 
ADRs occurring after the correct prescription of a drug. From this need, the scientific 
article that arose and the chapter about ADRs in Ophthalmology can be consulted in 
appendices 6 and 9, respectively. 
 
 
Methods 
We performed a systematic review of studies that assessed ophthalmic ADR to 
systemic drugs according to the guidelines of the Cochrane Collaboration and PRISMA 
Statement. 
We used the following definition for adverse drug reaction: “any noxious, unintended 
and undesired effect of a drug, which occurs at doses used in humans for prophylaxis, 
diagnosis, or therapy”, according to WHO definition of 1972. We wanted to specifically 
assess ADRs, therefore we did not consider adverse events. 
 
 
Search methods 
We searched through several electronic databases (last date of search was 1/7/2012): 
Medline, SCOPUS, ISI web of knowledge, ISI Conference Proceedings, International 
Pharmaceutical Abstracts and Google scholar. We used a search query created after a 
pilot study to add specificity (full search query available if requested to the 
corresponding author) that included the terms: eye, ocular, ophthalmic, 
ophthalmology, adverse and reaction. We searched for grey literature and unpublished 
data, and hand-searched all references of included studies and relevant reviews. 
 
Selection criteria 
Studies were included if they followed all inclusion criteria listed below:  
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1. Studies in which the primary purpose was to assess an ophthalmic ADR to a systemic 
medication. Since there is a wide misuse of the terms ADR, adverse event (AE) and 
adverse drug event (ADE), we obtained also the full-text of studies who claimed to 
assess AEs or ADEs, to verify their methodology, and to include the studies that 
actually assessed ADRs, although they called it AEs or ADEs. 
2. Studies with patient evaluation performed by an ophthalmologist. 
3. Studies that specified diagnostic criteria for an ocular ADR. 
We also included studies with different languages (we hired a translator), any country, 
experimental studies (if any). We did so to have a more thorough and complete 
literature search. We did not exclude systematic reviews nor narrative reviews if they 
added useful information about ocular ADRs, as we intended to have a general 
overview that, on the one hand, summarized and added further systematization to 
existing evidence, and on the other hand, identified areas or specific ophthalmic ADRs 
that lacked systematization or assessment. 
 
Exclusion criteria: 
1. Studies assessing adverse events that did not correspond to ADRs (we excluded 
reports of capsular rupture in phacoemulsification surgery, but we did not exclude 
reports of capsular rupture due to intra-operatory floppy iris syndrome, a syndrome 
caused by tamsulosine or other drugs). 
2. Systemic ADRs to topical ophthalmic drugs or ophthalmic ADRs to topical 
ophthalmic drugs (they were not the purpose of our study and would increase 
heterogeneity and decrease clarity of our review). 
3. Studies that were comments or letters, if they would not add new scientific 
evidence to our review. However, letters or comments that included case reports not 
published elsewhere about specific ocular ADRs were not excluded, in order to identify 
rare ophthalmic ADRs. 
4. Studies assessing drugs already removed from the market. 
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Data collection and extraction 
Two independent reviewers first examined each title and abstract to exclude obviously 
irrelevant reports, and then independently examined each full text report, to 
determine eligibility according to inclusion criteria. Disagreements were solved by 
consensus, recorded and analyzed using kappa statistics. 
Primary outcome was the presence and type of ocular ADR and the respective 
causative systemic drug. We also registered: ocular structure affected, diagnosis, 
serious or vision-threatening ADR. All symptoms, visual acuity (VA), signals, and results 
of complementary examination performed at presentation were recorded, as well as 
after a follow-up. Attitude or treatment performed for each ADR was also registered 
(suspension of the causative drug, specific treatment, administration of an antidote, no 
treatment necessary). If VA was not recorded in the logMAR scale (Ferris 1982), it was 
converted. 
We always assessed the drug name, identified the therapeutic drug class according to 
Anatomical Therapeutic Chemical Classification System of WHO (WHO 2005), and 
reported the number of days during which the drug was used and the administration 
route (if that information was available). We verified if causality was assessed in the 
original studies (and according to what classification, preferably WHO’s or Naranjo’s 
and respective results) as well as predictability of ADRs (using Hartwig’s predictability 
scale, 1992), preventability (e.g.. Schumok & Thornton’s preventability criteria, 1992) 
and types of ADRs (Rawlins and Thompson’s classification, 1977). We did not intend to 
identify all of the ophthalmic ADRs, but to systematize the most important and the 
most frequent ADRs according to the results of our systematic search. 
 
 
Risk of bias assessment 
We performed risk of bias assessment for each included study, and recorded it in a 
standardized form created to assess ADR studies (in a previous work, Miguel 2012) and 
adapted to Ophthalmology after a pilot study. We did not use scales (discouraged by 
the Cochrane approach, 2008) but criteria from Cochrane, STROBE (Vandenbroucke et 
al, 2007), QUOROM (Moher et al, 1999) and PRISMA (Moher et al, 2009) adapted to 
V. OPHTHALMIC ADVERSE DRUG REACTIONS 
| 79 
the particular scope of ophthalmic ADRs evaluation, which included: complete 
description of study design, description of study type (case report, case series, 
prospective observational study, trial,...), adequate diagnostic criteria for ophthalmic 
ADR, complete ophthalmologic evaluation at presentation, quantified visual acuity at 
presentation and follow-up, results of complementary testing described at 
presentation and follow-up, definition of ADR presented, rationale for study size, 
causality assessment of ADR, preventability assessment of ADR, description of all 
statistical methods, characterization of study participants, description of methods to 
prevent bias (information bias, selection bias and other bias), presentation of complete 
summary measures. The two reviewers independently assessed study quality and risk 
of bias; disagreements were solved by consensus. Studies were divided in low risk of 
bias (5 or less parameters with medium, unclear or high risk of bias), medium risk (6 to 
9) and high risk (10 or more parameters evaluated as medium, unclear or high risk of 
bias). 
 
Quantitative analysis 
Statistical analyses were done with the Chi-square test for categorical variables, 
Student's t-test for normally distributed continuous variables and Mann-Whitney or 
Kruskal-Wallis when dealing with variables without normal distribution, using SPSS 
v17. Quality evaluation graphs, heterogeneity analysis, subgroup analysis and random 
effects meta-analysis were performed using Review Manager - version 5.0. The a priori 
level of significance for all hypothesis tests was p<0.05. 
 
 
Results 
Literature search 
Pubmed search yielded 124 results; SCOPUS yielded 72 results; Google Scholar 60; ISI 
Web of Knowledge yielded 154; others yielded 152. From these 562 studies 
(corresponding to 300 distinct studies), 163 were selected to obtain full-text and then 
32 studies were included (Figure V2): 1 systematic review of ADRs to a specific drug, 11 
narrative reviews, 1 trial, 1 prospective study, 6 case-control or cohort or cross-
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sectional studies, 6 spontaneous reports and 6 case reports or case series. Kappa 
agreement for study inclusion was 0.80 during the first phase and 0.82 during the full 
text review (good agreement). 
 
 
Figure V2. Flowchart of the search strategy. 
 
 
Characteristics of included studies 
Table V3 summarizes the characteristics of included studies. We identified several 
types of studies of ocular ADRs, most of them narrative reviews without systematic 
criteria nor bibliographic search.  
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Year, author Study type Drug studied Ophthalmic ADR(s) reported* Summary of study 
1986 Davidson32 Narrative review Several 
Many ocular ADRs caused by: 
corticosteroids, chloroquine, amiodarone, 
phenothiazines, tamoxifen... 
Narrative review without 
definition of ADR nor causality 
assessment 
1989 Curran33 Case series Doxorrubicin Iritis, conjunctivitis, periorbital edema, keratitis, optic neuropathy 
Case series of 4 cases of ocular 
ADRs to doxorrubicin 
1991 Hobley34 Case report Digoxin Scintillating visual field loss (central scotoma) + dischromatopsia  
Case report: visual field defect 
due to digoxin (therapeutic 
level) 
1992 Malek35 Narrative review Oral contraceptives  Retinal hemorrhage or emboli, macular or papillary edema, optic neuropathy 
Narrative review of ocular 
ADRs by oral contraceptives.  
1993 Goldman36 Narrative review Anticonvulsivants 
 Carbamazepine: diplopia, paresis of 
extraocular muscles, nistagmus, visual 
allucinations 
 Phenytoin: nistagmus without oscillopsia, 
mydriasis 
 Others: paresis of extraocular muscles 
Narrative review of ocular 
ADRs of common 
anticonvulsivants 
1994 Macarol37 Spontaneous reports Pamidronate Scleritis, conjunctivitis, anterior uveitis 
Retrospective series of 
spontaneous case reports 
1995 Oshika38 Narrative review Neuropsychiatric drugs 
 Phenothiazine: corneal et lens deposits 
 Thioridazine: retinopathy 
 Tricyclic antidepressants: glaucoma, 
decreased accommodation 
 Lithium: papilledema, exophthalmia 
 Chlorpromazine: keratopathy 
A narrative review of 
ophthalmic ADRs of 
neuropsychiatric drugs 
1995 Fraun- 
Felder9 
Letter with 
spontaneous 
reports 
Leuprolide Blurred vision 
A retrospective study of series 
of spontaneous reports of 
ocular ADRs of leuprolide 
1995 b 
Fraun- 
Felder39 
Retrospective 
case-control 
study 
Niacin Dryness, blurred vision, diplopia, cystoid maculopathy  
ADRs of patients taking niacin 
were compared to other 
dyslipidemia drugs 
1997 Sweeney40 Prospective study Risperidone Eye movements affected: prolonged latency after and alteration of saccadic movements 
Prospective study of patients 
with risperidone (4 weeks) 
1999 Dulley41 Narrative review Tamoxifen 
 Retinopathy with deposits 
 Keratopathy with deposits 
 Colour vision defects 
 Foveal disfunction and ERG change 
Narrative review about ocular 
ADRs of tamoxifen 
1999 Solomon42 Letter with case reports Influenza vaccine 
 Case 1: anterior uveitis 
 Case 2: reactivation of herpetic keratitis 
 Case 3: left keratoplasty rejection 
Letter with case reports not 
previously published 
1999 Doughty43 Narrative review Migraine drugs 
Cyproheptadine, pizotyline, amitriptiline, 
propranolol, timolol, clonidine, flunarizine: 
dry eye 
A narrative review of 
medications of headaches and 
their ocular ADRs 
2001 Ikaheimo44 
Observational 
cross-sectional 
study 
Flecainide  Corneal deposits  Dry eye 
Observational study in which 
38 flecainide medicated 
patients were examined. 
2001 
Fraunfelder45 
Case series of 
spontaneous 
reports 
Isotretinoin 
 Many ADRs: abnormal meibomian glands, 
blepharoconjunctivitis, corneal opacities, 
decreased vision, keratitis, ... 
Analysis of 1741 spontaneous 
reports with possible ocular 
ADRs to isotretinoin 
2002 Ikaheimo46 
Observational 
cross-sectional 
study 
Amiodarone 
 Corneal deposits (in 100% of the patients) 
 Anterior subcapsular lens deposit (22.2%) 
 Dry eyes (9.1%) 
Observational study in which 
22 patients with long term 
amiodarone were studied 
2003 Fraun- 
Felder18 Narrative review Several 
  Amiodarone: cornea verticillata, 
periocular staining, optic neuropathy 
  Cetirizine: mydriasis, oculogyric crisis... 
  Hydroxychloroquine: corneal deposits, 
epiphora, extraocular paresis, ptosis 
  Isotretinoin: conjunctitivis, corneal 
deposits, acute myopia, optic neuritis 
  Biphosphonates: episcleritis, 
conjunctivitis, nerve palsy,...  
 Sildenafil: dischromatopsia, blurred vision 
 Topiramate: acute glaucoma, acute 
myopia, ocular pain, uveitis,...  
A narrative review was 
performed of ocular ADRs, 
without systematic study 
search but with systematic 
WHO causality assessment 
whenever possible. Offers good 
guidelines and clinical 
implications for each drug. 
2004 Fraun- 
Felder47 
Retrospective 
series of reports Several 
  Biphosphonates: conjunctivitis, uveitis, 
blurred vision, scleritis 
  Cetirizine: blurred vision, 
keratoconjunctivitis sicca, oculogyric crisis 
  Isotretinoin: blurred vision 
  Topiramate: acute glaucoma, acute 
A large retrospective series of 
spontaneous reports of ocular 
ADRs to different systemic 
drugs. WHO's definition of ADR 
and WHO's causality 
assessment were performed. 
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myopia, periorbital edema, scleritis 
2006 Fraun- 
Felder48 
Letter with 
retrospective 
reports of 
spontaneous 
reports of ocular 
ADRs 
Cyclooxygenase-2 
Inhibitors 
Blurry vision and conjunctivitis were the 
most reported ADRs 
Letter with large series of 
spontaneous reports (1006) of 
ocular ADRs to cyclooxygenase-
2 Inhibitors (238 reports of 
blurry vision and 71 of 
conjunctivitis from celecoxib). 
2007 Santaella49 Narrative review Several 
Several drugs were assessed, such as: 
pamidronate, alendronate, risedronate, 
topiramate 
Narrative review of several 
retrospective case series and 
reports of ocular ADRs to 
specific systemic drugs.  
2007 Sowka50 Case report Sildenafil Optic atrophy after the use of sildenafil in a 68-year old man.  
Case report with a follow-up of 
4 months. No causality 
assessment of ADR nor WHO's 
definition of ADR was used. 
2008 Mandal51 Two case reports 
Topiramate, >6 
months, 100-
150mg/day 
Defects in visual field (case 1-quadrantic 
defects, case 2-arcuate defects)  
Two case reports of visual field 
alterations induced by 
topiramate, (Naranjo's CA was 
performed). 
2009 Bell52 Retrospective study Tamsulosin 
Intra-operatory floppy iris (IFIS) and related 
surgical outcomes 
Retrospective cohort study of 
96128 patients: tamsulosine 
was associated with IFIS and 
intraoperatory complications 
2009 Cordel53 Trial Sildenafil and tadalafil 
Electroretinography (ERG) responses were 
the same for placebo, sildenafil and 
tadalafil. 
Subjects were randomized to 
use of a placebo (n=82), 
tadalafil (n=85) or sildenafil 
(n=77) daily for 6 months.  
2009 El-
Domyati54 Case report Sildenafil 
A 48-year-old nonsmoker patient suffered 
from nonarteritic ischemic optic 
neuropathy. "Several weeks later", the 
visual acuity gradually improved 
Case report. Causality 
assessment of WHO was not 
performed. Follow-up of 
"several weeks later", not 
specified. 
2010  
Richa55 Narrative review Psychotropics 
  Phenothiazines, lithium: 
keratoconjunctivitis 
 Chlorpromazine: periocular pigmentation 
  Tricyclic antidepressants, topiramate: 
uveitis 
 TCAs, typical antipsychotics, selective 
serotonin reuptake inhibitors: mydriasis 
A narrative review was 
performed with several 
psychotropic drugs 
2010 Al-
Hussaini56 
Comprehensive 
narrative review Alpha-Blockers 
Intra-operative Floppy Iris Syndrome (IFIS). 
"There is no evidence to support alpha-
blocker discontinuation prior to surgery." 
Review about IFIS and drugs.  
2011 Lebreton57 
Narrative review 
with systematic 
search 
Corticosteroids 
 Ocular hypertension 
 Cataract (posterior subcapsular) 
 Central Serous Chorioretinopathy 
  Ptosis 
  Exophthalmia 
A narrative review was 
performed of ophthalmic ADRs 
of corticosteroids 
2011 Azzouni58 Systematic review Sildenafil 
Anterior and posterior nonarteritic ischemic 
optic neuropathy, central retinal vein 
occlusion, cilio-retinal artery occlusion, 
acute angle closure glaucoma and optic 
atrophy after sildenafil use. 
Systematic review of ocular 
ADRs by sildenafil. WHO's 
causality assessment was 
performed and of National 
Registry of Drug-Induced 
Ocular Side Effects. 
2012 Seitz59 Case-crossover study Antidepressants 
Acute angle-closure glaucoma (AACG) (odds 
ratio for any antidepressant exposure in the 
period immediately preceding AACG was 
1.62, 95% confidence interval of 1.16-2.26). 
Authors searched acute angle -
closure glaucoma, and 
investigated whether they had 
an exposure to antidepressants 
previously, using administrative 
databases.  
2012 Saint-
Jean60 Case series  
Inhibitor of 
epidermal growth 
factor receptor 
(EGFR)  
Multiple epithelial defects, corneal melting, 
ectropion and corneal perforation (requiring 
a penetrating keratoplasty). 
Retrospective case series of 10 
patients with ocular ADRs. 
Definition of ADR was not used.  
2012 
Neudorfer61 
Retrospective 
study of 
outcomes 
Isotretinoin 
An association was found between 
isotretinoin and conjunctivitis, hordeolum, 
chalazion, blepharitis, eye pain, and dry eye. 
Retrospective study with 
medical databases to identify 
ADRs in patients using 
isotretinoin. 
Table V3. Included studies in this systematic review. *Ophthalmic ADRs will be described with further detail in 
table V4. 
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Ophthalmic ADRs  
Many different ophthalmic ADRs exist to many systemic drugs. In table V4, we 
represent a summary of the main ophthalmic ADRs found in this systematic review, 
according to each specific drug, dose, risk factors and tried to characterize the 
ophthalmic ADR (if reported). Keratitis, retinopathy, glaucoma, dry eye and blurred 
vision were the most frequent ADRs identified.  
We identified many ophthalmic ADRs to drugs that have original studies but are 
currently lacking a systematic review (therefore representing an opportunity for 
further studies). Many studies were found but only one systematic review (of 
ophthalmic ADRs to sildenafil) and few narrative reviews with systematic search were 
performed. Therefore, examples of drugs that cause ophthalmic ADRs that would 
benefit from a recent and specific systematic review are: tamoxifen, amiodarone, 
antidepressants, phenotiazines, hydroxychloroquine, oral contraceptives, etc. 
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Therapeutic group Drug(s) responsible(s) 
Description of ocular ADR 
- Patient (P), ocular segment/complaints (O) 
- Complementary examination (C) 
- Reversibility of ADR (R), follow-up time (F) 
Classification of ADR 
- Rawlin's type A/B 
- Severity assessment 
(SA); causality 
assessment (CA) 
- Reporting studies 
- Study's level of 
evidence (Oxford 
classification62) 
Acne treating 
agents Isotretinoin 
Certain ADRs: pseudotumour cerebri, meibomian gland 
alterations, blepharoconjunctivitis, keratitis, myopia, 
corneal opacities, ocular discomfort, dry eye, 
photophobia, decreased vision, and teratogenic ocular 
abnormalities. (Many other ADRs were reported). 
A recent study61 identified a hazard ratio of 1.70 (p<0.05) 
for ocular ADRs after isotretinoin. 
- Type A and B 
- With CA (WHO's) 
Narrative review18 and 
case series45 (level 4) 
Retrospective study 
using medical 
databases61 (level 2c) 
Anti-allergic Anti-histamines: cetirizine 
Pupillary changes, anisocoria, decreased 
accommodation and blurred vision. Dry eye47 
Oculogyric crisis18: "eyes and lids are tonically elevated 
and the neck is hyperextended, usually without visual 
complaints". It is a certain ADR18. 
- Type B: all except 
oculogyric crisis (A). 
- WHO's causality 
assessment (CA) was 
performed18. 
Narrative reviews18,47 
(level 4) 
Anti-arrhythmics 
Flecainide 
Corneal deposits: 14.5% 
Dry eye: 10.5% 
- 13 to 132 months of follow-up 
- Type A 
- No CA nor SA 
- Cross-sectional study44 
- Level 2c 
Amiodarone 
Corneal deposits: 100% of the patients32,46 
Anterior subcapsular lens deposits46: 22% 
Dry eye46: 9% 
Amiodarone-optic neuropathy18: more insidious in onset 
and resolution, more bilateral, less involvement in visual 
acuity compared to non-arteritic ischaemic neuropathy. 
Other47: Photosensitivity, periocular skin pigmentation, 
blepharoconjunctivitis, thyroid eye disease, loss of 
eyelashes, pseudotumor cerebri. 
- 3 to 131 months of follow-up in a prospective study46 
Certain ADRs18: photosensitivity, corneal deposits, visual 
changes, skin pigmentation, blepharoconjunctivitis, 
thyroid eye disease.  
- Type A: dry eye, 
corneal and lens 
deposits. Rest: type B. 
- WHO causality18 
- Cross-sectional study46 
(level 2c) and narrative 
reviews18,32,46 (level 4) 
Anticonvulsivants 
- Carbamazepine 
(CB) 
- Phenytoin(PH)  
- Phenobarbital(PB) 
and other 
barbiturates 
 
Diplopia:  caused by CB in 0.2-4% of patients36 (if CB+ 
other anticonvulsivants, frequency can rise to 88%). 
Diplopia can be reversible with dose reduction36.  
Nystagmus: in 75% of patients with CB+PH36. 
Also reported after primidone and PH. 
Decreased ocular movements: by CB and PB36 
Ophthalmoplegia: by PB and PH 
Oculogyric crisis:  by CB (in a 8-y., reversible36) 
Blurred vision: CB36;  Mydriasis: PH36 
Disorders of convergence, miosis: barbiturates36 
Papilledema: CB36 (C, F: not specified in any study) 
- All Rawlin's type B 
(although diplopia may 
resolve with dose 
reduction38), except: 
Type A: decreased 
ocular movements, 
mydriasis, changes in 
convergence 
- No study with SA nor 
CA 
- Narrative review 
based on case reports36 
- All studies Level 4 
Antidepressants 
and antipsicotics 
- Phenotiazine (PT) 
- Thioridazine  
- Tricyclic 
antidepressants 
(TA) 
- Lithium 
- Chlorpromazine 
(CP) 
- Monoamine 
oxidase inhibitors 
(MAOIs) 
- Risperidone 
Corneal and lens deposits: by PT, CP38, levopromazine; 
these deposits usually do not interfere with visual acuity 
Keratopathy: Corneal edema by PT (reversible if 
stopped), epitelial keratopathy by CP38 (visual acuity 
remains good, may be reversible if CP is stopped) 
Pigmentary retinopathy55: by thioridazine (more frequent 
in high dose, may be irreversible); rarely also by CP and 
trifluoperazine38 
Papilledema, exophthalmia: lithium38 
Alteration of saccadic eye movements: risperidone38,40 
Angle-closure glaucoma: by TA, in susceptible patients 
with shallow anterior chamber59,63 
Decreased accommodation: TA, MAOIs 
 (C, F, frequency: not specified) 
- Usually type B 
(decreased 
accomodation is type 
A) 
- Na CA nor SA was 
performed 
- Narrative reviews of 
case series of several 
psychiatric drugs38,55 
- Prospective study of 
risperidone40 
- Case crossover study59 
- Level 4 (low evidence) 
for the narrative 
reviews38,55, level 2c for 
case crossover59 and 2b 
for the prospective 
study40 
Anti-erectile 
disfunction 
agents 
Sildenafil 
Certain ADRs18,47: dyschromatopsia (objects appear more 
blue/green), blurred vision, changes in light perception, 
electrorretinogram changes, conjunctival hyperemia and 
photophobia.  
Case report50: optic atrophy (without CA). 
Trial53: no changes in electroretinography responses for 
placebo, sildenafil and tadalafil (no ADR). 
Others58: Anterior and posterior nonarteritic ischemic 
optic neuropathy, central retinal vein occlusion, cilio-
retinal artery occlusion, acute angle closure glaucoma. 
- Type A and B 
- With CA: WHO's18,47 
and Naranjo's58 
- Without CA nor SA50 
Narrative reviews18,47, 
systematic review of 
case reports58 and case 
report50 (level 4) 
Trial53 (level 1b) 
Anti-
inflammatory 
drugs 
Cyclooxygenase-2 
Inhibitors 
Blurry vision and conjunctivitis by rofecoxib, celecoxib 
and valdecoxib (positive dechallenge and rechallenge 
tests) 
- Type B 
- With CA 
Retrospective series of 
spontaneous reports48 
(level 4) 
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Corticosteroids 
Ocular hypertension: Odds ratio 1.41 (CI95% 1.2-1.6)64 
Glaucoma reportedly in up to 30% of patients32 
Cataract (posterior subcapsular): 4.7%-15.3%65,32 
Central serous chorioretinopathy: OR 37(CI95% 6-222)57 
Others: ptosis, exophthalmia (6-8%57), viral retinitis, 
delay in corneal cicatrization 
- Type A: cataract 
- Type B: other ADRs 
- Without CA nor SA 
Narrative reviews32,57 
(level 4) 
Case-control studies64,65 
(level 3b) 
Benign prostatic 
hyperplasia drugs 
Alpha-blockers (e.g. 
tamsulosin) 
More post-operatory complications (in 14 days) in 
patients with tamsulosine52: intra-operatory floppy iris 
Intra-operative Floppy Iris Syndrome (IFIS). IFIS severity is 
related with number of the following criteria: 
  iris billows with intraocular irrigation currents 
  iris prolapse tendency 
  intraoperatory pupilary constriction 
- Without CA 
- With SA 
Retrospective study52 of 
96128 patients(level 2b) 
Narrative review with 
systematic search56 
Biphosphonates 
Pamidronate 
Risedronate 
Alendronic acid 
Zolendronate 
Risedronate sodium 
Etidronate 
dissodium 
Anterior uveitis: uni or bilateral, 24h to 17 days after 
medication37, mild to severe (2 hospitalizations) 
Scleritis, episcleritis: unilateral, in 1-6 days. 
Conjunctivitis: mild, in 1-48h.  
Nerve palsy, retrobulbar neuritis,  
yellow vision, blurred vision 
C, F, frequency: not specified. Causality assessment18,47: 
Certain ADR: blurred vision, ocular irritation, 
conjunctivitis, pain, epiphora, photophobia, anterior 
uveitis, anterior scleritis, episcleritis, orbital edema.  
Possible: retrobulbar neuritis, yellow vision, diplopia, 
cranial nerve palsy, ptosis, visual hallucinations. 
- Type B 
- No CA37, but 
rechallenge was 
performed in 5 
patients with uveitis (4 
positive rechallenge 
tests) 
- With CA18 performed 
in a narrative review 
 
- Retrospective series of 
spontaneous case 
reports37 and narrative 
reviews18,47 
- Level 4 
Drugs used in 
heart failure Digoxin 
- 36 year-old female 
Dischromatopsia + scintillating visual field (VF) 
alterations, 3 months after administration of digoxin 
Colour test FM-100: defect on blue colour. 
- Reversibility, follow-up: not specified 
- Rawlin's: 
B/idiosyncratic ADR 
- No SA  
- No CA  
- Case report34  
- Level 4 (low evidence). 
Many other studies not 
included because toxic 
digoxin levels 
Drugs used in 
neoplastic 
disorders 
Imatinib 
Periorbital edema (after CA, certain ADR).  
Epiphora( probable ADR) 
Other possible ADRs: extraocular muscle paresis, ptosis 
and blepharoconjunctivitis. 
- Type A: periorbital 
edema. Rest: type B. 
- With CA (WHO's) 
Narrative review18 (level 
4) 
Inhibitor of 
epidermal growth 
factor receptor 
(EGFR) 
Multiple epithelial defects (in 10 eyes of all cases), 
corneal melting (in 3 eyes of 2 patients), lower lid 
ectropion (2 eyes of 1 patient) and corneal perforation 
requiring a penetrating keratoplasty (in 2 eyes of 2 
patients). Variable follow-ups (all > 1month). 
- Type B 
- No CA nor SA 
Retrospective series of 
spontaneous reports60 
(level 4) 
Drugs used in 
Rheumatology 
Chloroquine 
Hydroxychloroquine 
Corneal deposits, epiphora, ophthalmoplegia, ptosis 
Maculopathy: dramatic retinopathy with macular atrophy 
in a bull's-eye pattern. No frequency is reported but: 
"approximately one million people have used 
hydroxychloroquine, with only 20 cases of retinal toxicity 
in the low dose range (< 6.5 mg/kg/day)"18 
Baseline and anual ophthalmic examinations are 
recommended with: visual acuity, amsler's grid, colour 
test, and ideally fundus photograph and visual field. 
- Type A: maculopathy 
(related to cumulative 
dose), corneal deposits 
- Type B: 
ophthalmoplegia, 
ptosis 
- With CA (WHO)18 and 
without32 
Narrative reviews18,32 
(level 4) 
Hormone-related 
therapy 
Oral contraceptives 
Retinal hemorrhage or emboli, Macular edema, Papillary 
edema, Retrobulbar optic neuropathy 
- Patient: not specified 
- Ocular segment: posterior (retinal alterations and 
papillary edema, vascular changes) 
- Complementary examination: angiography, CT scan 
- Follow-up: variable (case reports) 
- Rawlin's type B 
- No SA 
- No CA 
- Narrative review35 
based on few case 
reports (low evidence) 
- Level 4 
Leuprolide 
Blurred vision: duration between 1h and 15 days, may be 
associated with headaches or dizziness. 
Other:  papilledema, ocular pain, "ocular vascular 
accidents" 
- Type B 
- No CA nor SA 
- Series of spontaneous 
case reports9 
- Level 4 
Tamoxifen 
Crystallin retinopathy: in the macula, may be associated 
with macular edema 
Keratopathy with whorl-like opacities 
Colour vision defects 
Foveal disfunction with ERG changes 
- Usually type B 
- No CA nor SA41  
- CA(WHO causality)47 
- Narrative review41,47 
- Level 4 
Doxorrubicin 
Case 1: iritis, conjunctivitis 
Case 2: periorbital edema 
Case 3: keratitis 
Case 4: optic neuropathy (F, C, follow-up: not reported)  
- Type B 
- No CA nor SA 
- Case series of 4 cases33 
(level 4) 
Lipid lowering 
agents Niacin 
Dry eye (Fisher exact test p=0.011),  
Blurred vision(p=0.0011) 
Diplopia(p=0.5, non statistically significant)  
- Type B 
- No CA nor SA 
- Case-control study39 
- Level 3b 
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Cystoid maculopathy (2 cases) 
Migraine drugs 
Cyproheptadine, 
pizotyline, 
amitriptiline, 
propranolol, 
timolol, clonidine, 
flunarizine 
Dry eye: all 
Diplopia: cyproheptadine, pizotyline, amytriptiline 
Mydriasis: cyproheptadine, pizotyline, amytriptiline 
Decrease in accommodation: propranolol, timolol 
Changes in intraocular pressure: all 
- Type A 
- No SA nor CA 
- Narrative reviews43,18 
- Level 4 
Topiramate 
Certain ADRs by topiramate: acute angle closure 
glaucoma (usually bilateral, in 1-14 days, suprachoroidal 
effusion), decreased vision, headaches, hyperemia, 
mydriasis, uveitis, visual field defects, myopia. 
Probable ADRs by topiramate: blepharospasm and 
oculogyric crisis. 
Case reports of others ADRs, as visual field defects51 
- CA performed by 
Fraunfelder18 
- Narrative reviews18,51 
- Level 4 
Vaccines Influenza vaccine 
Case1: 41y, man, reversible anterior uveitis 
Case 2: 72 y, woman, reactivation of herpetic keratitis 
Case 3: 74 y, man, left keratoplasty rejection 
- Type B 
- No CA nor SA were 
performed 
- Letter with case 
reports42 
- Level 4 
Table V4. Summary of ophthalmic adverse drug reactions. 
 
Risk of bias assessment 
Few studies had low risk of bias. Only one study performed rationale for study size. 
Most studies (25) performed a complete initial evaluation by an ophthalmologist, but 
only 11 performed a follow-up of at least 1 month. Only 13 studies performed causality 
assessment for ADR and only 7 applied or presented WHO's definition of an ADR. Risk 
of bias graph is presented in figure V3. 
 
 
 
Figure V3. Risk of bias graph 
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 B) DETECTION OF OPHTHALMIC ADRS THROUGH DATABASE METHODOLOGIES 
 
After identifying examples of specific ophthalmic ADRs and after developing general 
methods for ADR detection, we intended to adapt  those methodologies to detect 
ophthalmic ADRs (the scientific paper resulting from this work is available in appendix 
7). 
 
Methods 
Study design 
A retrospective study was performed for ADR identification using hospital 
administrative databases with information from all hospitals in Portugal, from 2000 to 
2009, obtained from our National Health Department. These databases contained 
information on encrypted patient identification, episode and process number, and also 
information on age, sex, admission date, discharge date, ward(s), hospital attended 
(public, private), area of Healthcare, district, outcome (death, discharge, transfer), 
payment data and International Classification of Diseases 9th Revision- Clinical 
Modification (ICD-9-CM) codes for: diagnoses (main diagnosis, other diagnosis up to 
19), procedures (up to 20) and external causes (up to 20). Patient population included 
all patients hospitalized in all hospitals in Portugal, from 2000 to 2009 (inpatients and 
outpatients). Data from the second semester of 2009 was not available. 
 
ADR definition and identification 
We followed WHO's definition of ADR of 1972. Hospital databases included 
information of diagnosis. Codes searched for ADR identification were adapted to 
the specificities of Ophthalmology and resulted from a thorough search of: all terms 
of ICD-9-CM in Ophthalmology that included "drug-induced", "iatrogenic", "toxic" 
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and all codes that could signal an ADR, such as "362.55- toxic maculopathy" or 
"365.03 - steroid responsers", as detailed in the Results Section. 
We also performed a search of general ADRs through the use of ‘E’ codes (ICD-9-CM 
codes from E930 to E949.9, designed to represent ADRs and already excluding 
wrong doses, errors and intoxications) to assess if these general ADRs could detect 
ocular ADRs.  
 
In this study, we performed a query of Ophthalmology in a Nationwide study using 
administrative databases, including inpatients and outpatients.  
Our main outcome was ADR detection. Secondary outcomes were: ADR in 
inpatients (ADRI), ADRs in outpatients (ADRO), ADR related to admission (ADRAd) 
versus ADR during hospitalization period (ADRIn), age, gender, admission diagnosis, 
other diagnoses, hospital stay and year (we aimed to assess trends in ADRs from 
2000 to 2009). 
 
Statistical analysis 
Statistical analyses were done with the Chi-square test for categorical variables (or 
exact Fisher's test whenever possible), Student's t-test for normally distributed 
continuous variables and Mann-Whitney or Kruskal-Wallis for variables without 
normal distribution, using SPSS v20.The a priori level of significance was p<0.05. 
 
Results 
Study population 
The baseline characteristics of the study population (n=11,944,725) are shown in 
table V5. The mean age of hospitalized patients was 46 years and 56% of the 
patients were female.  
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Characteristic Value  
Mean age 48 27 sd 
Female gender (%) 6598266 55.24% 
District with higher number of hospitalizations 1st: Lisbon 21.2% 
2nd: Porto 17.2% 
3rd: Setubal 7.66% 
Mean hospital stay in inpatients (days) 7.1 3.21sd 
Number of ocular ADRs 1564  
Table V5. Socio-demographic characteristics of study population. 
 
From 2000, there was a slight increase in the number of hospitalizations in Portugal. 
1524 specific ocular ADRs were detected through the search of codes that could 
represent particular ocular ADRs, as shown in table V6. Additionally, 100 episodes 
that could possibly correspond to an ophthalmic ADR were also detected (table V6). 
Therefore, a total of 1624 possible ocular ADRs were detected.  
 
ICD-9-CM code Diagnosis Number of 
episodes 
Specific ocular ADR codes 
362.55 Toxic maculopathy 1388 
365.03 Steroid responders 4 
365.31, 365.32 Corticosteroid-induced glaucoma 0 
364.55 Miotic pupillary cyst 2 
364.81 Floppy iris syndrome 2 
366.45 Toxic cataract 83 
367.89 Other drug-induced disorders of refraction and accommodation, 
Toxic disorders of refraction and accommodation 
25 
377.34 Toxic optic neuropathy, Toxic amblyopia 20 
Possible signs of ocular ADRs 
366.46 Cataract associated with radiation and other physical influences 10 
372.54 
372.55 
372.56 
Conjunctival concretions 
Conjunctival pigmentations, including conjunctival argyrosis 
Conjunctival deposits 
67 
368.55 
368.59 
Acquired color vision deficiencies 
Other color vision deficiencies 
23 
0 
 Sub-TOTAL for specific ophthalmic ADRs 1524 
 TOTAL 1624 
Table V6. Clinical codes searched and respective results in the portuguese database. 
 
The search of general ADRs through the use of E codes allowed us to identify 
116,720 ADRs, but only 62 of them corresponded to the ocular ADRs that were 
identified, consequently, a specific search must be performed for ophthalmic ADRs.  
V. OPHTHALMIC ADVERSE DRUG REACTIONS 
 
| 90 
 
Therefore, databases are a useful methodology for the detection of ocular ADRs, 
but require adapted diagnoses codes. 
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 C) SYSTEMATIC REVIEW OF SPECIFIC OPHTHALMIC ADRS 
 
After the general systematic review performed about ADRs, we were able to identify 
good targets of drugs that could benefit from a specific systematic review (if possible 
with meta-analysis), such as statins (we performed a pilot study of a Cochrane 
Collaboration review of ocular ADRs caused by statins: appendix 6). Other examples of 
drugs that have apparently good original studies but no recent systematic review to 
confirm respective ocular ADRs are: tamoxifen, antituberculous agents, angiotensin-
converting enzyme inhibitors and cidofovir.  
 
 
Ophthalmic ADRs caused by statins 
 
To analyze the ophthalmic ADRs caused by statins, we performed a systematic review, 
performed as a Cochrane Collaboration Review - Eyes and Vision Group. We have 
finished the protocol for the pilot study and are have performed the title registration 
by the Cochrane Collaboration. The protocol is available in appendix 6. 
 
Introduction 
Many ophthalmic ADRs provoked by systemic drugs are known by spontaneous 
reporting, without systematic assessment nor definitive evidence. An ophthalmic ADR 
can affect every structure in the eye (Fraunfelder 2007), but some systemic drugs tend 
to provoke specific ophthalmic ADRs, namely amiodarone which frequently provokes 
cornea verticillata (Hollander 2004) and rarely provokes optic neuropathy (but with 
potential for irreversible blindness, Carelli 2002). 
Statins are widely used for the treatment of dyslipidemia and cardiovascular 
pathologies (Taylor 2011). They provoke general ADRs that are well documented, such 
as myopathy, liver transaminases elevation and renal failure (Andrejak 2003). On the 
other hand, ophthalmic ADRs provoked by statins have been reported by some authors 
(Hermans 2011), but lack a systematic review. Specific types of ADRs that were 
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reported to occur after statin use include cataract formation, which is controversial, 
with some studies reporting an increase in the incidence of cataract (Hippisley-Cox et 
al, 2010) and others reporting a decrease (Klein et al, 2006). Other ADRs that have 
been reported are: dry eye (Smidt et al, 2011), diplopia (Fraunfelder et al, 2008), ptosis 
(Fraunfelder et al, 2008; Ertas et al, 2006) and ophthalmoplegia (Fraunfelder et al, 
2008). 
On the other hand, statins may have a protective role also in the delay of vitreous 
haemorrhage in diabetic patients (Banerjee et al, 2004) and in the development of 
age-related maculopathy (McGwin et al, 2003).  
Statins (or HMG-CoA reductase inhibitors) are a class of drugs used to lower 
cholesterol levels. They inhibit the enzyme HMG-CoA reductase, which plays a central 
role in the production of cholesterol in the liver. They are widely used as lipid-lowering 
agents (Taylor 2011). 
We will search ophthalmic adverse drug reactions provoked by statins systemically 
administered, in the correct dose, administration and indication, according to WHO's 
definition of ADR (WHO 2002). 
Rationale 
The specific ocular anatomy of the eye may facilitate the occurrence of ADRs. After a 
drug (namely a statin) is administered systemically, it can reach ocular tissues through 
uveal or retinal circulation and the fenestrated endothelium may allow the drug to 
pass through ocular barriers and to accumulate in ocular structures (Wren 2000). This 
may cause a pathological alteration of ocular structure or function and provoke an 
ophthalmic/ocular ADR. Nevertheless, there is controversy regarding statins: some 
state that its antioxidative and anti-inflammatory power may decrease the risk of 
cataract formation (Klein 2006), while others report an increase in the incidence of 
cataracts (Collins 2012, Hippisley-Cox 2010) and others report no association (Hermans 
2011). Statins have been found inside the lens (Grosse 2004), and therefore may alter 
the lens fiber functioning, disrupting the delicate lens metabolism and consequently 
accelerating cataract formation. Also, the lens membrane contains cholesterol, 
therefore, statins can induce cataract formation because they may reduce lens 
cholesterol synthesis (Cenedella 1996). 
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In summary, the ophthalmologist should know the specific ophthalmic ADRs to 
systemic medication to recognize them in clinical practice. Methods of ADR detection 
have been explored and adapted to the specificity of ophthalmic ADRs. 
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The fact that ADRs are so important in Public Health Care and yet are so 
heterogeneously and incompletely studied and detected, is a signal of the urgency of 
the development of methodological approaches for ADR detection. The relevance of 
this thesis, the methodological advantages and limitations of our studies and of these 
Pharmacovigilance methodologies, and our conclusions and recommendations are 
presented below. 
 A) MAIN FINDINGS AND ANSWERS TO RESEARCH QUESTIONS  
 
1.  What is known about the frequency of  adverse drug reactions 
(ADRs) that occur in hospitalized patients? 
After performing a systematic review which included several studies of ADRs in 
hospitalized patients in different hospitals in the World, we estimated the mean 
frequency of 17% (CI95%:14, 20%). This estimate had heterogeneity, as expected and 
previously reported in the literature (Lazarou et al, 1998). However, we were able to 
identify heterogeneity moderators: risk of bias, population, ward, and methodology for 
ADR identification. Low risk of bias studies adjusted for population (pediatric versus 
adult) had no statistical heterogeneity (I2 = 0%), which is a new finding and supports 
our recommendations of higher methodological quality in further studies about ADRs. 
 
 
2. What methodologies can be explored for the detection of ADRs 
besides spontaneous reporting?  
Spontaneous reporting the most utilized methodology for ADR detection, because of 
low resources needed, but has the worse detection rate of all methodologies. The 
limitations of spontaneous reporting, along with the high costs of intensive or 
prospective monitoring, the economic impossibility to build a complete computerized 
system in Portugal, led us to  develop two methodologies: one based in databases, and 
the other based on a simple computerized method that allowed computer chart-
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assisted review (with low computation resources to maintain respective costs low). We 
compared directly our database methodology with spontaneous reporting and with 
manual chart review, and we compared our computerized approach with spontaneous 
reporting and with manual chart review. In figure VI1, we present the summary of all 
methodologies approached in this thesis. We believe that we have developed two 
methodologies that are promising. The database methodology has a detection rate 
(2.4%) that is many times higher than spontaneous reporting, with low resources 
(2PH); whereas the computerized approach has a remarkable detection rate (24.8%) 
with half the costs of a comprehensive manual chart review (35 PH). 
 
 
Figure VI1. Comparison of the different methodologies approached in this thesis for ADR 
detection. PH: Person-hours spent in the application of the methodology. 
 
We applied the database methodology to the population hospitalized patients of 
public hospitals of Portugal, from 2000 to 2009, and obtained the first National 
estimate of ADRs. There were 9,271,122 hospitalizations, with 116,720 hospital ADRs 
detected by the database methodology (prevalence of 1%; 97% of the ADRs were 
ADRIn). There were 13,562 spontaneous reports of ADRs (ambulatory and hospital) 
from 2000 to 2009 in Portugal (prevalence of 0.1%, ten times lower). We were also 
able to characterize the population who suffered from ADR (all statistically significant): 
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they were older, had longer mean hospitalization period, more frequently of the 
female gender and had a higher risk of death. We additionally verified that several 
comorbidities may be risk factors for ADRs (p<0.05, Fisher's exact test in all): heart 
failure, septicemia, dysrhythmias, hypotension, cerebrovascular disease, stroke, 
diabetes, ischemic heart disease, malignancies and pneumonia. We therefore believe 
that the database methodology can be applied continuously, complementing 
spontaneous reporting.  
Finally, the following table presents the comparison between all methodologies 
explored in this thesis. In this table the adjusted resources show that the database 
methodology may be the methodology with lesser costs. 
 
Methodology 
Number of ADRs 
identified / number 
of patients exposed 
Prevalence (%) 
of ADRs  
detected 
Resources spent (PH: 
person-hours) 
Adjusted 
resources 
(PH per 100 
ADRs 
detected) 
Database 325 / 13471 2.41% 2 PH (per 325 ADRs) 0.6 
Spontaneous 
reporting 7/13471 0.05% 1 PH (7 reports of ADRs) 14 
Computerized 65 / 117 25% 29.5 PH (65 ADRs) 45 
Succint chart 
review 9/100 9% 35 PH (9 ADRs) 389 
Comprehensive 
chart review 12/117 10% 69 PH (12 ADRs) 575 
Table VI1. Comparison of all methodologies for ADR detection. PH: Person-hours. 
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3.  How can ocular ADRs be systematized and characterized? 
 
We believe that we have contributed for the increase in the assessment and 
systematization of ophthalmic ADRs.  
We built a general systematic review of ophthalmic ADRs (appendix 5), to add 
systematization and to identify specific ADRs lacking assessment. From 562 studies, we 
included 32 studies that summarized the most known systemic drugs causing ADRs and 
identified areas lacking specific systematic reviews. Then we performed a specific 
systematic review to systemic drugs in those areas lacking clarification and 
systematization, namely ophthalmic ADRs caused by statins (a Cochrane review in the 
protocol phase, appendix 6). Finally, we utilized the knowledge gained in the previous 
studies for the adaptation of our database methodology (appendix 7) to the 
specificities of Ophthalmology to detect ophthalmic ADRs. From all public hospitals 
from 2000 to 2009, 1524 specific ocular ADRs were detected through the search of 
codes that could represent particular ocular ADRs. Additionally, 100 episodes that 
could possibly correspond to an ophthalmic ADR were also detected. 
We believe that the application of databases can help to increase systematization in 
Ophthalmology, if several adaptations are performed. Also, the increase in 
Ophthalmologists' education about ADRs and building protocols with other specialties 
if high-risk drugs are prescribed, may be of value in the further characterization and 
assessment of ADRs in Ophthalmology. 
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 B) ADVANTAGES AND LIMITATIONS 
 
We will discuss the advantages and limitations of each of the studies performed within 
the scope of this thesis below. 
 
1) Frequency of ADRs in hospitalized patients 
We believe that our systematic review provides an up-to-date, comprehensive 
assessment of the literature regarding the frequency of ADRs occurring during 
hospitalization with quantitative assessment and systematic evaluation of the quality 
of included studies. It was possible to identify multiple heterogeneity moderators, 
indicating the need to standardize methods and definitions used in ADR studies.  
 
 
Heterogeneity sources 
We were able to identify several sources of heterogeneity in studies about ADRs, 
particularly risk of bias and population: low risk of bias studies presented with I2=0% 
either for pediatric or adult population, however in moderate and high risk of bias 
studies there was heterogeneity even after adjusting for age (I2≥97%). Other 
heterogeneity moderators were ward and method for ADR identification. 
The studies that most contributed to heterogeneity were, on one hand, studies with 
the highest incidences: Egger (2000) (I=60.7%) and Zopf (2008) (I=35.2%). Zopf may 
have overestimated ADR incidence because: they included 26 intoxications diagnosis 
(excluded in our analysis), there were some conflicting numbers. The same happened 
with Egger, that did not explicitly exclude ADRAd and studied a geriatric ward. 
On the other hand, Bates (1993) (3.6% [1.8,5.4]), Ramesh (2003) (3.7%[3.1,4.3]) and 
Arulmani (2006) (3.8[2.9,4.7]) had the lowest incidences, which was probably due to 
the incomplete method used for ADR identification: Bates used prospective monitoring 
performed solely by a nurse; Ramesh used reporting and chart review. Arulmani 
reports performing intensive monitoring but did not perform daily evaluation and 
there are some doubts if they have performed the same follow-up to all patients. 
VI. DISCUSSION 
 
| 100 
 
 
Comparison of methodologies for ADR detection in our systematic review 
Several of the included studies used different methodologies, but only four (Fattinger 
et al, 2000; Egger et al, 2003; Somers et al, 2003; Haffner et al, 2005) used different 
concurrent methodologies for ADR identification (there are also several reported in the 
literature, but they were excluded because nor validation of ADR nor intensive 
monitoring of all patients were applied); unfortunately we couldn't compare 
methodologies' performances without biasing because of insufficient data or because 
the population was not exactly the same for both methods. 
 
 
Strengths and limitations of the systematic review 
We believe that this work has several strengths, namely the complete and systematic 
literature search; the rigid and objective selection criteria for a good level of evidence; 
the subgroup analyses to identify heterogeneity factors and the risk of bias assessment 
of included studies. This work, however, has also some limitations, such as possible 
publication bias (few unpublished studies were found and the funnel plot was not 
completely symmetrical) and the heterogeneity found in meta-analysis and in almost 
all subgroup analyses (therefore, our quantitative analyses must be viewed with 
caution).  
 
Conclusion 
We found several studies of ADRs, but almost all had extremely different 
methodologies for ADR detection (even when the same methodology was reported to 
be used, namely intensive monitoring, the methods and criteria that were utilized in 
each study were highly variable) and few studies had with good methodological 
quality. Further studies about ADRs should be methodologically improved, 
methodologies for ADR detection should be standardized, definition of ADR of WHO 
should be always followed, and causality assessment for ADR (WHO's or Naranjo's) 
should be applied.  
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2) Methodological issues in the detection of ADRs 
Several approaches for ADR detection were explored and compared in this thesis, in 
order to identify respective advantages, disadvantages, detection rate, resources 
required and other methodological issues.  
 
2.1) Spontaneous reporting 
Spontaneous reporting largely underestimates the real number of ADRs (Davies et al, 
2007; Herdeiro et al, 2008): our studies found a small prevalence of ADRs detected by 
this method and are consistent with others (McGettigan et al, 1997; Smith et al, 1996). 
However, spontaneous reporting has a widespread utilization due to its low costsand is 
the basis for the WHO Drug Monitoring Program (WHO 2012). It is possible to increase 
its low detection rate (using continuous education, change in attitudes associated with 
underreporting and stimulating spontaneous reports) but these measures increase not 
only detection but also costs. 
 
2.2) Validation study of the database methodology 
We built a database methodology for ADR detection that is simple, cheap and 
effective, through the use of coding information available in administrative databases.  
Several efforts have been performed to build a database methodology: First, we 
performed a complete test of 114 diagnostic codes' performance as well as E codes. 
Second, there was validation of ADR code signals (through chart review of more than 
350 signals), to assess positive predictive value of each code. Third, unlike previous 
literature that solely identified E codes, we identified the queries that added 
information to E codes (not queries that would generate repeated information to E 
codes), to decrease validation resources and to complement E codes. Fourth, our 
database method required reduced resources (2 person-hours) in ADR detection, in 
comparison with chart review (35 person-hours) per 100 cases. Fifth, there was an 
enhanced ability to detect ADRs, with a detection rate several times higher than the 
most widely used method in Pharmacovigilance: spontaneous reporting (325 versus 7 
ADRs). 
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There were limitations in this study, such as the fact that we didn't validate all of the 
initial 10752 ADR signals. Validating all signals would be ideal but too resource-
consuming, therefore this two-phase approach (of first selecting the best codes, then 
validating them) was a practical approach that can be used in other hospitals. The fact 
that this is a one hospital centered study might also be a limitation. We chose the 
codes that best describe this hospital's reality, but it may also be interesting to retest 
all codes in other hospitals, populations, years and countries, to understand on the 
one hand, which are the most universal codes, and on the other hand,  which occur 
more in one country, or in one hospital type, or in a particular population. 
There are also database-related limitations, namely: probable incomplete and wrong 
information in some cases in databases (which might occur in every large database), 
"coding creep" (this is a possible bias of all billing databases, in which more expensive 
codes are preferred and registered to increase the case-mix, diagnosis-related-group 
and consequently to increase reimbursement of that hospital) (Zuhair et al, 2010).  
 
2.3) Nation-wide study of ADRs using the database methodology 
In the first nationwide study of ADRs in Portugal using a methodology beyond 
spontaneous reporting, we identified 166,720 ADRs of 9,271,122 inpatients stays 
(mean prevalence of 1.3%) of all public portuguese hospitals from 2000 to the first half 
of 2009.  
These estimates were consistent with those presented in other studies that identified 
risk factors of ADRs, such as comorbidities (Seiber, 2007), diabetes (Zhang et al, 2009), 
renal failure (Corsonello et al, 2005a), female sex (WHO, 2012) and age (Davies et al, 
2007). They were also consistent with the frequency of ADRs identified by previous 
studies that used administrative databases: 0.89% in Spain (used solely E codes) 
(Salmerón-García, 2010), 0.9% in England (Corsonello et al, 2005b), 1.83% in the 
Netherlands (van der Hooft et al, 2060) and 0.8% in Australia (Wu et al, 2010). 
The advantages of this study include its comprehensive database which contains data 
from all hospitalizations in every acute care public hospital in Portugal within almost a 
decade, as well as the validation study previously performed, a far greater detection 
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rate than spontaneous reporting (detecting only 12% of the ADRs identified by the 
database), and its reasonable costs (affordable for continuous Pharmacovigilance). 
One limitation might be the use of a small one-centered validation study to a large 
National database; we assumed that the population was the same but we could be 
inducing bias if the population is different.  
 
2.4) Chart review 
From the two chart reviews performed in this thesis, a moderate detection rate was 
obtained (9-10.2%) but the costs were quite high (35 to 69 PH in 100-118 patients) 
which is consistent with other studies, namely Jha (1998) that reported costs of 55 PH. 
Some authors consider it as the goldstandard (Tinoco et al, 2011), but all agree that it 
is too resource-consuming to be continuously and widely used as a Pharmacovigilance 
methodology. 
 
2.5) Computerized chart review 
We developed and validated a computerized methodology easy and fast to apply, and 
costless to our National Health System, that detected five times more ADRs (65 versus 
12 ADRs) than manual chart review with half the resources (69 versus 29.5 person-
hours).  
Unlike other expensive computerized methodologies, we started from chart review 
with integrated data (instead of separate laboratorial data or other indicators from 
health systems), and developed databases and algorithms to create automation, while 
leaving the ultimate decision of ADR causality assessment to the health professional 
reviewer, with a simple user-friendly interface. 
The good detection rate and the low resources required (a mean of 15 minutes per 
patient), much lower than complete manual chart review, are advantages of this 
method. In small hospitals where it isn't feasible to implement complex computerized 
systems, ADR monitoring can be improved through this cheap system. The program 
Chart Helper also elaborates a list of frequent and fatal ADRs per drugs administered 
to each patient, allowing even inexperienced reviewers to detect symptoms (or signs, 
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laboratorial data or codes) that may constitute an ADR, working as a supporting 
memory tool.  Another advantage is this method integrates validation and causality 
assessment during each assessment and the fact that we performed a validation study 
in all patients using chart review. 
Nevertheless, further testing and validation must be performed. Although this method 
is resource-sparing because it has a low level of automation, it would be interesting to 
integrate it in the Health System and to add further automation (the costs would rise 
exponentially, but we believe that interesting results would be provided).  
 
 
3. Application in Ophthalmology 
Several ophthalmic/ocular ADRs were detected, either through the application of 
adapted Pharmacovigilance methodologies, and with systematic reviews of general 
and specific ophthalmic ADRs. We performed first a general systematic overview to 
summarize existing evidence and identify specific ophthalmic ADRs that were lacking 
systematization and meta-analysis. We then performed systematic reviews of those 
specific ophthalmic ADRs, as well as other studies to identify ophthalmic ADRs. We 
also tested and adapted database methodology for the detection of ADRs. 
 
3.1) General systematic review of ophthalmic ADRs 
There is an increasing number of studies of ophthalmic ADRs. In spite of the common 
belief that ADRs in Ophthalmology are rare, some ADRs might be extremely frequent 
(such as cornea verticillata caused by amiodarone (Hollander et al, 2004)), but require 
specific ophthalmological examination for its detection. Every ocular structure might 
be affected by an ADR. 
Strengths of our overview lie in the comprehensive search performed, on the general 
increase in systematization of ophthalmic ADRs, summary of existing evidence 
according to WHO's causality criteria for ADR and WHO's definition of ADR, and finally 
in the identification of specific ophthalmic ADRs that could benefit from a specific 
systematic review with possible meta-analysis. 
VI. DISCUSSION 
 
| 105 
Limitations of our overview include not only the heterogeneity found in different types 
of ADR but also the extreme variability in the methodologies of studies of ophthalmic 
ADRs (from isolated case reports to retrospective series of spontaneous reports and 
prospective observational studies). These limitations were expected, considering that 
it is a general overview and that the detection of ADRs highly depends of the degree of 
suspicion in an ophthalmologic examination. Many ophthalmic ADRs are only detected 
by case reports originating from ophthalmologic examination, representing a limitation 
but simultaneously an opportunity to improve. 
 
3.2) Specific ophthalmic ADRs 
We performed a systematic review of specific ophthalmic ADRs caused by statins (in 
the phase of pilot study of a Cochrane Collaboration review).  
Future studies are also needed in other drugs that have apparently good original 
studies reporting ophthalmic ADRs but no recent systematic review to confirm 
respective ocular ADRs are: tamoxifen, antituberculous agents, angiotensin-converting 
enzyme inhibitors and cidofovir. 
 
3.3) Application of the database methodology in the detection of ophthalmic ADRs 
The database methodology allowed the identification of 1524 specific ocular ADRs 
(and other 100 probable ophthalmic ADRs) in a portuguese population of all public 
hospitals from 2000 to the first half of 2009.  
To our knowledge, this was the first Nationwide estimate of ophthalmic ADRs in 
Portugal. Additionally, we did not identify any other study performed internationally 
that used an adapted database methodology for the identification of ophthalmic ADRs, 
or any other method in a Nationwide level except for spontaneous reports of ocular 
ADRs. We also assessed a comprehensive population within almost a decade. The 
search of general ADRs through the use of E codes allowed us to identify 116,720 
ADRs, but only 62 of them corresponded to the ocular ADRs that were identified, 
therefore, a specific search must be performed for ophthalmic ADRs.  
Limitations of this study include possible incomplete or wrong data, which can occur in 
every large database, the impossibility to validate all of these alerts and the small 
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prevalence of ocular ADRs found, namely caused by corticosteroids (which was lower 
than expected). Nevertheless, this may be an interesting and new approach to identify 
ocular ADRs at a nationwide level. Future studies include further utilization of these 
codes in other countries to identify if other ADRs can be identified, and trials of 
educational interventions to increase detection and coding of ocular ADRs. 
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 C) CONCLUSIONS AND RECOMMENDATIONS 
 
Recommendations for studies about ADRs 
ADRs in hospitalized patients can occur in 16.9% (CI95%:13.6, 20.2%) of patients during 
hospitalization, but there was heterogeneity, particularly in high risk of bias studies. 
Therefore, quality of ADRs studies should be improved, current methodologies for ADR 
detection should be standardized, and new methodologies for ADR detection should 
be developed and explored. Recommendations for future studies concerning ADRs 
include: improvement of methodological study quality (through minimization of risk of 
bias during the planning phase of each ADR study),  standardization of methodologies 
(namely a standardization of intensive monitoring with strict criteria), identification of 
new Pharmacovigilance approaches, a clear definition of ADR (WHO) and causality 
assessments (Naranjo or WHO) for ADRs.  
We recommend strict criteria for intensive monitoring, such as: 
• Monitoring performed by team members specialized or experienced in ADRs  
• With daily patient interview (and if necessary patient examination) from admission 
until discharge 
• With daily chart review 
• With at least weekly medical team interview (including doctor, nurse and 
pharmacist; clinical rounds are useful) 
• With strict application of WHO's definition of ADR 
• With causality assessment (from WHO or Naranjo) verified prior to discharge 
• With similar follow-up for patients with and without ADR suspicion 
 
Conclusions and recommendations regarding new methodologies for ADR detection 
1. Database methodology and computerized chart review are promising 
From the comparison of all methodologies, we can conclude that the methodologies 
developed in this thesis, database methodology and computerized chart review, are 
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promising and might be integrated as effective and even cheap Pharmacovigilance 
methodologies.  
The database methodology, validated by us, "lies is the middle" of spontaneous 
reporting and chart review: it is resource-sparing enough for continuous application (it 
may be even more resource-sparing than spontaneous reporting, according to 
adjusted-resources calculation), it offers a detection rate much higher than 
spontaneous reporting and it has a good PPV (similar  to chart review).  
Computerized chart review might be an useful Pharmacovigilance methodology in the 
future, particularly at a time of world economic crisis, since it may allow continuous (or 
at least regular) surveillance with a higher ADR detection with half the resources 
needed by manual chart review.  
 
2. Different methods complement each other 
In our studies, we reported that chart review, database and computerized 
methodologies seemed to detect different types of ADRs and ADRs that occur with 
different drugs, complementing each other. Other studies that compared different 
methodologies for ADR and ADE detection also reported that each methodology tends 
to detect different ADRs, concluding that multiple methods for ADR detection should 
be used complementarily for patient safety enhancement (Petratos et al, 2011).  
Therefore, database methodology and computerized chart review are effective 
Pharmacovigilance methods and should be used complementarily with spontaneous 
reporting. 
 
 
Conclusions and recommendations in Ophthalmology 
Ophthalmology represents simultaneously a challenge and an opportunity to identify 
ADRs. Databases are a useful methodology for the detection of ocular ADRs, but 
require adapted diagnoses codes.  
VI. DISCUSSION 
 
| 109 
 
Adapted methodologies were successful in detecting either general and specific 
ophthalmic ADRs and should be used continuously.  
We also believe that all spontaneous reports of ophthalmic adverse drug reactions 
could be sent for analysis by an ophthalmologist experienced with ADRs, for further 
study and orientation, in an attempt of a multidisciplinary and complete analysis.  
Ophthalmologists' knowledge about ophthalmic ADRs is essential for its detection and 
should be stimulated. Therefore, strong suggestions for the future include promoting 
ophthalmologists' education (to increase recognition of ophthalmic ADRs) and 
disseminating protocols of collaboration between Ophthalmology and other Medicine 
specialties whenever high-risk drugs are prescribed (such as sildenafil, biphosphonates, 
psychiatric medication, tamoxifen, hydroxichloroquine). 
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REVIEW
Frequency of adverse drug reactions in hospitalized patients: a
systematic review and meta-analysis†
Ana Miguel*, Luís Filipe Azevedo, Manuela Araújo and Altamiro Costa Pereira
Department of Health Information and Decision Sciences, Faculty of Medicine, Porto University, Portugal
ABSTRACT
Purposes To perform a comprehensive systematic review of prospective studies about frequency of adverse drug reactions (ADRs)
occurring during hospitalization (ADRIn), including a thorough study quality assessment, meta-analysis and heterogeneity evaluation.
Methods Systematic review of several databases: Pubmed, EMBASE, CINAHL, Cochrane, ISI, International Pharmaceutical Abstracts,
Scirus, NHS economic, and others, as well as manual search. Inclusion criteria were: prospective studies (assessing all patients before
discharge, by a specialized team, at least once a week); with data about ADRs occurring during hospitalization, using WHO’s or similar
deﬁnition of ADR. Two independent reviewers assessed eligibility criteria, extracted data, and evaluated risk of bias.
Results From 4139 studies initially found, 22 were included. Meta-analysis indicate that ADRs may occur in 16.88% (CI95%:
13.56,20.21%) of patients during hospitalization; however, this estimate has to be viewed with caution because there was signiﬁcant
heterogeneity (I2 = 99%). The most signiﬁcant moderators of heterogeneity were risk of bias, population, ward, and methodology for
ADR identiﬁcation. Low risk of bias studies adjusted for population (pediatric versus adult) had I2 = 0%.
Conclusions These data are useful as a broad characterization of in-hospital ADRs and their frequency. However, due to heterogeneity,
our estimates are crude indicators. The wide variation in methodologies was one of the most important moderators of heterogeneity
(even among studies using intensive monitoring). We suggest criteria to standardize methodologies and reduce the risk of bias. Copyright
© 2012 John Wiley & Sons, Ltd.
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INTRODUCTION
Adverse drug reactions (ADRs) are frequent, important,
expensive, and can be fatal.1,2 In 1998, Lazarou
estimated that ADRs were between the fourth and the
sixth leading causes of death in the US3 but there was
heterogeneity.4 ADRs are the cause of 2.7% to 15.7%
hospital admissions.5–7
They may lead to US$1.56 billion in direct hospital
costs per year in the US,8 and drug-related morbidity
may lead to US$136.8 billion in indirect costs.9 Each
ADR may represent a cost of US$2500 per patient.10
Although there are numerous studies about ADRs,
the methods of identiﬁcation and reporting ADRs vary
greatly.11–14 Some studies have assessed difﬁculties in
building a quality systematic review of ADRs or
adverse drug events,15,16 while others have established
useful recommendations.17–19 There are several good
systematic reviews about ADRs that cause hospital
admission(ADRAd);20,5 however, it is still lacking in
the literature a current and adequately performed
systematic review regarding the frequency of ADRs
occurring during hospitalization(ADRIn). Moreover,
in systematic reviews of general ADRs, there is the
need for more complete, thorough, and meticulous
systematic literature search; using a single and
standardized deﬁnition of ADR; and a more thorough
and appropriate heterogeneity analysis.
Our primary purpose was to systematically review the
literature regarding the frequency of ADRIn. Secondary
objectives were the characterization of ADRs3,13,21 and
their identiﬁcation by each pharmacovigilance method.
We also aimed to undertake a thorough analysis of the
methodological quality of the included studies and of
factors associated with heterogeneity.
*Correspondence to: Ana Miguel, Rua Quinta do Sardoal, VE3, n10, 4430–182
V.N.Gaia, Portugal. E-mail: myworld_ana@hotmail.com
†Sponsor: the authors had no sponsoring
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METHODS
We performed a systematic review of studies that
assessed ADR frequency among hospitalized patients.
Since there is a wide variation of terms, we present
some deﬁnitions.
Deﬁnition of adverse drug reactions
Adverse drug reaction: “any noxious, unintended and
undesired effect of a drug, which occurs at doses used
in humans for prophylaxis, diagnosis, or therapy”,
according to the World Health Organization (WHO)
deﬁnition of 1972.22 This deﬁnition is the most widely
used, but there are others, like Karch and Lasagna’s23
(similar but excludes therapeutic failures) and
Edwards and Aronson’s24: “an appreciably harmful
or unpleasant reaction, resulting from an intervention
related to the use of a medicinal product, which pre-
dicts hazard from future administration and warrants
prevention or speciﬁc treatment, or alteration of the
dosage regimen, or withdrawal of the product”.
Adverse drug events (ADE) were not the purpose of
our review: “An injury related to the use of a drug,
although the causality of this relationship may not be
proven”.25 They include errors and ADRs.
Search methods
Our review adhered to the Cochrane approach26 and
PRISMA Statement.27
We searched through several electronic databases
(last date of search was 2/4/2010): Medline, EMBASE,
Cochrane Central, SCOPUS, EBSCO, ISI web of
knowledge, ISI Conference Proceedings, International
Pharmaceutical Abstracts, DARE, LILACS, Scirus,
NHS economic evaluation database, other conference
proceedings, clinicaltrials.gov, and Google scholar.
We used a search query created after two pilot studies
(full search query in supplemental material).
We emailed experts10–12 for grey literature and
unpublished data, and hand-searched all references of
included studies and relevant reviews.
Selection criteria
Studies were included if they followed all inclusion
criteria listed below:
1. Prospective studies, that followed hospitalized patients
from admission to discharge, assessing in all patients
the existence of ADRs prior to discharge, and in
which investigators were able to interview physi-
cians, patients, or nurses at least once per week.
Studies assessing ADRs only at hospital entry or in
emergency wards were not included.
2. Studies that previously planned and described a
consistent and reproducible methodology for ADR
detection, later applied to all patients in a stan-
dardized manner. These methodologies included:
2.1. Intensive monitoring applied to all patients.
To reduce the high methodological variability
of studies that claim to perform intensive
monitoring, we created strict criteria for consid-
ering a methodology as intensive monitoring:
• Monitoring was performed by specialized
team member(s) with experience in ADR
identiﬁcation.
• Monitoring included a daily review of the
chart, visiting of the ward and interview
of the patient. If necessary, the patient was
examined.
• Monitoring included an interview of the
health care team at least once a week.
• A daily chart review without patient inter-
view nor examination was not considered
intensive monitoring (it was considered
chart review).
2.2. Prospective monitoring applied to all patients.
This would include studies in which monitor-
ing of patients was performed with assess-
ment of ADRs before discharge, with patient
interview or examination or health team in-
terview at least weekly, but without fulﬁlling
all the criteria above for intensive monitoring
(even if the authors called it intensive
monitoring).
2.3. Prospective chart review applied to all patients,
with patient interview or examination or health
team interview.
2.4. Computerized monitoring if another meth-
odology (chart review, prospective, or inten-
sive monitoring) was also applied to all
patients. Computerized monitoring in which
only computer alerts were validated were
excluded, because it was not a methodology
equally applied to all patients.
2.5. Database search if another methodology (chart
review, prospective, or intensive monitoring)
was equally applied to all patients.
2.6. Spontaneous or solicited reporting if another
methodology (chart review, prospective, or
intensive monitoring) was applied to all patients.
a. miguel et al.
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3. Studies with sufﬁcient data about frequency of
ADRs (if a study focused on ADE, it needed to
have separate data on ADR).
4. Studies of ADRs that occurred during hospitalization
(ADRIn). We were not interested on ADRs as a cause
of hospital admissions (ADRAd).
5. Studies that used WHO’s deﬁnition of ADR.23
Studies with other similar deﬁnitions (like Karch
and Lasagna24) were included but analyzed separately
(in order to identify if this added heterogeneity).
When studies provided their own deﬁnition described
in detail, we sought inconsistencies with WHO’s
deﬁnition (if inconsistent, they were excluded).
When no deﬁnition or an imprecise deﬁnition was
reported, we emailed authors. Studies that claimed
to assess frequency of ADEs but provided WHO’s
deﬁnition and criteria of ADRs were included (they
studied ADRs although they inappropriately called
them ADEs). Studies with Edwards and Aronson’s
ADR deﬁnition25 were not included because
although it is a good deﬁnition, it is rather different
from WHO’s deﬁnition.
We also included studies with different languages
(English, Portuguese, Spanish, French, German - we
hired a translator), any country, any ward (we included
pediatric wards for a comprehensive view), experimental
studies (if any), and year of study (although we only
included studies after WHO’s deﬁnition of 1972). We
did so to have a more thorough and complete literature
search and to have the opportunity to analyze them as
subgroups and identify sources of heterogeneity.
Exclusion criteria:
1. Studies including only patients with particular pathol-
ogies (we did not exclude studies that systematically
identiﬁed ADRs in particular wards; although we
planned to analyze them separately)
2. Studies for speciﬁc drug exposures (speciﬁc ADRs
such as bleeding were not excluded per se)
3. Studies in which the primary objective was not ADR
identiﬁcation (like trials of drug effectiveness), in
order to warrant a methodology systematically
applied to assess ADRs frequency.
Outcomes assessment
Primary outcome was frequency of ADRIn (number of
ADRs, number of patients exposed to drugs, length of
hospital stay if reported). The number of patients
exposed to drugs was sometimes not speciﬁed by the
authors; in that case, we emailed them and if without
response assumed that it was equal to number of
patients included in the study (assumed data, raw data,
and calculated data are all explicit in Table 1).
We calculated cumulative incidence, more adequate as
a proportion than as a rate, because in a rate, we would
need to know length of stay for each patient. The cumula-
tive incidence of ADRIn (I) was calculated as follows:
We calculated its standard error (E): E = square
(I(1-I)/N))
Other variables of interest, if reported, were: particular
diagnosis, year of study, ward and hospital type, mean
age of patients, average length of hospital stay, mean
number of drugs per patient. If reported which drug
was used, we identiﬁed the therapeutic drug class
according to Martindale’s reference book,28 number of
days in which the drug was used, and administration
route. We always veriﬁed if causality was assessed
(and according to what classiﬁcation, preferably WHO’s
or Naranjo’s29) as well as predictability of ADRs (using
Hartwig’s predictability scale, for example),30 prevent-
ability (e.g. Schumok and Thornton’s preventability
criteria)31 and types of ADRs (Rawlins and Thompson’s
classiﬁcation21); otherwise, we emailed authors.
Data collection and analysis
Two independent reviewers, AM and MA, ﬁrst
examined each title and abstract to exclude obviously
irrelevant reports, and then independently examined
each full text report, to determine eligibility according
to inclusion criteria.
We performed a pilot test to evaluate the selection
procedure and criteria on a sample of reports, as
recommended by the Cochrane approach.26 We then
performed another pilot test with 100 random studies.
We used those tests to reﬁne criteria and train
reviewers. Disagreements were solved by consensus,
recorded, and analyzed using kappa statistics.
I ¼ number of patients with ADRIn=number of patients exposed to any drug
a systematic review of adverse drug reactions
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Risk of bias assessment
Wealso performed two pilot studies using a standardized
form to evaluate the methodological quality of included
studies. We did not use scales (discouraged by the
Cochrane approach26) but criteria from Cochrane,
STROBE,32 QUOROM,33 and PRISMA27 adapted to
the scope of ADRs frequency evaluation, which in-
cluded: complete description of study design, veriﬁca-
tion if all parts of study were prospective, number of
hospitals in which study occurred, adequate selection
criteria, deﬁnition of ADR, rationale for study size,
causality assessment of ADR, avoidability assessment
of ADR, description of all statistical methods, character-
ization of study participants and of number of partici-
pants at each stage, description of methods to prevent
information and selection bias, intensive monitoring,
description of methods to avoid other bias, presentation
of complete summary measures. The two reviewers
independently assessed study quality and risk of bias;
disagreements were solved by consensus.
Studies were divided in low risk of bias (ﬁve or
less parameters with medium, unclear, or high risk
of bias), medium risk (six to nine) and high risk
(ten or more parameters evaluated as medium,
unclear, or high risk of bias).
Quantitative analysis
Statistical analyses were done with the Chi-square
test for categorical variables, Student’s t-test for
normally distributed continuous variables, and
Mann–Whitney or Kruskal–Wallis when dealing
with variables without normal distribution, using
SPSS v17. Excel was used for incidence and
standard error calculations. Quality evaluation graphs,
heterogeneity analysis, subgroup analysis, and random
effects meta-analysis were performed using Review
Manager - version 5.0. The a priori level of signiﬁ-
cance for all hypothesis tests was p< 0.05.
Subgroup analyses
High heterogeneity was expected according to previ-
ous studies. Our purpose was to identify heterogeneity
sources, therefore, several subgroup analyses were
planned:
• Study location - subgroups based on continent
or country
• Methodology for ADR detection
1. Intensive monitoring
2. Prospective monitoring
3. Chart reviewTa
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4. Computerized monitoring that generated
ADR alerts (included only if alerts were val-
idated by team and if other methodology was
also applied to all patients, such as chart
review or prospective or intensive monitoring)
5. Database monitoring (included only if other
concurrent methodology applied to all patients)
6. Spontaneous or solicited reporting (included
only if other methodology was concurrently used
in all patients)
7. If several methodologies were concurrently
applied in a study, we planned to compare them
(only if the population was strictly the same).
• Ward type - internal medicine, general surgery,
intensive care unit, pediatric, geriatric, obstetric, or
other as reported by authors. We registered if the
study was performed on several wards without
specifying number of patients for each, and also if
ward was not reported.
• Hospital type - teaching/university versus non teaching
hospital - as reported by authors (if conﬂicting or
unreported, we searched the internet).
Figure 1. Flowchart of search strategy
Figure 2. Subgroup analysis based on wards
a. miguel et al.
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• Risk of bias
• Adult Vs pediatric (<18 years) versus geriatric
(>64years) population.
• ADR deﬁnition - WHO’s strict deﬁnition23 versus
Karch and Lasagna’s24 or WHO’s deﬁnition with
slight imprecisions in application
• Study duration (short follow-up studies <3 months;
medium: 4–11 months; long≥ 12months)
RESULTS
Literature search and selection process
Pubmed search yielded 1124 results; EMBASE yielded
653 results; CINAHL 173; Cochrane 7; ISI Conference
Proceedings 95; ISI Web of Knowledge 573; Interna-
tional Pharmaceutical Abstracts 887; Google Scholar
60; Scirus 61; NHS economic evaluations database
14; others yielded 492. From these 4139 studies
(corresponding to 2853 distinct studies), 230 were
selected to obtain full text and then 22 studies were
included34–55 (Figure 1). A list of exclusions can be
obtained from the corresponding author. During the ﬁrst
phase, Kappa agreement for study inclusion was 0.77;
during the full text review, was 0.89 (good agreement).
Characteristics of included studies
Table 1 summarizes the characteristics of included
studies; within these, there were 18 818 hospitalized
patients exposed to drugs; 2458 of them suffered an
ADR while hospitalized; 3553 ADRIn were identiﬁed.
ADR incidence
The pooled ADR cumulative incidence estimated in
the meta-analysis was 16.88 (CI95% of 13.56,20.12);
however, there was heterogeneity: I2 = 99%.
Studies with the highest incidence estimates were:
• Egger42: 60.74% (CI95%: 53.23,68.25). A study from
Germany that performed prospective monitoring of all
patients admitted to a geriatric ward to compare the
ADR rate predicted by a computerized pharmaceutical
database to that determined by direct observation.
• Zopf52: with 35.17% (CI95%: 32.05,38.29). A
Germany cohort of all patients admitted to two
medical wards in two university hospitals, with
intensive monitoring (daily, by a trained team of
three physicians, one pharmacologist, and two phar-
macists) to characterize risk factors associated with
ADRs after admission.
Figure 3. Subgroup analysis based on study location
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Studies with the lowest incidences were:
• Bates34: 3.57% (CI95%: 1.79,5.35). AnAmerican pro-
spective cohort in seven wards of a tertiary hospital,
with daily chart review by a nurse and solicited report-
ing, to evaluate incidence and preventability of ADEs.
• Ramesh43: 3.71%(CI95%:3.10,4.32). An Indian
study in which spontaneous, solicited notiﬁcation,
and chart review were performed in all hospitalized
patients. Intensive monitoring was performed only
in patients suspects of having an ADR.
• Arulmani51: 3.75% (CI95%: 2.85,4.65). An Indian
prospective cohort study of patients admitted to three
wards, using solicited reporting and prospective mon-
itoring to ascertain ADR frequency, severity, and cost.
Subgroup analysis
The most relevant heterogeneity moderators were 1st:
risk of bias, 2nd: population, 3rd: ward, 4st: method.
Ward (Figure 2): there was signiﬁcant heterogeneity in
every ward (I2≥96%), and statistically signiﬁcant
difference between wards (p=0.03).
Study location (Figure 3): there was also heterogeneity
(I2≥98%) and statistically signiﬁcant difference
between continents (p=0.01).
Risk of bias (Figure 4): Moderate and high risk of bias
studies presented high heterogeneity (I2 = 99%), that
did not disappear after we adjusted for population age
(pediatric versus adult). Low risk of bias studies
presented low heterogeneity (I2 = 54%) that disappeared
when we adjusted for population type (I2 = 0% either in
adult or in pediatric group).
Method for ADR identiﬁcation (Figure 5):Many studies
had more than one methodologies but none applied
exactly to the same population; therefore, none was truly
comparable; in that case, we attributed to that study the
subgroup of the methodology that was more comprehen-
sive. All subgroups presented heterogeneity, slightly
smaller in intensive monitoring (I2 = 98%), non statisti-
cally signiﬁcant (p=0.90).
Other subgroup analyses performed (in supplemental
material) revealed also heterogeneity: hospital type
Figure 4. Subgroup analysis of risk of bias adjusted for population age
a. miguel et al.
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(I2 = 99% in teaching and non teaching hospitals, no
difference between subgroups p= 0.41), population
(adult I2 = 99%, pediatric I2 = 96% and two geriatric
studies that presented I2 = 97%, p= 0.42), study duration
(small studies I2 = 100%, medium I2 = 99%, long
I2 = 97%, p=0.19), strict deﬁnition of ADR (I2 = 99%
for all subgroups, p=0.76). We also performed a post-
hoc subgroup analysis according to team member
responsible for ADR detection during the study; all had
heterogeneity: physician I2 = 88%, pharmacist I2 = 99%,
and multidisciplinary team I2 = 98%, p< 0.00001.
We plotted ADR incidence against study size56:
smaller studies tended to identify higher incidences.
Our funnel plot was not completely symmetric (proba-
bly because although we emailed authors asking for
unpublished data, none was supplied).
Risk of bias assessment
In Figure 6, we present the summary of our quality
evaluation of included studies, according to each
parameter assessed - risk of bias graph. All studies
had low risk of bias in the description of study design,
while only one study calculated the intended study
sample size. Most studies reported strategies to pre-
vent selection bias (like strict intensive or prospective
monitoring, applied to all patients and not just to
ADR suspects), but the majority did not report strate-
gies to prevent information bias.
Table 2 shows the performance of each study
in each quality criteria. Few studies had low risk
of bias,36,37,45,49,54 and several had moderate
risk.34,35,38,39,41,46–48,50–53,55
DISCUSSION
What this study adds
This systematic review provides an up-to-date, com-
prehensive assessment of the literature regarding
the frequency of ADRs occurring during hospitaliza-
tion with quantitative assessment and systematic
evaluation of the quality of included studies. It was
Figure 5. Subgroup analysis of methodology for ADR identiﬁcation
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possible to identify multiple heterogeneity moderators,
indicating the need to standardize methods and deﬁni-
tions used in ADR studies.
The objective of this study was to estimate ADRIn
frequency and to identify and explore sources of
heterogeneity. Because there was signiﬁcant heteroge-
neity in almost all analyses, quantitative data must
be viewed with caution.
Several sources of heterogeneity were identiﬁed;
however, adjusting for them surprisingly did not
change signiﬁcantly the results except for risk of bias
and population: low risk of bias studies presented
with I2 = 0% either for pediatric or adult population;
however, in moderate and high risk of bias studies,
there was heterogeneity even after adjusting for age
(I2≥ 97%). This reveals the absolute importance of
creating speciﬁc quality criteria for studies about
ADRs, as well as following guidelines and deﬁnitions
of ADRs, and standardizing methodologies for ADR
Table 2. Risk of bias assessment. We report risk of bias assessment criteria and results for all included studies
Study (author, year) Multicenter?
All parts
prospective?
Describe
study
design*
Objective and
adequate
selection
criteria*
Diagnostic
criteria/
deﬁnition
of ADR
Causality
assessment
Avoidability
assessment
Methods
to avoid
selection
bias *
1993 Bates N Y Y Y Y (WHO) Y (Naran-jo) Y (“4 point
scale”)
U
1998 Moore N Y Y U U (just serious
ADRs)
y U N
1999 Gholami N Y Y Y Y (WHO) Y (Naran-jo) Y
(Schumok)
Y
1999 Martínez-Mir N Y Y Y Y (WHO) Y(Spanish
Drug)
N Y
2000 Bemt Y Y Y Y Y (WHO
deﬁnition)
U N Y
2000 Fattinger Y Y Y U U (just
included
“clinically
relevant”)
Y (Naranjo) U N
2002 Buajordet N Y Y Y Y N N U
2002 Weiss N Y Y Y Y (WHO) Y (Naranjo
modiﬁed)
Y Y
2003 Egger N Y Y Y Y (WHO) Y (Schumok) Y(Naranjo) U
2003 Ramesh N U Y Y Y (WHO) Y (WHO) N N
2003 Somers N Y Y Y Y Y(WHO) U N
2003 Vargas N Y Y Y U(Karch and
Lasagna)
Y (WHO) Y Y
2005 Fattahi N Y Y Y Y (WHO) Y (WHO) N Y
2005 Haffner N Y Y Y Y (WHO) Y (WHO) N U
2006 Camargo N Y Y U Y (WHO) Y(Naranjo) N Y
2006 Santos N Y Y Y Y (WHO) Y (WHO) N Y
2006 Tribiño N Y Y Y Y (WHO) Y (Naranjo) N U
2007 Arulmani N Y Y Y Y WHO) Y (Naranjo) N Y
2008 Zopf Y Y Y U U (WHO,
imprecisions)
Y (Naranjo) U Y
2009 Joshua N Y Y Y Y(WHO) Y(WHO) N U
2009 Pourseyed N Y Y Y Y (WHO) Y (WHO) Y
(Schumok)
Y
2009 Santos N Y Y Y Y (WHO) Y (Naranjo) N N
Abbreviations and symbols used: *: Adapted from STROBE criteria, N: no, Y: yes, U: unclear, WHO: deﬁnition of WHO used for ADR
Figure 6. Risk of bias graph
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detection. The biggest heterogeneity moderator was
risk of bias, followed by population, ward, and method
for ADR identiﬁcation.
We included surprisingly few studies from the US,34
which is related to our strict inclusion criteria. Many
US studies used computerized methods of ADR iden-
tiﬁcation for patient screening but followed just ADR
suspects, not all hospitalized patients, therefore not
assessing equally in all patients the existence of ADRs.
On the one hand, it is clear that the present and future
of pharmacovigilance involves computer systems; on
the other hand, we wanted to include only computer-
ized studies that used a concurrent systematic valida-
tion by evaluating all patients (either with chart review
or prospective or intensive monitoring), to obtain a
more valid estimate of ADR incidence. Since many
American hospitals use electronic health records, com-
puterized approach could replace manual chart review;
however, all of the chart review included studies
perform concurrently patient examination and ward
visit of all patients, which is still lacking in computer-
ized approaches for us to consider computerized
approach enough per se as an inclusion criteria in this
review in particular.
Asian studies showed a tendency to have smaller
incidences of ADRs (10.04[6.06,14.02]) (Figure 3),
and Europe higher (22.09[15.25–28.92]), with statisti-
cally signiﬁcant differences between all continents;
however, since there was heterogeneity in all, we do
not know it this tendency is real.
The studies that most contributed to heterogeneity
were, on one hand, studies with the highest incidences:
Egger42 (I=60.74%) and Zopf52 (I=35.17%). In our
sensitivity analysis, Zopf added most heterogeneity
(smaller standard error). Zopf may have overestimated
ADR incidence because: they included 26 intoxications
diagnosis (excluded in our analysis), there were some
conﬂicting numbers (for example, on page 792: “907
Table 2. Continued
Methods to
avoid
information
bias*
Rationale
for study
size*
Describe all
statistical
methods*
Report nr of
individuals at
each stage*
Characterize
study
participants*
Complete
summary
measures*
Report other
analyses
performed*
Intensive
monitoring
(see text)?
Methods to
avoid other
bias?
Y N Y Y U U Y U (nurse) U
N N Y Y Y Y Y Y U
Y N Y Y U N U Y Y
Y N Y U Y Y Y Y U
Y (adjusted
Odds Ratio)
N Y Y N Y Y Y
(pharmacist)
U
N N N Y Y Y Y N N
U N N N U Y U N (daily chart
review)
U
N N Y N Y N N N U
U N U Y U U U N U
N N Y U U U Y N U
U N U Y Y U U N U
U N Y Y Y Y Y Y U
U N Y U U Y U Y U
U N Y Y Y Y Y Y U
U Y Y Y Y Y U N N
U N Y Y Y Y Y Y U
U N Y Y U Y Y N U
U N N U U N Y N U
U N Y U N N Y Y Y
U N Y Y U Y Y N U
U N Y Y Y Y Y Y Y
N N U Y Y Y N N N
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patients were intensively followed [. . .] comprising 480
males and 423 females”[which gives only 903]), and
did not clearly exclude ADRAd (although they refer
to “ADRs following hospital admissions”). The same
happened with Egger, that did not explicitly exclude
ADRAd, but studied “occurrence of ADRs during
hospitalization”; if ADRAd were included, this might
explain the high incidence reported. Also, Egger studied
a geriatric ward, and ADRs tend to occur more
frequently in the elderly.
On the other hand, Bates34 (3.57% [1.79,5.35]),
Ramesh43 (3.71%[3.10,4.32]), and Arulmani51 (3.75
[2.85,4.65]) had the lowest incidences. This was
probably due to the method used for ADR identiﬁca-
tion: Bates used prospective monitoring performed
solely by a nurse without latter pharmacist or physi-
cian validation; Ramesh did not use intensive moni-
toring (he used reporting and chart review). Arulmani
reports performing intensive monitoring, but does
not specify daily patient evaluation (“patient exam
and interview when necessary”), and there are some
doubts if they have performed the same follow-up to
all patients.
Several of the included studies used different
methodologies, but only four used different concurrent
methodologies for ADR identiﬁcation39,42,44,47 (there
are also several reported in the literature, but they were
excluded because nor validation of ADR nor intensive
monitoring of all patients were applied); unfortunately,
we could not compare methodologies’ performances
without biasing because of insufﬁcient data or because
the population was not exactly the same for both
methods.
Several studies claimed to have performed intensive
monitoring but used extremely different methodologies;
consequently, we recommend strict criteria for inten-
sive monitoring, such as:
• Monitoring performed by team members special-
ized or experienced in ADRs
• With daily patient interview (and if necessary
patient examination) from admission until discharge
• With daily chart review
• With at least weekly medical team interview
(including doctor, nurse, and pharmacist; clinical
rounds are useful)
• With strict application of WHO’s deﬁnition of ADR
• With causality assessment (from WHO or Naranjo)
veriﬁed prior to discharge
• With similar follow-up for patients with and without
ADR suspicion
The strengths of this systematic review are: ﬁrst, a
complete and systematic literature search; second, a
choice of studies within rigid and objective selection cri-
teria for a good level of evidence; third, planning several
subgroup analysis to identify heterogeneity factors;
fourth, objective quality evaluation of included studies.
The limitations of this study include possible publi-
cation bias because few unpublished studies were
found (none through email response of experts and
some through bibliographic search) and the funnel plot
was not completely symmetrical.
The biggest limitation of this study is its heterogene-
ity and the inability to surpass it and to estimate
the real ADR incidence. This heterogeneity is also
present in the other systematic reviews of ADRs, since
Lazarou’s3(the reason for criticism4) to more recent
studies, either about ADRs associated with hospital
admissions5–7 or ADRs during hospitalization.
There are many studies about ADRs but almost
all add heterogeneity; therefore, attention must be
directed to several methodological aspects of ADRs
studies. The frequency, relevance, and impact of
ADRIn clearly indicate the need for further studies of
this nature in the future. Improvement of methodolog-
ical study quality (through minimization of risk of bias
during the planning phase of each ADR study), stan-
dardization of methodologies (namely, a standardiza-
tion of intensive monitoring with strict criteria), a clear
deﬁnition of ADR (WHO), causality(Naranjo), and
preventability assessments are suggestions for studies
in the future.
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KEY POINTS
• Hospital adverse drug reactions(ADRs) are
frequent, important, expensive, and can be fatal.
• Meta-analysis of available studies indicates
that ADRs may occur in 16.88% (CI95%:
13.56-20.21) of patients during hospitalization
(however, this estimate has to be evaluated
with caution because there is high heterogene-
ity among studies).
• The most signiﬁcant moderators of heterogeneity
were the study methodological quality (risk of
bias), population, ward studied, and method used
for ADR identiﬁcation.
• Few studies regarding frequency of ADRs in
hospitalized patients have low risk of bias,
thus improvement of study quality is highly
recommended.
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BRIEF REPORT
Methodologies for the detection of adverse drug reactions: comparison
of hospital databases, chart review and spontaneous reporting
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ABSTRACT
Purpose To evaluate a methodology for adverse drug reactions (ADRs) detection through hospital databases.
Methods A retrospective analysis was conducted to identify ADRs using diagnostic codes from databases, later validated by chart review.
An independent chart review was performed for comparison, as well as assessment of spontaneous reports.
Results 325 ADRs were identiﬁed (prevalence of 2.41%, positive predictive value of 87.6%). Independent chart review identiﬁed 9% of
ADRs at a cost of 35 person-hours (versus two person-hours in databases). There were seven spontaneous reports of ADRs.
Conclusions Although not frequently used, the detection of ADRs through databases is a relatively less expensive, fast and effective
methodology that can improve current pharmacovigilance systems. Copyright © 2012 John Wiley & Sons, Ltd.
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INTRODUCTION
Adverse drug reactions (ADRs) represent an impor-
tant burden in Health Care1: they are between the
fourth and the sixth leading causes of death in the
US2 and lead to US$1.56 to US$4 billion in direct hos-
pital costs per year in the US. 3
The methodology of ADR detection and monitoring
varies widely, and in the last decades, several approaches
to pharmacovigilance have been developed1:
1. Spontaneous reporting of a potential ADR by a
health team member is the main method used in
Europe, but underreporting4 is a problem. The
World Health Organization (WHO) Programme
for International Drug Monitoring relies on spon-
taneous reports from more than 100 countries
including Portugal and builds a global database to
identify possible relationships between the use of
a drug and adverse effects and ADRs.
2. Intensive monitoring is the gold standard, in which
an expert team prospectively examines hospitalized
patients and applies criteria to identify and classify
ADRs; however, it is extremely resource and time
consuming for routine use. 5
3. Chart review (prospective or retrospective) is
reasonable but also resource and time consuming. 6
4. Computerized systems generate ADR signals in
several groups of patients, later validated by an
expert team. 7 This is an interesting method, but
attention is needed to build rules and algorithms
with high speciﬁcity, otherwise it may also be
resource consuming. Other problems of this method-
ology are the dependency of structured data and the
difﬁculty with using data from narrative notes.
5. Administrative databases are not widely used, but
they may have some advantages. 8
In many European countries including Portugal,
spontaneous reporting is the only continuously applied
pharmacovigilance method due to its low cost. Prospec-
tive monitoring is also frequently performed in several
countries in Europe. In the United States, computerized
methods and the search through large insurance data-
bases are widely used.
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VE3, nº10, 4430–182V.N.Gaia, Portugal. E-mail: myworld_ana@hotmail.com
Copyright © 2012 John Wiley & Sons, Ltd.
pharmacoepidemiology and drug safety 2013; 22: 98–102
Published online 1 October 2012 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3348
In our hospital (Hospital University Centre of
Coimbra, General Hospital - HUCC-HG), there are
no speciﬁc methodologies currently applied for ADR
detection. There is currently no speciﬁc formation for
physicians, pharmacists or nurses to develop prospec-
tive or intensive monitoring for ADR detection and
characterization on a regular basis. Also, considering
the Portuguese economic crisis, it is not possible at
the moment for this hospital to invest in building a
computerized system for ADR detection or even
for adjusting the existing computerized systems to
prospectively detect ADRs in hospitalized patients.
The limitations of spontaneous reporting, the high
cost of intensive monitoring, the economic impossibility
to build a computerized system in our hospital and the
fact that in Portugal and many other countries there
are no real data about ADRs that occur during hospital-
ization (ADRIn) were the motivations of this project.
Our purpose was to develop and validate a method-
ology of ADR detection through diagnostic codes of
administrative databases, allowing us to identify and
characterize ADRs. We also intended to evaluate this
methodology, comparing it with chart review and with
spontaneous reporting.
METHODS
Study design
A retrospective study was performed for ADR detection
using International Classiﬁcation of Diseases 9th
Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic
codes of an administrative database, with all hospitaliza-
tions in 2008 from HUCC, Portugal. This Hospital
Centre is composed of eight hospitals in Coimbra (three
psychiatric hospitals, two maternities, one pediatric hos-
pital, one university hospital and one general hospital).
The study was performed in the General Hospital of
HUCC -HUCC-HG, a tertiary hospital in Coimbra, with
341 beds and a mean number of 12 500 hospitalized
patients per year. This study was performed according
to HUCC’s Ethics Committee.
Development of a methodology
We intended to develop a methodology that allowed us
to, through HUCC-HG’s database: identify and charac-
terize ADRs (namely prevalence, clinical manifestations
associated, drugs more frequently involved and risk
factors), select the codes within the database with higher
predictive positive value (PPV) and validate them by
chart review. We also aimed to compare our database
methodology with spontaneous reporting and with chart
review. We did so in order to build a complementary
methodology that could help the Portuguese pharma-
covigilance system without increased costs.
Database and coding information
The clinical information in our database used coding
based on ICD-9-CM. Codes searched included not only
E codes (from E930 to E949.9, codes designed to mark
ADRs, already excluding wrong doses, errors and
intoxications) but also diagnostic codes, such as
“733.09 - Drug-induced osteoporosis” (as reported in
the literature6,8–10 or others considered useful). We also
tested every diagnosis with the expressions: “Due to
drugs”, “drug-related”, “medicamentosa” and “iatrogenic”.
For validation, we selected the E codes and the 40
diagnostic codes that allowed us to identify more cases
of ADR suspects which added information relatively to
E codes, more speciﬁcally, that identiﬁed more cases of
ADR suspects and did not have an E code (this is the
result of bad coding, since ICD-9-CM instructs to use
an E code with every diagnosis signaling an ADR; we
wanted to detect it to increase ADR detection and
improve coding).
Methodology validation
A chart review was performed to validate ADR
signals by an experienced team member (AM), using
several strict criteria (among other data to be ﬁlled in
a previously built and tested formulary):
• WHO’s deﬁnition of ADR: “any noxious, unin-
tended and undesired effect of a drug, which occurs
at doses used in humans for prophylaxis, diagnosis,
or therapy”. 11 Adverse drug events, which include
ADRs and errors, were not the purpose of our study;
an adverse drug event is: “an injury related to the
use of a drug, although the causality of this relation-
ship may not be proven”.12
• WHO’s causality assessment of ADR11
• Schumok’s preventability assessment13
• Hartwig’s severity assessment14
• Rawlin’s type A andB classiﬁcation of each ADR15
Each query was evaluated independently to calcu-
late its PPV. Afterwards, we intended to select a few
queries with the highest PPV, to build a methodology
with a good global performance and easily applied in
other databases, other hospitals and other years.
Comparison with other pharmacovigilance methods
We compared database performance with spontaneous
reporting and chart review (for that, a randomized
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group of 100 patients from the same period and
hospital was selected for independent chart review).
The number of person-hours spent during the
application of each methodology was assessed.
Statistical analysis
We previously calculated sample size to independent
chart review (95 patients necessary) using an online
calculator. 16 Statistical analyses were done with
the Chi-square test for categorical variables, Student’s
t-test for normally distributed continuous variables and
Mann–Whitney or Kruskal–Wallis for variables with-
out normal distribution, using SPSS v20. The a priori
level of signiﬁcance was p< 0.05.
RESULTS
During the year 2008, there were 13 471 hospitalizations
in HUCC-HG (10 600 patients were admitted more than
once during that year). Mean participant age was
64 years (sd =19.45). Forty ﬁve percent were female.
E codes generated 283 signals in the database,
corresponding to 270 ADRs (in 270 patients) after
validation (PPV= 95%). 114 additional diagnostic
codes were tested in the database, from which the
best 40 codes generated 10 752 ADR signals (data in
supplementary Table 1). For those 40 codes, 371
random ADR signals were validated through chart
review, allowing the detection of 114 true ADRs with
a general PPV of 32.0% (supplementary Table 2).
For a simpler methodology with higher PPV global
value, we selected the six queries with the best PPV, from
which we obtained 371 signals that corresponded to 325
true ADRs (global PPV of 87.6%, prevalence of ADRs
of 2.41%). After validation, this method required only
two person-hours to identify and register ADRs. In
Table 1, the database methodology is described.
Patients with true ADRs were older and had greater
length of stay than patients without ADRs (p< 0.0001
Table 1. ADR identiﬁcation through a simple methodology of six selected codes in administrative databases
Frequency of ADRs Number of signals Positive predictive value
1) E codes (E930-E949) 284 95%
2) Diagnostic codes (in database records without E code,
i.e. without ADR diagnosis)
Number of signals without concomitant E code Positive predictive value
Other disorders of pancreatic internal secretion
(including hipoglicemia)
6 83%
Drug-induced neutropenia or unspeciﬁed 32 60%
Hepatitis, unspeciﬁed 46 60%
Other anaphylactic shock incl. drugs 2 100%
Shock due to anesthesia 1 100%
Full algorithm (1 + 2) 371 signals 87.6%
Table 2. Comparison of methodologies: administrative database versus chart review. Abbreviations: nr = number, sd = standard deviation
Methodology Database Chart review
ADR prevalence (nr of ADRs / nr patients with drugs) 2.41% 9%
(320/13 471) (9/100)
% ADR during hospitalization (versus present on admission) 45.82% 77.78%
Mean person-hours required 2 35
Mean age (sd) 64 years (sd: 19.45) 60 years (sd: 20.23)
% female 45.48 % 42%
Most frequent drug groups involved 1. 5.9% Insulins and antidiabetic agents 1. 33.3% NSAIDs
2. 2.7% Antineoplastic and chemotherapy 2. 22.2% Diuretics
3. 2.7% Anticoagulants 3. 11.1% each: antibiotic, anticoagulant,
chemotherapy, not speciﬁed
Most frequent manifestations associated with ADRs 1. 2.70% Acute renal failure All with 11.1%:
2. 2.70% Hypoglycemia •Hypokalemia
3. 2.43% Hepatitis •Disrhythmias
•Edema
•Medulary aplasia
•Acute renal failure
•Gastrointestinal haemorrhages
•Altered INR
•Rash
•Bronchoespasm
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and p= 0.027, respectively). There was no statistically
signiﬁcant difference in gender. No other risk factors
for ADRs were identiﬁed.
During the year of 2008, there were seven ADRs
detected through spontaneous reporting that were
generated from HUCC-HG (prevalence of ADR of
0.0005%).
Independent chart review identiﬁed nine ADRs
(seven during hospital stay and two present on admis-
sion): prevalence of 9%. Only two ADRs had an E
code. Both methodologies are compared in Table 2.
According to OMS’s causality assessment11, three
ADRs were classiﬁed as certain, three probable and
one unlikely. Four ADRs were preventable. 13 Three
ADRs were severe14, one was moderate and four were
mild. Eight ADRs were type A and one was type B
(according to Rawlins and Thomson classiﬁcation of
ADRs15, type A are Augmented, predictable and
dose-related adverse reactions, while type B are
Bizarre, rare and unpredictable ADRs).
DISCUSSION
What this study adds
This work allowed us to build a methodology of ADR
detection that is simple, cheap and effective, through
the use of coding information available in administrative
databases. We identiﬁed 325 ADRs of 13 471 inpatients
stays (prevalence of 2.41%).
The strengths of this work are: First, we performed
a complete test of 114 diagnostic codes’ performance
as well as E codes. Second, there was validation of
ADR code signals (through chart review of more than
350 signals), to assess PPV of each code. Third, unlike
previous literature, we identiﬁed the queries that added
information to E codes (not queries that would
generate repeated information to E codes), to decrease
validation resources and to complement E codes.
Fourth, our database method required reduced
resources (two person-hours) in ADR detection, in
comparison with chart review (35 person-hours). Fifth,
there was an enhanced ability to detect ADRs, with a
detection rate 46 times higher than the most widely
used method in pharmacovigilance: spontaneous
reporting (325 versus seven ADRs).
The limitations of this study may include: probably
incomplete and wrong information in some cases in
databases (which might occur in every large database),
“coding creep” (this is a possible bias of all billing
databases, in which more expensive codes are
preferred and registered to increase the case-mix,
diagnosis-related group and consequently to increase
reimbursement of that hospital17) and the fact that we
did not validate all of the initial 10 752 ADR signals.
Validating all signals would be ideal but too resource
consuming; therefore, this two-phase approach (of ﬁrst
selecting the best codes, then validating them) was a
practical approach that can be used in other hospitals.
The fact that this is a one hospital centred study might
also be a limitation. We chose the codes that best
describe this hospital’s reality, but other hospitals
and countries, where coding systems have either
changed to ICD-10 or may still employ ICD-9 but with
different coding considerations or payment structures,
might represent other realities. Therefore, other hospi-
tals and countries might allow the selection of different
codes. Indeed, it may be very interesting to retest all
codes in other hospitals, populations, years and
countries, to understand, on the one hand, which are
the most universal codes, and on the other hand, which
occur more in one country, or in one hospital type, or
in a particular population. Consequently, suggestions
for studies in the future include not only further
validation of this methodology in other hospitals,
years and countries, but also a nation-wide study for
detection of ADRs using databases.
We believe that the smaller prevalence of ADRs
identiﬁed by the database methodology compared to
independent chart review (2.41% versus 9%) is not a
limitation, considering the small resources utilized
(two person-hours versus 35 person-hours) and the
high PPV obtained (87.6%). On the one hand, chart
review, prospective and intensive monitoring have
good detection rates but are too resource consuming
for continuous application; on the other hand, sponta-
neous reports grossly underestimate ADRs. Therefore,
we validated a database methodology that “lies is the
middle”: it is resource sparing enough for continuous
application, with a detection rate much higher than
spontaneous reporting and with a good PPV. In addi-
tion, in our work, we noticed that chart review and
database seemed to detect different types of ADRs and
with different drugs, complementing each other. Other
studies that compared different methodologies for
ADR and ADE detection also reported that each meth-
odology tends to detect different ADRs, concluding that
multiple methods for ADR detection should be used
complementarily for patient safety enhancement. 18,19
In conclusion, the use of national or administrative
databases to identify ADRs is not a widely validated
approach, but it may have advantages, such as:
1. Information already available about inpatient stays,
with different useful clinical and demographic
data, available in almost every hospital and in
most countries.
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2. Nearly no cost added. This factor is increasingly
important in an era of economic crisis.
3. Few human resources necessary to validate ADRs.
4. The possibility of a national perspective.
5. Coding information including not only E codes
(speciﬁcally referring to ADRs: E930-E949.9) but
also diagnostic codes (that can improve ADR
detection and further coding).
Therefore, we believe that this methodology should be
embraced as an effective methodology of pharmacovigi-
lance. The identiﬁcation of ADRs through databases
can complement other established pharmacovigilance
methodologies and increase our knowledge about ADRs,
leading to their detection and ultimately prevention.
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Detection of adverse drug reactions using hospital databases—
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ABSTRACT
Purpose This study aimed to detect and characterize adverse drug reactions (ADRs) that occurred during hospitalization (ADRIn) and
ADRs associated with admission (ADRAd) in Portugal from 2000 to 2009. We also intended to compare the results of this methodology with
spontaneous reporting.
Methods We conducted a nationwide study using a hospital administrative database that included all acute care public hospitalizations in
Portugal, from 2000 to 2009. We used International Classiﬁcation of Diseases—9thRevision—Clinical Modiﬁcation coding data for the
detection of ADRs. Codes searched included “E” codes (E930 to E949.9, codes that exclude poisonings and errors) and ﬁve groups of
diagnoses codes associated with high prevalence of ADR as found in a previous study: hypoglycemia, drug-induced neutropenia, hepatitis
unspeciﬁed, anaphylactic shock due to drugs, and shock due to anesthesia.
Results From 9 271 122 hospitalizations within that period, 116 720 ADRs were detected through the database methodology, representing
1.26% from all hospitalizations. Of the ADRs, 97.3% occurred during hospitalization (ADRIn), whereas 2.7% were associated with
admission. Age, female sex, and comorbidities such as pneumonia, heart failure, diabetes, and malignancies were associated with ADRs
(all with differences statistically signiﬁcant). There were 13 562 spontaneous reports from 2000 to 2009.
Conclusions Several methods have been used for the detection of ADRs, but they are difﬁcult to apply at a national level. Spontaneous
reporting is widely used but grossly underestimates the frequency of ADRs. The database methodology can be very useful to estimate ADRs
frequency and to perform a simple characterization of ADRs nationwide. Copyright © 2013 John Wiley & Sons, Ltd.
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INTRODUCTION
Adverse drug reactions (ADRs) are a major health
care and patient safety problem, being responsible for
signiﬁcant morbidity, mortality, and costs in health
care systems.1–3 It is estimated that they occur in a
mean of 16.88% of patients during hospitalization
(95%CI: 13.56–20.21)4 and that they are associated
with an overall median of 5.3% of hospital admissions
(interquartile range 2.7–9.0%).5 The cost of drug-
related problems, which include ADRs, may be
higher than the total cost of cardiovascular or diabetes
care.6 Therefore, the identiﬁcation and prevention of
ADRs is increasingly important.
Pharmacovigilance is the science and activities
related to the detection, assessment, understanding,
and prevention of all ADRs and of any other
drug-related problem.7 Several methods can contribute
to pharmacovigilance, from spontaneous reporting to in-
tensive monitoring, but all have methodological issues:
Spontaneous reporting (reports of a health care
member whenever there is a suspicion of an ADR) is
a cheap method, good at the identiﬁcation of new
ADRs, and is the basis of the International Monitoring
Program.7 The limitations of spontaneous reporting
include underreporting,8 heterogeneous report quality,9
and risk of bias.10
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The utilization of administrative databases and
hospital episodes statistics has been performed by a
few authors to identify ADRs.11–14 Although not widely
used, it may have advantages if developed and validated
as a methodology, such as follows: information of
several hospitals, years and countries already available,
clinical coding data from which signals of ADRs might
be extracted, low resources needed, and a detection rate
higher than spontaneous reporting.15
Computerized methodologies are interesting and
have good detection rates,16 but need to be performed
in hospitals where patient data is computerized, which
is not possible in many countries. Other difﬁculty is
related to the low speciﬁcity of some algorithms,
causing an override of alerts and making them less
effective and more costly.17
Manual chart review for ADR detection consists of
retrospectively or prospectively reviewing patient charts
to identify ADRs, generally by experts in ADRs.18,19
However, it is time and personnel costly: some studies
estimated a cost of 55 person-hours per week.19
Prospective and intensive monitoring20 refer to
studies performed prospectively in hospitalized patients,
with patient interview or examination and health team
members interview, performed by experts, to detect
ADRs before discharge. They usually have the highest
detection rate (intensive monitoring is considered the
gold standard) but the highest cost,21 not allowing a
nationwide study.
These methods were developed for different purposes
and thus not all are eligible for a nationwide measure-
ment of the frequency of a disease as an epidemiological
tool. In fact, spontaneous reporting is used frequently to
estimate frequency of ADRs, but inappropriately (one
would need the number of patients receiving drugs,
details of administration, and other data).
Our purpose was to identify and characterize ADRs
in a nationwide study, using hospital databases with
clinical information. Secondarily, we aimed to assess
trends in hospitalization and in the frequency of ADRs
throughout the years of 2000 to 2009.
METHODS
Study design
A retrospective study was performed for ADR identiﬁ-
cation using hospital administrative databases with
information from all episodes in acute care public hospi-
tals in Portugal, from 2000 to 2009, obtained from
Administração Central do Sistema de Saúde (ACSS),
the Ministry of Health’s Central Authority for Health
Services. This national database is built by ACSS,
which aggregates data from each hospital. The hospital
database is ﬁrst built and maintained at each hospital
(using a standardized national approach), and then
centrally by ACSS.22 To enable this, every hospital
uses the same software to store patient information.
Coders input data after reading the discharge note
and all clinical data, and then attribute a clinical code
according to International Classiﬁcation of Diseases
9th Revision—Clinical Modiﬁcation (ICD-9-CM).
Unlike other countries, all coders in Portugal are phy-
sicians, who perform a standardized national course
and examination, to assure repeatability (so that the
same information recorded by different coders in
different hospitals is coded similarly). There are also
auditors (internal within the hospital and external at
the national level of the ACSS) that perform routine
veriﬁcation to detect and correct errors and to assure
quality; currently, they all use the same program for
that purpose, “Auditor”. If ACSS has any doubt when
aggregating the hospital databases into one national
database, they contact each hospital, which will
review the processes to standardize the information
and clarify that issue.
Therefore, the national database (that we obtained
from ACSS) contains information on anonymized pa-
tient identiﬁcation, episode, and process number, and
also information on age, sex, admission date, discharge
date, ward(s), hospital attended (tertiary, university),
district, outcome (death, discharge, transfer), payment
data (Diagnosis Related Groups), and ICD-9-CM codes
for the following: diagnoses (principal diagnosis and
secondary diagnoses up to 19), procedures (up to 20),
and external causes (up to 20). Patient population in-
cluded all patients hospitalized in all acute care public
hospitals in Portugal, with discharges between 2000
and 2009 (we excluded outpatient episodes). At the time
of execution of this work, hospital administrative data
from the second semester of 2009 was not available.
ADR deﬁnition and identiﬁcation
We followed WHO’s deﬁnition of ADR: “any
noxious, unintended, and undesired effect of a drug,
which occurs at doses used in humans for prophylaxis,
diagnosis, or therapy.”21 We were not interested in
adverse effects nor medication errors, considering that
they are excluded by this deﬁnition.
The database of public hospitals in Portugal in-
cluded information of diagnoses in the form of codes
of ICD-9-CM. Codes searched for ADR identiﬁcation
included “E” codes and diagnostic codes. “E” codes
belong to a chapter in ICD-9-CM that aims to classify
external causes of injury; “E” codes from E930 to
E949.9 are already designed to represent ADRs and
a. miguel et al.
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exclude wrong doses, errors, and poisonings. The ﬁve
diagnostic codes searched in this study were selected
after a validation study previously performed.15
In that study, “E” codes and 114 diagnostic codes
were tested in a hospital database. Those 115 groups
of codes included every code in the ICD-9-CM that
contained the expressions: “Due to drugs”, “drug-
related”, “medicamentosa”, “iatrogenic”, and “drug-
induced”; others considered useful as “bleeding”,
“diarrhea”, “dysrhythmias”; and others reported in
the literature.11–14 A list of all tested codes can be
requested from the corresponding author. From those
115 tested codes (which generated thousands of
signals), the 40 codes with the highest numbers of
signals were selected for chart review (we selected the
signals that added information to the E codes and were
not already detected in the E codes). However, consider-
ing that the 40 code groups generated more than 10 000
ADR signals, 10–20 random patient charts for each
code were selected (more than 350 patient processes
were reviewed) for validation. Chart review was consid-
ered the gold standard for the assessment of the positive
predictive value for each code. Finally, the six groups of
codes with higher PPV (positive predictive value) were
selected to build a simple database methodology, with a
global PPV value of 87.6%, and included the following:
(1) “E” codes (ICD-9-CM codes of E930 to E949.9;
PPV of 95%).
(2) Other disorders of pancreatic internal secretion includ-
ing hypoglycemia (ICD-9-CM codes: 251.0–2251.9;
PPV of 83%).
(3) Drug-induced or unspeciﬁed neutropenia (ICD-9-
CM codes 288.00, 288.03, 288.09; PPV of 60%)
(4) Hepatitis unspeciﬁed (ICD-9-CM 573.3; PPV of
60%).
(5) Other anaphylactic shock including drugs (ICD-9-
CM codes 995.0 to 995.3; PPV of 100%).
(6) Shock due to anesthesia (ICD-9-CM code 995.4;
PPV of 100%).
In this study, we applied those six previously vali-
dated codes for ADR detection as a simple and fast
methodology,15 in a nationwide study using administra-
tive databases, through a simple query to detect ADR
episodes. We excluded repeated cases on the basis of
episode number, hospital, birthday date, sex, year, ward,
and hospitalization date and time.
Our main outcome was ADR detection. Secondary
outcomes were the following: ADR related to admission
(ADRAd) versus ADR during hospitalization period
(ADRIn), age, sex, admission diagnosis, other diagnoses,
hospital length of stay, and year (we aimed to assess
trends in ADRs from 2000 to 2009).
Spontaneous reporting
The number of spontaneous reporting of ADRs in
hospitalized patients from 2000 to 2009 was not avail-
able in the database and was obtained from Portuguese
National Authority of Medicines and Health Products
(INFARMED).
Statistical analysis
Statistical analyses regarding frequency of ADRs were
carried out with the Chi-square test for categorical
variables (or exact Fisher’s test whenever possible),
Student’s t-test for normally distributed continuous
variables and Mann–Whitney or Kruskal–Wallis for
variables without normal distribution, using SPSS v20
(IBM Corp., Armonk, NY, USA). The a priori level
of signiﬁcance was p< 0.05. For the identiﬁcation of a
trend throughout the years, we performed a simple lin-
ear regression, using the ADR frequency as the depen-
dent variable and the year as the independent variable.
RESULTS
Study population
The baseline characteristics of the study population
(n= 9 271 122) are shown in Table 1, in comparison
with the demographic characteristics of the subgroup
of patients that suffered an ADR. The mean age of
all hospitalized patients was 46 years, and 56% of the
patients were female.
From 2000 to 2008, there was a slight increase in the
number of hospitalizations in Portugal (in 2009 data
refer only to ﬁrst semester). There were 116 720 ADRs
detected from 2000 to 2009, with a mean prevalence
of 1.26%. There was an increase trend in the incidence
of ADRs, statistically signiﬁcant (p< 0.001) in linear
regression analysis; in 2000, there were 8301 signals,
whereas in 2008, there were 14 352 signals. Of the
ADRs, 2.7% were associated with admissions, and
97.3% occurred during hospitalization.
Each alert of ADR identiﬁed through the database is
characterized in Table 2.
The number of national spontaneous notiﬁcations of
ADRs from 2000 to 2009 was 13 562, corresponding
to a mean prevalence of 0.1%. In Table 3, we illustrate
trends of hospitalization, spontaneous notiﬁcations, and
ADRs identiﬁed in databases throughout time.
Risk factors of ADRs
In comparison with patients that did not suffer from an
ADR, patients with ADRs were older (p< 0.001,
Mann–Whitney test), had higher mean length of stay
(p< 0.001, Mann–Whitney test), were more frequently
adr detection using hospital databases
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of the female sex (p< 0.0002, Fisher’s exact test), and
had a higher risk of death (p< 0.001, Fisher’s exact test).
Additionally, we veriﬁed that several comorbidities
(identiﬁed also through the use of diagnostic codes)
were associated with a higher risk of developing an
ADR: heart failure (p< 0.0001, Fisher’s exact test),
septicemia (p< 0.0001, Fisher’s exact test), dysrhyth-
mias (p< 0.0001, Fisher’s exact test), hypotension
(p< 0.0001, Fisher’s exact test), cerebrovascular disease
(p< 0.0001, Fisher’s exact test), stroke (p= 0.0000045,
Fisher’s exact test), diabetes (p< 0.0001, Fisher’s exact
test), ischemic heart disease (p< 0.0001, Fisher’s exact
test), malignancies (p< 0.0001, Fisher’s exact test),
and pneumonia (p= 0.0000026, Fisher’s exact test).
DISCUSSION
To our knowledge, this was the ﬁrst estimate of the
frequency of ADRs in a nationwide level in Portugal.
We identiﬁed 166 720 ADRs of 9 271 122 inpatients
stays (prevalence of 1.26%); if we applied respective
Table 1. Socio-demographic characteristics of study population compared with subgroup of patients that suffered from ADRs
General population Subgroup of ADRs
p-valueCharacteristic Value % or SD Value % or SD
Total number 9 271 122 NA 116 720 NA NA
Mean age 46 28.04 SD 60 23.4 SD <0.001
Female sex 5.152.684 56 % 63 186 54.1% <0.0002
Death 410.253 4.4% 10 650 8.8% <0.001
Mean hospital length of stay (days) 7.1 3.21 SD 13.7 22 SD <0.001
Abbreviations: SD, standard deviation; NA, not applicable.
Table 2. Characterization of adverse drug reactions identiﬁed through the hospital database
ADR alerts
Total
number
Type of ADRs
Mean
age
Number of
female gender
(%)
Mean
hospital
length
of stay
Number
of
deaths
(%)ADR at admission ADR during hospitalization
E codes 90 260 252 90 008 62 49 628 (55.0%) 14 6906
Hypoglycemia 6684 1273 5411 55 3611 (54.0%) 10 1187
Neutropenia 17 035 1515 15 521 47 8140 (47.8%) 14 1968
Hepatitis 606 60 546 48 605 (99.8%) 6 4
Anaphylactic shock 2133 356 1777 47 1201 (56.3%) 12 0
Shock due to anesthesia 1 0 1 0 1(100%) 88 0
Table 3. Trends in hospitalizations, spontaneous reports and ADRs identiﬁed in databases
Year
Number of
hospitalizations
Spontaneous
reporting
ADRs identiﬁed
by the database
(%)
ADRs database—type of alert
E
codes
Hypogly-
cemia Neutropenia Hepatitis
Anaphylactic
shock
Shock due to
anesthesia
2000 949 427 641 8301 (0.82%) 5750 829 1338 49 335 0
2001 959 895 1342 8769 (0.91%) 6184 699 1576 62 248 0
2002 973 328 1251 10 602 (1.1%) 8073 709 1573 92 155 0
2003 991 804 1097 12 371 (1.25%) 9853 731 1574 52 161 0
2004 982 627 1623 12 918 (1.31%) 10 423 727 1545 85 138 0
2005 1 013 770 1259 13 444 (1.33%) 9987 698 2443 86 230 0
2006 973 887 1284 13 778 (1.41%) 10 855 656 2002 69 195 1
2007 965 576 1424 14 744 (1.53%) 11 686 689 2042 48 279 0
2008 965 463 1603 14 325 (1.49%) 11 452 601 2000 44 255 0
2009* 495 345 2038 7440 (1.50%) 5997 345 942 19 137 0
Total 9 271 122 13 562 116 720 (1.26%) 90 260 6684 17 035 606 2133 1
Types of alerts identiﬁed in the databases are also identiﬁed.
*For the year of 2009, only the ﬁrst semester data was available.
a. miguel et al.
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PPV values (PPV values were estimated in the valida-
tion study15), this would detect 104 015 true ADRs.
We identiﬁed an increase in the number of hospitali-
zations from 2000 to 2009 (as expected along the evolu-
tion of the National Health Care) and in the number and
percentage of ADRs. The reported increase in the
frequency of ADRs is also expected, considering the
higher number of drugs available, the tendency of
prescribing multiple drugs per patient, improved register
of clinical conditions in databases, improvement of clin-
ical coding, and even population ageing. Each prescrib-
ing physician should consider the risk of ADRs carefully
before prescribing an additional drug to a patient.
Our results were consistent with those presented in
other studies that identiﬁed risk factors of ADRs, such
as comorbidities,14 diabetes,23 renal failure,23 female
sex,24 and age.1,24 They were also consistent with the
frequency of ADRs identiﬁed by previous studies that
used administrative databases for a nationwide esti-
mate: 0.89% in Spain,11 0.9% in England,25 1.83%
in the Netherlands,12 and 0.8% in Australia.26 The
Spanish study11 identiﬁed a smaller frequency of ADRs,
0.89%, perhaps because the authors utilized solely E
codes, in opposition to our work, in which we used E
codes and other validated diagnostic codes. Whitstock
and colleagues26 utilized a methodology beyond data-
bases, linking clinical trial data with administrative
health data, but tested it solely for newly released drugs
and older population in Australia, consequently identi-
fying a smaller frequency of ADRs, 0.8%. Wu and
colleagues25 searched several codes using the ICD-10
coding system, but estimated only the frequency of
ADRs associated with hospital admission, which might
explain the slightly inferior estimate in comparison with
us, 0.9%. However, a higher frequency of ADRs was
found by Hooft et al.12 (1.83%) although they were only
referring to ADRs associated with hospital admission
(including ADRs that directly caused admissions and
ADRs that did not cause but were present at admission)
and although they only searched E codes. This higher
estimate might be related to the fact that in the Nether-
lands (unlike Portugal and many other countries), the
coding is independent of reimbursement;12 therefore,
there is no tendency to omit a “negative” code (which
could lead to bias, usually known as “coding creep”27).
The strengths of our study include our comprehensive
database, which contains data from all hospitalizations
in every acute care public hospital in Portugal within
almost a decade. Another strength comes from the
validation study previously performed,15 which has
enabled us to add measures of error to our estimate,
identify diagnostic codes that may represent signals for
ADRs other than “E” codes, and identify the error
associated with “E” codes (the PPV for “E” codes was
just 95% because several drug-related errors were
erroneously coded as ADRs). The database methodol-
ogy has a far greater detection rate than spontaneous
reporting (detecting only 12% of the ADRs identiﬁed
by the database), which is perhaps the greatest
advantage of this methodology considering the purpose
for which it was built: to obtain a good detection rate
with reasonable costs (affordable for continuous
pharmacovigilance). Therefore, spontaneous reporting
can be used for the identiﬁcation of new ADRs, and
the database methodology can be used for a fast and
large-scale estimate of incidence of ADRs.
Limitations of our work are inherent to the use of
administrative databases, which often contain incom-
plete or wrong information because of its purpose. If
on one hand, reimbursement databases assure compre-
hensive data, on the other, they might lead to coding
bias (“code creep”, in which coders select a different
code to increase reimbursement to their hospital27). It
is not possible to estimate the error caused by these
biases. Another limitation is related to the fact that
we applied the PPV value of a small one-centered
validation study to a large national database; for that,
we had to assume that the population was the same.
We could be inducing bias if the population is differ-
ent. If we use the methodology of previous database
studies (in which they assume that all “E” codes repre-
sent an ADR and simply search “E” codes), we would
have 90 260 ADRs (“E” codes), with a prevalence of
0.97%, which is a prevalence somewhat similar to the
one that we obtained. Nonetheless, we believe that this
methodology is more comprehensive and enables us to
identify codes that add information to “E” codes and
therefore to identify ADRs previously undetected.
Additionally, we suggest multi-centered validation
studies in different countries to select speciﬁc diagnostic
codes associated with ADRs within each country and
to build an estimate of error associated with each
methodology.
Although the database methodology allows us to
obtain a higher frequency of ADRs than spontaneous
reporting, it is low in comparison with prospective
monitoring and intensive monitoring (the main method-
ologies used in the included studies of the systematic
review that estimated a mean of 16.88% of ADRs in
hospitalized patients4). Nevertheless, these methodolo-
gies have the highest costs, making them impossible to
use in a large-scale study such as our own.
Additionally, several studies report that different
methods tend to identify different types of ADRs,15,16
and many authors suggest the simultaneous use of sev-
eral methodologies to enhance ADR detection.28,29
adr detection using hospital databases
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Therefore, future studies should include a complete es-
timate and characterization of ADRs, nationwide, pro-
spectively to allow the use of different methods
complementarily, with causality assessment of each
ADR and ideally with cost analysis.
CONCLUSION
In conclusion, this is the ﬁrst nationwide estimate of
ADRs in Portugal throughout almost a decade: a mean
prevalence of 1.26% of ADRs (2.7% of which were
associated with admission) was detected. The database
methodology has ﬂaws and underestimates the real
number of ADRs, but it should be used continuously
as a methodology that can complement (but not replace)
other pharmacovigilance methodologies.
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KEY POINTS
• Spontaneous reporting is the only pharma-
covigilancemethod continuously used in Portugal.
This method grossly underestimates the number of
adverse drug reactions (ADRs). Chart review,
computerized methods, and intensive monitoring
are too resource-consuming to be utilized in a
nationwide level in Portugal.
• Using hospital administrative databases, we have
built a nationwide estimate of ADRs in Portuguese
hospitals, from 2000 to 2009.We detected 116 720
ADRs (97.3% of which occurred during hospitali-
zation and 2.7% were the cause of admission),
with a prevalence of 1.26% of all hospitalizations.
Throughout this time, there were only 13 562
spontaneous reports of ADRs in Portugal (preva-
lence of 0.1%).
• Databases are not widely used as a pharma-
covigilance methodology, but havemany potential
advantages, such as a moderate ADR detection rate
and relatively low resources needed.
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Abstract 
Aims: To develop and validate a computerized methodology of adverse drug reactions (ADRs) detection that 
could assist manual chart review (CR), with low costs of implementation and maintenance. 
Methods: A computerized clinical decision support tool (CT) was built, as well as drug databases and algorithms 
that allowed to identifying ADRs from few input data obtained through chart review. A retrospective study of 118 
random patients was performed for validation. 
Results: CT detected 65 ADRs in 29 patients (versus 12 ADRs in 12 patients in CR) with low resources needed 
(29.5 versus 69 person-hours), allowing to identify a prevalence of 24.8% ADRs (versus 10.2%). CT suggested 
ADRs and also described frequent ADRs for each drug (allowing inexperienced reviewers to identify previously 
unsuspected ADR signs). 
Conclusions: CT is a promising Pharmacovigilance methodology, particularly at a time of world economic crisis, 
since it allows continuous surveillance with five times greater detection and half the resources needed by CR. It 
may be of use in hospitals without electronic records. 
Keywords: adverse drug reactions, pharmacovigilance, chart review, computers. 
Introduction: 
Adverse drug reactions (ADRs) are frequent, costly, often preventable and are responsible for many deaths in 
hospitalized patients. ADRs are among the most frequent causes of death in developed countries1. It is estimated 
that they occur in a mean of 16.88% of patients during hospitalization (CI95%:13.56-20.21)2 and that they are 
associated with an overall median of 5.3% of hospital admissions (interquartile range 2.7-9.0%)3. The costs of 
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drug-related problems (which include ADRs) may be higher than the total cost of cardiovascular or diabetes care4; 
while the mean additional cost attributable to an ADR is estimated to be US$33325.  
Consequently, the identification and ultimately the prevention of ADRs is one of the few ways to simultaneously 
increase quality in Health Care and decrease its costs. There are several methods of ADR identification6. Manual 
chart review has good detection rates and is considered by some as the "gold standard" to identify adverse drug 
reactions in health care organizations7, but it is time and personnel costly: some studies estimated a cost of 55 
person-hours per week8. This makes it impossible to use as a methodology of continuous detection of ADRs in all 
hospitalized patients. 
On the other hand, computerized surveillance is increasingly appealing9,10. Many different strategies of 
computerized Pharmacovigilance were assessed in a recent systematic review11, with different levels of complexity 
in implementation and integration, and consequently with a variety of costs in acquisition and maintenance. 
However, this type of surveillance requires that all patient information is computerized, which is not possible in 
many hospitals, such as ours. 
Therefore, our purpose was to design and validate a computerized tool for ADR detection that would assist chart 
review, simultaneously increasing detection and decreasing associated costs for the detection of ADRs. Since we 
live in an era of social and economic crisis, we wanted to build a program that would have low costs of 
implementation and maintenance, and that did not require health system integration. 
Materials and methods 
Study setting 
A retrospective study was performed at Central University Hospital of Coimbra, Portugal. From all hospitalized 
patients in 2010, we selected a random sample of 118 patients to perform manual chart review and computerized 
assessment, independently, to validate our methodology and to compare: number and types of ADRs identified, 
risk factors for ADRs, and time spent in each methodology. The study was approved by hospital's institutional 
review board. 
Definition of ADR 
World Health Organization's definition of an ADR was applied: "any noxious, unintended and undesired effect of 
a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy"12. Previous works utilized 
Ana IM Miguel* et al. International Journal Of Pharmacy & Technology 
 
 
IJPT | April-2013 | Vol. 5 | Issue No.1 | 5106-5128                                                                                     Page 5120 
 
computerized systems to identify adverse drug events ("an injury resulting from medical intervention related to a 
drug")13-16, but we aimed to assess specifically ADRs.  
Outcome assessment 
The primary outcome was frequency of ADRs (including ADRs that led to admission, ADRAd, and ADRs that 
occurred during hospitalization, ADRIn). We assessed: number of ADRs, number of patients that suffered from an 
ADR, number of patients exposed to drugs, length of hospital stay. We registered number of ADRs computer-
detected and number of ADRs computer-undetected. Secondary outcomes included: particular diagnosis, ward, 
age, gender, length of hospital stay, number and name of drugs administered to each patient, and other clinical data 
as detailed below.  
Manual chart review 
From each patient, chart was reviewed, including: discharge note, diaries, all drugs administered, laboratory and 
coding data, as well as every aspect that could constitute a symptom or sign of an ADR, even if not detected 
previously by responsible medical team. For complete validation, all cases were reviewed (not just the cases with a 
positive computer alert).  
All ADRs were registered, described and classified according to WHO's causality assessment17, preventability 
(Schumock criteria18) and severity (Hartwig19). ADRs classified as conditional or unlikely were excluded from the 
analysis (but registered). Associated drugs (and all administered) were registered. Reviewer also registered if ADR 
was previously undetected, as well as age, gender, ward, hospitalization time, and other relevant clinical 
information. 
Computerized system - Chart Helper 
Considering the need of a costless computerized system, we built a program that did not require Health system 
integration. The main difficulty was to build manually databases with drug information in portuguese, since there 
were none available in our country that linked adverse drug reactions, their symptoms and signs to each drug. We 
used the Hospital Formulary20, and the official list of portuguese ambulatory drugs, available in the site of 
INFARMED21, the Portuguese Regulatory Authority of Drugs, to build a database with all drugs available in 
Portugal. We then built an ADR database with the 10 more frequent ADRs, all ADRs that were potentially fatal 
for each drug, and other clinically relevant ADRs for each drug according to INFARMED21 and Meyler's side 
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effects of Drugs book22. We also added to that database: the symptoms of each ADR, signs, laboratorial 
alterations, diagnosis and compatible coding information (for that, we used also International Classification of 
Diseases 9th Revision, Clinical Modification: ICD-9-CM23). 
We built a program, Chart Helper, with Visual Studio 2010, aiming for a simple and user-friendly interface with 
the reviewer. For each patient, the user of Chart Helper (the chart reviewer) registered age, gender, chart number, 
hospitalization and discharge dates (duration of hospital stay was automatically calculated), and diagnosis and 
procedures codes (from ICD-9-CM23). Some data must be input manually because in most of portuguese hospitals, 
not all patient data is computerized (most data is stored in paper records). 
All drugs administered during hospitalization were also selected from a list by the reviewer, as well as relevant 
symptoms, signs and laboratorial alterations. The user could input symptoms and signs not previously present in 
the database, but detected in the chart review, therefore increasing overall detection of ADRs.  
We intended to take advantage of two types of input data: first, already existing coding and administrative data 
with useful clinical information, and second, manual chart review to identify symptoms or other alterations 
missing in coding data but detected by the user. The program tool used all of these input data, our ADR databases 
and some algorithms to generate two types of results: 
1. Suggested ADR(s) for that patient. The program detected if a symptom, sign, diagnostic code or laboratorial 
alteration that the patient had, was compatible with an ADR of any of the drugs administered to him. 
Respective drug, ADR and alert were specified by program as a decision support tool, and then the reviewer 
would decide if the suggested ADR really occurred and would classify it according to WHO's causality 
assessment17 (available in the program): certain, probable/likely, possible, conditional/unclassified, 
inaccessible /unclassifiable. 
2. Frequent ADRs for each drug. For each drug administered to that patient, a list of frequent (and of fatal) ADRs 
was available for consultation by the user. Therefore, this memory support tool would allow less experienced 
users to pay more attention to certain signs and symptoms throughout the chart that could indicate an 
undiagnosed ADR of a drug administered to that patient.  
All data (input and result data) were automatically stored in a database by Chart Helper for further analysis. 
Conditional and unlikely ADRs were excluded from our analysis (but also automatically registered in the 
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database). 
Data analysis 
We calculated sample size (to identify ADR prevalence of 10%) using an online calculator (100 patients were 
necessary)24. Statistical analyses were done with the Chi-square test for categorical variables (or Fisher's exact test 
whenever possible), Student's t-test for normally distributed continuous variables and Mann-Whitney or Kruskal-
Wallis when dealing with variables without normal distribution, using SPSS v20. The a priori level of significance 
for all comparisons was p<0.05. 
Results 
Characterization of sample 
From the random sample of 118 patients hospitalized in 2010, mean participant age was 60 years. 40.7% were 
female.  
Table-1: Describes socio-demographic participants' characteristics. 
 
 
 
 
 
 
 
 
 Demographic characteristics of participants 
Chart review 
Chart review allowed the identification of 12 ADRs in 12 patients, one of them fatal (due to infection after the use 
of chemotherapy). 117 patients were exposed to drugs, thus ADR prevalence was 10.2% (12/117).  
Characteristics Number Relative 
frequency 
(%) 
Female gender 48 40.7 % 
Age (sd: standard deviation) Mean: 60 years sd: 20 
Mean number of days hospitalized (sd) 10.1 sd: 20.0 
Mean number of drugs administered 
per patient 
5.2 sd: 3.8 
Wards more frequently occupied   
    Surgery 18 15.25 % 
    Urology 14 11.86 % 
   Medicine 10 8.48 % 
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The most frequent ADRs were hyperkalemia (16.7% of all ADRs) and warfarin leading to International 
Normalized Ratio levels that led to surgery delay (16.7%).  
Systems more frequently affected were hematologic (33.3%), renal (25%) and cardiovascular (16.7%). Drugs more 
frequently involved were non steroidal anti-inflammatory drugs (NSAIDs, 25%), antibiotics (16.7%), 
anticoagulants (16.7%) and diuretics (16.7%). 
Five ADRs were preventable (according to Schumok's classification). There were 3 severe ADRs, 5 moderate and 
4 mild (Hartwig classification). Twenty-four adverse events were identified. 
Patients with ADRs were exposed to a higher number of drugs than patients without ADRs (Mann-Whitney test, 
p=0.001); there was no statistically significant difference in age, hospitalization time, number of days in intensive 
care units, or gender (Fisher's exact test). 
Computerized clinical decision tool 
1. Program 
Chart helper, the program built, requires that some data are entered as the chart review is performed, as detailed in 
the Methods section and illustrated in figure 1a. Afterwards, according to each patient, two types of results are 
generated: list of frequent ADRs for drugs administered and list of suggested ADRs (figure 1b and 1c). 
 
Figure-1: Some examples of Chart Helper interface. 
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1a. Data input (above)  
Some of the data that must be entered by reviewer (red square): coding data (if available), drug names 
administered to that patient, symptoms and signs and laboratorial data. 1b. List of ADRs (middle) List of frequent 
and fatal ADRs for the drugs administered to that patient, working as a "memory enhancer". This allows less 
experienced reviewers to pay more attention to certain symptoms (or other alterations) that may represent an ADR 
in that patient. 1c Suggested ADRs (below) If the patient had symptoms, signs, codes or any laboratorial alteration 
that is compatible of an ADR to a drug administered to that patient, the program suggests an ADR and respective 
drug (an ADR alert). In the example above, there are 2 ADRs suggested for that patient (hemorrhage by warfarin 
and lethargy or depression by oxazepam). These must be classified according to WHO's causality of ADRs (red 
arrow) by the reviewer. 
2. ADR detection 
Sixty-five ADRs (unlikely ADRs were excluded) were identified by computerized system in 29 patients, leading to 
a prevalence of ADRs of 24.8% (29/117) and including 17 ADRs certain or probable (prevalence of 14.5%). Two 
ADRs were undetected by computer (both with warfarin leading to INR levels that caused surgery delay). On the 
other hand, 53 ADRs were only detected by computerized system (manual chart review did not detect them), all of 
which were validated by further manual chart review to identify if they were true ADRs. From 81 alerts, 65 were 
true ADRs (positive predictive value of 80%). 
Most frequent ADRs detected by computer were laboratorial alterations (24.29% of ADRs), agitation (14.63%) 
and diarrhea or constipation (13.82%). Systems more frequently affected were: hematologic (31.71%), 
gastrointestinal (26.02%) and renal (16.23%). 
The drugs more frequently involved were: NSAIDs (15.45%), antihypertensives (14.63%) and antidepressants or 
antianxiety agents (14.63%).  
Discussion 
Our work allowed us to develop and validate a computerized methodology easy and fast to apply, and nearly 
costless to our National Health System. This effective computerized methodology detected five times more ADRs 
(65 versus 12 ADRs) than manual chart review with approximately half the resources (69 versus 29.5 person-
hours).  
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Our approach is new, because we started from chart review with integrated data (instead of separate laboratorial 
data or other indicators from health systems), and developed databases and algorithms to create automation, while 
leaving the ultimate decision of ADR causality assessment to the health professional reviewer (the user of the 
system), with a simple user-friendly interface. 
Methodology comparison 
Table-2: Presents the comparison between manual chart review and computerized methodology. 
 
Manual chart  
review 
Computerized 
method 
Total number of ADRs (excluding 
"unlikely") 
12 65 
Patients with ADR 12 29 
ADR prevalence 10.2% 24.8% 
Total number of person-hours spent  69  29.5  
Fatal ADRs 1 1 
ADRs previously diagnosed in clinical 
history 
3 3 
ADRs previously coded (E code) 1 1 
Number of adverse events (including ADR) 24 77 
Number of ADR associated with admission 
versus ADR that occurred during 
hospitalization 
2 vs 10 2 vs 63 
WHO's causality assessment   
Certain 4 7 
Probable / likely 5 15 
Possible 3 43 
Unlikely or conditional/unclassified or 
inaccessible /unclassifiable 
0 31 
     Comparison of ADR detection by each methodology. 
Strengths of this study 
We believe our work has several strengths. The greatest strength of this study lies in its results, showing a clear 
superiority over manual chart review, with a prevalence of ADRs identified of 24.8%.  
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Second, the low resources required, much lower than manual chart review, allows the application of this method as 
a continuous method of Pharmacovigilance, which was not previously possible for chart review. Even in small 
hospitals where it isn't feasible to implement complex computerized systems, ADR monitoring can be improved 
through this resource sparing system. In fact, we believe that this solution might be interesting for those hospitals 
in which patient information is not computerized. 
Third, this program elaborates a list of frequent and fatal ADRs per drugs administered to each patient, allowing 
even inexperienced reviewers to detect symptoms (or signs, laboratorial data or codes) that may constitute an 
ADR, working as a supporting memory tool.  
Fourth, it does not need a posteriori validation, since it integrates validation and causality assessment performed 
by a reviewer during each assessment.  
Last, unlike the previously published studies that reviewed only charts of ADR alerts, we intended to identify also 
ADRs undetected by this computerized methodology and to perform a true validation, therefore we performed 
chart review to all patients. 
Limitations of this work and suggestions for future work 
This work has also several limitations. Further testing and validation should be performed, namely in other 
hospitals, other countries, and with a higher number of patients. This validation study had a retrospective design, 
but it would be interesting to test this computerized approach prospectively, to enhance ADRs detection and 
treatment. It is a resource-sparing tool because it has a low level of automation, however, it would be interesting to 
integrate it in the health system and to add further automation: although the costs would rise exponentially, we 
believe that interesting results would be provided. This program also allows us to compare different reviewers, 
therefore a study in which we compare ADR detection with this computerized system among different reviewers 
could reveal subjectivity factors unknown so far.  
Finally, although one of the biggest difficulties was building it in portuguese language, translation into English 
(and the adaptation of all databases of drugs and ADRs) for validation in other countries is relatively easy and 
could also show interesting results. 
Conclusions 
This computerized clinical decision support tool for ADR detection might be an useful Pharmacovigilance 
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methodology in the future, particularly at a time of world economic crisis, since it allows continuous surveillance 
with a higher ADR detection (five times greater) and half the resources needed by manual chart review. It is a 
promising method that requires further studies. 
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• Ophthalmology is perhaps one of the medical specialties in which there are the 
few assessed ADRs, but the eye is a complex organ in which minimal 
impairment can produce a substantial functional effect.  
• We performed a systematic review regarding ophthalmic ADRs to systemic 
drugs, to systematically summarize evidence and to identify specific areas that 
lacked systematization or assessment. 
• From 562 studies initially found, only 32 were included, and few studies had 
low risk of bias.  Drugs frequently involved included amiodarone, sildenafil, 
hydroxychloroquine and biphosphonates. 
• Many ophthalmic ADRs are frequent but remain unnoticed, therefore the 
systematization of specific ophthalmic ADRs, the increase of knowledge and the 
dissemination of protocols of collaboration are suggested. 
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Abstract: 
Purpose: To perform a comprehensive and systematic review regarding 
ophthalmic ADRs to systemic drugs to: 1) systematically summarize existing evidence, 
2) identify areas, ophthalmic ADRs or drugs that lacked systematization or assessment 
(namely drugs with original studies characterizing specific ophthalmic ADRs but 
without causality assessment nor without meta-analysis). 
Methods: Systematic review of several electronic databases (last search 
1/7/2012): Medline, SCOPUS, ISI web of knowledge, ISI Conference Proceedings, 
International Pharmaceutical Abstracts and Google scholar. Search query included: 
eye, ocular, ophthalmic, ophthalmology, adverse and reaction. Inclusion criteria were: 
1. Primary purpose was to assess an ophthalmic ADR to a systemic medication; 2. 
Patient evaluation performed by an ophthalmologist; 3. Studies that specified 
diagnostic criteria for an ocular ADR. Different types of studies were included and 
analyzed separately. Two independent reviewers assessed eligibility criteria, extracted 
data, and evaluated risk of bias. 
Results: From 562 studies found, 32 were included (1 systematic review to 
sildenafil, 11 narrative reviews, 1 trial, 1 prospective study, 6 transversal studies, 6 
spontaneous reports and 6 case series). Drugs frequently involved included 
amiodarone, sildenafil, hydroxychloroquine and biphosphonates. Frequent ophthalmic 
ADRs included: keratopathy, dry eye and retinopathy. 
Conclusions: To increase evidence about ophthalmic ADRs, there is a need for 
performing specific systematic reviews, applying strictly the World Health 
Organization's (WHO) definition of ADR and WHO  causality assessment of ADRs. 
Some ophthalmic ADRs may be frequent, but require ophthalmological 
examination, therefore ophthalmologists' education and protocols of collaboration 
between other specialties whenever they prescribe high-risk drugs are suggestions for 
the future.  
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Introduction 
Ophthalmology is perhaps one of the medical specialties in which there are the 
fewest assessed ADRs, representing a particular challenge in Pharmacovigilance1. 
However, the eye is a complex organ in which minimal impairment can produce a 
substantial functional effect2. Ophthalmic ADRs are usually not continuously detected, 
although they might be either frequent or specific of a drug or drug group, such as 
acute angle-closure glaucoma and myopic shift caused by topiramate3, cataracts 
provoked by corticosteroids4, floppy iris syndrome caused by tamsulosine5 and uveitis 
caused by rifabutin6.  
Some ADRs are rare but can cause irreversible blindness (such as in optic atrophy 
provoked by ethambutol)7, while others are extremely frequent but usually harmful 
(namely cornea verticillata caused by amiodarone)8.  
There are reports that suggest ophthalmic ADRs provoked by a systemic drug, but 
remain unsupported because no systematic review has been performed. Many 
ophthalmic ADRs have been identified solely due to spontaneous reports, namely 
blurred vision caused by leuprolide9, or other ophthalmic ADRs caused by different 
drugs such as biphosphonates, cetirizine or isotretinoin2. Therefore, on the one hand, 
prospective studies or trials should be performed to study the causality of each drug to 
each ophthalmic ADR; on the other hand, a systematic review should be performed to 
clarify and assess what ophthalmic ADRs can occur after the correct prescription of 
each drug. A systematic review would be useful not only to identify drugs in which 
ophthalmic ADRs are frequent or serious, but also to increase knowledge of physicians 
(prescribing physicians and ophthalmologists), enabling a greater detection of 
ophthalmic ADRs after a ophthalmic examination and enabling the construction of 
multi-disciplinary protocols whenever a high-risk drug is prescribed. 
General ADRs are estimated to cause of 2.7% to 15.7% hospital admissions and to 
occur in 16.9 % of hospitalized patients (confidence interval 95%: 13.6%, 20.2%)11. In a 
study performed in the United States (US) it was estimated that more than 100000 
people die every year as a consequence of fatal ADRs, placing fatal ADRs between the 
fourth and sixth leading causes of death in the US12. However, the specific frequency of 
ophthalmic ADRs is not known. 
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Although there are several studies about ophthalmic ADRs, this theme presents 
with specific difficulties13,14, and the methods of identification and reporting ADRs vary 
greatly15,16. Some studies have established recommendations17,18, and others offer 
guidelines to performing systematic reviews of studies of ophthalmic ADRs19,20. 
We intended to perform a general systematic review about ophthalmic ADRs to 
systemic drugs in order to, on the one hand, systematically summarize existing 
evidence, and on the other hand, identify areas of specific ophthalmic ADRs or drugs 
that lacked systematization or assessment. This includes the identification of drugs 
that cause specific ophthalmic ADRs which are well described in original studies but 
without systematic review nor meta-analysis (therefore, opportunities for specific 
systematic reviews with meta-analysis in the future are also identified).  
 
Methods 
We performed a systematic review of studies that assessed ophthalmic ADRs to 
systemic drugs according to the guidelines of the Cochrane Collaboration19 and 
PRISMA Statement21, adapted to this theme. 
 
Definitions 
We used the following definition for adverse drug reaction: “any noxious, 
unintended and undesired effect of a drug, which occurs at doses used in humans for 
prophylaxis, diagnosis, or therapy”, according to the World Health Organization (WHO) 
definition22 of 1972.  
An adverse event is: "an injury related to medical management, in contrast to 
complications of disease"23. Medical management includes all aspects of care, 
including diagnosis and treatment, failure to diagnose or treat, and the systems and 
equipment used to deliver care23. Therefore, to increase specificity, we wanted to 
assess only adverse drug reactions. 
 
Search methods 
We searched through several electronic databases (last date of search was 
1/7/2012): Medline, SCOPUS, ISI web of knowledge, ISI Conference Proceedings, 
International Pharmaceutical Abstracts and Google scholar. We used a search query 
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created after a pilot study to add specificity (full search query available if requested to 
the corresponding author) that included the terms: eye, ocular, ophthalmic, 
ophthalmology, adverse and reaction. We searched for grey literature and unpublished 
data, and hand-searched all references of included studies and relevant reviews. 
 
Selection criteria 
Studies were included if they followed all inclusion criteria listed below:  
1. Studies in which the primary purpose was to assess an ophthalmic ADR to a 
systemic medication. Since there is a wide misuse of the terms ADR, adverse event 
(AE) and adverse drug event (ADE), we obtained also the full-text of studies who 
claimed to assess AEs or ADEs, to verify their methodology, and to include the studies 
that actually assessed ADRs, although they called it AEs or ADEs. 
2. Studies with patient evaluation performed by an ophthalmologist. 
3. Studies that specified diagnostic criteria for an ocular ADR. 
We also included studies with different languages (we hired a translator), any 
country and experimental studies (if any). We did so to have a more thorough and 
complete literature search. We did not exclude systematic nor narrative reviews if they 
added useful information about ocular ADRs, as we intended to have a general 
overview that summarized and added further systematization to existing evidence, and 
to identify areas or specific ophthalmic ADRs that lacked systematization or 
assessment. 
 
Exclusion criteria: 
1. Studies assessing adverse events that did not correspond to ADRs (for example, 
we excluded reports of capsular rupture in phacoemulsification surgery, but we did not 
exclude reports of capsular rupture due to intra-operatory floppy iris syndrome, a 
syndrome that is an ADR provoked by tamsulosine or other drugs). 
2. Systemic ADRs to topical ophthalmic drugs, or ophthalmic ADRs to topical 
ophthalmic drugs (they were not the purpose of our study and would increase 
heterogeneity and reduce clarity of our study). 
3. Studies that were comments or letters, if they would not add new scientific 
evidence to our review. However, letters or comments that included case reports not 
Ophthalmic adverse drug reactions - systematic review 
6 
 
published elsewhere about specific ocular ADRs were not excluded, in order to identify 
rare ophthalmic ADRs. 
4. Studies assessing drugs already removed from the market. 
 
Data collection and extraction 
Two independent reviewers, AM and FH, first examined each title and abstract to 
exclude obviously irrelevant reports, and then independently examined each full text 
report, to determine eligibility according to inclusion criteria. Disagreements were 
solved by consensus, recorded and analyzed using kappa statistics. 
Primary outcome was the presence and type of ocular ADR and the respective 
causative systemic drug. Secondary outcomes included: ocular structure affected, 
diagnosis, serious or vision-threatening ADR. All symptoms, visual acuity (VA), signals, 
and results of complementary examination performed at presentation were recorded, 
as well as after a follow-up. Attitude or treatment performed for each ADR was also 
registered (suspension of the causative drug, specific treatment, administration of an 
antidote, no treatment necessary). If VA was not recorded in the logMAR scale24, it was 
converted. 
We always assessed the drug name, identified the therapeutic drug class 
according to Anatomical Therapeutic Chemical Classification System of WHO25, and 
reported the number of days during which the drug was used and the administration 
route (if that information was available). We verified if causality was assessed in the 
original studies (and according to what classification, preferably WHO’s23 or 
Naranjo’s26, and respective results) as well as predictability of ADRs (using Hartwig’s 
predictability scale, for example)27, preventability (eg. Schumok & Thornton’s 
preventability criteria)28 and types of ADRs (Rawlins and Thompson’s classification29). 
We did not intend to identify all of the ophthalmic ADRs, but to systematize the most 
important and the most frequent ADRs according to the results of our systematic 
search. 
 
Risk of bias assessment 
We performed risk of bias assessment for each included study, and recorded it in 
a standardized form created to assess ADR studies (in a previous work10) and adapted 
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to Ophthalmology after a pilot study. We did not use scales (discouraged by the 
Cochrane approach20) but criteria from Cochrane, STROBE30, QUOROM31 and PRISMA21 
adapted to the particular scope of ophthalmic ADRs evaluation, which included: 
complete description of study design, description of study type (case report, case 
series, prospective observational study, trial,...), adequate diagnostic criteria for 
ophthalmic ADR, complete ophthalmologic evaluation at presentation, quantified 
visual acuity at presentation and follow-up, results of complementary testing 
described at presentation and follow-up, definition of ADR presented, rationale for 
study size, causality assessment of ADR, preventability assessment of ADR, description 
of all statistical methods, characterization of study participants, description of 
methods to prevent bias (information bias, selection bias and other bias), presentation 
of complete summary measures. The two reviewers independently assessed study 
quality and risk of bias; disagreements were solved by consensus. 
Studies were divided in low risk of bias (5 or less parameters with medium, 
unclear or high risk of bias), medium risk (6 to 9) and high risk (10 or more parameters 
evaluated as medium, unclear or high risk of bias). 
 
 
Results 
Literature search  
Pubmed search yielded 124 results; SCOPUS yielded 72 results; Google Scholar 60; 
ISI Web of Knowledge yielded 154; others yielded 152. From these 562 studies 
(corresponding to 300 distinct studies), 163 were selected to obtain full-text and then 
32 studies were included9,17,32-61 (Figure 1): 1 systematic review of ADRs to a specific 
drug, 11 narrative reviews, 1 trial, 1 prospective study, 6 case-control or cohort or 
cross-sectional studies, 6 spontaneous reports and 6 case reports or case series. Kappa 
agreement for study inclusion was 0.80 during the first phase and 0.82 during the full 
text review (good agreement). 
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Figure 1. Flowchart of search strategy. 
 
Characteristics of included studies 
Table 1 summarizes the characteristics of included studies. We identified several 
types of studies of ocular ADRs, most of them narrative reviews without systematic 
criteria nor bibliographic search.  
Table 1 (end of manuscript) 
 
Ophthalmic ADRs  
Many different ophthalmic ADRs exist to many systemic drugs. In table 2, we 
represent a summary of the main ophthalmic ADRs found in this systematic review, 
according to each specific drug, dose, risk factors and tried to characterize the 
ophthalmic ADR (if reported). Keratitis, retinopathy, glaucoma, dry eye and blurred 
vision were the most frequent ADRs identified.  
Table 2 (end of manuscript) 
We identified many ophthalmic ADRs to drugs that have original studies but are 
currently lacking a systematic review (therefore representing an opportunity for 
further studies, as described in the Discussion Section, below). Many studies were 
found but only one systematic review (of ophthalmic ADRs to sildenafil56) and few 
narrative reviews with systematic search were performed. Therefore, examples of 
drugs that cause ophthalmic ADRs that would benefit from a recent and specific 
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systematic review are: tamoxifen, amiodarone, antidepressants, phenotiazines, 
hydroxychloroquine, oral contraceptives, etc. 
Risk of bias assessment  
In figure 2 we present the summary of our quality evaluation of included studies, 
according to each parameter assessed - risk of bias graph. Few studies had low risk of 
bias. Only one study performed rationale for study size. Most studies (25) performed a 
complete initial evaluation by an ophthalmologist, but only 11 performed a follow-up 
of at least 1 month. Only 13 studies performed causality assessment for ADR and only 
7 applied or presented WHO's definition of an ADR. Risk of bias summary, which 
contains detailed risk of bias assessment for each included study, is available if 
requested to contact author. 
 
Figure 2. Risk of bias graph. 
 
Discussion 
What this study adds 
There is an increasing number of studies of ophthalmic ADRs. In spite of the 
common belief that ADRs in Ophthalmology are rare, some ADRs might be extremely 
frequent (such as cornea verticillata caused by amiodarone8), but require specific 
ophthalmological examination for its detection. Every ocular structure might be 
affected by an ADR. There is a need for performing specific systematic reviews of 
ophthalmic ADRs, because the majority of included studies were narrative non-
systematic reviews, most of which without the strict application of WHO's definition of 
ADR nor causality assessment of ADRs. 
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Several drugs that may provoke different ophthalmic ADRs were identified, 
namely amiodarone, sildenafil, psychotropic drugs, alpha-blockers, corticosteroids and 
topiramate. Although cornea verticillata is found very frequently in patients medicated 
with amiodarone (authors report a rate of 100%46), this finding rarely reduces visual 
function; on the other hand, amiodarone may provoke a rare optic neuropathy that 
may provoke marked visual loss18. Sildenafil and tadalafil have been recently studied, 
but while some authors report no difference between ERG patterns of placebo versus 
these drugs53, others found several ADRs associated with sildenafil58, namely: ischemic 
optic neuropathy, central retinal vein occlusion, cilio-retinal artery occlusion, acute 
angle closure glaucoma and optic atrophy. 
Strengths of our systematic review lie in the comprehensive search performed, 
the general increase in systematization and characterization of ophthalmic ADRs, the 
summary of existing evidence according to WHO's causality criteria for ADR and WHO's 
definition of ADR, and finally the identification of specific ophthalmic ADRs that could 
benefit from future specific systematic reviews with possible meta-analysis. 
Limitations of our systematic review include not only heterogeneity found in 
different types of ADRs but also the extreme variability in the methodologies of studies 
of ophthalmic ADRs (from isolated case reports to retrospective series of spontaneous 
reports, prospective observational studies and trials). These limitations were expected, 
because this was a systematic review with a very general scope; and because the 
detection of ophthalmic ADRs depends on the degree of suspicion and an adequately 
performed ophthalmologic examination. Many ophthalmic ADRs are only detected by 
case reports or spontaneous reports, representing a limitation but simultaneously an 
opportunity to improve. Consequently, there are many ophthalmic ADRs that are 
based on a low level of evidence. We believe this is an additional reason for applying 
systematically the WHO definition for ADR and a causality assessment (whether WHO's 
or Naranjo's), in order to decrease doubts. High risk drugs such as the ones identified 
in table 2 should be associated with protocols of evaluation (specially in susceptible 
individuals or in high doses) by an ophthalmologist, in order to detect sooner and with 
higher sensitivity and specificity the respective ophthalmic ADRs. 
Conclusion 
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Ophthalmologists' education (to increase recognition of ophthalmic ADRs) and the 
dissemination of protocols of collaboration between Ophthalmology and other 
Medicine specialties whenever they prescribe high-risk drugs (such as sildenafil, 
biphosphonates, psychiatric medication, tamoxifen, hydroxichloroquine) are strong 
suggestions for the future. 
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Year, author Study type Drug studied Ophthalmic ADR(s) reported* Summary of study 
1986 Davidson32 Narrative review Several 
Many ocular ADRs caused by: 
corticosteroids, chloroquine, amiodarone, 
phenothiazines, tamoxifen... 
Narrative review without 
definition of ADR nor causality 
assessment 
1989 Curran33 Case series Doxorrubicin Iritis, conjunctivitis, periorbital edema, keratitis, optic neuropathy 
Case series of 4 cases of ocular 
ADRs to doxorrubicin 
1991 Hobley34 Case report Digoxin Scintillating visual field loss (central scotoma) + dischromatopsia  
Case report: visual field defect 
due to digoxin (therapeutic 
level) 
1992 Malek35 Narrative review Oral contraceptives  Retinal hemorrhage or emboli, macular or papillary edema, optic neuropathy 
Narrative review of ocular 
ADRs by oral contraceptives.  
1993 Goldman36 Narrative review Anticonvulsivants 
 Carbamazepine: diplopia, paresis of 
extraocular muscles, nistagmus, visual 
allucinations 
 Phenytoin: nistagmus without oscillopsia, 
mydriasis 
 Others: paresis of extraocular muscles 
Narrative review of ocular 
ADRs of common 
anticonvulsivants 
1994 Macarol37 Spontaneous reports Pamidronate Scleritis, conjunctivitis, anterior uveitis 
Retrospective series of 
spontaneous case reports 
1995 Oshika38 Narrative review Neuropsychiatric drugs 
 Phenothiazine: corneal et lens deposits 
 Thioridazine: retinopathy 
 Tricyclic antidepressants: glaucoma, 
decreased accommodation 
 Lithium: papilledema, exophthalmia 
 Chlorpromazine: keratopathy 
A narrative review of 
ophthalmic ADRs of 
neuropsychiatric drugs 
1995 Fraun- 
Felder9 
Letter with 
spontaneous 
reports 
Leuprolide Blurred vision 
A retrospective study of series 
of spontaneous reports of 
ocular ADRs of leuprolide 
1995 b 
Fraun- 
Felder39 
Retrospective 
case-control 
study 
Niacin Dryness, blurred vision, diplopia, cystoid maculopathy  
ADRs of patients taking niacin 
were compared to other 
dyslipidemia drugs 
1997 Sweeney40 Prospective study Risperidone Eye movements affected: prolonged latency after and alteration of saccadic movements 
Prospective study of patients 
with risperidone (4 weeks) 
1999 Dulley41 Narrative review Tamoxifen 
 Retinopathy with deposits 
 Keratopathy with deposits 
 Colour vision defects 
 Foveal disfunction and ERG change 
Narrative review about ocular 
ADRs of tamoxifen 
1999 Solomon42 Letter with case reports Influenza vaccine 
 Case 1: anterior uveitis 
 Case 2: reactivation of herpetic keratitis 
 Case 3: left keratoplasty rejection 
Letter with case reports not 
previously published 
1999 Doughty43 Narrative review Migraine drugs 
Cyproheptadine, pizotyline, amitriptiline, 
propranolol, timolol, clonidine, flunarizine: 
dry eye 
A narrative review of 
medications of headaches and 
their ocular ADRs 
2001 Ikaheimo44 
Observational 
cross-sectional 
study 
Flecainide  Corneal deposits  Dry eye 
Observational study in which 
38 flecainide medicated 
patients were examined. 
2001 
Fraunfelder45 
Case series of 
spontaneous 
reports 
Isotretinoin 
 Many ADRs: abnormal meibomian glands, 
blepharoconjunctivitis, corneal opacities, 
decreased vision, keratitis, ... 
Analysis of 1741 spontaneous 
reports with possible ocular 
ADRs to isotretinoin 
2002 Ikaheimo46 
Observational 
cross-sectional 
study 
Amiodarone 
 Corneal deposits (in 100% of the patients) 
 Anterior subcapsular lens deposit (22.2%) 
 Dry eyes (9.1%) 
Observational study in which 
22 patients with long term 
amiodarone were studied 
2003 Fraun- 
Felder18 Narrative review Several 
  Amiodarone: cornea verticillata, 
periocular staining, optic neuropathy 
  Cetirizine: mydriasis, oculogyric crisis... 
  Hydroxychloroquine: corneal deposits, 
epiphora, extraocular paresis, ptosis 
  Isotretinoin: conjunctitivis, corneal 
deposits, acute myopia, optic neuritis 
  Biphosphonates: episcleritis, 
conjunctivitis, nerve palsy,...  
 Sildenafil: dischromatopsia, blurred vision 
 Topiramate: acute glaucoma, acute 
myopia, ocular pain, uveitis,...  
A narrative review was 
performed of ocular ADRs, 
without systematic study 
search but with systematic 
WHO causality assessment 
whenever possible. Offers good 
guidelines and clinical 
implications for each drug. 
2004 Fraun- 
Felder47 
Retrospective 
series of reports Several 
  Biphosphonates: conjunctivitis, uveitis, 
blurred vision, scleritis 
  Cetirizine: blurred vision, 
keratoconjunctivitis sicca, oculogyric crisis 
  Isotretinoin: blurred vision 
  Topiramate: acute glaucoma, acute 
A large retrospective series of 
spontaneous reports of ocular 
ADRs to different systemic 
drugs. WHO's definition of ADR 
and WHO's causality 
assessment were performed. 
myopia, periorbital edema, scleritis 
2006 Fraun- 
Felder48 
Letter with 
retrospective 
reports of 
spontaneous 
reports of ocular 
ADRs 
Cyclooxygenase-2 
Inhibitors 
Blurry vision and conjunctivitis were the 
most reported ADRs 
Letter with large series of 
spontaneous reports (1006) of 
ocular ADRs to cyclooxygenase-
2 Inhibitors (238 reports of 
blurry vision and 71 of 
conjunctivitis from celecoxib). 
2007 Santaella49 Narrative review Several 
Several drugs were assessed, such as: 
pamidronate, alendronate, risedronate, 
topiramate 
Narrative review of several 
retrospective case series and 
reports of ocular ADRs to 
specific systemic drugs.  
2007 Sowka50 Case report Sildenafil Optic atrophy after the use of sildenafil in a 68-year old man.  
Case report with a follow-up of 
4 months. No causality 
assessment of ADR nor WHO's 
definition of ADR was used. 
2008 Mandal51 Two case reports 
Topiramate, >6 
months, 100-
150mg/day 
Defects in visual field (case 1-quadrantic 
defects, case 2-arcuate defects)  
Two case reports of visual field 
alterations induced by 
topiramate, (Naranjo's CA was 
performed). 
2009 Bell52 Retrospective study Tamsulosin 
Intra-operatory floppy iris (IFIS) and related 
surgical outcomes 
Retrospective cohort study of 
96128 patients: tamsulosine 
was associated with IFIS and 
intraoperatory complications 
2009 Cordel53 Trial Sildenafil and tadalafil 
Electroretinography (ERG) responses were 
the same for placebo, sildenafil and 
tadalafil. 
Subjects were randomized to 
use of a placebo (n=82), 
tadalafil (n=85) or sildenafil 
(n=77) daily for 6 months.  
2009 El-
Domyati54 Case report Sildenafil 
A 48-year-old nonsmoker patient suffered 
from nonarteritic ischemic optic 
neuropathy. "Several weeks later", the 
visual acuity gradually improved 
Case report. Causality 
assessment of WHO was not 
performed. Follow-up of 
"several weeks later", not 
specified. 
2010  
Richa55 Narrative review Psychotropics 
  Phenothiazines, lithium: 
keratoconjunctivitis 
 Chlorpromazine: periocular pigmentation 
  Tricyclic antidepressants, topiramate: 
uveitis 
 TCAs, typical antipsychotics, selective 
serotonin reuptake inhibitors: mydriasis 
A narrative review was 
performed with several 
psychotropic drugs 
2010 Al-
Hussaini56 
Comprehensive 
narrative review Alpha-Blockers 
Intra-operative Floppy Iris Syndrome (IFIS). 
"There is no evidence to support alpha-
blocker discontinuation prior to surgery." 
Review about IFIS and drugs.  
2011 Lebreton57 
Narrative review 
with systematic 
search 
Corticosteroids 
 Ocular hypertension 
 Cataract (posterior subcapsular) 
 Central Serous Chorioretinopathy 
  Ptosis 
  Exophthalmia 
A narrative review was 
performed of ophthalmic ADRs 
of corticosteroids 
2011 Azzouni58 Systematic review Sildenafil 
Anterior and posterior nonarteritic ischemic 
optic neuropathy, central retinal vein 
occlusion, cilio-retinal artery occlusion, 
acute angle closure glaucoma and optic 
atrophy after sildenafil use. 
Systematic review of ocular 
ADRs by sildenafil. WHO's 
causality assessment was 
performed and of National 
Registry of Drug-Induced 
Ocular Side Effects. 
2012 Seitz59 Case-crossover study Antidepressants 
Acute angle-closure glaucoma (AACG) (odds 
ratio for any antidepressant exposure in the 
period immediately preceding AACG was 
1.62, 95% confidence interval of 1.16-2.26). 
Authors searched acute angle -
closure glaucoma, and 
investigated whether they had 
an exposure to antidepressants 
previously, using administrative 
databases.  
2012 Saint-
Jean60 Case series  
Inhibitor of 
epidermal growth 
factor receptor 
(EGFR)  
Multiple epithelial defects, corneal melting, 
ectropion and corneal perforation (requiring 
a penetrating keratoplasty). 
Retrospective case series of 10 
patients with ocular ADRs. 
Definition of ADR was not used.  
2012 
Neudorfer61 
Retrospective 
study of 
outcomes 
Isotretinoin 
An association was found between 
isotretinoin and conjunctivitis, hordeolum, 
chalazion, blepharitis, eye pain, and dry eye. 
Retrospective study with 
medical databases to identify 
ADRs in patients using 
isotretinoin. 
Table 1. Included studies in this systematic review. *Ophthalmic ADRs will be described with further detail in table 
2. 
Therapeutic group Drug(s) responsible(s) 
Description of ocular ADR 
- Patient (P), ocular segment/complaints (O) 
- Complementary examination (C) 
- Reversibility of ADR (R), follow-up time (F) 
Classification of ADR 
- Rawlin's type A/B 
- Severity assessment 
(SA); causality 
assessment (CA) 
- Reporting studies 
- Study's level of 
evidence (Oxford 
classification62) 
Acne treating 
agents Isotretinoin 
Certain ADRs: pseudotumour cerebri, meibomian gland 
alterations, blepharoconjunctivitis, keratitis, myopia, 
corneal opacities, ocular discomfort, dry eye, 
photophobia, decreased vision, and teratogenic ocular 
abnormalities. (Many other ADRs were reported). 
A recent study61 identified a hazard ratio of 1.70 (p<0.05) 
for ocular ADRs after isotretinoin. 
- Type A and B 
- With CA (WHO's) 
Narrative review18 and 
case series45 (level 4) 
Retrospective study 
using medical 
databases61 (level 2c) 
Anti-allergic Anti-histamines: cetirizine 
Pupillary changes, anisocoria, decreased 
accommodation and blurred vision. Dry eye47 
Oculogyric crisis18: "eyes and lids are tonically elevated 
and the neck is hyperextended, usually without visual 
complaints". It is a certain ADR18. 
- Type B: all except 
oculogyric crisis (A). 
- WHO's causality 
assessment (CA) was 
performed18. 
Narrative reviews18,47 
(level 4) 
Anti-arrhythmics 
Flecainide 
Corneal deposits: 14.5% 
Dry eye: 10.5% 
- 13 to 132 months of follow-up 
- Type A 
- No CA nor SA 
- Cross-sectional study44 
- Level 2c 
Amiodarone 
Corneal deposits: 100% of the patients32,46 
Anterior subcapsular lens deposits46: 22% 
Dry eye46: 9% 
Amiodarone-optic neuropathy18: more insidious in onset 
and resolution, more bilateral, less involvement in visual 
acuity compared to non-arteritic ischaemic neuropathy. 
Other47: Photosensitivity, periocular skin pigmentation, 
blepharoconjunctivitis, thyroid eye disease, loss of 
eyelashes, pseudotumor cerebri. 
- 3 to 131 months of follow-up in a prospective study46 
Certain ADRs18: photosensitivity, corneal deposits, visual 
changes, skin pigmentation, blepharoconjunctivitis, 
thyroid eye disease.  
- Type A: dry eye, 
corneal and lens 
deposits. Rest: type B. 
- WHO causality18 
- Cross-sectional study46 
(level 2c) and narrative 
reviews18,32,46 (level 4) 
Anticonvulsivants 
- Carbamazepine 
(CB) 
- Phenytoin(PH)  
- Phenobarbital(PB) 
and other 
barbiturates 
 
Diplopia:  caused by CB in 0.2-4% of patients36 (if CB+ 
other anticonvulsivants, frequency can rise to 88%). 
Diplopia can be reversible with dose reduction36.  
Nystagmus: in 75% of patients with CB+PH36. 
Also reported after primidone and PH. 
Decreased ocular movements: by CB and PB36 
Ophthalmoplegia: by PB and PH 
Oculogyric crisis:  by CB (in a 8-y., reversible36) 
Blurred vision: CB36;  Mydriasis: PH36 
Disorders of convergence, miosis: barbiturates36 
Papilledema: CB36 (C, F: not specified in any study) 
- All Rawlin's type B 
(although diplopia may 
resolve with dose 
reduction38), except: 
Type A: decreased 
ocular movements, 
mydriasis, changes in 
convergence 
- No study with SA nor 
CA 
- Narrative review 
based on case reports36 
- All studies Level 4 
Antidepressants 
and antipsicotics 
- Phenotiazine (PT) 
- Thioridazine  
- Tricyclic 
antidepressants 
(TA) 
- Lithium 
- Chlorpromazine 
(CP) 
- Monoamine 
oxidase inhibitors 
(MAOIs) 
- Risperidone 
Corneal and lens deposits: by PT, CP38, levopromazine; 
these deposits usually do not interfere with visual acuity 
Keratopathy: Corneal edema by PT (reversible if 
stopped), epitelial keratopathy by CP38 (visual acuity 
remains good, may be reversible if CP is stopped) 
Pigmentary retinopathy55: by thioridazine (more frequent 
in high dose, may be irreversible); rarely also by CP and 
trifluoperazine38 
Papilledema, exophthalmia: lithium38 
Alteration of saccadic eye movements: risperidone38,40 
Angle-closure glaucoma: by TA, in susceptible patients 
with shallow anterior chamber59,63 
Decreased accommodation: TA, MAOIs 
 (C, F, frequency: not specified) 
- Usually type B 
(decreased 
accomodation is type 
A) 
- Na CA nor SA was 
performed 
- Narrative reviews of 
case series of several 
psychiatric drugs38,55 
- Prospective study of 
risperidone40 
- Case crossover study59 
- Level 4 (low evidence) 
for the narrative 
reviews38,55, level 2c for 
case crossover59 and 2b 
for the prospective 
study40 
Anti-erectile 
disfunction 
agents 
Sildenafil 
Certain ADRs18,47: dyschromatopsia (objects appear more 
blue/green), blurred vision, changes in light perception, 
electrorretinogram changes, conjunctival hyperemia and 
photophobia.  
Case report50: optic atrophy (without CA). 
Trial53: no changes in electroretinography responses for 
placebo, sildenafil and tadalafil (no ADR). 
Others58: Anterior and posterior nonarteritic ischemic 
optic neuropathy, central retinal vein occlusion, cilio-
retinal artery occlusion, acute angle closure glaucoma. 
- Type A and B 
- With CA: WHO's18,47 
and Naranjo's58 
- Without CA nor SA50 
Narrative reviews18,47, 
systematic review of 
case reports58 and case 
report50 (level 4) 
Trial53 (level 1b) 
Anti-
inflammatory 
drugs 
Cyclooxygenase-2 
Inhibitors 
Blurry vision and conjunctivitis by rofecoxib, celecoxib 
and valdecoxib (positive dechallenge and rechallenge 
tests) 
- Type B 
- With CA 
Retrospective series of 
spontaneous reports48 
(level 4) 
Corticosteroids 
Ocular hypertension: Odds ratio 1.41 (CI95% 1.2-1.6)64 
Glaucoma reportedly in up to 30% of patients32 
Cataract (posterior subcapsular): 4.7%-15.3%65,32 
Central serous chorioretinopathy: OR 37(CI95% 6-222)57 
Others: ptosis, exophthalmia (6-8%57), viral retinitis, 
delay in corneal cicatrization 
- Type A: cataract 
- Type B: other ADRs 
- Without CA nor SA 
Narrative reviews32,57 
(level 4) 
Case-control studies64,65 
(level 3b) 
Benign prostatic 
hyperplasia drugs 
Alpha-blockers (e.g. 
tamsulosin) 
More post-operatory complications (in 14 days) in 
patients with tamsulosine52: intra-operatory floppy iris 
Intra-operative Floppy Iris Syndrome (IFIS). IFIS severity is 
related with number of the following criteria: 
  iris billows with intraocular irrigation currents 
  iris prolapse tendency 
  intraoperatory pupilary constriction 
- Without CA 
- With SA 
Retrospective study52 of 
96128 patients(level 2b) 
Narrative review with 
systematic search56 
Biphosphonates 
Pamidronate 
Risedronate 
Alendronic acid 
Zolendronate 
Risedronate sodium 
Etidronate 
dissodium 
Anterior uveitis: uni or bilateral, 24h to 17 days after 
medication37, mild to severe (2 hospitalizations) 
Scleritis, episcleritis: unilateral, in 1-6 days. 
Conjunctivitis: mild, in 1-48h.  
Nerve palsy, retrobulbar neuritis,  
yellow vision, blurred vision 
C, F, frequency: not specified. Causality assessment18,47: 
Certain ADR: blurred vision, ocular irritation, 
conjunctivitis, pain, epiphora, photophobia, anterior 
uveitis, anterior scleritis, episcleritis, orbital edema.  
Possible: retrobulbar neuritis, yellow vision, diplopia, 
cranial nerve palsy, ptosis, visual hallucinations. 
- Type B 
- No CA37, but 
rechallenge was 
performed in 5 
patients with uveitis (4 
positive rechallenge 
tests) 
- With CA18 performed 
in a narrative review 
 
- Retrospective series of 
spontaneous case 
reports37 and narrative 
reviews18,47 
- Level 4 
Drugs used in 
heart failure Digoxin 
- 36 year-old female 
Dischromatopsia + scintillating visual field (VF) 
alterations, 3 months after administration of digoxin 
Colour test FM-100: defect on blue colour. 
- Reversibility, follow-up: not specified 
- Rawlin's: 
B/idiosyncratic ADR 
- No SA  
- No CA  
- Case report34  
- Level 4 (low evidence). 
Many other studies not 
included because toxic 
digoxin levels 
Drugs used in 
neoplastic 
disorders 
Imatinib 
Periorbital edema (after CA, certain ADR).  
Epiphora( probable ADR) 
Other possible ADRs: extraocular muscle paresis, ptosis 
and blepharoconjunctivitis. 
- Type A: periorbital 
edema. Rest: type B. 
- With CA (WHO's) 
Narrative review18 (level 
4) 
Inhibitor of 
epidermal growth 
factor receptor 
(EGFR) 
Multiple epithelial defects (in 10 eyes of all cases), 
corneal melting (in 3 eyes of 2 patients), lower lid 
ectropion (2 eyes of 1 patient) and corneal perforation 
requiring a penetrating keratoplasty (in 2 eyes of 2 
patients). Variable follow-ups (all > 1month). 
- Type B 
- No CA nor SA 
Retrospective series of 
spontaneous reports60 
(level 4) 
Drugs used in 
Rheumatology 
Chloroquine 
Hydroxychloroquine 
Corneal deposits, epiphora, ophthalmoplegia, ptosis 
Maculopathy: dramatic retinopathy with macular atrophy 
in a bull's-eye pattern. No frequency is reported but: 
"approximately one million people have used 
hydroxychloroquine, with only 20 cases of retinal toxicity 
in the low dose range (< 6.5 mg/kg/day)"18 
Baseline and anual ophthalmic examinations are 
recommended with: visual acuity, amsler's grid, colour 
test, and ideally fundus photograph and visual field. 
- Type A: maculopathy 
(related to cumulative 
dose), corneal deposits 
- Type B: 
ophthalmoplegia, 
ptosis 
- With CA (WHO)18 and 
without32 
Narrative reviews18,32 
(level 4) 
Hormone-related 
therapy 
Oral contraceptives 
Retinal hemorrhage or emboli, Macular edema, Papillary 
edema, Retrobulbar optic neuropathy 
- Patient: not specified 
- Ocular segment: posterior (retinal alterations and 
papillary edema, vascular changes) 
- Complementary examination: angiography, CT scan 
- Follow-up: variable (case reports) 
- Rawlin's type B 
- No SA 
- No CA 
- Narrative review35 
based on few case 
reports (low evidence) 
- Level 4 
Leuprolide 
Blurred vision: duration between 1h and 15 days, may be 
associated with headaches or dizziness. 
Other:  papilledema, ocular pain, "ocular vascular 
accidents" 
- Type B 
- No CA nor SA 
- Series of spontaneous 
case reports9 
- Level 4 
Tamoxifen 
Crystallin retinopathy: in the macula, may be associated 
with macular edema 
Keratopathy with whorl-like opacities 
Colour vision defects 
Foveal disfunction with ERG changes 
- Usually type B 
- No CA nor SA41  
- CA(WHO causality)47 
- Narrative review41,47 
- Level 4 
Doxorrubicin 
Case 1: iritis, conjunctivitis 
Case 2: periorbital edema 
Case 3: keratitis 
Case 4: optic neuropathy (F, C, follow-up: not reported)  
- Type B 
- No CA nor SA 
- Case series of 4 cases33 
(level 4) 
Lipid lowering 
agents Niacin 
Dry eye (Fisher exact test p=0.011),  
Blurred vision(p=0.0011) 
Diplopia(p=0.5, non statistically significant)  
- Type B 
- No CA nor SA 
- Case-control study39 
- Level 3b 
Cystoid maculopathy (2 cases) 
Migraine drugs 
Cyproheptadine, 
pizotyline, 
amitriptiline, 
propranolol, 
timolol, clonidine, 
flunarizine 
Dry eye: all 
Diplopia: cyproheptadine, pizotyline, amytriptiline 
Mydriasis: cyproheptadine, pizotyline, amytriptiline 
Decrease in accommodation: propranolol, timolol 
Changes in intraocular pressure: all 
- Type A 
- No SA nor CA 
- Narrative reviews43,18 
- Level 4 
Topiramate 
Certain ADRs by topiramate: acute angle closure 
glaucoma (usually bilateral, in 1-14 days, suprachoroidal 
effusion), decreased vision, headaches, hyperemia, 
mydriasis, uveitis, visual field defects, myopia. 
Probable ADRs by topiramate: blepharospasm and 
oculogyric crisis. 
Case reports of others ADRs, as visual field defects51 
- CA performed by 
Fraunfelder18 
- Narrative reviews18,51 
- Level 4 
Vaccines Influenza vaccine 
Case1: 41y, man, reversible anterior uveitis 
Case 2: 72 y, woman, reactivation of herpetic keratitis 
Case 3: 74 y, man, left keratoplasty rejection 
- Type B 
- No CA nor SA were 
performed 
- Letter with case 
reports42 
- Level 4 
Table 2. Summary of ophthalmic adverse drug reactions. 
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Background
Description of the condition
Adverse drug reactions (ADRs) are frequent, important, expensive and can be fatal (a study estimated that 
they are between the fourth and the sixth causes of death in the United States (Lazarou 1998). More recent 
estimates report that ADRs may occur in a mean of 16.88% of patients during hospitalization 
(CI95%:13.56-20.21) (Miguel 2012) and that they are associated with an overall median of 5.3% of hospital 
admissions (interquartile range 2.7-9.0%) (Kongkaew 2008).
However, Ophthalmology represents a challenge in Pharmacovigilance (Fraunfelder 2007). Several 
ophthalmic ADRs provoked by systemic drugs are known by spontaneous reporting, without systematic 
assessment nor definitive evidence. An ophthalmic ADR can affect every structure in the eye (Fraunfelder 
2007), but some systemic drugs tend to provoke specific ophthalmic ADRs, namely amiodarone which 
frequently provokes cornea verticillatta (Hollander 2004) and rarely provokes (but with potential for irreversible 
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blindness) optic neuropathy (Carelli 2002).
Statins are widely used for the treatment of dyslipidemia and cardiovascular pathologies (Taylor 2011). They 
provoke general ADRs that are well documented, such as myopathy, liver transaminases elevation and renal 
failure (Andrejak 2003). On the other hand, ophthalmic ADRs provoked by statins have been reported by some 
authors (Hermans 2011), but lack a systematic review. Specific types of ADRs that were reported to occur 
after statin use include cataract formation (which is controversial, with some studies reporting an increase in 
the incidence of cataract (Hippisley-Cox 2010) and others reporting a decrease (Klein 2006)). Other ADRs that 
have been reported are: dry eye (Smidt 2011), diplopia (Fraunfelder 2008), ptosis (Fraunfelder 2008, Ertas 
2006) and ophthalmoplegia (Fraunfelder 2008).
On the other hand, statins may have a protective role also in the delay of vitreous haemorrhage in diabetic 
patients (Banerjee 2004) and in the development of age-related maculopathy (McGwin 2003).
Description of the intervention
We will consider the following definitions:
Adverse drug reaction (ADR): any noxious, unintended and undesired effect of a drug, which occurs at 
doses used in humans for prophylaxis, diagnosis, or therapy , according to WHO s definition (WHO 2005).
Statins (or HMG-CoA reductase inhibitors) are a class of drugs used to lower cholesterol levels. They inhibit 
the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. They 
are widely used as lipid-lowering agents (Taylor 2011).
We will search ophthalmic adverse drug reactions provoked by statins systemically administered, in the correct 
dose, administration and indication.
How the intervention might work
The specific ocular anatomy of the eye may facilitate the occurrence of ADRs. After a drug (namely a statin) is 
administered systemically, it can reach ocular tissues through uveal or retinal circulations, and the fenestrated 
endothelium may allow the drug to pass through ocular barriers and to accumulate in ocular structures such as 
the lens, cornea, and trabecular meshwork (Wren 2000). This may cause a pathological alteration of ocular 
structure or function, provoking an ophthalmic ADR. Nevertheless, there is controversy regarding statins: some 
state that its antioxidative and antiinflammatory power may decrease the risk of cataract formation (Klein 
2006), while others report an increase in the incidence of cataracts (Collins 2012, Hippisley-Cox 2010) and 
others report no association (Hermans 2011). Statins have been found inside the lens (Grosse 2004), and 
therefore may alter the lens fiber functioning, disrupting the delicate lens metabolism and accelerating cataract 
formation. Also, the lens membrane contains cholesterol, therefore, statins can induce cataract formation 
because they may reduce lens cholesterol synthesis (Cenedella 1996).
Why it is important to do this review
The detection and prevention of ADRs is of increasing importance in Medicine. In Ophthalmology, there are 
several isolate reports of ophthalmic ADRs provoked by systemic drugs, but few specific systematic reviews, 
reducing evidence and increasing doubt. Statins are widely used and may provoke ophthalmic ADRs, such as 
the reported increase in cataratacts. It is important to systematically review these reports and to identify other 
ophthalmic ADRs provoked by this drug. On the other hand, if there is a protective effect in cataract formation, 
it is crucial to confirm it, since many studies have tried but failed to identify a drug that can offer protection 
against cataract formation, such as was tried with vitamin E (McNeil 2004) and with other micronutrients 
(Sackett 2002). It is also important to investigate whether statins have a protective role in ocular pathologies, 
such as vitreous haemorrhage in diabetic patients and in age-related maculopathy.
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Objectives
To determine whether statins provoke an increased incidence of cataratacts, myositis of ocular muscles, and 
to identify other ophthalmic ADRs provoked by statins. To classify the probability and the causality of each of 
these ophthalmic ADRs, according to the specific causality classification of WHO (WHO 2005). To investigate 
the clinical impact in each of the ADRs found, namely: visual acuity, symptoms, quality of life, need of any 
therapy or procedure, and improvement (whether spontaneous improvement, improvement after suspension of 
the drug or improvement after therapies/procedures). To perform a risk of bias assessment for each of the 
included studies.
Methods
Criteria for considering studies for this review
Types of studies
- We will include randomized controlled trials (RCTs) for this review preferably. However, since ophthalmic 
adverse drug reactions is a particular theme probably with few trials, we will consider also different types of 
studies, which will be analyzed separately according to study type and added only if they add new evidence. 
Clarifying, we will search:
First - randomized controlled trials (in which ophthalmic ADRs to statins are searched)
Second - prospective observational studies (searching for ophthalmic ADRs to statins)
Third (IF no evidence is found in first and second) - observational case-control studies and cross-sectional 
studies that searched ophthalmic ADRs to statins
Fourth (IF no evidence is found in the above search) - case series, case reports and letters (if they include new 
evidence of new ophthalmic ADRs not detected in the above search).
This phased search is proposed by us as an adapted search methodology to this particular theme, in order to 
increase sensibility and detection of ophthalmic ADRs.
- Additionally to including different types of studies, we will include studies with different languages (English, 
Portuguese, Spanish, French, German), any country, any ward. We will only include studies after WHO s 
definition of ADR of 1972. We will do so to have a more thorough and complete literature search and to have 
the opportunity to analyze them as subgroups and identify sources of heterogeneity.
Types of participants
Patients taking statins, that have ophthalmic symptoms or pathologies, presumably due to these drugs.
Indications for statins' use will include: dyslipidemia and other cardiovascular pathologies.
We will exclude errors in prescribing and administration of statins. We will also exclude patients which already 
have risk factors for the presumable ophthalmic ADR (for example, if the presumable ADR is cataract 
formation, we will exclude studies concerning patients already with cataratacts)
We will not exclude age, gender, ethnicity nor country.
Types of interventions
Systemic administration of statins. We will include all types of statins, namely: Atorvastatin; Cerivastatin; 
Fluvastatin; Lovastatin; Mevastatin; Pitavastatin; Pravastatin; Rosuvastatin; Simvastatin.
We will also study associations in which there is a statin, such as: Simvastatin+Ezetimibe; Lovastatin+Niacin 
extended-release; Atorvastatin+Amlodipine Besylate; Simvastatin+Niacin extended-release.
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Types of outcome measures
Primary outcomes
Primary outcomes will be the types of ophthalmic ADRs presumably provoked by statins.
We will apply assessments and classifications for each ADR found in each study, namely:
- Study types in which the ophthalmic ADR was reported
- WHO causality assessment of ADRs (appendix 1) (WHO 2005)
- Classification of type of ADR according to Rawlin's (Rawlin 1977)
- Schumok's preventability assessment of ADR (Schumok 1992)
- Classification of severity of ADR (Hartwig 1992)
Secondary outcomes
Secondary outcomes will include, for each ophthalmic ADR found:
-visual acuity at presentation
-ophthalmic symptoms,
-quality of life,
-need of any therapy or procedure, and
-improvement at 6 months and at 12 months or at available/reported follow-up (we will register whether this 
improvement is spontaneous, or after suspension of the drug or even after therapies/procedures).
-Risk of bias assessment for each study will also be a secondary outcome.
Search methods for identification of studies
Electronic searches
We intend to search several databases:
- Cochrane Central Register of Controlled Trials and The Cochrane Library)
- MEDLINE (search strategy in appendix 2)
- SCOPUS
- EBSCO
- ISI web of knowledge, ISI Conference Proceedings
- International Pharmaceutical Abstracts
- EMBASE
- LILACS
- www.controlled-trials.com and www.clinicaltrial.gov
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- Google scholar
Searching other resources
- Emails and letters sent to experts (namely Fraunfelder)
- Grey literature and unpublished studies as suggested or reported by experts
- Manual search of journals of Ophthalmology
- Search of references of included studies
- Search of references of general systematic or narrative reviews about ophthalmic ADRs, if they include 
information about ADRs provoked by statins
Data collection and analysis
Selection of studies
Two independent reviewers, AM and FH, will first examine each title and abstract to exclude obviously 
irrelevant reports. Disagreements will be solved by consensus, recorded, and analyzed using kappa statistics. 
If doubt remains after consensus, full-text of the articles will be obtained for further analysis.
Data extraction and management
Two independent reviewers, AM and FH, will examine full-text of articles to determine eligibility according to 
inclusion criteria.
If a study is excluded, the reviewers will fill a form with reasons for exclusion.
If a study is included, the reviewers will fill a form (previously build for this review: appendix 2) with: study type, 
summary of study, demographic data, number of patients assessed per study, dose and duration of statin 
therapeutics, name of the statin used, indication for statin, type and frequency of each ophthalmic ADR, 
baseline distance visual acuity (converted to LogMAR scale), patient symptoms, biomicroscopy findings, 
complementary examination performed, all diagnoses, all drugs administered, causality assessment (if 
performed by authors; if not, it will be performed by reviewers whenever possible), treatments performed (if 
any), distance visual acuity (logMAR) at 6 and 12 months after presentation (and all findings reported during 
follow-up, which will be registered for each study).
If a study lacks information for assessment, authors of the study will be contacted for further clarification. 
Disagreements will be solved by consensus and recorded for analysis using kappa statistics at this point; if 
doubt remains after consensus, a third author (LA) will decide. A pilot test will be performed to evaluate the 
selection procedure and criteria on a sample of 5 random reports, to refine criteria and train reviewers.
Assessment of risk of bias in included studies
Two independent reviewers will assess risk of bias in included studies, using a standardized form to evaluate 
the methodological quality of included studies, which will include: complete description of study design, 
verification if all parts of study were prospective, number of hospitals in which study occurred, number of 
patients, adequate selection criteria, presentation of a definition of ADR, rationale for study size, causality 
assessment of ADR, avoidability assessment of ADR, description of all statistical methods, characterization of 
study participants and of number of participants at each stage, visual acuity assessment at presentation, at 6 
months and at 12 months, description of methods to prevent information and selection bias, intensive 
monitoring for the detection of ophthalmic ADR, description of methods to avoid other bias, presentation of 
complete summary measures.
Disagreements will be solved by consensus. Studies will be divided in low risk of bias (five or less parameters 
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with medium, unclear, or high risk of bias), medium risk (six to nine) and high risk (ten or more parameters 
evaluated as medium, unclear, or high risk of bias). This evaluation will follow Cochrane's guidelines and allow 
us to build a Risk of Bias Summary and Risk of Bias Graph.
Measures of treatment effect
Chi-square test will be performed for categorical variables, Student s t-test for normally distributed continuous 
variables, and Mann Whitney or Kruskal Wallis when dealing with variables without normal distribution, using 
SPSS v20. Excel will be used for simple calculations, such as incidence and standard error calculations. 
Quality evaluation graphs, heterogeneity analysis, subgroup analysis, and random effects meta-analysis will 
be performed using Review Manager - version 5.0. The a priori level of significance for all hypothesis tests will 
be p<0.05.
Unit of analysis issues
We will assess whether original studies use patients, eyes or other unit of randomization in each case.
Dealing with missing data
Intention to treat analysis, contacting authors for further information.
Assessment of heterogeneity
Heterogeneity is expected, considering the theme and the scarce and heterogeneous original studies. Our 
objective is to obtain and summarize evidence about ophthalmic ADRs provoked by statins, raising 
Ophthalmologists' attention about this issue (and therefore, improving quality of future publications). 
Consequently, we believe that this systematic review will be useful even if significant heterogeneity is found. 
We will use the I2 statistic, the Q test and the forest plots to identify statistical heterogeneity. We will review 
original studies thoroughly to identify sources of methodological heterogeneity. Subgroup analysis will be 
performed, based on: study type, ophthalmic ADR type, location, type of statins and indications for statins 
treatment.
Assessment of reporting biases
Risk of bias evaluation will be extremely important in the assessment of reporting biases, as well as type of 
study and description of the study methodology.
For trials, we will assess sequence generation, allocation concealment, masking of participants and outcome 
assessors, incomplete outcome data, selective outcome reporting and other potential sources of bias. For 
other studies (and for trials), we will register: complete description of study design, verification if all parts of 
study were prospective, number of hospitals in which study occurred, number of patients, adequate selection 
criteria, presentation of a definition of ADR, rationale for study size, causality assessment of ADR, avoidability 
assessment of ADR, description of all statistical methods, characterization of study participants and of number 
of participants at each stage, visual acuity assessment at presentation, at 6 months and at 12 months, 
description of methods to prevent information and selection bias, description of methods to avoid other bias, 
presentation of complete summary measures.
We will build a funnel plot for the detection of publication bias (which we will try to avoid by manually searching 
studies, by searching grey literature and by emailing experts requesting unpublished studies with information 
on ophthalmic ADRs provoked by statins).
Data synthesis
If we have enough data to perform quantitative review, we will perform meta-analysis with a random-effects 
model. If not, we will perform a narrative analysis and summary of the available evidence.
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Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be performed, based on: study type, ophthalmic ADR type, location, type of statins and 
indications for treatment with statins.
Sensitivity analysis
If possible, a sensitivity analysis will be performed with the exclusion of observational studies, of high risk of 
bias studies and of studies with less than 5 patients (such as case reports or case series). We will also try to 
identify the individual studies that contribute the most to statistical heterogeneity.
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Appendices
1 WHO causality assessment
WHO's causality assessment
1. Certain ADR
A clinical event, including laboratory test abnormality, occurring in a plausible time 
relationship to drug administration, and which cannot be explained by concurrent 
disease or other drugs or chemicals. The response to withdrawal of the drug 
(dechallenge) should be clinically plausible. The event must be definitive 
pharmacologically or phenomenologically, using a satisfactory rechallenge 
procedure if necessary.
2. Probable ADR
A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug, unlikely to be attributed to concurrent 
disease or other drugs or chemicals, and which follows a clinically reasonable 
response on withdrawal (dechallenge). Rechallenge information is not required to 
fulfill this definition. A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, unlikely to be attributed to 
concurrent disease or other drugs or chemicals, and which follows a clinically 
reasonable response on withdrawal (dechallenge). Rechallenge information is not 
required to fulfill this definition.
3. Possible ADR
A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug, but which could also be explained by 
concurrent disease or other drugs or chemicals. Information on drug withdrawal 
may be lacking or unclear
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4. Unlikely ADR
A clinical event, including laboratory test abnormality, with a temporal relationship 
to drug administration which makes a causal relationship improbable, and in which 
other drugs, chemicals or underlying disease provide plausible explanations.
5. Conditional / 
unclassified ADR
A clinical event, including laboratory test abnormality, reported as an adverse 
reaction, about which more data is essential for a proper assessment or the 
additional data are under examination.
6. Inaccessible / 
unclassifiable
A report suggesting an adverse reaction which cannot be judged because 
information is insufficient or contradictory, and which cannot be supplemented or 
verified.
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 APPENDIX 7 
RESULTS: From 11944725 hospitalizations or ambula-
tory episodes within that period of time, we identified 
1524 probable ophthalmic ADRs (corresponding to a 
frequency of 1.28 per 10000 episodes) and an addi-
tional 100 possible ophthalmic ADRs. We used only 4 
person-hours in the application of this methodology. A 
total of 113 spontaneous reports arose from ophthal-
mic ADRs from 2000 to 2009 in Portugal (frequency of 
0.095 per 10000 episodes).To our knowledge, this was 
the first estimate of the frequency of ophthalmic ADRs 
through the use of databases, and the first nationwide 
estimate of ophthalmic ADRs, in Portugal. We identified 
1524 probable ADRs and 100 possible ADRs. 
CONCLUSION: This database methodology adapted 
for Ophthalmology may represent a new approach for 
the detection of ophthalmic ADRs, since these codes 
exist in the ICD-9-CM classification. Its performance 
was clearly superior to spontaneous reporting.
© 2013 Baishideng. All rights reserved.
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Core tip: We used International Classification of Dise-
ases - 9th Revision - Clinical Modification coding data 
for the detection of adverse drug reactions (ADRs). 
From 11944725 episodes, we identified 1524 probable 
ophthalmic ADRs. 113 spontaneous reports arose from 
that population. This was the first nationwide study of 
ophthalmic ADRs and may represent a new Pharmaco-
vigilance approach, with a higher detection than spon-
taneous reporting.
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Abstract
AIM: To detect ophthalmic adverse drug reactions 
(ADRs), that occurred in Portugal from 2000 to 2009, 
through the utilization of administrative hospital data-
bases. We also intended to compare the results of this 
methodology with spontaneous reporting.
METHODS: We conducted a retrospective nationwide 
study using hospital administrative databases, which 
included all inpatients and outpatients in all public hos-
pitals in Portugal, from 2000 to 2009. We used Interna-
tional Classification of Diseases - 9th Revision - Clinical 
Modification (ICD-9-CM) coding data that allowed the 
detection of ADRs. We used WHO’s definition for ADR. 
We searched all of ICD-9-CM terms in Ophthalmology 
for codes that included “drug-induced”, “iatrogenic”, 
“toxic” and all other that could signal an ADR, such 
as “362.55 - toxic maculopathy” or “365.03 - steroid 
responders”, and also “E” codes (codes from E930 to 
E949.9, that exclude intoxications and errors).
META-ANALYSIS
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INTRODUCTION
Adverse drug reactions (ADRs) are responsible for sig-
nificant morbidity, mortality and costs in Health Care 
systems[1]. They may occur in 16.9% of  patients during 
hospitalization (95%CI: 13.5-20.2)[2] and provoke 5.3% 
of  hospital admissions (interquartile range 2.7%-9.0%)[3]. 
ADRs are a frequent cause of  death in developed coun-
tries[4]. However, in Ophthalmology the evidence is scarce 
and lacks systematization[5]. A review about challenges 
in ADRs in Ophthalmology[5] concluded that there are 
several areas that can be improved, namely by applying 
always the definition of  ADR of  the World Health Orga-
nization (WHO)[6], by performing a causality assessment 
in each ADR (which determines the probability of  rep-
resenting a true ADR; the most utilized causality assess-
ments of  ADRs are from WHO[7] and from Naranjo[8]).
The development and validation of  new methodolo-
gies for an improved detection of  ADRs would be anoth-
er area of  improvement[5,9]. There are Pharmacovigilance 
methodologies[9] used for the detection of  ADRs and 
that can be adapted for detecting ADRs in Ophthalmol-
ogy, but they may have methodological issues: Spontane-
ous reporting is the most used (it needs low resources) 
and is the only Pharmacovigilance method continuously 
used in the majority of  countries, being the main support 
of  WHO International Drug Program. However, it has 
several limitations, namely, the smallest detection rate of  
several Pharmacovigilance methods[10], under-reporting[11], 
heterogeneous report quality[12] and increased risk of  
bias[12]. Intensive and prospective monitoring are meth-
odologies with good detection rates but too resource-
consuming for continuous application[13]. 
Administrative hospital databases have large clinical 
information and thus may represent an interesting Phar-
macovigilance approach with readily available and cheap 
information[10]. Some authors have utilized databases[10,14] 
for the detection of  ADRs, taking advantage of  the large 
quantity of  clinical information readily available, con-
taining coding data that can be used as an alert for the 
detection of  an ADR, with low relatively low resources 
required. 
Our purpose was to identify and characterize oph-
thalmic ADRs in a Nationwide study in Portugal, using 
hospital databases with clinical information.
MATERIALS AND METHODS
Study design
A retrospective study was performed for ADR identifica-
tion using hospital administrative databases with infor-
mation from all public hospitals in Portugal, from 2000 
to 2009, obtained from our National Health Department 
(data from the second semester of  2009 was not avail-
able). These databases contain anonymized data for 
patient identification, episode and process number, and 
also information on age, sex, admission date, discharge 
date, ward(s), hospital attended (tertiary, university), 
area of  Healthcare, district, outcome (death, discharge, 
transfer), payment data and International Classification 
of  Diseases - 9th Revision - Clinical Modification (ICD-
9-CM)[15] codes for: diagnoses (principal diagnosis, other 
diagnosis up to 19), procedures (up to 20) and external 
causes (up to 20). Patient population included all patients 
hospitalized or admitted for ambulatory care, in all public 
hospitals in Portugal, from 2000 to 2009 (inpatients and 
outpatients). All investigations were performed accord-
ing to the guidelines of  the Declaration of  Helsinki and 
Institutional Review Board approval from was obtained.
Definition of ADR
There is some misuse of  terms in this matter; therefore 
we present definitions.
An ADR[6] is: “any noxious, unintended and unde-
sired effect of  a drug, which occurs at doses used in hu-
mans for prophylaxis, diagnosis, or therapy”. Therefore, 
to increase specificity, we wanted to assess only ADRs. 
Adverse drug event is not a synonym of  ADR. There 
are other definitions of  ADR, namely from Karch et al[16] 
and from Edwards et al[17], but we used the definition 
of  WHO. An adverse event[18] is: “an injury related to 
medical management (all aspects of  care, including diag-
nosis and treatment, failure to diagnose or treat, and the 
systems and equipment used to deliver care), in contrast 
to complications of  disease”. An adverse drug event[19] 
is: “An injury related to the use of  a drug, although the 
causality of  this relationship may not be proven”. These 
include medication errors (namely the prescription of  
a wrong dose) and ADRs.We aimed to assess strictly 
ADRs.
Detection of ADRs
Hospital administrative databases include information 
of  diagnosis. Codes searched for ADR identification 
were adapted to the specificities of  Ophthalmology and 
resulted from a thorough search of: all terms of  ICD-
9-CM in Ophthalmology that included “drug-induced”, 
“iatrogenic”, “toxic” and all codes that could signal an 
ADR, such as “362.55 - toxic maculopathy” or “365.03 - 
steroid responsers”, as detailed in the Results Section.
We also performed a search of  general ADRs through 
the use of  ‘E’ codes (ICD-9-CM codes from E930 to 
E949.9, designed to represent ADRs and already exclud-
ing wrong doses, errors and intoxications) to assess if  
these general ADRs could detect ophthalmic ADRs. 
In this study, we performed a query of  Ophthalmol-
ogy in a nationwide study using administrative databases, 
including inpatients and ambulatory patients. Our main 
outcome was ADR detection. Secondary outcomes in-
cluded: type of  ADR, age, sex, admission diagnosis, other 
diagnoses, hospital length-of-stay and year of  discharge. 
We performed WHO’s causality assessments of  ADRs, 
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with two independent reviewers. Differences were re-
solved by consensus. A third review was consulted to 
help resolved differences. We also registered how many 
person-hours were spent in the application of  this meth-
odology, to estimate cost (resources spent). The number 
of  person-hours refers to the number of  hours and 
number of  people used in the application of  this meth-
odology; commonly used in the comparison of  different 
Pharmacovigilance methodologies[19]. The number of  
spontaneous reporting of  ADRs in hospitalized patients 
from 2000 to 2009 was obtained from Portuguese Na-
tional Authority of  Medicines (INFARMED), for com-
parison[20].
Statistical analysis
Statistical analyses were done using the χ 2 test for cat-
egorical variables (or exact Fisher’s test whenever pos-
sible), Student’s t-test for normally distributed continuous 
variables and Mann-Whitney or Kruskal-Wallis for vari-
ables without normal distribution, using SPSS v20. The a 
priori level of  significance was P < 0.05.
RESULTS
Study population
There were 11944725 patients hospitalized or with ambu-
latory episodes in public hospitals of  Portugal, from 2000 
to the first semester of  2009.The baseline characteristics 
of  the study population (n = 11944725) are shown in 
Table 1. The mean age of  hospitalized patients was 48 ± 
27 years and in 55.2% of  episodes the patient was female. 
We spent only 4 person-hours in the application of  this 
methodology.
From 2000, there was a slight increase in the num-
ber of  hospitalizations in Portugal. Specific ophthalmic 
ADRs (n = 1524) were detected through the search of  
codes that could represent particular ophthalmic ADRs, 
as shown in Table 2. This corresponds to a frequency of  
1.28 ophthalmic ADR per 10000 episodes. Additionally, 
100 episodes that could possibly correspond to an oph-
thalmic ADR were also detected (Table 2). Therefore, a 
total of  1624 possible ophthalmic ADRs were detected. 
These possible ADRs included: conjunctival concre-
tions, pigmentations and deposits (which can be caused 
by drugs such as topical adrenaline[21], but also by other 
factors, therefore may correspond to an ADR in some 
cases) and acquired color vision deficiencies (which may 
be caused by drugs such as sildenafil[22], but have other 
non related causes).
The search of  general ADRs through the use of  “E” 
codes allowed us to identify 116720 ADRs, but only 62 
of  them corresponded to the ophthalmic ADRs that 
were identified. 
The total number of  spontaneous notifications of  
ADRs in Portugal from 2000 to 2009 was 13562, from 
which 113 were spontaneous reports specific of  ophthal-
mic ADRs. There were 553 additional spontaneous re-
ports of  systemic ADRs that included some ophthalmic 
manifestations.
DISCUSSION
To our knowledge, this is the first estimate of  the fre-
quency of  ophthalmic ADRs through the use of  admin-
istrative databases, and the first to apply a nationwide 
estimate of  ophthalmic ADRs, in Portugal. We identified 
1524 probable ADRs and 100 possible ADRs. This may 
represent a new approach for the detection of  ophthal-
mic ADRs, since these codes exist in the ICD-9-CM clas-
sification.
The strengths of  our study include: our comprehen-
sive database, which contains data from all hospitaliza-
tions and ambulatory episodes in every public hospital 
in Portugal within almost a decade, the fact that this is a 
new methodology to aid ADR detection (until now only 
case reports and spontaneous reports were available for 
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Table 1  Socio-demographic characteristics of study population
Characteristic Value
Number of episodes (inpatient, ambulatory) 11944725
Mean age (yr, mean ± SD) 48 ± 27
Female gender n (%) 6598266 (55.2)
District with higher number of hospitalizations 1st: Lisbon 21.2%
2nd: Oporto 17.2%
3rd: Setubal 7.66%
Mean hospital length-of-stay for inpatients 
(d, mean ± SD)
  7.1 ± 3.21
Number of probable ophthalmic ADRs         1524
ADRs: Adverse drug reactions.
Table 2  Clinical codes searched and respective results in the 
portuguese database
ICD-9-CM code Diagnosis No. of 
episodes
Specific ophthalmic ADR codes
   362.55 Toxic maculopathy 1388
   365.03 Steroid responders       4
   365.31, 365.32 Corticosteroid-induced glaucoma       0
   364.55 Miotic pupillary cyst (provoked by 
pilocarpine)
      2
   364.81 Floppy iris syndrome       2
   366.45 Toxic cataract     83
   367.89 Other drug-induced disorders of 
refraction and accommodation, 
Toxic disorders of refraction and 
accommodation
    25
   377.34 Toxic optic neuropathy, Toxic amblyopia     20
Possible signs of ophthalmic ADRs
   366.46 Cataract associated with radiation and 
other physical influences
    10
   372.54 Conjunctival concretions     67
   372.55 Conjunctival pigmentations, including 
conjunctival argyrosis
   372.56 Conjunctival deposits
   368.55 Acquired color vision deficiencies     23
   368.59 Other color vision deficiencies
Sub-Total specific 1524
Total 1624
ICD-9-CM: Classification of Diseases - 9th Revision - Clinical Modification; 
ADRs: Adverse drug reactions.
ADR detection), and the fact that these codes are widely 
available and universal, making possible to easily build 
estimates of  ophthalmic ADRs in other countries and 
other years. In fact, it would be very interesting to see if  
ophthalmic ADRs in Portugal have the same distribution, 
frequency and characteristics in comparison with other 
countries, therefore further studies are necessary.
Limitations of  our work are inherent to the use of  
administrative databases, which may contain incomplete 
or wrong data and coding bias[23] (in which coders select 
a different code to increase reimbursement to their hos-
pital). The small number of  ADRs found may be consid-
ered a limitation, but on the other hand this is a method-
ology resource-sparing (only 4 person-hours spent in its 
application), having potential for widespread application 
in other countries. Also, this method identified 1524 
probable ADRs, a much higher number than the number 
of  ophthalmic ADRs found by spontaneous reporting: 
113. 
We suggest complementing spontaneous reporting 
with this database methodology to increase detection of  
ophthalmic ADRs. In fact, the complementary use of  
several methodologies is defended by several authors[24], 
in order to enhance ADR detection and increase patient 
safety. Finally, we believe that after this study, these codes 
should be applied prospectively in a future study in a 
nation-wide basis, enabling an expert to confirm each 
ADR and causing drug, to further complete and validate 
the data suggested here, and to integrate this method as a 
Pharmacovigilance methodology.
In conclusion, Ophthalmology represents simultane-
ously a challenge and an opportunity to identify ADRs. 
This is the first nationwide estimate of  ophthalmic 
ADRs. Administrative databases are a useful methodolo-
gy for the detection of  ocular ADRs, but require adapted 
diagnoses codes. They may underestimate the real num-
ber of  ADRs, but nevertheless they have the potential to 
complement spontaneous reporting as a methodology for 
ophthalmic ADR detection, with a higher detection rate.
ACKNOWLEDGMENTS
The authors would like to thank ACSS for providing ac-
cess to the data, and express gratitude to the statistical 
support given by the research project HR-QoD - Quality 
of  data (outliers, inconsistencies and errors) in hospital 
inpatient databases: methods and implications for data 
modeling, cleansing and analysis (project PTDC/SAU-
ESA/75660/2006). The authors would also like to thank 
the INFARMED, Portuguese National Authority of  
Medicines and Health Products, for the data kindly pro-
vided about spontaneous reporting in Portugal.
COMMENTS
Background
Adverse drug reactions (ADRs) are a frequent cause of death in developed 
countries. However, in Ophthalmology the evidence is scarce and lacks sys-
tematization.
Research frontiers
There are Pharmacovigilance methodologiesused for the detection of ADRs 
and that can be adapted for detecting ADRs in Ophthalmology, but they may 
have methodological issues.
Innovations and breakthroughs
This is the first estimate of the frequency of ophthalmic ADRs through the use 
of administrative databases, and the first to apply a nationwide estimate of oph-
thalmic ADRs, in Portugal.
Applications
The authors suggest complementing spontaneous reporting with this database 
methodology to increase detection of ophthalmic ADRs.
Peer review
This is a well written article reporting the adverse effects of ophthalmic drugs. 
The methods are well described, and the results are easy to understand.
REFERENCES
1 Davies EC, Green CF, Mottram DR, Pirmohamed M. Ad-
verse drug reactions in hospital in-patients: a pilot study. J 
Clin Pharm Ther 2006; 31: 335-341 [PMID: 16882102]
2 Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of 
adverse drug reactions in hospitalized patients: a systematic 
review and meta-analysis. Pharmacoepidemiol Drug Saf 2012; 
21: 1139-1154 [PMID: 22761169 DOI: 10.1002/pds.3309]
3 Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions 
associated with adverse drug reactions: a systematic review 
of prospective observational studies. Ann Pharmacother 2008; 
42: 1017-1025 [PMID: 18594048]
4 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug 
reactions in hospitalized patients: a meta-analysis of prospec-
tive studies. JAMA 1998; 279: 1200-1205 [PMID: 9555760]
5 Fraunfelder FW, Fraunfelder FT. Scientific challenges in 
postmarketing surveillance of ocular adverse drug reactions. 
Am J Ophthalmol 2007; 143: 145-149 [PMID: 17188050]
6 World Health Organization. Adverse Drug Reaction Moni-
toring. Available from: URL: http://www.who.int/medi-
cines/areas/quality_safety/safety_efficacy/advdrugreac-
tions/en/index.html
7 World Health Organization. The Importance of Pharmaco-
vigilance - Safety Monitoring of Medicinal Products. Avail-
able from: URL: http://apps.who.int/medicinedocs/en/d/
Js4893e/
8 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts 
EA, Janecek E, Domecq C, Greenblatt DJ. A method for esti-
mating the probability of adverse drug reactions. Clin Phar-
macol Ther 1981; 30: 239-245 [PMID: 7249508]
9 Davies EC, Green CF, Mottram DR, Pirmohamed M. Ad-
verse drug reactions in hospitals: a narrative review. Curr 
Drug Saf 2007; 2: 79-87 [PMID: 18690953]
10 Miguel A, Azevedo LF, Lopes F, Freitas A, Pereira AC. 
Methodologies for the detection of adverse drug reactions: 
comparison of hospital databases, chart review and sponta-
neous reporting. Pharmacoepidemiol Drug Saf 2013; 22: 98-102 
[PMID: 23027707 DOI: 10.1002/pds.3348]
11 Figueiras A, Herdeiro MT, Polónia J, Gestal-Otero JJ. An 
educational intervention to improve physician reporting 
of adverse drug reactions: a cluster-randomized controlled 
trial. JAMA 2006; 296: 1086-1093 [PMID: 16954488 DOI: 
10.1001/jama.296.9.1086]
12 Bandekar MS, Anwikar SR, Kshirsagar NA. Quality check of 
spontaneous adverse drug reaction reporting forms of differ-
ent countries. Pharmacoepidemiol Drug Saf 2010; 19: 1181-1185 
[PMID: 20845409]
13 Pourseyed S, Fattahi F, Pourpak Z, Gholami K, Shariatpa-
nahi SS, Moin A, Kazemnejad A, Moin M. Adverse drug 
reactions in patients in an Iranian department of internal 
medicine. Pharmacoepidemiol Drug Saf 2009; 18: 104-110 [PMID: 
19101919]
14 van der Hooft CS, Sturkenboom MC, van Grootheest K, 
4 August 26, 2013|Volume 1|Issue 2|WJMA|www.wjgnet.com
 COMMENTS
Kingma HJ, Stricker BH. Adverse drug reaction-related hos-
pitalisations: a nationwide study in The Netherlands. Drug 
Saf 2006; 29: 161-168 [PMID: 16454543]
15 Slee VN. The International Classification of Diseases: ninth 
revision (ICD-9). Ann Intern Med 1978; 88: 424-426 [PMID: 
629506]
16 Karch FE, Lasagna L. Adverse drug reactions. A critical re-
view. JAMA 1975; 234: 1236-1241 [PMID: 1242749]
17 Edwards IR, Aronson JK. Adverse drug reactions: defi-
nitions, diagnosis, and management. Lancet 2000; 356: 
1255-1259 [PMID: 11072960]
18 World Health Organization. WHO Draft Guidelines for 
Adverse Event Reporting and Learning Systems. 2005. 
Available from: URL: http://www.who.int/patientsafety/
events/05/Reporting_Guidelines.pdf
19 Nebeker JR, Barach P, Samore MH. Clarifying adverse drug 
events: a clinician’s guide to terminology, documentation, and 
reporting. Ann Intern Med 2004; 140: 795-801 [PMID: 15148066]
20 INFARMED - National Portuguese Authority of Drug and 
Health Products. Available from: URL: http://www.infarmed.
pt
21 Fong DS, Frederick AR, Richter CU, Jakobiec FA. Adreno-
chrome deposit. Arch Ophthalmol 1993; 111: 1142-1143 [PMID: 
8352696]
22 Azzouni F, Abu samra K. Are phosphodiesterase type 5 in-
hibitors associated with vision-threatening adverse events? 
A critical analysis and review of the literature. J Sex Med 
2011; 8: 2894-2903 [PMID: 21771280]
23 Seiber EE. Physician code creep: evidence in Medicaid and 
State Employee Health Insurance billing. Health Care Financ 
Rev 2007; 28: 83-93 [PMID: 17722753]
24 Whitstock MT, Pearce CM, Ridout SC, Eckermann EJ. Using 
clinical trial data and linked administrative health data to re-
duce the risk of adverse events associated with the uptake of 
newly released drugs by older Australians: a model process. 
BMC Public Health 2011; 11: 361 [PMID: 21600026]
P- Reviewers  Onakpoya I, Saokaew S    S- Editor  Zhai HH 
L- Editor  A    E- Editor  Zheng XM
5 August 26, 2013|Volume 1|Issue 2|WJMA|www.wjgnet.com
 APPENDIX 8 
36 Journal of Ocular Diseases and Therapeutics, 2013, 1, 36-40  
 
© 2013 Savvy Science Publisher 
Adverse Drug Reactions in Ophthalmology - are they a Myth? 
Ana Miguel1,2,* 
1Centre for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, 
Oporto University, Oporto, Portugal 
2Department of Ophthalmology, Central University Hospital of Coimbra, Coimbra, Portugal 
Abstract: Sometimes ocular (and systemic) therapeutics may cause ocular (and systemic) diseases, namely adverse 
drug reactions (ADRs). The Journal of Ocular Diseases and Therapeutics is therefore doubly adequate for discussion of 
the theme of ADRs in Ophthalmology. 
Many terms are utilized as synonyms but the correct definition of ADR (according to the World Health Organization, 
WHO) is: "any noxious, unintended and undesired effect of a drug, which occurs at doses used in humans for 
prophylaxis, diagnosis, or therapy". 
Ophthalmology is one of the medical specialties in which there is a high difficulty in continuous diagnosis, assessment 
and treatment. Additionally, the specific and delicate anatomy and physiology of the eye may easily be disrupted by an 
ADR, with possible irreversible consequences. Ocular ADRs may be frequent (such as cornea verticillata caused by 
amiodarone) or specific. On the other hand, systemic ADRs may occur after ocular treatments (such as hypotension 
after instillation of a beta-blocker drop). 
The timely detection and recognition of ADRs is therefore critical. Several methods exist for the detection of ADRs, but 
few are specific or apply to ADRs in Ophthalmology. Spontaneous reporting is a low-resource method for detection of 
ADRs but has flaws, namely under-detection and risk of bias. The literature can be confusing or incomplete, with several 
case reports and case series about ocular ADRs lacking a causality assessment (such as Naranjo's or WHO's).  
In conclusion, ADRs in Ophthalmology are a heterogeneous group of ADRs that lack detection, assessment and 
systematization. Studies about ADRs should increase their quality for further clarification. Each ophthalmologist should 
know the specific ocular ADRs to systemic medication, the specific systemic ADRs to ocular medication, and to detect 
and treat them adequately for good clinical practice.  
Keywords: Adverse drug reactions, Pharmacovigilance, Ophthalmology, Clinical practice, Therapeutics, 
Toxicology, Causality assessment, World Health Organization, Systemic drugs, Ocular Therapy. 
INTRODUCTION 
The Journal of Ocular Diseases and Therapeutics 
has an ambitious purpose of equipping professionals 
with skills to increase the detection of eye diseases and 
to improve the management of ocular therapeutics into 
good clinical practice.  
These skills are invaluable in the world of adverse 
drug reactions (ADRs), where many confusions and 
myths persist.  
This manuscript addresses ADRs in 
Ophthalmology, discusses some of the myths related to 
ADRs and attempts to clarify them, and provides 
recommendations to increase the quality in studies 
about ADRs and to improve recognition and 
management of ADRs in the clinical context. 
ADRS IN OPHTHALMOLOGY 
There are three basic types of ADRs in 
Ophthalmology: 
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1. Topical ADRs to a Topical Ocular Drug 
These ADRs are usually easy to recognize, since 
the prescribing ophthalmologist is the one who detects 
these ADRs in the follow-up of the patient. They can be 
caused either by the drug administered or by its topical 
conservatives. One example is ocular hyperemia 
frequently caused by topical prostaglandins for the 
treatment of glaucoma [1].  
2. Systemic ADRs to a Topical Ocular Drug 
Topical ocular medications can be absorbed by the 
ophthalmic mucosa and nasal mucosa [2, 3] and reach 
levels in the blood enough to cause ADRs. The most 
common topically administered ocular drugs causing 
systemic side effects are the epinephrine-like 
compounds, which can rapidly lead to increased blood 
pressure and tachycardia [3]. Periocular injection of 
anesthetics combined with epinephrine can cause the 
same effects quite rapidly, leading to respiratory 
collapse and even death [3].  
3. Topical/Ocular ADRs to a Systemic Drug 
These ADRs may be difficult to diagnose, 
considering that in this case a general physician 
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prescribes a drug, but a different physician usually is 
required for the diagnosis (an ophthalmologist). Other 
difficulty is the need of obtaining a complete medical 
history and registering the countless systemic 
medications prescribed for each patient.  
The correlation of the symptoms and ocular signs of 
the patient with the suspect of an ADR caused by a 
particular drug is another difficulty, and confirming the 
causality of an ADR is by far even more difficult. With 
all these difficulties, it is not surprising that myths and 
confusion persist around ADRs, particularly in 
Ophthalmology. 
MYTHS, ADRs AND OPHTHALMOLOGY 
1. First Myth: Many Terms are Erroneously Applied 
as Synonyms of ADRs 
To clarify this myth, we present definitions of 
different drug-related problems. 
• An adverse event is [4]: "an injury related to 
medical management, in contrast to 
complications of disease". Medical management 
includes "all aspects of care, including diagnosis 
and treatment, failure to diagnose or treat, and 
the systems and equipment used to deliver care" 
[4].  
• Drug-related problems are [5]: “a circumstance 
that involves a patient’s drug treatment that 
actually, or potentially, interferes with the 
achievement of an optimal outcome". They 
include ADRs. 
• An adverse drug event is [6]: “An injury related to 
the use of a drug, although the causality of this 
relationship may not be proven”. These events 
include medication errors (namely the 
prescription of a wrong dose) and ADRs. 
• A medication error is [7]: “Any error in the 
process of prescribing, dispensing or 
administering a drug, whether there are adverse 
consequences or not”. 
• An adverse drug reaction (ADR) is: “any noxious, 
unintended and undesired effect of a drug, which 
occurs at doses used in humans for prophylaxis, 
diagnosis, or therapy”, according to WHO’s 
definition [8] of 1972. This definition is the most 
widely used. Karch and Lasagna’s [9] have a 
definition for ADR which excludes therapeutic 
failures. An ADR according to Edwards and 
Aronson [10] is: “an appreciably harmful or 
unpleasant reaction, resulting from an 
intervention related to the use of a medicinal 
product, which predicts hazard from future 
administration and warrants prevention or 
specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product”.  
2. Second Myth: ADRs are not Important Nor 
Frequent 
Some years ago, Lazarou and colleagues [11] 
estimated ADRs to be between the fourth and sixth 
more frequent causes of death. Although this study 
was criticized due to heterogeneity [12], it brought 
attention to the scientific community about the 
importance of ADRs. The mean frequency of ADRs 
that occur during hospitalization is estimated to be of 
16.88% (95%CI: 13.56–20.21) [13] and the overall 
median of ADRs associated with hospital admissions is 
5.3% (interquartile range 2.7–9.0%) [14].  
ADRs are costly, representing US$1.56 billion in 
direct hospital costs per year (in the US) [15] and 
US$136.8 billion in indirect costs [16]. In fact, the cost 
of drug-related problems (including ADRs) is estimated 
to be higher than the total cost of cardiovascular or 
diabetes disease [5].  
Consequently, ADRs are frequent, expensive and 
can be fatal, deserving to be studied in order to be 
detected and prevented. 
3. Third Myth: ADRs in Ophthalmology are Not 
Specific 
The theme of ADRs in Ophthalmology presents a 
challenge in assessment and systematization [17]. 
ADRs in Ophthalmology can be frequent and specific 
(and even irreversible), therefore healthcare team 
members (namely the ophthalmologist, physician, 
nurse, pharmacist, pharmacologist or other) should 
have skills for detection of an ADR to a drug in each 
patient.  
The eye benefits of many barriers that limit access 
of drugs to intraocular structures, namely: tight 
junctions of the corneal epithelium and endothelium 
(which limit anterior access to the interior of the eye 
and belong to the blood-aqueous barrier), the vascular 
endothelium of the retina (non fenestrated and with 
tight junctions: inner blood-retinal barrier), tight 
junctions between the retinal pigment epithelium (with 
the Bruch's membrane: outer blood-retinal barrier) [2, 
18]. 
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Nevertheless, there is a plethora of possible ocular 
ADRs to ocular and systemic drugs. Fortunately, some 
systemic drugs tend to provoke specific ocular ADRs, 
enabling recognition of clinical patterns in specific 
drugs, namely: amiodarone which frequently provokes 
cornea verticillatta [19] and rarely provokes the 
potentially irreversible optic neuropathy [20], floppy iris 
syndrome caused by tamsulosine [21] and uveitis 
caused by rifabutin [22], among many others. 
4. Fourth Myth: ADRs can Only be Identified by 
Spontaneous Reports 
Many methods exist to aid Pharmacovigilance in the 
detection and verification of ADRs, but all have their 
methodological issues [23].  
Spontaneous reporting (a health team member 
reports a presumable ADR) is the most utilized 
Pharmacovigilance method in Europe [24], however 
subnotification [25] is a problem. Administrative 
databases (which contain large amounts of information 
with clinical data that can be searched for the 
identification of an ADR) have been explored for ADR 
detection [26, 27] and present good detection rates 
with low resources, enabling nationwide perspectives 
[27].  
Computerized methods are used for automatic 
alerts of ADRs with good results [28, 29]. 
Chart review (the revision of charts by an expert) is 
a reasonable methodology for ADR detection [30], 
however it is resource and time consuming, such as 
prospective monitoring and intensive monitoring 
[31] (both are monitoring methodologies performed by 
experts in a group of patients to detect ADRs) which 
are too costly to be performed regularly. Other methods 
exist, namely trials and pharmacogenetics studies.  
ADRs that occur in the context of Ophthalmology 
can be detected through each of the methods above, 
however spontaneous reporting (and studies such as 
case reports and case series) are frequently utilized 
due to practical reasons [17]. It is important to increase 
the quality of these studies about ADRs to enable the 
scientific community to decide which conclusions can 
be drawn about each specific reported or presumable 
ADR. 
INCREASING QUALITY IN STUDIES ABOUT ADRs 
A few simple steps can be useful to increase quality 
in every study about ADRs. 
First, I suggest the utilization of a definition of ADR 
(either WHO's definition of ADR [8], or other definition 
of ADR) which should have a reference in the study. 
Second, a causality assessment (the assessment of 
the probability of a suspected ADR being a true ADR) 
is crucial and lacks in many ADR manuscripts. The 
most important and widely used causality assessments 
are Naranjo's [32] and WHO's [33], which apply to all 
ADRs, and are presented in this manuscript.  
Third, if possible add further characterization of the 
ADR: present a classification of ADR according to 
Rawlins and Thomson's [34], evaluate the predictability 
of ADRs (using Hartwig’s predictability scale, for 
example [35]), use Schumok and Thornton’s 
preventability criteria [36], among others. Many 
technological breakthroughs in Ophthalmology allow us 
to provide an increased depth in the characterization of 
ocular ADRs with complementary testing and should be 
used [37].  
Finally, many bibliographic or general reviews exist 
about ocular ADRs, but few attempt to be systematic. I 
Table 1: Naranjo's Causality Assessment for ADRs [32] 
Naranjo's causality assessment Yes No Don't know 
1. Are there previous conclusive reports of this reaction? +1 0 0 
2. Did the adverse event appear after the suspect drug was administered? +2 -1 0 
3. Did the adverse reaction improve when the drug was discontinued? +1 0 0 
4. Did the adverse reaction reappear when the drug was readministered? +2 -1 0 
5. Are there alternate causes that on their own could have caused the reaction? -1 +2 0 
6. Did the reaction appear when a placebo was given? -1 +1 0 
7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? +1 0 0 
8. Was the reaction more severe when the dose was increased or less severe when decreased? +1 0 0 
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 
10. Was the adverse event confirmed by any objective evidence? +1 0 0 
Total score*  
*Interpretation of the Total Score: a) 9: Highly probable ADR; b) 5-8: Probable ADR; c) 1-4: Possible ADR: d)  0: Doubtful ADR. 
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and my co-authors have identified ocular ADRs to 
systemic drugs that have recent original studies but are 
currently lacking a specific systematic review, including 
ocular ADRs from the following drugs: statins (we are 
performing a systematic review in collaboration with the 
Cochrane -Eyes and Vision Group), antituberculous 
agents, angiotensin-converting enzyme inhibitors and 
cidofovir. These may represent opportunities for a 
specific systematic review. 
CONCLUSION 
Confusion and myths about ADRs persist. Future 
studies about ADRs should: present a definition of 
ADR, describe a methodology for ADR detection, 
present standard assessments (causality assessment 
of Naranjo or WHO, severity assessment, classification 
of ADR, among others) and should increase their 
methodological quality. 
Although spontaneous reporting is the most widely 
used method for detecting ADRs, other methods exist 
for that purpose. All methods have their methodological 
issues and probably should be used in conjunction to 
increase ADR detection.  
In Ophthalmology, the theme of ADRs deserves 
clarification and assessment. Ocular ADRs may be 
frequent, specific, serious or even cause irreversible 
blindness. Therefore, the detection of ADRs is very 
important.  
Methods of ADR detection should be explored and 
adapted to the specificity of ocular ADRs. 
Additionally, each health care member 
(ophthalmologist, physician, nurse, pharmacist, 
pharmacologist or other) should know the specific 
ocular ADRs to systemic medication, the specific 
systemic ADRs to ocular medication, and should detect 
and treat ADRs in Ophthalmology adequately for good 
clinical practice.  
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 APPENDIX 9 
Reações adversas medicamentosas em 
Oftalmologia 
 
 “The remedy often times proves worse than the disease” - William Penn 
 
 
Introdução 
 
  
 Uma reação adversa medicamentosa (RAM) é, segundo a 
Organização Mundial de Saúde (OMS)1: 
• Uma resposta  prejudicial e indesejada a um medicamento, que 
• Ocorre com a dose habitualmente usada no homem para profilaxia, 
diagnóstico ou modificação de uma função fisiológica, e em que 
• Existe um nexo de causalidade entre a ocorrência de 
RAM/medicamento. 
 
As RAM não devem ser confundidas com outros tipos de eventos adversos, cujas 
definições apresentamos seguidamente: 
• Evento adverso: "qualquer lesão relacionada com o tratamento médico, incluindo 
todos os aspetos relacionados com os cuidados de saúde"2. Esta definição inclui as 
complicações cirúgicas, erros de medicação e RAMs. 
• Evento adverso medicamentoso: "uma lesão relacionada com a utilização de um 
medicamento, apesar da causalidade desta relação poder não estar provada"3. Estes 
eventos incluem erros de medicação e RAMs. 
• Erro de medicação: "qualquer erro no processo de prescrição, dispensa ou 
administração de um medicamento"4.  
 
 
O diagnóstico de uma RAM nem sempre é fácil, e resulta de interacção 
complexa entre vários factores, como esquematizado na figura 1. 
 
 
 
Figura 1: Factores de risco e modificadores de uma reação adversa medicamentosa (RAM). 
 
 
 
As reacções adversas medicamentosas (RAMs) são frequentes e importantes. As 
RAM gerais podem ser fatais, estando entre a 4ª e a 6ª causa de morte nos 
países desenvolvidos5, e são responsáveis por 15-20% dos gastos hospitalares6. 
Estima-se que cada RAM seja responsável por um custo adicional de 2500 
dólares (aproximadamente 1890 euros)6 e que ocorram em média em 16.88% 
dos doentes hospitalizados (intervalo de confiança a 95%: 13,56-20,21)7. 
 
 
Quanto às RAM oftalmológicas, há algumas revisões sistematizadas ou 
bibliográficas8-11 mas poucas revisões sistemáticas ou outros estudos que nos 
levem à frequência e gravidade reais. O conhecimento das RAM oftalmológicas 
advém frequentemente de notificações espontâneas10, o que nem sempre 
permite sistematização ou verificação de causalidade. Todavia, são 
indubitavelmente importantes e podem ser específicas, pelo que devem ser 
matéria de estudo e devem pertencer ao conhecimento de todos e de cada 
oftalmologista. 
 
 
 
 
 
 
 
Pode haver três situações distintas de RAM em Oftalmologia: 
1. RAM oculares a medicação sistémica 
• Por exemplo, maculopatia provocada por utilização de tamoxifeno12. 
 
2. RAM sistémicas a medicação ocular tópica 
• Por exemplo, 1 gota de atropina numa criança susceptível pode causar  
rubor, agitação, taquicardia e até convulsões13. De fato, a atropina pode ser 
fatal, na dose de 100mg numa criança (1 simples frasco) - note-se que no 
caso de 100mg falar-se-ia de uma intoxicação e não de uma RAM (cujo 
conceito implica dose e administração correta). 
 
3. RAM oculares a medicação ocular tópica 
• Por exemplo, hiperemia ocular provocada por latanoproste14, colírio 
utilizado no tratamento de glaucoma. 
 
 
As RAM ocorrem frequentemente na 1ª semana, mas podem ocorrer em meses 
a anos após a exposição da medicação causadora, nomeadamente: 
• Cloroquina e retinopatia15 
• Ouro e queratopatia 
• Tamoxifeno e maculopatia12  
A maioria felizmente é reversível (algumas RAM são reversíveis mesmo sem a 
suspensão do fármaco causador), mas há excepções (vide infra). 
Este texto não pretende ser exaustivo, mas pretende exemplificar algumas RAM 
oftalmológicas frequentes ou graves que devemos conhecer. 
 
 
 
 
 
 
Exemplos de RAM de acordo com  
estrutura ocular afectada 
 
 
Seguem-se alguns exemplos de RAM seguidas de fármacos que 
frequente ou tipicamente podem causar essas reacções. 
 
Córnea 
 
Apesar de alguns fármacos provocarem depósitos corneanos frequentemente 
(como a amiodarona, em que um estudo17 estimou que a percentagem de 
doentes com depósitos corneanos era de 100% após 2 anos), raramente há 
diminuição da acuidade visual por esta RAM. 
 
• Queratite  
– Fenilbutazona  
– Vacinas 
• Depósitos corneanos (frequentemente em espiral: córnea verticillata) 
– Amiodarona17  
– Ciprofloxacina 
– Cloroquina  
– Clorpropamida  
– Clorpromazina  (provoca depósitos no estroma e endotélio 
corneanos, assim como na cápsula anterior do cristalino e até na retina) 
– Clofazimina  
– Indometacina (anti-inflamatório não esteróide) 
– Fenotiazinas (antipsicótico) 
– Vitamina D  
– Sais de ouro16: frequentemente pode acumular-se na córnea 
(denominando-se crisíase) particularmente se a dose cumulativa de 1g 
for ultrapassada 
– Prata: argirose (ocorrem depósitos na córnea, na membrana de 
Descemet e na conjuntiva) 
Conjuntiva 
 
• Inflamação e proliferação folicular 
– Antibióticos 
• Conjuntivite 
– Barbitúricos 
– Guanetidina e metildopa  
– Metisergida, Fenilbutazona 
– Inibidores da enzima de conversão de angiotensina (também 
podem provocar angioedema, entre outras RAM) 
• Síndrome de Stevens-Johnson  
– É uma reação rara  (1 por milhão/ano) e frequentemente fatal. 
Consiste numa reacção de hipersensibilidade tipo III tipo graft versus 
host disease, com deposição imunocomplexos na mucosa superficial, 
inflamação e degeneração fibrinóide do colagéneo. Causas incluem: 
• Barbitúricos 
• Clorpropamida (antidiabético oral) 
• Sulfonamidas 
 
Sistema lacrimal 
 
São inúmeros os fármacos que podem alterar a produção lacrimal ou as 
características da lágrima, com sintomas inconvenientes para os doentes. 
Destacam-se os mais importantes. 
• Aumento do lacrimejo  
– Agonistas adrenérgicos 
– Agonistas colinérgicos 
– Anti-hipertensores 
• Diminuição da produção lacrimal 
– Anticolinérgicos 
– Ansiolíticos e antidepressivos (tricíclicos e outros) 
– Anti-histamínicos 
– Análogos da vitamina A 
– Bloqueadores beta 
Músculos extraoculares 
 
• Nistagmo 
– Sais de ouro 
– Diazepam 
– Cetamina 
– Anticonceptionais orais (ACO) 
– Fenitoína  
– Salicilatos 
• Paralisia de um ou vários músculos 
– Penicilamina (agente quelante, usado também na doença de 
Wilson) 
– Fenitoína (antiepiléptico) 
– Clorpropamida (antidiabético oral) 
– Anestésicos e derivados curare 
• Ptose 
– Barbitúricos 
– Penicilamina 
– Guanetidina (antiHTA adrenérgico) 
 
 
Câmara anterior 
 
• Aumento da pressão intraocular 
– Corticosteróides 
– AINEs 
– Anfetaminas 
– Antidepressivos tricíclicos 
– Etambutol (causa um síndrome típico apesar de raro, com myopic 
shift e glaucoma agudo bilateral, devido a efusão uveal) 
• Intraoperative floppy iris syndrome (figura 2) 
– Tansulosina e outros fármacos utilizados na hiperplasia benigna 
da próstata 
 
 
 
Figura 2: Síndrome de íris flácida (floppy iris syndrome). 
 Trata-se de uma RAM que torna a facoemulsificação mais difícil. 
 
 
Cristalino 
 
De um modo geral, os fármacos que associados a depósitos corneanos também 
estão associados a depósitos no cristalino. 
 
• Catarata ou depósitos de fármaco no cristalino 
– Corticóides  
• Quer sistémicos, quer tópicos (mais frequentemente nos 
últimos) 
• Tipicamente deposição a nível subcapsular posterior 
• Apesar de estudos sugerirem que está relacionado com dose 
e duração, não há dose considerada segura. 
– Lovastatina (particularmente se associada a eritromicina) 
• Está atualmente a decorrer uma revisão sistemática, em 
associação com a Cochrane Collaboration, que visa 
determinar se as estatinas aumentam ou diminuem a 
incidência de cataratas. Os estudos originais atuais estão 
em conflito, porque uns indicam aumento de risco de 
cataratas18, outros indicam diminuição de risco19 (as 
estatinas funcionariam assim como fator protetor) e outros 
não identificaram associação. 
– Alopurinol (maior risco se a dose cumulativa for >400g ou se 
houver mais do que 3anos de exposição) 
– Bussulfano (quimioterápico utilizado no tratamento da LMC) 
– Haloperidol (antipsicótico) 
– Clorpromazina (antipsicótico) 
– Sais de ouro (particularmente se exposição > 3 anos) 
– Fenotiazinas (depósitos subcapsulares anteriores) 
 
 
 
Úvea 
 
• Uveíte 
– Antibióticos (rifabutina, sulfonamidas) 
• A rifabutina é utilizada no tratamento de infecções 
provocadas por Mycobacterium avium em doentes HIV+ 
• Pode provocar uveíte anterior aguda grave, tipicamente 
unilateral e frequentemente com hipópion, que pode ser 
confundida com endoftalmite. 
– Bifosfonatos (utilizados no tratamento da osteoporose) 
– Dietilcarbamazina (utilizada no tratamento da filariose) 
– Antihipertensores 
– Anticoncepcionais orais 
– Cidofovir 
• Pode ser utilizado no tratamento de retinite por 
citomegalovírus 
• Pode ocasionar uveíte anterior aguda, frequentemente com 
vitrite e hipópion. Caracteristicamente tem poucas células 
na câmara anterior e muita fibrina. 
• Geralmente não é necessário suspender cidofovir, podendo 
bastar corticoterapia associada a midríase farmacológica 
para que haja resolução desta RAM. 
 
 
Nervo ótico 
 
O atingimento do nervo ótico, apesar de ser raro, é de relevância particular 
porque pode estar associado a perda visual irreversível. Consequentemente, o 
conhecimento dos fármacos que podem dar RAM relacionadas com o nervo 
ótico é imperativo para diagnóstico atempado. 
 
• Atrofia ótica 
– Etambutol20  
• Se administrado numa dose 25mg/Kg, associa-se a atrofia 
óptica em 6% dos doentes  
• Se a dose for ≥15mg/Kg/dia, aconselha-se avaliação 
oftalmológica mensal 
• Em doses <15mg/Kg/dia: aconselha-se avaliação 
oftalmológica semetral ou bianual  
– Barbitúricos  
– Cloranfenicol 
– Iodoquinol (antiprotozoário) 
– Inibidores monoamina-oxídase (iMAO)  
– A atrofia ótica também pode decorrer, por exemplo de glaucoma 
induzido por corticóides 
 
• Nevrite óptica 
– Amiodarona 
– Antibióticos (nomeadamente cloranfenicol)  
– Antituberculosos (rifampicina, isoniazida, etambutol, 
estreptomicina) 
– Penicilamina  
– Dissulfiram  
– Morfina 
– Vigabatrina 
 
 
 
• Edema do disco óptico 
– Clorambucil 
– Antibióticos (tetraciclina, ácido nalidíxico) 
– Anticoncepcionais orais (pseudotumor cerebral) 
– Vitamina A 
 
 
Retina 
 
• Retinopatia 
– Digitálicos 
– Cloroquina 
• Pode provocar uma retinopatia (RP) em olho de boi 
(típica, mas não patognomónica), com diferentes estádios20: 
1. Pré-RP (Acuidade visual (AV) normal, fundoscopia 
normal, campo visual com escotoma central ou com 
alterações da grelha de Amsler) 
2. Precoce (AV ≈ 6/10, fundoscopia com ilha foveal 
pigmentada com um anel despigmentado circundante por 
atrofia do epitélio pigmentar da retina, angiografia 
permitindo identificar um defeito de janela) 
3. Moderada: maculopatia em olho de boi, AV 3/10 
4. Grave: atrofia coriorretiniana marcada além da 
maculopatia em olho de boi 
5. Terminal: atrofia coriorretiniana extensa, com 
visualização dos grandes vasos da coróide.  
• Esta RAM está relacionada com a dose, tendo maior risco a 
partir das 300g (dose cumulativa) ou com duração do tratamento 
superior a 6 anos. Contudo, não existe dose segura. 
• Recomenda-se triagem anual a partir de 6 anos de 
tratamento, com exame oftalmológico, ERG e grelha de Amsler 
 
 
 
– Hidroxicloroquina 
• Considerada mais segura do que a cloroquina. Todavia, 
também não tem dose segura (considera-se risco 
aumentado se dose >400mg/dia) 
– Fenotiazinas (antipsicóticos) 
• Pode provocar um tipo de RP em sal e pimenta, 
especialmente se doses altas (com 800mg por dia, pode 
surgir em semanas).  
•  Sintomas: diminuição da acuidade visual e nictalópia 
(dificuldade em ver à noite). 
• Sinais: RP em sal e pimenta (resulta de pigmentação em 
placas por perda do epitélio pigmentar da retina). 
– Tamoxifeno (utilizado no tratamento de cancro da mama) 
• Pode provocar dois tipos de RAM no pólo posterior: 
• Depósitos maculares cristalinos amarelo-brancos 
(inócuos e frequentes) 
• Cistos maculares ou edema macular (relativamente 
raro, contudo causa diminuição da AV)  
• Nem sempre é necessário suspender a medicação 
– Cantaxantina (autobronzeador, pode originar depósitos na retina) 
– Metoxiflurano (origina depósito de cristais de cálcio) 
– Nitrofurantoína 
– Interferão alfa (associado a exsudados e hemorragias retinianas) 
– Deferoxamina (quelante): pode provocar degeneração pigmentar 
macular diagnosticada por electroculograma (revela < light peak&dark 
through) 
– Ácido nicotínico 
• Está associada a edema macular cístico, particularmente se 
ultrapassar 1,5g de dose cumulativa. Esta RAM é geralmente 
reversível com a suspensão da medicação. 
 
 
Figura 3: Depósitos maculares provocados por tamoxifeno (esta imagem aguarda 
permissão de copyright) 
 
 
 
 
Figura 4: Maculopatia em olho de boi causada pela cloroquina (esta imagem aguarda 
permissão de copyright) 
 
 
 
• Edema da retina 
– Anticoncepcionais orais 
• Hemorragias retinianas 
– Anticoagulantes 
– Salicilatos e fenilbutazona 
– Antibióticos (sulfonamida) 
• Alteração do padrão vascular 
– Anticoncepcionais orais 
– Quinina 
– Hexametónio 
• Discromatopsia azul-verde 
– Sildenafil e família 
Gostaríamos ainda de destacar dois tipos de RAM que nem sempre correspondem a estrutura ocular isolada, mas devem ser do conhecimento dos oftalmologistas. 
 
Alteração do estado refrativo/acomodativo/"visão turva" 
 
São inúmeros os fármacos que podem provocar visão turva21-22: 
– Antihistamínicos 
– Antidepressivos 
– Anticonvulsivantes 
– Antineoplásicos 
– Bifosfonatos 
– Bloqueadores dos canais de cálcio 
– Corticóides 
– Diuréticos 
– iECAs 
– Sildenafil e família 
– Topiramato 
 
 
"Fotossensibilidade"10,21,22 
 
– AINEs 
– Antagonistas do ácido fólico 
– Antiarrítmicos e digitálicos 
– Antibióticos (ciprofloxacina, tetraciclinas) 
– Anticolinérgicos 
– Anticoncepcionais orais 
– Antidepressivos, antipsicóticos, tranquilizantes, fenotiazinas e 
estimuladores do sistema nervoso central 
– Antihistamínicos 
– Bloqueadores dos canais de cálcio, diuréticos tiazídicos, iECAs 
– Retinóides 
– Alguns produtos naturais (como Hyperium perforatum)  
RAM sistémicas a medicação ocular 
 
Primeiramente, para reduzir a probabilidade de ocorrerem RAM, o doente deve 
ser ensinado a administrar correctamente a sua medicação ocular, como 
demonstram as figuras seguintes. 
 
 
 
Figura 5: Exemplo de colocação correta de colírio ocular.  Não existe contacto do 
frasco com a superfície ocular, administra-se apenas uma gota de colírio. 
 
 
 
 
 
Figura 6: Concentração de fluoresceína no olho após colocar uma gota de acordo 
com diferentes técnicas. (Imagem da Academia Americana de Oftalmologia13, aguarda 
permissão de copyright). Legendas "NLO": oclusão ponto lacrimal, "Eyelid closure": com 
encerramento palpebral, "No NLO": simples colocação de colírio sem medidas adicionais. 
Podemos verificar que a concentração do princípio activo é bastante inferior caso o doente não 
faça encerramento palpebral nem oclusão dos pontos lacrimais. 
Passos aconselhados na técnica correta de colocação de colírios 
 
1) Lavar bem as mãos 
2) Inclinar a cabeça para trás e olhar para cima 
3) Expôr bem a conjuntiva palpebral e depois instilar uma gota no fórnix 
conjuntival inferior (idealmente sem aplicar o colírio directamente na córnea; e 
nunca tocar com o frasco na superfície ocular) 
4) Fechar os olhos e pressionar o canal nasolacrimal 
– Este aspecto é extremamente importante. Além de aumentar a 
concentração da substância activa (como demonstrado na figura 6), 
reduz a frequência de RAM sistémicas. Ao ocluir o canal nasolacrimal 
e os pontos lacrimais, estamos a reduzir a quantidade de colírio que 
vai para as mucosas nasal e oral. Estas mucosas, por serem 
densamente vascularizadas (particularmente a mucosa nasal), 
causam absorção sistémica rápida e eficaz, com consequente aumento 
do risco de RAM sistémicas. 
5) Limpar o excesso de medicação que tenha caído para a face 
 
 
  
Fármacos tópicos associados a RAM sistémicas 
 
 
Os medicamentos oftalmológicos que mais frequentemente podem 
causar RAM sistémicas encontram-se enumerados abaixo. 
 
 
• Adrenalina/epinefrina  
– É a RAM sistémica de medicação ocular mais frequente20  
– A absorção através das mucosas pode levar a taquicardia e 
hipertensão 
– A injecção periocular de anestésicos associados a adrenalina pode 
ser fatal  
• Outros midriáticos como a atropina e ciclopentolato 
– Atropina 
• Rubor, agitação, taquicardia, convulsões (particularmente 
nas crianças) 
• Pode ser fatal 
– Ciclopentolato 
• Nas crianças pode ser fatal (o antídoto é a fisostigmina) 
 
• Parassimpaticomiméticos 
– Exemplos: pilocarpina, carbacol 
– Podem provocar várias RAM 
• Diarreia  
• Hipersudorese  
• Miose 
• Náuseas/vómitos 
• Urgência urinária 
• Hipotensão 
• Dispneia 
 
 
 
• Antibióticos  
– Alergia 
– Síndrome Stevens-Johnson 
– Dispneia 
 
• Antivíricos  
– Alergia e dermatite contacto 
 
• Bloqueadores beta 
– Arritmias, bradicardia 
– Dificuldade respiratória 
– Hipotensão 
– Recorde-se que apesar de ser apenas um colírio, tem 
contraindicações absolutas: asma e doença pulmonar crónica obstrutiva, 
bloqueio auriculoventricular, bradicardia. 
 
 
 
 
Outros produtos ... inofensivos? 
 
Não devemos esquecer que mesmo os produtos tipicamente "inofensivos" 
podem causar reações adversas oftalmológicas graves. Nestes exemplos, apenas 
os anticonceptionais orais estão associados a RAM. O tabaco e o etanol não são 
evidentemente medicamentos, pelo que se aplica o termo genérico evento 
adverso. Os produtos naturais, apesar de serem estudados e regulamentados 
pelo INFARMED, não têm neste momento o estatudo de medicamento, pelo que 
o termo correto é também evento adverso. 
• Anticoncepcionais orais 
– Hipovisão, miopia, diplopia, oclusão venosa/arterial retina, nevrite 
óptica, entre outros. 
• “Produtos naturais” (Camomila, Ginkgo biloba, niacina, vitamina A5) 
– Maculopatia tóxica e neuropatia foram demonstradas. 
• Tabaco 
– Ambliopia tóxica e cegueira nocturna. 
• Etanol 
– Hipovisão, diplopia, cegueira nocturna, nistagmo, paralisia 
acomodação, oftalmoplegia e ambliopia tóxica. 
 
 
 
 
Conclusão 
 
Em conclusão, as RAM são mais frequentes e mais graves do que se imagina.  
Todos os oftalmologistas devem saber reconhecer as principais RAM 
oftalmológicas à medicação sistémica, quais as contraindicações de cada 
fármaco que administrem, e quais as RAM sistémicas à medicação oftalmológica  
- antes de a prescrever ou aplicar. 
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ABSTRACT
Biotechnology continuously improves living, however it also presents
challenges. Biotechnology has several applications in the pharmacy
industry, with an increasing numbers of new drugs being developed.
Nevertheless, each and every drug poses a risk of undesired affects,
namely adverse drug reactions (ADRs). ADRs are frequent, important,
expensive and can be fatal: they are estimated to be between the 4th and
6th more frequent causes of death. Pharmacovigilance, which includes
the detection and prevention of ADRs, represents one of the few ways in
which it is possible to increase Healthcare quality while decreasing
related costs. We present an overview about the importance of ADRs
and their methodological issues.
Key words: Pharmacovigilance, Adverse drug reactions, Biotechnology,
Methodologies, Databases, Intensive monitoring
1. INTRODUCTION
Background: Biotechnology, Pharmacology and Adverse Drug
Reactions
Biotechnology has been extremely useful for Humanity in many aspects,
from agriculture (Cantley, 2012) to medicine. The recent advances in
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biotechnology, including genomics, recombinant gene technologies,
applied immunology and biological engineering, have allowed an
improvement in the quality and number of pharmaceutical therapies
(Mesko B et al., 2012).
However, with an increase in the number of new drugs available,
comes an increase in the risk of adverse drug reactions (ADRs), which
can be serious and fatal (Davies et al., 2007). Consequently,
Pharmacovigilance, whose functions include the monitoring, detection
and prevention of ADRs, has a fundamental role in healthcare. The
detection of ADRs can be difficult and require experts. There are several
methods aimed at the detection of ADRs, but all have their
methodological issues.
ADRs: Some Concepts
To avoid confusion between many different terms, we present the
definition of ADR.
An adverse drug reaction is: “any noxious, unintended and undesired
effect of a drug, which occurs at doses used in humans for prophylaxis,
diagnosis, or therapy”, according to WHO’s definition of 1972 (WHO,
1972). This definition is the most widely used, but there are others,
like Karch and Lasagna’s (1975) and Edwards and Aronson (2000).
Fig. 1: Schematic conceptualization of adverse events
An adverse drug event includes medication errors (namely the
prescription of a wrong dose) and adverse drug reactions. An adverse
event includes any injury related to medical management (WHO, 2005).
These and other concepts are represented in the figure below.
Unfortunately, not enough studies that aim to detect ADRs present or
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respect the correct definitions of ADR; we suggest the use of WHO’s
definition of ADR.
Adverse events are injuries related to medical care. Drug related
problems are caused by drugs and include medication errors, adverse
drug events (ADE) and adverse drug reactions (ADR). Adapted from
WHO, 2005.
B. PHARMACOVIGILANCE
Identification, Causality Assessment and Characterization of
ADRs
From hundreds of newly released drugs, administered to thousands of
people, several ADRs can arise, with different manifestations, signs
and symptoms. These are usually detected by healthcare team members
(such as a physician, pharmacist or nurse), when a patient seeks help
as an outpatient or when he is hospitalized, or by an expert during a
study aimed to identify ADRs.
Previous studies have reported many risk factors for developing an
ADR, namely: other comorbidities (Seiber, 2007), diabetes (Zhang et
al., 2009), renal failure (Corsonello et al., 2005), female sex (WHO, 2012),
increased age (Davies et al., 2007) and also genetic factors (Pirmohamed
et al., 2001). These genetic factors might be used in Biotechnology
aiming to increase the detection of ADRs (as discussed below).
ADRs may be classified in type A (augmented, predictable ADRs
which are dose-dependent, such as bleeding after the use of
acetylsalicylic acid) or type B (bizarre, unpredictable, idiosyncratic
reactions, such as Stevens-Johnson syndrome) (Rawlins and Thompson,
1977).
In studies about ADRs, a causality assessment must be performed
in order to assess the probability of a suspected ADR being a true ADR.
Tables 1 and 2 detail the most used causality assessments.
Naranjo’s causality assessment Yes No Don’t
know
1. Are there previous conclusive reports of this reaction? +1 0 0
2. Did the adverse event appear after the suspect drug +2 –1 0
was administered?
3. Did the adverse reaction improve when the drug was +1 0 0
discontinued?
Contd...
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Naranjo’s causality assessment Yes No Don’t
know
4. Did the adverse reaction reappear when the drug was +2 -1 0
readministered?
5. Are there alternate causes that on their own could -1 +2 0
have caused the reaction?
6. Did the reaction appear when a placebo was given? -1 +1 0
7. Was the drug detected in the blood (or other fluids)
in concentrations known to be toxic? +1 0 0
8. Was the reaction more severe when the dose was
increased or less severe when decreased? +1 0 0
9. Did the patient have a similar reaction to the same or
similar drugs in any previous exposure? +1 0 0
10. Was the adverse event confirmed by any objective +1 0 0
evidence?
Total score*
Table 1: Naranjo’s causality assessment for ADRs (Naranjo et al. ,  1981).
*Interpretation of the Total Score: a)  9: Highly probable ADR; b) 5-8:
Probable ADR; c) 1-4: Possible ADR: d)  0: Doubtful ADR.
WHO’s causality assessment
1. Certain ADR A clinical event, including laboratory test abnormality, occurring
in a plausible time relationship to drug administration, and which
cannot be explained by concurrent disease or other drugs or
chemicals. The response to withdrawal of the drug (dechallenge)
should be clinically plausible. The event must be definitive
pharmacologically or phenomenologically, using a satisfactory
rechallenge procedure if necessary.
2. Probable ADR A clinical event, including laboratory test abnormality, with a
reasonable time sequence to administration of the drug, unlikely
to be attributed to concurrent disease or other drugs or chemicals,
and which follows a clinically reasonable response on withdrawal
(dechallenge). Rechallenge information is not required to fulfill
this definition. A clinical event, including laboratory test
abnormality, with a reasonable time sequence to administration
of the drug, unlikely to be attributed to concurrent disease or other
drugs or chemicals, and which follows a clinically reasonable
response on withdrawal (dechallenge). Rechallenge information
is not required to fulfill this definition.
3. Possible ADR A clinical event, including laboratory test abnormality, with a
reasonable time sequence to administration of the drug, but which
could also be explained by concurrent disease or other drugs or
chemicals. Information on drug withdrawal may be lacking or
unclear
4. Unlikely ADR A clinical event, including laboratory test abnormality, with a
temporal relationship to drug administration which makes a causal
relationship improbable, and in which other drugs, chemicals or
underlying disease provide plausible explanations.
Contd...
Table 1: Contd...
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WHO’s causality assessment
5. Conditional / unclassified ADR A clinical event, including laboratory test
abnormality, reported as an adverse reaction, about which more
data is essential for a proper assessment or the additional data are
under examination.
6. Inaccessible / A report suggesting an adverse reaction which cannot be judged
unclassifiable because information is insufficient or contradictory, and which
cannot be supplemented or verified.
Table 2: WHO’s causality assessment for ADRs (WHO, 2005).
The American Food and Drug Administration uses the following criteria
for characterizing  an ADR as serious, if associated with either of:
 Death
 Life-threatening
 Hospitalization (an ADR that causes or prolongs hospitalization)
 Disability
 Congenital anomaly
 Requires intervention to prevent permanent impairment or
damage
A severe ADR is an intense or painful ADR (not to be confused with
a serious ADR).
ADRs can also be characterized according to predictability (Hartwig
et al., 1992), preventability (Schumock and Thornton, 1992) and other
factors.
Frequency of ADRs
Although ADRs may be difficult to detect, they are frequent: they are
estimated to cause 5.3% of hospital admissions (Kongkaew et al., 2008)
and to occur in a mean of 16.88% of patients during hospitalization
(CI95%:13.56-20.21) (Miguel et al., 2012).
Fatal ADRs may be between the fourth and sixth leading causes of
death in the US (Lazarou et al., 1998). They may lead to US$1.56 billion
in direct hospital costs per year in the US (Classen et al., 1997), and
drug related morbidity may lead to US$136.8 billion in indirect costs
(Johnson and Bootman, 1995).  Each ADR may represent a cost of
US$2500 per patient (Bates et al., 1995).
Table 1: Contd...
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Drug development and detection of ADRs
At the time a drug is licensed, information about its ADRs is limited.
Some ADRs are difficult to detect during the clinical research phases
prior to commercialization, namely ADRs of low incidence or ADRs that
occur several years after administration. This may also be due to the
fact that pre-marketing trials are often underpowered, have limited
follow-up or that drug information sent from companies to health
authorities might sometimes be incomplete (Psaty et al., 2004).
In Fig. 2, we depict the four stages of clinical trials, in which ADRs
of a drug can be detected, before and after a drug commercialization.
In Phase 1 trials, researchers test an experimental drug or treatment
in a small group of volunteers (20-80) for the first time, to evaluate its
general safety. In Phase 2 trials, the experimental study drug is
administered to a larger group of people (100-300) to see if it is effective
and to further evaluate its safety. In Phase 3 trials, the experimental
study drug is administered to large groups of people (1000-3000) under
strict inclusion criteria to confirm its effectiveness, to identify further
ADRs, to compare it to commonly used treatments, and to collect
information that will allow the experimental drug or treatment to be
used safely. In Phase 4 trials, post marketing trials identify additional
information such as rare or late-effect ADRs. There is an increasing
number of patients throughout the different trial phases. After the drug
approval, not only post marketing trials but also postmarketing
observational studies can be performed to identify ADRs.
Fig. 2: Trial phases and possibilities for ADR detection.
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Several drugs have been withdrawn from the market in the last
decade after being approved by competent health authorities, such as
rofecoxib, that has caused 100000 cardiovascular events in the US before
the market withdrawal (Gudbjornsson, 2010). This demonstrates the
importance of postmarketing surveillance.
C. POSTMARKETING METHODOLOGIES FOR THE DETECTION
OF ADRS
Several methods can be used for the detection of ADRs:
1. Spontaneous reporting (in which a health team member reports
a presumable ADR) is the main Pharmacovigilance method used
in Europe, since it is cheap; however subnotification (Figueiras et
al., 2006; Herdeiro et al., 2008) is a problem.
2. Administrative databases. Recurring to national hospital
administrative databases is not a widely used method, but it may
have some advantages, like low cost and the possibility of a
National perspective (Salmerón-García et al., 2010).
3. Chart review (prospective or retrospective) is a reasonable
methodology for ADR (Mullins et al., 2011), however it is also
resource and time consuming.
4. Computerized systems include all methods in which a
computerized hospital system generates ADR alerts in several
groups of patients, later validated by an expert team (Tinoco et
al., 2011). This is an evolving and interesting method of
Pharmacovigilance, but attention is needed to build rules and
algorithms with high specificity (too many ADR alerts with little
specificity consume time in ADR validation and make it
unpractical).
5. Intensive monitoring is the gold standard, in which an expert
team prospectively examines a cohort of patients (recurring to
chart review, patient examination and medical team interview)
and applies strict criteria to identify and classify ADRs. However,
this method is extremely resource and time consuming (Pourseyed
et al., 2009), making it unpractical to perform regularly.
6. Prospective monitoring is a monitoring similar to intensive
monitoring but less rigorously (Fattinger et al., 2000).
7. Trials are not used solely for the identification of ADRs of a
particular drug, but are growingly assessing ADRs as an essential
component of a drug evaluation (de Vries and van Roon, 2010).
8. Other methods are promising for the detection of ADRs.
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These methodologies are different, although not always mutually
exclusive (for example, intensive monitoring can and should include
chart review and prospective monitoring), and each of which presents
with its advantages and disadvantages.
1. Spontaneous reporting - International Drug Monitoring
Program
The World Health Organization (WHO) has built an International Drug
Monitoring Program, that incorporated adverse events’ (and ADRs)
information derived from State Members later in 1971. The Program
for International Drug Monitoring relies on spontaneous reports from
more than 100 countries, and builds a global database to identify
possible relationships between the use of a drug and adverse effects
and ADRs. Whenever a report of a suspect ADR arises, its data is shared
through every State Member. Also, the majority of countries have a
National Health Drug Regulatory Agency. However, these agencies rely
mainly on spontaneous reporting (WHO, 2005), largely underestimating
the real number of ADRs (as will be described below).
In summary, National and International Drug Regulatory Agencies
currently use spontaneous reporting as a continuous Pharmacovigilance
method.
Methodological issues of spontaneous reporting
In spite of being the most commonly used method for Pharmacovigilance
due to its reduced costs, there are several limitations to spontaneous
reporting: under-reporting, heterogeneous report quality and risk of
bias.
Under-reporting is the main limitation: several studies have
estimated that spontaneous reporting only detects 5-10% of ADRs
(McGettigan et al., 1997; Smith et al., 1996), due to intrinsic factors
(knowledge, attitudes) and extrinsic factors (relationship between
patient-doctor, the national health system and pharmaceutical
companies) (Herdeiro et al., 2004). Some studies have demonstrated
that spontaneous reporting rate can be increased (Biagi et al., 2012;
Figueiras et al., 2006), however this effect was temporary. Health
Professionals that can report ADRs should be subject to continuous
education on Pharmacovigilance, to maintain an acceptable reporting
rate, which has costs.
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Other limitation is the report quality. Different quality in reporting
will result as different skilled health professionals assess and write
that information about ADRs. Also, in different countries there are
different forms, which might result in discrepancy (Bandekar et al.,
2010).
The third limitation is methodological bias. This occurs because a
simple report with uncontrolled information and variables, in
comparison with namely a trial, is more prone to suffer from bias, as
suggested by some authors (Pariente et al., 2007).
2. DATABASES
The utilization of hospital episodes statistics has been performed only
by a few authors to identify ADRs. Although not widely used, it may
have advantages if developed and validated as a methodology, such as:
information of several hospitals, years and countries already available,
clinical coding data from which signals of ADRs might be extracted,
low resources needed and a detection rate higher than spontaneous
reporting.
Hospital administrative databases are built in many countries for
reimbursement and/or administrative purposes, and contain useful
clinical information that can be utilized for detecting ADRs. This
information may include: anonymized patient identification, episode
and process number, age, sex, admission date, discharge date, ward(s),
hospital attended (tertiary, university), district, outcome (death,
discharge, transfer), payment data (Diagnosis Related Groups) and ICD-
9-CM codes for: diagnoses (principal diagnosis, and secondary diagnoses
usually up to 19), procedures (up to 20) and external causes (up to 20).
Therefore, these large sources of information can be very useful to
identify ADRs even in nation-wide studies, namely allowing to detect
ADR frequencies of: 0.89% in Spain (Salmerón-García A et al., 2010),
0.9% in England (Wu et al, 2010), 1.83% in the Netherlands (van der
Hooft et al., 2006), 0.8% in Australia (Whitstock et al., 2011) and 1.26%
in Portugal (throughout the same study period and population,
spontaneous reporting only detected a prevalence of 0.001% ADRs)
(Miguel et al., 2013b).
Methodological issues of databases
There are limitations in the database methodology, such as: probable
incomplete and wrong information might occur in every large database,
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and coding creep (this is a possible bias of all billing databases, in which
more expensive codes are preferred and registered to increase the case-
mix, diagnosis-related group and consequently to increase
reimbursement of that hospital) (Seiber, 2007).
Multi-centered validation studies of databases in different countries
should be performed to select specific diagnostic codes associated with
ADRs within each country, and to build an estimate of error associated
with each methodology.
Although the database methodology allows us to detect a higher
frequency of ADRs than spontaneous reporting, it is low in comparison
with prospective monitoring and intensive monitoring.
3. MANUAL CHART REVIEW
Manual chart review for ADR detection consists of retrospectively or
prospectively reviewing patient charts to identify ADRs, generally
performed by one or two experts in ADRs, that latter assess concordance
for verification of ADRs (Mullins et al., 2011; Tinoco et al., 2011). Specific,
strict and objective guidelines are recommended for this assessment
(Cornelius et al., 2009), namely the use of a definition of ADR (usually
WHO definition) and causality assessment of ADRs.
Methodological issues of chart review
Manual chart review has good detection rates (Tinoco et al., 2011), but
it is time and personnel costly: some studies estimated a cost of 55
person-hours per week (Jha et al., 1998). We performed two studies of
ADRs using chart review, the first detecting a prevalence of 9% ADRs
with a cost of 35 person-hours for 100 patients, in comparison with 2
person-hours for 100 patients in the database methodology (Miguel et
al., 2013). Our second chart review, more detailed to further characterize
ADRs, unfortunately obtained a similar prevalence of ADRs, 10.2%, at
a much higher cost: 69 person-hours (Miguel et al., 2013b).
Other limitations of chart review include the methodological
heterogeneity between the different studies (Davies et al., 2007), namely
because of the use of different definitions of ADR, the use of different
causality assessment for ADRs, prospective or retrospective design of
study (and different time of data collection), and the use of different
number of sources for detection of ADRs: some just search through
patient charts (Bates et al.,1993), while others also interview health
team whenever doubts arise (Somers et al., 2003).
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Additionally, the quality of records in different hospitals can vary,
generating differences in the detection of ADRs through chart review
(Davies et al., 2007; Cassidy et al., 2002), further adding heterogeneity.
4. COMPUTERIZED METHODOLOGIES
Computerized methodologies for the detection of ADRs are appealing.
Many different strategies of computerized Pharmacovigilance were
assessed in a recent systematic review (Forster et al., 2012), with
different levels of complexity in implementation and integration, and
consequently with a variety of costs in acquisition and maintenance.
Computerized methods are frequently used in US hospitals, in which
almost all clinical data is already computerized and structured.
Methodological issues of computerized methods
In the one hand, low level of automation methods may be resource-
sparing and interesting for the use of simple ADR detection in hospitals
without computerized clinical information. On the other hand,
integrated and high complexity computerized methods are more
complete and allow prospective detection (and prevention of ADRs,
alerting the physician and even suggesting dose changes in certain
patients) (Hassan et al., 2010). Additionally, computerized methods
require algorithms and continuous adjustment (and resources) to avoid
too many alerts without specificity for a true ADR.
5. OTHER METHODS: INTENSIVE MONITORING, PROSPECTIVE
MONITORING AND TRIALS
Intensive monitoring is the gold standard because it implies direct and
prospective observation by an expert team, having the highest detection
rate - and the highest cost (Pourseyed et al., 2009; Davies et al., 2007).
For that reason, it is impossible to use as a continuous
Pharmacovigilance method in all patients.
Although prospective monitoring is cheaper and has high detection
rates, it is also too resource-consuming to use continuously.
Trials are performed in extremely selected populations within a
relatively short period of time, therefore other methods must be used
to detect ADRs in the general population.
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6. BIOTECHNOLOGY AND PHARMACOGENOMICS FOR THE
DETECTION OF ADRS
Biotechnology not only has offered new methods of designing drugs,
but also aids  in the detection of ADRs, namely through the development
of pharmacogenomics. Pharmacogenomics is the study of how genes
and gene variation can produce different phenotypic drug responses
(Altman and Klein, 2012). Consequently, for each patient these
phenotypic drug responses may be predicted, either to increase
effectiveness according to the drug response rates (Wilkinson, 2005)
and to prevent ADRs, namely by changing the drug type or dose
according to each specific genotype) (Davies et al., 2007; Pirmohamed
and Park, 2001).
Pharmacogenomics and personalized medicine are connected and
are promising in Pharmacology, Pharmacovigilance and Medicine
(Desiere and Spica, 2012). However, many issues of regulation, ethics
and cost-effectiveness must be addressed with the use of
pharmacogenetics testing (Howland, 2009) and a rational global drug
use policy must be applied (Roederer et al., 2011).
Mesko B and colleagues (Mesko et al, 2012) propose the utilization
of a triad in the control of personalized medicine: biotechnology,
pharmacogenomics (including gene expression profiling) and regulatory
issues.
C. CONCLUSIONS
Many developments in biotechnology have allowed an improvement in
medicine and pharmacology, with an increase in the discovery of new
drugs. However, this leads to an increase in the risk of ADRs.
Consequently, Pharmacovigilance must evolve to increase the detection
rate of ADRs. Several methods can be used for that detection, all with
methodological issues.
Spontaneous reporting is widely used due to its low cost, being a
part of the International Drug Monitoring Program; however, there is
an extremely low detection rate. Nevertheless, this method is very good
for identifying new ADRs to new drugs.
Database and computerized methodologies are promising and might
be integrated as effective Pharmacovigilance methodologies. The
database methodology is resource-sparing for continuous application
but with a detection rate much higher than spontaneous reporting,
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allowing nation-wide estimates. Computerized chart review may allow
regular surveillance with a good ADR detection.
Chart review, prospective monitoring and trials have a very good
detection rate, however their costs are too high for continuous
surveillance.
Biotechnology application in Pharmacogenomics is promising for the
individualized prevention of ADRs.
Different methods tend to identify different ADRs, therefore, multiple
methods for ADR detection should be used complementarily for patient
safety enhancement.
REFERENCES
Altman, R.B. and Klein, T.E. (2002). Challenges for biomedical informatics and
pharmacogenomics. Ann. Rev. Pharmacol. Toxicol., 42: 113–33.
Bandekar, M.S., Anwikar, S.R. and Kshirsagar, N.A. (2010). Quality check of
spontaneous adverse drug reaction reporting forms of different countries.
Pharmacoepidemiol Drug Saf., 19(11): 1181–5.
Bates, D.W. et al. (1995). Incidence of adverse drug events and potential adverse
drug events – implications for prevention. JAMA, 274: 307–311.
Bates, D.W., Leape, L.L. and Petrycki, S. (1993). Incidence and preventability of
adverse drug events in hospitalized adults. J. Gen. Intern. Med., 8: 289–294.
Biagi, C., Montanaro, N., Buccellato, E., Roberto, G., Vaccheri, A. and Motola, D.
(2012). Underreporting in pharmacovigilance: An intervention for Italian GPs
(Emilia–Romagna region). Eur. J. Clin. Pharmacol., 69(2): 237–44.
Cantley, M. (2012). European attitudes on the regulation of modern biotechnology
and their consequences. GM Crops Food, 3(1): 40–7.
Cassidy, L.D., Marsh, G.M., Holleran, M.K. and Ruhl, L.S. (2002). Methodology to
improve data quality from chart review in the managed care setting. Am. J.
Manag Care, 8(9): 787–93.
Classen, D.C., Pestonik, S.L., Evans, R.S., Lloyd, J.F. and Burke, J.P. (1997).
Adverse drug events in hospitalized patients: Excess length of stay, extra costs
and attributable mortality. JAMA, 277: 301–306.
Cornelius, V.R., Perrio, M.J., Shakir, S.A.W. and Smith, L.A. (2009). Systematic
reviews of adverse effects of drug interventions: A survey of their conduct and
reporting quality. Pharmacoepidemiology and Drug Safety, 18: 1223–1231.
Corsonello, A., Pedone, C., Corica, F., Mussi, C., Carbonin, P. and AntonelliIncalzi,
R. (2005). Concealed renal insufficiency and adverse drug reactions in elderly
hospitalized patients. Arch. Intern. Med., 165: 790–5.
Davies, E.C., Green, C.F., Mottram, D.R. and Pirmohamed, M. (2007). Adverse
drug reactions in hospitals: A narrative review. Current Drug Safety, 2: 79–87.
Desiere, F. and Romano Spica, V. (2012). Personalised medicine in 2012: Editorial
to the special issue of New Biotechnology on “molecular diagnostics and
personalised medicine. N. Biotechnol., 15; 29(6): 611–2.
de Vries, T.W. and van Roon, E.N. (2010). Low quality of reporting adverse drug
reactions in paediatric randomised controlled trials. Arch. Dis. Child,
95(12):1023–6. Epub 2010 Jun 15.
14 Biotechnology Vol. 9: Diseases, Diagnostics and Therapeutics
Edwards, I.R. and Aronson, J.K. (2000). ADRs: Definition, diagnosis and
management. Lancet, 356: 1255–9.
Fattinger, K., Roos, M. and Veregeres, P. (2000). Epidemiology of drug exposure
and adverse drug reactions in two Swiss departments of internal medicine. Br.
J. Clin. Pharmacol., 49: 158–167.
Figueiras, A. et al. (2006). An educational intervention to improve physician
reporting of adverse drug reactions: A cluster–randomized controlled trial.
JAMA, 296(9): 1086–1093.
Forster, A.J., Jennings, A., Chow, C., Leeder, C. and van Walraven, C. (2012). A
systematic review to evaluate the accuracy of electronic adverse drug event
detection. J. Am. Med. Inform. Assoc., 19(1): 31–8.
Gudbjornsson, B., Thorsteinsson, S.B. and Sigvaldason, H. (2010). Rofecoxib, but
not celecoxib, increases the risk of thromboembolic cardiovascular events in
young adults–a nationwide registry–based study. Eur. J. Clin. Pharmacol.,
66(6): 619–25.
Hartwig SC, Siegel J, Schneider PJ. 1992. Preventability and severity assessment
in reporting adverse drug reactions. Am J Hosp Pharm; 49: 2229–32.
Hassan, E., Badawi, O., Weber, R.J. and Cohen, H. (2010). Using technology to
prevent adverse drug events in the intensive care unit. Crit. Care Med., 38(6
Suppl): S97–S105.
Herdeiro, M.T., Polónia, J., Gestal–Otero, J.J. and Figueiras, A. (2008). Improving
the reporting of adverse drug reactions: A cluster–randomized trial among
pharmacists in Portugal. Drug Saf., 31(4): 335–44.
Howland, R.H. (2009). Pharmacogenetics and pharmacovigilance. Drug Saf., 32(3):
265–70.
Jha, A.K. et al. (1998). Identifying adverse drug events: Development of a computer–
based monitor and comparison with chart review and stimulated voluntary
report. J. Am. Med. Inform. Assoc., 5(3): 305–14.
Johnson, J.A. and Bootman, J.L. (1995). Drug–related morbidity and mortality a
cost–of–illness model. Arch. Intern. Med., 155: 1949–56
Karch, F.E. and Lasagna, L. (1975). Adverse drug reaction– a critical review. JAMA,
234: 1236–41.
Kongkaew, C., Noyce, P.R. and Ashcroft, D.M. (2008). Hospital admissions
associated with adverse drug reactions: A systematic review of prospective
observational studies. The Annals of Pharmacotherapy, 42: 1–9.
Lazarou, J., Pomeranz, B.H. and Corey, P.N. (1998). Incidence of adverse drug
reactions in hospitalized patients: A meta–analysis of prospective studies.
JAMA., 279(15):1200–5.
McGettigan, P., Golden, J., Conroy, R.M., Arthur, N. and Feely, J. (1997). Reporting
of adverse drug reactions by hospital doctors and the response to intervention.
Br. J. Clin. Pharmacol., 44: 98–100.
Mesko, B., Zahuczky, G. and Nagy, L. (2012). The triad of success in personalised
medicine: Pharmacogenomics, biotechnology and regulatory issues from a
Central European perspective. N. Biotechnol., 15; 29(6): 741–50.
Miguel, A., Azevedo, L.F., Araújo, M. and Pereira, A.C. (2012). Frequency of adverse
drug reactions in hospitalized patients: A systematic review and meta–analysis.
Pharmacoepidemiol Drug Saf., 21(11): 1139–54.
Miguel, A., Azevedo, L.F., Lopes, F., Freitas, A. and Pereira, A.C. (2013).
Methodologies for the detection of adverse drug reactions: Comparison of
hospital episodes statistics databases, chart review and spontaneous reporting.
Pharmacoepidemiol Drug Saf., 22(1): 98–102.
 15Stem cell and Drug discovery: Novel Approach in human and Veterinary...
Miguel, A., Marques, B., Freitas, A., Lopes, F., Azevedo, L. and Pereira, A.C. (2013b).
Detection of adverse drug reactions using hospital databases – a nationwide
study in Portugal. Accepted for publication in Pharmacoepidemiol Drug Saf,
May 2013.
Mullins, M., Cannarozzi, A.A., Bailey, T.C. and Ranganathan, P. (2011).
Unrecognized fatalities related to colchicine in hospitalized patients. Clin.
Toxicol., (Phila) 49(7): 648–52.
Naranjo, C.A., Busto, U. and Sellers, E.M. (1981). A method for estimating the
probability of adverse drug reactions. Clin. Pharmacol. Ther., 30: 239–245.
Pariente, A., Gregoire, F., Fourrier–Reglat, A., Haramburu, F. and Moore, N. (2007).
Impact of safety alerts on measures of disproportionality in spontaneous
reporting databases: The notoriety bias. Drug Saf., 30(10): 891–8.
Pirmohamed, M. and Park, B.K. (2001). Genetic susceptibility to adverse drug
reactions. Trends Pharmacol. Sci., 22(6): 298–305.
Pirmohamed, M. and Park, B.K. (2003). Adverse drug reactions: Back to the future.
Br. J. Clin. Pharmacol., 55: 486–492.
Pourseyed, S. et al. (2009). Adverse drug reactions in patients in an Iranian
department of internal medicine. Pharmacoepidemiol. Drug Saf., 18: 104–110.
Psaty, B.M., Furberg, C.D., Ray, W.A. and Weiss, N.S. (2004). Potential for conflict
of interest in the evaluation of suspected adverse drug reactions: Use of
cerivastatin and risk of rhabdomyolysis. JAMA, 292: 2622–2631.
Rawlins, M.D. and Thompson, J.W. (19770. Pathogenesis of adverse drug reactions.
In: Davies, D.M. Ed.) Textbook of adverse drug reactions. Oxford University
press, Oxford..
Roederer, M.W., Sanchez–Giron, F., Kalideen, K., Kudzi, W., McLeod, H.L. and
Zhang, W. (2011). Pharmacogenetics for every nation initiative.
Pharmacogenetics and rational drug use around the world. Pharmacogenomics,
12(6): 897–905.
Salmerón–García, A. and CabezaBarrera, J. (2010). Detection of adverse drug
reactions through the minimum basic data set. Pharm World Sci., 32(3): 322–
8.
Schumock, G.T. and Thornton, J.P. (1992). Focusing on the preventability of adverse
drug reactions. Hosp Pharm., 27: 538.
Seiber, E.E. (2007). Physician code creep: Evidence in Medicaid and State Employee
Health Insurance billing. Health Care Financ. Rev., 28(4): 83–93.
Smith, C.C., Bennett, P.M., Pearce, H.M., Harrison, P.I., Reynolds, D.J.M., Aronson,
J.K. and Graham–Smith, D.G. (1996). Adverse drug reactions in a hospital
general medical unit meriting notification to the committee on safety of
medicine. Br. J. Clin. Pharmacol., 42: 423–429.
Somers, A., Petrovic, M., Robays, H. and Bogaert, M. (2003). Reporting adverse
drug reactions on a geriatric ward: A pilot project. Eur. J. Clin. Pharmacol.,
58: 707–714.
Tinoco, A., Evans, R.S., Staes, C.J., Lloyd, J.F., Rothschild, J.M. and Haug, P.J.
(2011). Comparison of computerized surveillance and manual chart review for
adverse events. J. Am. Med. Inform. Assoc., 18(4): 491–7.
van der Hooft, C.S., Sturkenboom, M.C., van Grootheest, K., Kingma, H.J., Stricker,
B.H. (2006). Adverse drug reaction–related hospitalisations: A nationwide study
in The Netherlands. Drug Saf., 29(2): 161–8.
Wilkinson, G.R. (2005). Drug metabolism and variability among patients in drug
response. NEJM, 352(21): 2211–2224.
16 Biotechnology Vol. 9: Diseases, Diagnostics and Therapeutics
Whitstock, M.T., Pearce, C.M., Ridout, S.C. and Eckermann, E.J. (2011). Using
clinical trial data and linked administrative health data to reduce the risk of
adverse events associated with the uptake of newly released drugs by older
Australians: A model process. BMC Public Health, 11: 361.
World Health Organization. International Drug Monitoring: (1966). The Role of
the Hospital. Geneva, Switzerland: World Health Organization; Technical
Report Series No. 425. Updated in 1972.
World Health Organization. (2005). The importance of Pharmacovigilance – safety
monitoring of medicinal products. Accessed from:  http://apps.who.int/
medicinedocs/en/d/Js4893e/. Accessed April 2013.
Wu, T., Jen, M.H. and Bottle, A. (2010). Ten–year trends in hospital admissions
for adverse drug reactions in England 1999–2009. J. R. Soc. Med., 1; 103(6):
239–250. (doi:  10.1258/jrsm.2010.100113).
Zhang, M., Holman, C.D., Price, S.D., Sanfilippo, F.M., Preen, D.B. and Bulsara,
M.K. (2009). Comorbidity and repeat admission to hospital for adverse drug
reactions in older adults: Retrospective cohort study. BMJ., 7; 338:a2752(doi:
10.1136/bmj.a2752).

